<table><tr><td colspan="2">Choosing to Become a Leader / 11</td></tr><tr><td>and Clinical Outcomes / 11 The Impo: Leaders! rtance of Diversity and ip 12</td><td></td></tr><tr><td>Leadership Styles</td><td>12</td></tr></table>
======================================
<table><thead><th>CORE COMPETENCY</th><th>DESCRIPTION</th></thead><tr><td>Patient care</td><td>To be able to provide compassionate and effective healthcare in the modern-day healthcare environment</td></tr><tr><td>Medical knowledge</td><td>To effectively apply current medical knowledge in patient care and to be able to use medical tools (i.e., PubMed) to stay current in medical education</td></tr><tr><td>Practice-based learning and improvement</td><td>To critically assimilate and evaluate information in a systematic manner to improve patient care practices</td></tr><tr><td>Interpersonal and communication skills</td><td>To demonstrate sufficient communication skills that allow for efficient information exchange in physician-patient interactions and as a member of a healthcare team</td></tr><tr><td>Professionalism</td><td>To demonstrate the principles of ethical behavior (i.e., informed consent, patient confidentiality) and integrity that promote the highest level of medical care</td></tr><tr><td>Systems-based practice</td><td>To acknowledge and understand that each individual practice is part of a larger healthcare delivery system and to be able to use the system to</td></tr></table>
======================================
<table><thead><th>LEADERSHIP SKILL</th><th>DESCRIPTION AND APPLICATION IN THE FIELD OF MEDICINE</th></thead><tr><td>Vision</td><td>The act of establishing tangible goals of care for patients on both a daily basis as well as for long-term purposes.</td></tr><tr><td>Effective communication</td><td>Establishing an open, respectful, and nonjudgmental forum for communication among different members of the healthcare team and with the patient.</td></tr><tr><td>Willingness to lead</td><td>Taking on full responsibility for the care of patients and remaining ethical, professional, and committed despite the especially challenging rigors of joining the field of surgery.</td></tr><tr><td>Willingness to learn</td><td>A commitment to lifelong learning of the latest scientific, medical, and surgical updates to deliver optimized patient care.</td></tr><tr><td>Conflict resolution</td><td>The art of resolving conflicts in a peaceful and ethical manner in team settings.</td></tr></table>
======================================
<table><thead><th>Low education, low</th><th>High education, low</th></thead><tr><td>service value (Ex: Waiting during</td><td>service value</td></tr><tr><td>mandatory in-house call)</td><td>(Ex: Teaching conferences)</td></tr><tr><td>Low education, high service value</td><td>High education, high</td></tr><tr><td>(Ex: Repeatedly performing</td><td>service value</td></tr><tr><td>History &amp; Physicals)</td><td>(Ex: Operating with a mentor)</td></tr></table>
======================================
<table><thead><th>Important</th><th>Quadrant |</th><th>Quadrant II</th></thead><tr><td>Nonimportant</td><td>Quadrant III</td><td>Quadrant IV</td></tr><tr><td></td><td>Urgent</td><td>Nonurgent</td></tr></table>
======================================
<table><thead><th>SKILLS</th><th>IMPORTANCE MEAN SCORE</th><th>| COMPETENCE | MEAN SCORE*</th></thead><tr><td>Academic program development</td><td>3.2</td><td>2.4*</td></tr><tr><td>Leadership training</td><td>3.8</td><td>Dea!</td></tr><tr><td>Leadership theory</td><td>3.2</td><td>Dell</td></tr><tr><td>Effective communication</td><td>3.7</td><td>Delt</td></tr><tr><td>Conflict resolution</td><td>3.8</td><td>Bi</td></tr><tr><td>Management principles</td><td>3.7</td><td>Qe?</td></tr><tr><td>Negotiation</td><td>3.7</td><td>2.8*</td></tr><tr><td>Time management</td><td>4</td><td>2.8*</td></tr><tr><td>Private or academic practice, managed care</td><td>| 3.6</td><td>De</td></tr><tr><td>Investment principles</td><td>3.5</td><td>Dgy?</td></tr><tr><td>Ethics</td><td>3.6</td><td>3.2</td></tr><tr><td>Billing, coding, and compliance</td><td>3.5</td><td>i</td></tr><tr><td>Program improvement</td><td>3</td><td>2</td></tr><tr><td>Writing proposals</td><td></td><td></td></tr><tr><td>Writing reports</td><td></td><td></td></tr><tr><td>Public speaking</td><td></td><td></td></tr><tr><td>Effective presentations</td><td></td><td></td></tr><tr><td>Risk management</td><td></td><td></td></tr><tr><td>Total</td><td></td><td></td></tr></table>
======================================
<table><thead><th>ORGANIZATION NAME</th><th>DESCRIPTION</th><th>MAIN SKILLS, CONDITIONS, OR QUALITIES EVALUATED</th><th>EVALUATION OF TECHNICAL SKILLS?</th><th>EVALUATION | NONTECHNICAI SKILLS?</th></thead><tr><td>Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS)</td><td>A public reporting initiative that measures patient perspectives on and satisfaction with hospital care based on qualities of healthcare that patients view as important.</td><td>| Communication with nurses, communication with doctors, responsiveness of hospital staff, pain management, communication about medicines, discharge information, care transition</td><td>No</td><td>Yes</td></tr><tr><td>Clinical and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS)</td><td>A public reporting initiative that | measures patient perspectives on and satisfaction with care provided in an office setting based on qualities of healthcare that patients view as important.</td><td>Access to care, provider communication, test results, office staff, overall provider rating</td><td>No</td><td>Yes</td></tr><tr><td>Datix, Incident Reporting</td><td>A database of incidents that improves reliability of physicians by improving rates of reporting, promoting ownership of mistakes, and improving patient safety.</td><td>System issues, patient safety and quality issues, provider behavior, leadership style</td><td>Yes</td><td>Yes</td></tr><tr><td>Patient Advocacy Reporting System (PARS)</td><td>A system that compiles patient complaints into a complaint index for each physician for comparison with other medical group members and to help identify high-malpractice-risk physicians who may benefit from peer intervention.</td><td>Unprofessional behavior deemed as disrespectful and rude</td><td>| No</td><td>Yes</td></tr><tr><td>Co-worker Observation Reporting System</td><td>A system in which physicians document coworker unprofessional conduct in order to provide nonjudgmental and timely feedback and to encourage self-reflection and change.</td><td>Unprofessional behavior deemed as disrespectful and unsafe</td><td>| Yes</td><td>Yes</td></tr></table>
======================================
<table><thead><th>ORGANIZATION NAME</th><th>DESCRIPTION</th><th>MAIN SKILLS, CONDITIONS, OR QUALITIES EVALUATED</th><th>EVALUATION OF TECHNICAL SKILLS?</th><th>EVALUATION OF | NONTECHNICAL SKILLS?</th></thead><tr><td>American Board of Surgery (ABS) Maintenance of Certification (MOC) Program</td><td>A program that documents a surgeon’s ongoing commitment to professionalism, lifelong learning, and practice improvement through self-report.</td><td>Restrictions on medical license, | |___ restrictions on hospital privileges, continuing medical education, self-assessment of continuing medical education, cognitive expertise, ongoing participation in quality assessment program relevant to the surgeon’s practice</td><td>Yes</td><td>Yes</td></tr><tr><td>Hospital Compare</td><td>A database that is part of the Centers for Medicare &amp; Medicaid Services (CMS) Hospital Quality Initiative and provides information on hospital performance and quality of care based on consumer perspectives so that patients can assess and compare hospitals.</td><td>Hospital Compare is based on data from HCAHPS and evaluates hospitals by the same guidelines as HCAHPS</td><td>No</td><td>Yes</td></tr><tr><td>Federation of State Medical Boards (FSMB)</td><td>An organization representing all | state medial and osteopathic boards in the United States that</td><td>Medical knowledge, patient complaints, violations of the law</td><td>Yes</td><td>Yes</td></tr><tr><td>Internet clinical scores |</td><td>the United States Medical Licensing Examination. A database of direct patient opinions of physicians, provided through various sources, including</td><td>Professionalism, communication, timeliness</td><td>| No</td><td>Yes</td></tr><tr><td>Hospital-Acquired Condition Reduction Program</td><td>Yelp. A government program that | _ provides incentives for hospitals) to reduce the number of undesirable patient conditions resulting from their stay in the hospital and that could have been avoided by adjusting hospital reimbursement rates</td><td>Foreign objects retained after _ surgery, air embolism, blood incompatibility, pressure ulcers, falls, poor glycemic control, catheter- associate infections, surgical site infections, deep vein thrombosis, pulmonary embolism,</td><td>Yes</td><td>No</td></tr><tr><td>American College of</td><td>accordingly. A program that collects</td><td>pneumothorax Surgical complications rates,</td><td>Yes</td><td>No</td></tr></table>
======================================
<table><tr><td>METHOD OF LEADERSHIP MEASUREMENT</td><td>DESCRIPTION</td></tr><tr><td>Multifactor Leadership Questionnaire (MLQ)</td><td>The MLQ is a questionnaire based on the differences between transformation and transactional approaches of leadership. It identifies leadership qualities through the rater’s beliefs about effective leadership.</td></tr><tr><td>NEO Five-Factor Personality Inventory (NEO)</td><td>NEO explores different facets of five different personality traits—neuroticism, extraversion, openness to experience, agreeableness, and conscientiousness—through a questionnaire.</td></tr><tr><td>Surgeon’s Leadership Inventory (SLI)</td><td>The SLI is a questionnaire based on literature on leadership in surgery and surgeon’s leadership behaviors observed in the operating room. It includes eight elements of surgeon’s leadership in the operating room, which are maintaining standards, managing resources, making decisions, directing, training, supporting others, communicating, and coping with pressure.</td></tr><tr><td>Patient feedback</td><td>Patient complaints are inversely related to leadership effectiveness and can thus be used as Opportunities to improve and as a measure of leadership.</td></tr><tr><td>Objective Structured Clinical Examination (OSCE)</td><td>The OSCE can be administered in a controlled environment with attending feedback on various aspects of leadership tackled in the practice cases. Videotaped sessions provide further opportunities for improvement as residents will be able to later observe their own behaviors and reflect on ways to improve their approach to the case presented.</td></tr><tr><td>Consumer Assessment of Healthcare Providers and Systems (CAHPS)</td><td>CAHPS surveys are based on aspects of healthcare that matter most to patients, such as physician communication. The results are made public and can be used to shed light on areas of leadership physicians can improve on to work towards a patient-centered approach to care.</td></tr></table>
======================================
<table><thead><th>ELEMENT</th><th>DESCRIPTION</th></thead><tr><td>Maintaining standards</td><td>Practicing safe and quality patient care by following established protocols and asking for help when needed</td></tr><tr><td>Making decisions</td><td>Making informed judgments and communicating decisions with relevant personnel</td></tr><tr><td>Managing resources</td><td>Appropriately assigning resources and tasks to team members</td></tr><tr><td>Directing</td><td>Clearly communicating expectations and instructions and demonstrating confidence in leadership ability</td></tr><tr><td>Training</td><td>Educating and training team members when the opportunity arises</td></tr><tr><td>Supporting others</td><td>Offering assistance where appropriate and encouraging open communication</td></tr><tr><td>Communicating |</td><td>Sharing information in a timely manner and encouraging input from others</td></tr><tr><td>Coping with pressure</td><td>Showing flexibility when required to meet goals</td></tr></table>
======================================
<table><thead><th>TERM</th><th>DEFINITION</th></thead><tr><td>Infection</td><td>Identifiable source of microbial insult</td></tr><tr><td>SIRS</td><td>Two or more of following criteria are met: Temperature 238°C (100.4°F) or &lt;36°C (96.8°F) Heart rate 290 beats per minute Respiratory rate 220 breaths per minute or Paco, &lt; 32 mmHg or mechanical ventilation Abnormal white blood cell count (212,000/uL or &lt;4000/uL or 210% immature band forms)</td></tr><tr><td>Sepsis</td><td>Identifiable source of infection + SIRS</td></tr><tr><td>Severe sepsis</td><td>Sepsis + organ dysfunction</td></tr><tr><td>Septic shock Paco, = partial</td><td>Sepsis + cardiovascular collapse (requiring vasopressor support) pressure of arterial carbon dioxide.</td></tr></table>
======================================
<table><tr><td>DAMP MOLECULE</td><td>PUTATIVE RECEPTOR(S)</td></tr><tr><td>HMGB-1</td><td>TLRs (2,4,9), RAGE</td></tr><tr><td>Heat shock proteins</td><td>TLR2, TLR4, CD40, CD14, Siglecs</td></tr><tr><td>$100 protein</td><td>TLR4, RAGE</td></tr><tr><td>Mitochondrial DNA</td><td>TLR9O</td></tr><tr><td>Hyaluran</td><td>TLR2, TLR4, CD44</td></tr><tr><td>Biglycan</td><td>TLR2 and TLR4</td></tr><tr><td>Formyl] peptides (mitochondrial)</td><td>Formyl] peptide receptor 1</td></tr><tr><td>IL-la</td><td>IL-1 receptor</td></tr></table>
======================================
<table><thead><th></th><th>CELL LOCATION</th><th>RECOGNIZED AS DAMP</th><th>IMMUNOMODULATORY FUNCTION</th></thead><tr><td>HSP90</td><td>| Cytoplasm, endoplasmic reticulum Can function both inside and outside the cell</td><td>| May act as DAMP chaperone | to activate innate immune response</td><td>Binds and optimizes RNA polymerase II action to regulate gene transcription Stabilizes glucocorticoid receptor in the cytoplasm Important for processing and membrane expression of TLR Chaperones include IKK Facilitates antigen presentation to dendritic cells</td></tr><tr><td>HSP70</td><td>| Can function both inside and outside the cell Endoplasmic reticulum homolog is BiP</td><td>| Exogenous HSP70 elicits cellular calcium flux, NF-KB activation, cytokine production</td><td>Can have anti-inflammatory actions when expression is increased Inhibits TLR-mediated cytokine production via NF-KB Reduces dendritic cell capacity for T-cell stimulation BiP sequesters proteins important to the unfolded protein response</td></tr><tr><td>HSP60</td><td>| Mitochondria</td><td>Exogenous HSP60 inhibits NF-kB activation</td><td>Plays a role in intracellular protein trafficking Modulates cytokine synthesis</td></tr></table>
======================================
<table><thead><th colspan="3">Cytokines and their sources</th></thead><thead><th>CYTOKINE</th><th>SOURCE</th><th>COMMENT</th></thead><tr><td>TNF</td><td>Macrophages/monocytes Kupffer cells Neutrophils NK cells Astrocytes Endothelial cells T lymphocytes Adrenal cortical cells Adipocytes Keratinocytes Osteoblasts. Mast cells Dendritic cells</td><td>Among earliest responders after injury; half-life &lt;20 min; activates TNF receptors 1 and 2; induces significant shock and catabolism</td></tr><tr><td>IL-1</td><td>Macrophages/monocytes B and T lymphocytes NK cells Endothelial cells Epithelial cells Keratinocytes Fibroblasts Osteoblasts. Dendritic cells Astrocytes Adrenal cortical cells Megakaryocytes Platelets Neutrophils Neuronal cells</td><td>Two forms (IL-1 o and IL-1 8); similar physiologic effects as TNF; induces fevers through prostaglandin activity in anterior hypothalamus; promotes B-endorphin release from pituitary; half-life &lt;6 min</td></tr><tr><td>IL-2</td><td>T lymphocytes</td><td>Promotes lymphocyte proliferation, immunoglobulin production, gut barrier integrity; half-life &lt;10 min; attenuated production after major blood loss leads to immunocompromise; regulates lymphocyte apoptosis</td></tr><tr><td>IL-3</td><td>T lymphocytes Macrophages Eosinophils Mast cells</td><td></td></tr><tr><td>IL-4</td><td>T lymphocytes Mast cells</td><td>Induces B-lymphocyte production of IgG4 and IgE, mediators of allergic and anthelmintic response; downregulates TNF, IL-1, IL-6, IL-8</td></tr></table>
======================================
<table><thead><th colspan="3">Cytokines and their sources (Continued)</th></thead><thead><th>CYTOKINE</th><th>SOURCE</th><th>COMMENT</th></thead><tr><td></td><td>Astrocytes Synovial cells Adipocytes Osteoblasts Megakaryocytes Chromaffin cells Keratinocytes</td><td></td></tr><tr><td>IL-8</td><td>Macrophages/monocytes T lymphocytes Basophils Mast cells Epithelial cells Platelets</td><td>Chemoattractant for neutrophils, basophils, eosinophils, lymphocytes</td></tr><tr><td>IL-10</td><td>T lymphocytes B lymphocytes Macrophages Basophils Mast cells Keratinocytes</td><td>Prominent anti-inflammatory cytokine; reduces mortality in animal sepsis and ARDS models</td></tr><tr><td>IL-12</td><td>Macrophages/monocytes Neutrophils Keratinocytes Dendritic cells B lymphocytes</td><td>Promotes Th1 differentiation; synergistic activity with IL-2</td></tr><tr><td>IL-13</td><td>T lymphocytes</td><td>Promotes B-lymphocyte function; structurally similar to IL-4; inhibits nitric oxide and endothelial activation</td></tr><tr><td>IL-15</td><td>Macrophages/monocytes Epithelial cells</td><td>Anti-inflammatory effect; promotes lymphocyte activation; promotes neutrophil phagocytosis in fungal infections</td></tr><tr><td>IL-18</td><td>Macrophages Kupffer cells Keratinocytes Adrenal cortical cells Osteoblasts</td><td>Similar to IL-12 in function; levels elevated in sepsis, particularly gram-positive infections; high levels found in cardiac deaths</td></tr><tr><td>IFN-y</td><td>T lymphocytes NK cells Macrophages</td><td>Mediates IL-12 and IL-18 function; half-life of days; found in wounds 5—7 d after injury; promotes ARDS</td></tr><tr><td>GM-CSF</td><td>T lymphocytes</td><td>Promotes wound healing and inflammation through activation of leukocytes</td></tr></table>
======================================
<table><thead><th>ORGAN/FUNCTION</th><th>STIMULATOR</th><th>INHIBITOR</th></thead><tr><td colspan="3">Pancreas</td></tr><tr><td>Glucose-stimulated insulin secretion</td><td>12-HPETE</td><td>PGE,</td></tr><tr><td>Glucagon secretion</td><td>PGD,, PGE,</td><td></td></tr><tr><td colspan="3">Liver</td></tr><tr><td>Glucagon-stimulated glucose production</td><td></td><td>PGE,</td></tr><tr><td colspan="3">Fat</td></tr><tr><td>Hormone-stimulated lipolysis</td><td></td><td>PGE,</td></tr><tr><td colspan="3">Bone</td></tr><tr><td>Resorption</td><td>PGE,, PGE-m, 6-K-PGE,, PGF, ,, PGI,</td><td></td></tr><tr><td colspan="3">Pituitary</td></tr><tr><td>Prolactin Luteinizing hormone Thyroid-stimulating</td><td>PGE, PGE,, PGE,, 5-HETE PGA,, PGB,,</td><td></td></tr><tr><td>hormone</td><td>PGE,, PGE,</td><td></td></tr><tr><td>Growth hormone</td><td>PGE,</td><td></td></tr><tr><td colspan="3">Parathyroid</td></tr><tr><td>Parathyroid hormone</td><td>PGE,</td><td>PGF,</td></tr><tr><td colspan="3">Lung</td></tr><tr><td>Bronchoconstriction</td><td>PGF,,, TXA,, LTC,, LTD,, LTE,</td><td>PGE,</td></tr><tr><td colspan="3">Kidney</td></tr><tr><td>Stimulation of renin secretion</td><td>PGE,, PGI,</td><td></td></tr><tr><td colspan="3">Gastrointestinal system</td></tr><tr><td colspan="3">Cytoprotective effect</td></tr><tr><td colspan="3">Immune response</td></tr><tr><td>Suppression of lymphocyte activity</td><td></td><td></td></tr><tr><td>Hematologic system</td><td></td><td></td></tr></table>
======================================
<table><thead><th>ADHESION MOLECULE</th><th>ACTION</th><th>ORIGIN</th><th>INDUCERS OF EXPRESSION</th><th>TARGET CELLS</th></thead><tr><td colspan="5">Selectins</td></tr><tr><td>L-selectin P-selectin E-selectin</td><td>Fast rolling Slow rolling Very slow rolling</td><td>Leukocytes Platelets and endothelium Endothelium</td><td>Native Thrombin, histamine Cytokines</td><td>Endothelium, platelets, eosinophils Neutrophils, monocytes Neutrophils, monocytes, lymphocytes</td></tr><tr><td colspan="5">Immunoglobulins</td></tr><tr><td>ICAM-1 ICAM-2 VCAM-1 PECAM-1</td><td>Firm adhesion/ transmigration Firm adhesion Firm adhesion/ transmigration Adhesion/</td><td>Endothelium, leukocytes, fibroblasts, epithelium Endothelium, platelets Endothelium Endothelium, platelets, leukocytes</td><td>Cytokines Native Cytokines Native</td><td>Leukocytes Leukocytes Monocytes, lymphocytes Endothelium, platelets, leukocytes</td></tr><tr><td></td><td>transmigration</td><td></td><td></td><td></td></tr><tr><td colspan="5">B,-(CD18) Integrins</td></tr><tr><td>CD18/Ila</td><td>Firm adhesion/ transmigration</td><td>Leukocytes</td><td>Leukocyte activation</td><td>— Endothelium</td></tr><tr><td>CD18/11b (Mac-1)</td><td>Firm adhesion/ transmigration</td><td>Neutrophils, monocytes, natural killer cells</td><td>Leukocyte activation</td><td>— Endothelium</td></tr><tr><td>CD18/11c</td><td>Adhesion</td><td>Neutrophils, monocytes, natural killer cells</td><td>Leukocyte activation</td><td>— Endothelium</td></tr><tr><td colspan="5">B,-(CD29) Integrins</td></tr><tr><td>VLA-4</td><td>Firm adhesion/ transmigration</td><td>Lymphocytes, monocytes</td><td>Leukocyte activation</td><td>| Monocytes, endothelium, epithelium</td></tr></table>
======================================
<table><thead><th colspan="2">A. COMPONENT</th><th rowspan="2">MASS (kg) 49</th><th colspan="2">ENERGY (kcal)</th><th>DAYS AVAILABLE</th></thead><tr><td colspan="2">Water and minerals</td><td></td><td colspan="3">0 0</td></tr><tr><td colspan="2">Protein</td><td>6.0</td><td colspan="2">24,000</td><td>13.0</td></tr><tr><td colspan="2">Glycogen</td><td>0.2</td><td colspan="2">800</td><td>0.4</td></tr><tr><td colspan="2">Fat</td><td>15.0</td><td colspan="2">140,000</td><td>78.0</td></tr><tr><td rowspan="2">Total B. SUBSTRATE</td><td></td><td>70.2</td><td>164,800</td><td></td><td>91.4</td></tr><tr><td></td><td>0, CONSUMED (L/g)</td><td>| CO, PRODUCED (L/g)</td><td>RESPIRATORY | QUOTIENT</td><td>kcal/g</td><td>RECOMMENDED DAILY REQUIREMENT</td></tr><tr><td>Glucose</td><td>0.75</td><td>0.75</td><td>1.0</td><td>4.0</td><td>7.2 g/kg per day</td></tr><tr><td>Dextrose</td><td>=</td><td>=</td><td>=</td><td>3.4</td><td>=</td></tr><tr><td>Lipid</td><td>2.0</td><td>1.4</td><td>0.7</td><td>9.0</td><td>1.0 g/kg per day</td></tr><tr><td>Protein</td><td>1.0</td><td>0.8</td><td>0.8</td><td>4.0</td><td>0.8 g/kg per day</td></tr></table>
======================================
<table><thead><th>CONDITION</th><th>kcal/kg PER DAY</th><th>ADJUSTMENT ABOVE BEE</th><th>GRAMS OF PROTEIN/ kg PER DAY</th><th>NONPROTEIN CALORIES: NITROGEN</th></thead><tr><td>Normal/moderate malnutrition</td><td>25-30</td><td>1</td><td>1.0</td><td>150:1</td></tr><tr><td>Mild stress</td><td>25-30</td><td>1.2</td><td>1.2</td><td>150:1</td></tr><tr><td>Moderate stress</td><td>30</td><td>1.4</td><td>1.5</td><td>120:1</td></tr><tr><td>Severe stress</td><td>30-35</td><td>1.6</td><td>2.0</td><td>90-120:1</td></tr><tr><td>Burns</td><td>35-40</td><td>2.0</td><td>2.5</td><td>90-100:1</td></tr></table>
======================================
<table><thead><th>Options for enteral</th><th>feeding access</th></thead><thead><th>ACCESS OPTION</th><th>COMMENTS</th></thead><tr><td>Nasogastric tube _</td><td>Short-term use only; aspiration risks; nasopharyngeal trauma; frequent dislodgment</td></tr><tr><td>Nasoduodenal/ nasojejunal tube</td><td>Short-term use; lower aspiration risks in jejunum; placement challenges (radiographic assistance often necessary)</td></tr><tr><td>Percutaneous endoscopic gastrostomy (PEG)</td><td>Endoscopy skills required; may be used for gastric decompression or bolus feeds; aspiration risks; can last 12-24 mo; slightly higher complication rates with placement and site leaks</td></tr><tr><td>Surgical gastrostomy</td><td>Requires general anesthesia and small laparotomy; procedure may allow placement of extended duodenal/ jejunal feeding ports; laparoscopic placement possible</td></tr><tr><td>Fluoroscopic gastrostomy</td><td>Blind placement using needle and T-prongs to anchor to stomach; can thread smaller catheter through gastrostomy into duodenum/jejunum under fluoroscopy</td></tr><tr><td>PEG-jejunal tube |</td><td>Jejunal placement with regular endoscope is operator dependent; jejunal tube often dislodges retrograde; two-stage procedure with PEG placement, followed by fluoroscopic conversion with jejunal feeding tube through PEG</td></tr><tr><td>Direct percutaneous endoscopic jejunostomy (DPEJ)</td><td>Direct endoscopic tube placement with enteroscope; placement challenges; greater injury risks</td></tr><tr><td>Surgical jejunostomy</td><td>Commonly carried out during laparotomy; general anesthesia; laparoscopic placement usually requires assistant to thread catheter; laparoscopy offers direct visualization of catheter placement</td></tr><tr><td>Fluoroscopic jejunostomy</td><td>Difficult approach with injury risks; not commonly done</td></tr></table>
======================================
<table><tr><td>Introduction</td><td>83</td></tr><tr><td>Body Fluids</td><td>83</td></tr><tr><td colspan="2">Total Body Water / 83</td></tr><tr><td>Fluid Compartments / 83</td><td></td></tr><tr><td>Composition of Fluid Compartments /</td><td>83</td></tr><tr><td>Osmotic Pressure / 84</td><td></td></tr><tr><td colspan="2">Electrolytes / Classification of Body Fluid Changes / 85</td></tr><tr><td>Disturbances in Fluid Balance / 85</td><td></td></tr><tr><td>Volume Control / 86</td><td></td></tr></table>
======================================
<table><tr><td>Extracellular volume</td><td>14,000 mL</td><td>10,000 mL</td></tr><tr><td>Interstitial</td><td>10,500 mL</td><td>7500 mL</td></tr><tr><td rowspan="2">Intracellular volume</td><td>28,000 mL</td><td>20,000 mL</td></tr><tr><td></td><td>42,000 mL</td><td>30,000 mL</td></tr></table>
======================================
<table><thead><th>Water exchange (60- to</th><th>80-kg man)</th><th></th><th></th></thead><thead><th>ROUTES</th><th>AVERAGE DAILY VOLUME (mL)</th><th>MINIMAL (mL)</th><th>MAXIMAL (mL)</th></thead><tr><td colspan="4">H,O gain:</td></tr><tr><td colspan="4">Sensible:</td></tr><tr><td>Oral fluids</td><td>800-1500</td><td>0</td><td>1500/h</td></tr><tr><td>Solid foods</td><td>500-700</td><td>0</td><td>1500</td></tr><tr><td colspan="4">Insensible:</td></tr><tr><td>Water of oxidation</td><td>250</td><td>125</td><td>800</td></tr><tr><td>Water of solution</td><td>0</td><td>0</td><td>500</td></tr><tr><td colspan="4">H,0 loss:</td></tr><tr><td colspan="4">Sensible:</td></tr><tr><td>Urine</td><td>800-1500</td><td>300</td><td>1400/h</td></tr><tr><td>Intestinal</td><td>0-250</td><td>0</td><td>2500/h</td></tr><tr><td>Sweat</td><td>0</td><td>0</td><td>4000/h</td></tr><tr><td colspan="4">Insensible:</td></tr><tr><td>Lungs and skin</td><td>600</td><td>600</td><td>1500</td></tr></table>
======================================
<table><thead><th>SYSTEM</th><th>VOLUME DEFICIT</th><th>| VOLUME EXCESS</th></thead><tr><td rowspan="2">Generalized</td><td>Weight loss</td><td>Weight gain</td></tr><tr><td></td><td>Decreased skin turgor</td><td>Peripheral edema</td></tr><tr><td rowspan="4">Cardiac</td><td>Tachycardia</td><td>Increased cardiac output</td></tr><tr><td></td><td>Orthostasis/ hypotension</td><td>Increased central venous pressure</td></tr><tr><td></td><td>Collapsed neck veins</td><td>Distended neck veins</td></tr><tr><td></td><td></td><td>Murmur</td></tr><tr><td rowspan="2">Renal</td><td></td><td>Oliguria</td><td>=</td></tr><tr><td>Azotemia</td><td></td></tr><tr><td>GI</td><td>Tleus</td><td>Bowel edema</td></tr><tr><td>Pulmonary</td><td></td><td>Pulmonary edema</td></tr></table>
======================================
<table><thead><th colspan="6">Composition of GI secretions</th></thead><thead><th>TYPE OF SECRETION</th><th>| VOLUME (mL/24 h)</th><th>| (mEq/L)</th><th>K (mEq/L)</th><th>CL (mEq/L)</th><th>HCO,” (mEq/L)</th></thead><tr><td>Stomach</td><td>1000-2000</td><td>60-90</td><td>10-30</td><td>100-130</td><td>0</td></tr><tr><td>Small intestine</td><td>2000-3000</td><td>120-140</td><td>5-10</td><td>90-120</td><td>30-40</td></tr><tr><td>Colon</td><td>—_—</td><td>60</td><td>30</td><td>40</td><td>0</td></tr><tr><td>Pancreas</td><td>600-800</td><td>135-145</td><td>5-10</td><td>70-90</td><td>95-115</td></tr><tr><td>Bile</td><td>300-800</td><td>135-145</td><td>5-10</td><td>90-110</td><td>30-40</td></tr></table>
======================================
<table><tr><td></td><td>Volume status</td><td></td></tr><tr><td rowspan="3">High |</td><td>y</td><td></td></tr><tr><td></td><td>Normal</td><td>Low</td></tr><tr><td></td><td>!</td><td></td></tr><tr><td>Increased intake</td><td>Hyperglycemia</td><td>Decreased sodium intake</td></tr><tr><td>Postoperative ADH secretion</td><td>TPlasma lipids/proteins</td><td>Gl losses</td></tr><tr><td rowspan="5">Drugs</td><td>SIADH</td><td>Renal losses</td></tr><tr><td></td><td>Water intoxication</td><td>Diuretics</td></tr><tr><td></td><td>Diuretics</td><td>Primary renal disease</td></tr><tr><td></td><td>Volume status</td><td></td></tr><tr><td></td><td>Y</td><td></td></tr><tr><td>High</td><td>Normal</td><td>Low</td></tr><tr><td>|</td><td>|</td><td>|</td></tr><tr><td>latrogenic sodium administration</td><td>Nonrenal water loss</td><td>Nonrenal water loss</td></tr><tr><td>Mineralocorticoid excess</td><td>Skin</td><td>Skin</td></tr><tr><td>Aldosteronism</td><td>Gl</td><td>Gl</td></tr><tr><td>Cushing’s disease</td><td>Renal water loss</td><td>Renal water loss</td></tr><tr><td rowspan="3">Congenital adrenal hyperplasia</td><td>Renal disease</td><td>Renal (tubular) disease</td></tr><tr><td></td><td>Diuretics</td><td>Osmotic diuretics</td></tr><tr><td></td><td>Diabetes insipidus</td><td>Diabetes insipidus</td></tr></table>
======================================
<table><thead><th>BODY SYSTEM</th><th>HYPONATREMIA</th></thead><tr><td>Central nervous system</td><td>Headache, confusion, hyperactive or hypoactive deep tendon reflexes, seizures, coma, increased intracranial pressure</td></tr><tr><td>Musculoskeletal</td><td>Weakness, fatigue, muscle cramps/ twitching</td></tr><tr><td>GI</td><td>Anorexia, nausea, vomiting, watery diarrhea</td></tr><tr><td>Cardiovascular</td><td>Hypertension and bradycardia if intracranial pressure increases significantly</td></tr><tr><td>Tissue</td><td>Lacrimation, salivation</td></tr><tr><td>Renal</td><td>Oliguria</td></tr><tr><td>BODY SYSTEM</td><td>HYPERNATREMIA</td></tr><tr><td>Central nervous system</td><td>Restlessness, lethargy, ataxia, irritability, tonic spasms, delirium, seizures, coma</td></tr><tr><td>Musculoskeletal</td><td>Weakness</td></tr><tr><td>Cardiovascular</td><td>Tachycardia, hypotension, syncope</td></tr><tr><td>Tissue</td><td>Dry sticky mucous membranes, red swollen tongue, decreased saliva and tears</td></tr><tr><td>Renal</td><td>Oliguria</td></tr></table>
======================================
<table><thead><th>SYSTEM</th><th>POTASSIUM</th><th>MAGNESIUM</th><th>CALCIUM</th></thead><tr><td>GI</td><td>Nausea/vomiting, colic, diarrhea</td><td>Nausea/vomiting</td><td>Anorexia, nausea/vomiting, abdominal pain</td></tr><tr><td>Neuromuscular</td><td>Weakness, paralysis, respiratory failure</td><td>Weakness, lethargy, decreased reflexes</td><td>Weakness, confusion, coma, bone pain</td></tr><tr><td>Cardiovascular</td><td>Arrhythmia, arrest</td><td>Hypotension, arrest</td><td>Hypertension, arrhythmia, polyuria</td></tr><tr><td>Renal</td><td></td><td></td><td>Polydipsia</td></tr></table>
======================================
<table><thead><th>SYSTEM</th><th>POTASSIUM</th><th>MAGNESIUM</th><th>CALCIUM</th></thead><tr><td>GI</td><td>Tleus, constipation</td><td>—</td><td>—</td></tr><tr><td>Neuromuscular</td><td>Decreased reflexes, fatigue, weakness, paralysis</td><td>Hyperactive reflexes, muscle tremors, tetany, seizures</td><td>Hyperactive reflexes, paresthesias, carpopedal spasm, seizures</td></tr><tr><td>Cardiovascular</td><td>Arrest</td><td>Arrhythmia</td><td>Heart failure</td></tr></table>
======================================
<table><tr><td>Predicted changes in acid-base</td><td>disorders</td></tr><tr><td>DISORDER</td><td>PREDICTED CHANGE</td></tr><tr><td>Metabolic Metabolic acidosis Metabolic alkalosis Respiratory</td><td>Pco, = 1.5 x HCO; +8 Pco, = 0.7 x HCO, +21</td></tr><tr><td></td><td></td></tr></table>
======================================
<table><thead><th rowspan="2">TYPE OF ACID-BASE DISORDER</th><th></th><th colspan="3">ACUTE UNCOMPENSATED</th><th colspan="2">CHRONIC (PARTIALLY COMPENSATED)</th></thead><thead><th></th><th>pH</th><th>Pco, (RESPIRATORY COMPONENT)</th><th>PLASMA HCO,~* (METABOLIC COMPONENT)</th><th>pH</th><th>Pco, (RESPIRATORY COMPONENT)</th><th>PLASMA HCO, (METABOLIC COMPONENT)</th></thead><tr><td>Respiratory acidosis</td><td>W</td><td>tT</td><td>N</td><td>L</td><td>TT</td><td>tT</td></tr><tr><td>Respiratory alkalosis</td><td>TT</td><td>dt</td><td>N</td><td>tT</td><td>dW</td><td>L</td></tr><tr><td>Metabolic acidosis</td><td>W</td><td>N</td><td>dt</td><td>L</td><td>L</td><td>4</td></tr><tr><td>Metabolic alkalosis</td><td>tT</td><td>N</td><td>tT</td><td>tT</td><td>tT</td><td>tT</td></tr></table>
======================================
<table><thead><th>SOLUTION</th><th>Na</th><th>cl</th><th>K</th><th>HCO,~</th><th>Ca</th><th>Mg</th><th>mOsm</th></thead><tr><td>Extracellular fluid</td><td>142</td><td>103</td><td>4</td><td>27</td><td>5</td><td>3</td><td>280-310</td></tr><tr><td>Lactated Ringer’s</td><td>130</td><td>109</td><td>4</td><td>28</td><td>3</td><td></td><td>273</td></tr><tr><td>0.9% Sodium chloride</td><td>154</td><td>154</td><td></td><td></td><td></td><td></td><td>308</td></tr><tr><td>D, 0.45% Sodium chloride</td><td>77</td><td>71</td><td></td><td></td><td></td><td></td><td>407</td></tr><tr><td>D5W</td><td></td><td></td><td></td><td></td><td></td><td></td><td>253</td></tr><tr><td>3% Sodium chloride</td><td>513</td><td>513</td><td></td><td></td><td></td><td></td><td>1026</td></tr><tr><td>Plasma-Lyte</td><td>140</td><td>98</td><td>5</td><td>27</td><td></td><td>3</td><td>295</td></tr></table>
======================================
<table><thead><th colspan="4">Alternative resuscitative fluids</th></thead><thead><th>SOLUTION</th><th>MOLECULAR WEIGHT</th><th>| OSMOLALITY (mOsm/L)</th><th>| SODIUM (mEq/L)</th></thead><tr><td>Hypertonic saline (7.5%)</td><td>_</td><td>2565</td><td>283</td></tr><tr><td>Albumin 5%</td><td>70,000</td><td>300</td><td>30-160</td></tr><tr><td>Albumin 25%</td><td>70,000</td><td>1500</td><td>30-160</td></tr><tr><td>Dextran 40</td><td>40,000</td><td>308</td><td>54</td></tr><tr><td>Dextran 70</td><td>70,000</td><td>308</td><td>54</td></tr><tr><td>Hetastarch</td><td>450,000</td><td>310</td><td>54</td></tr><tr><td>Hextend</td><td>670,000</td><td>307</td><td>43</td></tr><tr><td>Gelofusine</td><td>30,000</td><td></td><td>54</td></tr></table>
======================================
<table><tr><td>For the first 0-10 kg</td><td>Give 100 mL/kg per day</td></tr><tr><td>For weight &gt;20 kg</td><td>per day Give an additional 20 mL/kg per day</td></tr></table>
======================================
<table><thead><th>Table 4-3</th><th></th></thead><tr><td colspan="2">Coagulation factors synthesized by the liver</td></tr><tr><td colspan="2">Vitamin K-dependent factors: II (prothrombin factor),</td></tr><tr><td colspan="2">Fibrinogen Factor V</td></tr><tr><td colspan="2">Plasminogen</td></tr><tr><td>Protein C and protein S</td><td></td></tr></table>
======================================
<table><tr><td>J warfarin effect</td><td>Barbiturates, oral contraceptives,</td></tr><tr><td>1 warfarin effect</td><td>Phenylbutazone, clofibrate,</td></tr></table>
======================================
<table><thead><th></th><th>NORMAL LEVEL</th><th>LIFE SPAN IN VIVO (HALF-LIFE)</th><th>FATE DURING | COAGULATION</th><th>LEVEL REQUIRED FOR SAFE HEMOSTASIS</th><th>IDEAL AGENT ACD BANK BLOOD (4°C [39.2°F])</th><th>IDEAL AGENT FOR REPLACI</th></thead><tr><td>)</td><td>200-400 mg/100 mL |</td><td>72h</td><td>Consumed</td><td>60-100 mg/100 mL</td><td>Very stable</td><td>Bank blood; concentrated</td></tr><tr><td>bin)</td><td>20 mg/100 mL (100% of normal level)</td><td>| 72h</td><td>Consumed</td><td>15%-20%</td><td>Stable</td><td>Bank blood; concentrated</td></tr><tr><td>erin, x globulin, tor)</td><td>00% of normal level</td><td>| 36h</td><td>Consumed</td><td>5%-20%</td><td>Labile (40% of normal level at | wk)</td><td>| Fresh frozen plasma; bloo:</td></tr><tr><td>vertin, thrombin n accelerator, tor)</td><td>00% of normal level</td><td>| 5h</td><td>Survives</td><td>5%-30%</td><td>Stable</td><td>Bank blood; concentrated</td></tr><tr><td>mophilic itihemophilic</td><td>00% of normal level (50%-150% of normal level)</td><td>| 6-12 h</td><td>Consumed</td><td>30%</td><td>Labile (20%—40% of normal level at 1 wk)</td><td>Fresh frozen plasma; conc antihemophilic factor; cryoprecipitate</td></tr><tr><td>as factor, omboplastin nt)</td><td>00% of normal level</td><td>| 24h</td><td>Survives</td><td>20%-30%</td><td>Stable</td><td>Fresh-frozen plasma; bank concentrated preparatio</td></tr><tr><td>‘ower factor)</td><td>100% of normal level</td><td>| 40h</td><td>Survives</td><td>15%-20%</td><td>Stable</td><td>Bank blood; concentrated</td></tr><tr><td>lastin t)</td><td>100% of normal level</td><td>| Probably 40-80 h |</td><td>Survives</td><td>10%</td><td>Probably stable</td><td>Bank blood</td></tr><tr><td>an factor)</td><td>100% of normal level</td><td>Unknown</td><td>Survives</td><td>Deficit produces no bleeding tendency</td><td>Stable</td><td>Replacement not required</td></tr><tr><td rowspan="2">se, fibrin- g factor)</td><td>100% of normal level</td><td>| 4-7 d</td><td>Survives</td><td>Probably &lt;1%</td><td>Stable</td><td>Bank blood</td></tr><tr><td></td><td>150,000-400,000/uL =</td><td>8-11 d</td><td>Consumed.</td><td>60,000—100,000/uL</td><td>Very labile (40% of normal |</td><td>Fresh blood or plasma; fres</td></tr></table>
======================================
<table><thead><th>transfusion</th><th></th></thead><tr><td>Fresh frozen plasma (FFP)</td><td>As soon as the need for massive transfusion is recognized. For every 6 red blood cells (RBCs), give 6 FFP (1:1 ratio).</td></tr><tr><td>Platelets</td><td>For every 6 RBCs and plasma, give one 6-pack of platelets. 6 random-donor platelet packs = | apheresis platelet unit. Platelets are in every cooler. Keep platelet counts &gt;100,000.</td></tr><tr><td>Cryoprecipitate</td><td>After first 6 RBCs, check fibrinogen level. If &lt;200 mg/dL, give 20 units</td></tr></table>
======================================
<table><tr><td>AUTHOR</td><td>VARIABLES</td><td>ROC AUC VALUE</td></tr><tr><td>McLaughlin et al!?*</td><td>| SBP, HR, pH, Het |</td><td>0.839</td></tr><tr><td>Yiicel et al!”</td><td>SBP, HR, BD, Hgb, male, + FAST, long bone/pelvic fracture</td><td>0.892</td></tr><tr><td>Moore et al!*?</td><td>SBP, pH, ISS &gt;25 |</td><td>0.804</td></tr><tr><td>Schreiber et al'*!</td><td>Hgb &lt;11, INR &gt;1.5, penetrating injury</td><td>0.80</td></tr><tr><td>Cotton et al!”</td><td>HR, SBP, FAST, penetrating injury</td><td>0.83-0.90</td></tr></table>
======================================
<table><thead><th>ABBREVIATION</th><th>| COMPLICATION</th><th>SIGNS AND SYMPTOMS — |</th><th>FREQUENCY</th><th>MECHANISM</th><th>PREVENTION</th></thead><tr><td rowspan="3">NHTR</td><td>Febrile, nonhemolytic transfusion reaction</td><td>Fever</td><td>0.5%-1.5% of transfusions</td><td>Preformed cytokines | Host Ab to donor lymphocytes</td><td>Use leukocyte- reduced blood Store platelets &lt;5 d</td></tr><tr><td></td><td>Bacterial contamination</td><td>High fever, chills | Hemodynamic changes | DIC Emesis, diarrhea Hemoglobinuria</td><td>&lt;0.01% of blood &lt;0.05% of platelets</td><td>Infusion of contaminated blood</td><td></td></tr><tr><td></td><td>Allergic reactions</td><td>| Rash, hives Itching</td><td>0.1%-0.3% of units</td><td>| Soluble transfusion constituents</td><td>Provide antihistamine prophylaxis</td></tr><tr><td>TACO</td><td>Transfusion- associated circulatory overload</td><td>Pulmonary edema</td><td>1:200-1:10,00 of transfused patients</td><td>Large volume of blood transfused into an older patient with CHF</td><td>Increase transfusion time | Administer diuretics Minimize associated fluids</td></tr><tr><td rowspan="3">TRALI</td><td>Transfusion- related acute _ lung injury</td><td>Acute (&lt;6 h) hypoxemia Bilateral infiltrates + Tachycardia, hypotension</td><td></td><td>Anti-HLA or anti- HNA Abin transfused blood attacks circulatory and pulmonary leukocytes</td><td>Limit female donors</td></tr><tr><td></td><td>Hemolytic reaction, acute</td><td>Fever | Hypotension DIC Hemoglobinuria Hemoglobinemia Renal insufficiency</td><td>1:33,000— 1:1,500,000 units</td><td>Transfusion of ABO- | incompatible blood Preformed IgM Ab to ABO Ag</td><td>Transfuse appropriately matched blood</td></tr><tr><td></td><td>Hemolytic reaction, delayed (2-10 d)</td><td>Anemia Indirect hyperbilirubinemia Decreased haptoglobin level Positive result on direct Coombs’ test</td><td></td><td>IgG mediated</td><td>Identify patient’s Ag to prevent recurrence</td></tr></table>
======================================
<table><tr><td>Classification of shock</td></tr><tr><td>Hypovolemic Cardiogenic</td></tr><tr><td>Septic (vasogenic) Neurogenic</td></tr><tr><td>Obstructive</td></tr></table>
======================================
<table><thead><th>TYPE OF SHOCK</th><th>CARDIAC INDEX</th><th>SVR</th><th>VENOUS CAPACITANCE</th><th>CvP/PCWP</th><th>Svo,</th><th>CELLULAR/METABOLIC EFFECTS</th></thead><tr><td>Hypovolemic</td><td>L</td><td>tT</td><td>L</td><td>L</td><td>L</td><td>Effect</td></tr><tr><td>Septic</td><td>TT</td><td>L</td><td>tT</td><td>TW</td><td>TL</td><td>Cause</td></tr><tr><td>Cardiogenic</td><td>Iw</td><td>TT</td><td>&gt;</td><td>T</td><td>L</td><td>Effect</td></tr><tr><td>Neurogenic</td><td>T</td><td>L</td><td>&gt;</td><td>L</td><td>J</td><td>Effect</td></tr></table>
======================================
<table><thead><th>Inflammatory mediators of</th><th>shock</th></thead><tr><td colspan="2">PROINFLAMMATORY ANTI-INFLAMMATORY</td></tr><tr><td>Interleukin-1o/B Interleukin-2</td><td>Interleukin-4 Interleukin-10</td></tr><tr><td>Interleukin-6 Interleukin-8</td><td>Interleukin-13 Prostaglandin E,</td></tr></table>
======================================
<table><thead><th rowspan="2">PARAMETER</th><th colspan="4">CLASS</th></thead><thead><th></th><th>I</th><th>II</th><th>II</th><th>Iv</th></thead><tr><td>Blood loss (mL)</td><td>&lt;750</td><td>750-1500</td><td>1500-2000</td><td>&gt;2000</td></tr><tr><td>Blood loss (%)</td><td>&lt;I5</td><td>15-30</td><td>30-40</td><td>&gt;40</td></tr><tr><td>Heart rate (bpm)</td><td>&lt;100</td><td>&gt;100</td><td>&gt;120</td><td>&gt;140</td></tr><tr><td>Blood pressure</td><td>Normal</td><td>Orthostatic</td><td>Hypotension</td><td>Severe hypotension</td></tr><tr><td>CNS symptoms</td><td>Normal</td><td>Anxious</td><td>Confused</td><td>Obtunded</td></tr></table>
======================================
<table><tr><td>Causes of obstructive shock</td></tr><tr><td>Pericardial tamponade</td></tr><tr><td>Pulmonary embolus</td></tr><tr><td>Tension pneumothorax</td></tr><tr><td>Gravid uterus on IVC Neoplasm</td></tr><tr><td>Increased intrathoracic pressure</td></tr></table>
======================================
<table><thead><th rowspan="2">SYSTEM</th><th colspan="5">SCORE</th></thead><thead><th></th><th>0</th><th>1</th><th>2</th><th>3</th><th>4</th></thead><tr><td>Respiratory PaO,/FiO,, mmHg (kPa)</td><td>| 2400 (53.3)</td><td>| &lt;400 (53.3)</td><td>&lt;300 (40)</td><td>&lt;200 (26.7) with respiratory support</td><td>&lt;100 (13.3) with respiratory support</td></tr><tr><td>Coagulation Platelets, x 10°/uL</td><td>| 2150</td><td>&lt;150</td><td>&lt;100</td><td>&lt;50</td><td>&lt;20</td></tr><tr><td>Hepatic Bilirubin, mg/dL</td><td>&lt;1.2 (20)</td><td>1.2-1.9 (20-32)</td><td rowspan="2">2-5.9 (33-101)</td><td rowspan="2">6-11.9 (102-204)</td><td rowspan="2">&gt;12 (204)</td></tr><tr><td>(umol/L)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Cardiovascular</td><td>MAP 270 mmHg</td><td>MAP &lt;70 mmHg</td><td>Dopamine &lt;5 or dobutamine</td><td>Dopamine 5.1-15 or epinephrine &lt;0.1 or norepinephrine &lt;0.1</td><td>| Dopamine &gt;15 or epinephrine &gt;0.1 or norepinephrine &gt;0.1</td></tr><tr><td>CNS</td><td></td><td rowspan="2">13-14</td><td></td><td rowspan="2">10-12</td><td></td><td></td><td rowspan="2">&lt;6</td><td></td></tr><tr><td>GCS score</td><td>15</td><td>6-9</td></tr><tr><td>Renal Creatinine, mg/dL (umol/L)</td><td>| &lt;1.2(110)</td><td>‘| 1.2-1.9(110-170)</td><td>| 2-3.4 (171-299)</td><td>3.54.9 (300-440)</td><td>&gt;5 (440)</td></tr><tr><td>Urine output, mL/24 hours</td><td></td><td></td><td></td><td>&lt;500</td><td>&lt;200</td></tr></table>
======================================
<table><thead><th>ANTIFUNGAL</th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td>Amphotericin B</td><td>Broad- spectrum, inexpensive</td><td>Renal toxicity, premeds, IV only</td></tr><tr><td>Liposomal Amphotericin B</td><td>Broad-spectrum |</td><td>Expensive, IV only, renal toxicity</td></tr><tr><td colspan="3">Azoles</td></tr><tr><td>Fluconazole</td><td>IV and PO availability</td><td>Narrow-spectrum, drug interactions</td></tr><tr><td>Itraconazole</td><td>TV and PO availability</td><td>Narrow spectrum, no CSF penetration Drug interactions, decreased cardiac contractility</td></tr><tr><td>Posaconazole</td><td>Broad- spectrum, zygomycete activity</td><td>PO only</td></tr><tr><td>Voriconazole Echinocandins</td><td>IV and PO availability, broad- spectrum</td><td>IV diluent accumulates in renal failure, Visual disturbances</td></tr><tr><td>Anidulofungin, Caspofungin, micafungin</td><td>Broad-spectrum |</td><td>IV only, poor CNS penetration</td></tr></table>
======================================
<table><thead><th>CLASS, ME</th><th>TRADE NAME</th><th>MECHANISM OF ACTION</th><th>S Pyogenes</th><th>|MSSA</th><th>|MRSA</th><th>|S epidermidis</th><th>| Enterococcus</th><th>|VRE</th><th>|E coli</th><th>|P aeruginosa</th></thead><tr><td></td><td></td><td>Cell wall synthesis inhibitors (bind penicillin-binding protein)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="3"></td><td></td><td></td><td>1</td><td>0</td><td>0</td><td>0</td><td>+/—</td><td>0</td><td></td><td></td></tr><tr><td></td><td>Nallpen, Unipen</td><td></td><td>1</td><td>1</td><td>0</td><td>+/-</td><td>0</td><td>0</td><td></td><td></td></tr><tr><td></td><td>Pipracil</td><td></td><td>1</td><td>0</td><td>0</td><td>0</td><td>+/—</td><td>0</td><td></td><td></td></tr><tr><td>-lactamase combinations</td><td></td><td>Cell wall synthesis inhibitors/B- lactamase inhibitors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>sulbactam</td><td>Unasyn</td><td></td><td>1</td><td></td><td>0</td><td>+/-</td><td>1</td><td>+/-</td><td>|1</td><td>0</td></tr><tr><td>lavulanate</td><td>Timentin</td><td></td><td>1</td><td></td><td>0</td><td>+/—</td><td>+/—</td><td>0</td><td>1</td><td>1</td></tr><tr><td>Vtazobactam</td><td>Zosyn</td><td></td><td>1</td><td></td><td>0</td><td>1</td><td>+/—</td><td>0</td><td>1</td><td>1</td></tr><tr><td>ation porins</td><td></td><td>Cell wall synthesis inhibitors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>ephalexin</td><td>Ancef, Keflex</td><td></td><td>1</td><td></td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td rowspan="4">eration porins</td><td></td><td>Cell wall synthesis</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Mefoxin</td><td>inhibitors</td><td>1</td><td></td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td></td><td>Cefotan</td><td></td><td>1</td><td>1</td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td></td><td>Ceftin</td><td></td><td>1</td><td>1</td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td>fourth- mn</td><td></td><td>Cell wall synthesis inhibitors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>porins</td><td>Rocephin</td><td></td><td>1</td><td>1</td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td rowspan="3"></td><td>Fortaz</td><td></td><td>1</td><td>+/—</td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td></td><td>Maxipime</td><td></td><td>1</td><td>1</td><td>0</td><td>+/-</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td></td><td>Cefotaxime</td><td></td><td>1</td><td>1</td><td>0</td><td>+/-</td><td>0</td><td>0</td><td>1</td><td>+/—</td></tr></table>
======================================
<table><thead><th rowspan="2">CLASS, ME</th><th rowspan="2">TRADE NAME</th><th rowspan="2">MECHANISM OF ACTION</th><th colspan="8">ORGANISM</th></thead><thead><th></th><th></th><th></th><th>S Pyogenes</th><th>|MSSA</th><th>|MRSA_</th><th>|S epidermidis</th><th>| Enterococcus</th><th>|VRE</th><th>|E coli</th><th>|P aeruginosa</th></thead><tr><td>ns</td><td></td><td>Cell wall synthesis inhibitors</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="4">lastatin</td><td>Primaxin</td><td></td><td>1</td><td>1</td><td>0</td><td>1</td><td>+/—</td><td>0</td><td>1</td><td>1</td></tr><tr><td></td><td>Merrem</td><td></td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td></td><td>Invanz</td><td></td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>+/-</td></tr><tr><td></td><td>Azactam</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td rowspan="2">sides</td><td></td><td></td><td>Alteration of cell membrane, binding and inhibition of 30S ribosomal subunit</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>0</td><td>1</td><td>0</td><td>+/-</td><td>1</td><td>0</td><td>1</td><td>1</td></tr><tr><td>amikacin</td><td></td><td></td><td>0</td><td>1</td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td>plones</td><td></td><td>Inhibit topo- isomerase II and IV (DNA synthesis inhibition)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>n</td><td>Cipro</td><td></td><td>+/-</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>1</td></tr><tr><td>1</td><td>Levaquin</td><td></td><td>1</td><td>1</td><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td><td>+/-</td></tr><tr><td>les</td><td></td><td>Cell wall synthesis inhibition (peptidoglycan synthesis inhibition)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>Vancocin</td><td></td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td></tr><tr><td>-dalfopristin</td><td>| Synercid</td><td>Inhibits 2 sites on 50S ribosome (protein synthesis inhibition)</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td></tr></table>
======================================
<table><thead><th></th><th>Zyvox</th><th>Inhibits 50S ribosomal activity</th><th>1</th><th></th><th>1</th><th>1</th><th>1</th><th>1</th><th>0</th><th>0</th></thead><tr><td rowspan="2"></td><td>Cubicin</td><td>Binds bacterial membrane, results in depolarization, lysis</td><td>1</td><td></td><td>1</td><td>1</td><td>1</td><td>1</td><td>0</td><td>0</td></tr><tr><td></td><td></td><td>Inhibits DNA- dependent RNA polymerase</td><td>1</td><td></td><td>1</td><td>1</td><td>+/—</td><td>0</td><td>0</td><td>0</td></tr><tr><td>in</td><td>Cleocin</td><td>Inhibits 50S ribosomal activity</td><td>1</td><td></td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>ole</td><td>Flagyl</td><td>Production of toxic intermediates (free radicals)</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td></td><td></td><td>Inhibit SOS ribosomal activity (protein synthesis inhibition)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>in</td><td></td><td></td><td>1</td><td>+/—</td><td>0</td><td>+/—</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>in</td><td>Zithromax</td><td></td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>cin</td><td>Biaxin</td><td></td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>iim- oxazole</td><td>Bactrim, Septra</td><td>Inhibits sequential steps of folate metabolism</td><td>+/—</td><td>1</td><td>0</td><td>I</td><td>0</td><td>0</td><td>1</td><td>0</td></tr><tr><td>es</td><td></td><td>Bind 30S ribosomal unit (protein synthesis inhibition)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>le</td><td>Minocin</td><td></td><td>1</td><td>1</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td>le</td><td>Vibromycin</td><td></td><td>1</td><td>+/—</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1</td><td>0</td></tr></table>
======================================
<table><thead><th>SITE</th><th>ANTIBIOTIC</th><th>ALTERNATIVE (E.G., PENICILLIN ALLERGIC)</th></thead><tr><td>Cardiovascular surgery</td><td>Cefazolin, cefuroxime</td><td>Vancomycin, clindamycin</td></tr><tr><td>Gastroduodenal area Small intestine, nonobstructed</td><td>Cefazolin</td><td>Clindamycin or vancomycin + aminoglycoside or aztreonem or fluoroquinolone</td></tr><tr><td>Biliary tract: open procedure, aparoscopic high risk</td><td>Cefazolin, cefoxitin, cefotetan, ceftriaxone, ampicillin-sulbactam</td><td>Clindamycin or vancomycin + aminoglycoside or aztreonem or fluoroquinolone Metronidazole + aminoglycoside or fluoroquinolone</td></tr><tr><td>Biliary tract: laparoscopic low risk</td><td></td><td></td></tr><tr><td>Appendectomy, uncomplicated</td><td>Cefoxitin, cefotetan, cefazolin + metronidazole</td><td>Clindamycin + aminoglycoside or aztreonem or fluoroquinolone Metronidazole + aminoglycoside or fluoroquinolone</td></tr><tr><td>Colorectal surgery, obstructed small intestine</td><td>Cefazolin or ceftriaxone plus metronidazole, ertapenem, cefoxitin, cefotetan, ampicillin-sulbactam</td><td>Clindamycin + aminoglycoside or aztreonem or fluoroquinolone, metronidazole + aminoglycoside or fluoroquinolone</td></tr><tr><td>Head and neck; clean contaminated</td><td>Cefazolin or cefuroxime + metronidazole, ampicillin-sulbactam</td><td>Clindamycin</td></tr><tr><td>Neurosurgical procedures</td><td>Cefazolin</td><td>Clindamycin, vancomycin</td></tr><tr><td>Orthopedic surgery</td><td>Cefazolin, ceftriaxone</td><td>Clindamycin, vancomycin</td></tr><tr><td>Breast, hernia</td><td>Cefazolin</td><td>Clindamycin, vancomycin</td></tr></table>
======================================
<table><thead><th>WOUND CLASS</th><th>EXAMPLES OF CASES</th><th>EXPECTED INFECTION RATES</th></thead><tr><td>Clean (class I)</td><td>Hernia repair, breast biopsy</td><td>1-2%</td></tr><tr><td>Clean/ contaminated (class ID)</td><td>Cholecystectomy, elective GI surgery (not colon)</td><td>| 2.1-9.5%</td></tr><tr><td>Clean/ contaminated (class ID)</td><td>Colorectal surgery</td><td>| 4-14%</td></tr><tr><td>Contaminated (class IID)</td><td>Penetrating abdominal trauma, large tissue injury, enterotomy during bowel obstruction</td><td>3.4-13.2%</td></tr><tr><td>Dirty (class IV)</td><td>Perforated diverticulitis, necrotizing soft tissue infections</td><td>3.1-12.8%</td></tr></table>
======================================
<table><thead><th>ABBREVIATION</th><th>ORGANIZATION</th><th>WEBSITE</th></thead><tr><td>NSQIP</td><td>National Surgical Quality Improvement Program</td><td>acsnsqip.org</td></tr><tr><td>THI</td><td>Institute for Healthcare Improvement</td><td>www.ihi.org</td></tr><tr><td>CMS</td><td>Centers for Medicare &amp; Medicaid Services</td><td>www.medicare.gov www.cms.gov/</td></tr><tr><td>NCQA</td><td>National Committee for Quality Assurance</td><td>www.ncqa.org</td></tr><tr><td>SIS</td><td>Surgical Infection Society</td><td>www.sisna.org</td></tr><tr><td>CDC</td><td>Centers for Disease Control and</td><td>www.cde.gov/HAI/ssi/ ssi.html</td></tr></table>
======================================
<table><thead><th></th><th></th><th>ADULTS</th><th>INFANTS/CHILDREN</th></thead><tr><td rowspan="4">Eye opening</td><td>4</td><td>Spontaneous</td><td>Spontaneous</td></tr><tr><td></td><td>3</td><td>To voice</td><td>To voice</td></tr><tr><td></td><td>2</td><td>To pain</td><td>To pain</td></tr><tr><td></td><td>1</td><td></td><td></td></tr><tr><td rowspan="5">Verbal</td><td>5</td><td>Oriented</td><td>Alert, normal vocalization</td></tr><tr><td></td><td>4</td><td>Confused</td><td>Cries, but consolable</td></tr><tr><td></td><td>3</td><td>Inappropriate words</td><td>Persistently irritable</td></tr><tr><td></td><td>2</td><td>Incomprehensible words</td><td>Restless, agitated, moaning</td></tr><tr><td></td><td>1</td><td></td><td></td></tr><tr><td rowspan="6">Motor response</td><td>6</td><td>Obeys commands</td><td>Spontaneous, purposeful</td></tr><tr><td></td><td>5</td><td>Localizes pain</td><td>Localizes pain</td></tr><tr><td></td><td>4</td><td>Withdraws</td><td>Withdraws</td></tr><tr><td></td><td>3</td><td>Abnormal flexion</td><td>Abnormal flexion</td></tr><tr><td></td><td>2</td><td>Abnormal extension</td><td>Abnormal extension</td></tr><tr><td></td><td>1</td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th>CLASS I</th><th>CLASS IT</th><th>CLASS III</th><th>CLASS IV</th></thead><tr><td>Blood loss (mL)</td><td>Up to 750</td><td>750-1500</td><td>1500-2000</td><td>&gt;2000</td></tr><tr><td>Blood loss (% BV)</td><td>Up to 15%</td><td>15%-30%</td><td>30% 40%</td><td>&gt;40%</td></tr><tr><td>Pulse rate</td><td>&lt;100</td><td>&gt;100</td><td>&gt;120</td><td>&gt;140</td></tr><tr><td>Blood pressure</td><td>Normal</td><td>Normal</td><td>Decreased</td><td>Decreased</td></tr><tr><td>Pulse pressure (mmHg)</td><td>Normal or increased</td><td>Decreased</td><td>Decreased</td><td>Decreased</td></tr><tr><td>Respiratory rate</td><td>14-20</td><td>&gt;20-30</td><td>30-40</td><td>&gt;35</td></tr><tr><td>Urine output (mL/h)</td><td>&gt;30</td><td>&gt;20-30</td><td>5-15</td><td>Negligible</td></tr><tr><td>CNS/mental status</td><td>Slightly anxious</td><td>Mildly anxious</td><td>Anxious and confused</td><td>—_ Confused and lethargic</td></tr></table>
======================================
<table><tr><td></td><td>TRAUMA</td><td>| STAB WOUNDS</td></tr><tr><td>Red blood cell count</td><td>&gt;100,000/mL</td><td>| &gt;10,000/mL</td></tr><tr><td>White blood cell count</td><td>&gt;500/mL</td><td>&gt;500/mL</td></tr><tr><td>Amylase level</td><td>&gt;19 IU/L</td><td>&gt;19 IU/L</td></tr><tr><td>Alkaline phosphatase level</td><td>&gt;2 IU/L</td><td>&gt;2 IU/L</td></tr><tr><td>Bilirubin level</td><td>&gt;0.01 mg/dL</td><td>| &gt;0.01 mg/dL</td></tr></table>
======================================
<table><thead><th>Grade I</th><th>&lt;10% of surface area</th><th>&lt;1 cm in depth</th></thead><tr><td>Grade II</td><td>10%-50% of surface area</td><td>1-3 cm</td></tr><tr><td>Grade III</td><td>= &gt;50% of surface area or &gt;10 cm in depth</td><td>&gt;3 cm</td></tr><tr><td>GradeIV</td><td>| 25%-75% of a hepatic lobe</td><td></td></tr><tr><td>Grade V</td><td>&gt;75% of a hepatic lobe</td><td></td></tr><tr><td>Grade VI</td><td>__ Hepatic avulsion</td><td></td></tr></table>
======================================
<table><thead><th>Grade I</th><th>&lt;10% of surface area</th><th>&lt;1 cm in depth</th></thead><tr><td>Grade II</td><td>10%-50% of surface area</td><td>1-3 cm</td></tr><tr><td>Grade III</td><td>| &gt;50% of surface area or &gt;10 cm in depth</td><td>&gt;3 cm</td></tr><tr><td>GradeIV</td><td>| &gt;25% devascularization</td><td>Hilum</td></tr><tr><td>Grade V</td><td>Shattered spleen Complete devascularization</td><td></td></tr></table>
======================================
<table><tr><td colspan="2">Signs and symptoms of peripheral arterial injury</td></tr><tr><td>HARD SIGNS (OPERATION</td><td>SOFT SIGNS (FURTHER</td></tr><tr><td>MANDATORY)</td><td>EVALUATION INDICATED)</td></tr><tr><td>Pulsatile hemorrhage</td><td>Proximity to vasculature</td></tr><tr><td>Absent pulses</td><td>Significant hematoma</td></tr><tr><td>Acute ischemia</td><td>Associated nerve injury</td></tr><tr><td></td><td>A-A index of &lt;0.9</td></tr><tr><td></td><td>Thrill or bruit</td></tr></table>
======================================
<table><thead><th>Abdominal</th><th>compartment syndrome</th><th>grading system</th></thead><tr><td colspan="3">BLADDER PRESSURE</td></tr><tr><td>GRADE</td><td>mmHg</td><td>cmH,0</td></tr><tr><td>I</td><td>10-15</td><td>13-20</td></tr><tr><td>I</td><td>16-25</td><td>21-35</td></tr><tr><td>Il</td><td>26-35</td><td>36-47</td></tr><tr><td>IV</td><td>&gt;35</td><td>&gt;48</td></tr></table>
======================================
<table><tr><td>ACTIVITY</td><td>MEDIATORS</td></tr><tr><td>Phagocytosis</td><td>Reactive oxygen species Nitric oxide</td></tr><tr><td>Debridement</td><td>Collagenase, elastase</td></tr><tr><td>Cell recruitment and activation</td><td>Growth factors: PDGF, TGF-B, EGF, IGF Cytokines: TNF-a, IL-1, IL-6 Fibronectin</td></tr><tr><td>Matrix synthesis</td><td>Growth factors: TGF-B, EGF, PDGF Cytokines: TNF-o, IL-1, IFN-y Enzymes: arginase, collagenase Prostaglandins Nitric oxide</td></tr><tr><td>Angiogenesis</td><td>Growth factors: FGF, VEGF Cytokines: TNF-a Nitric oxide</td></tr></table>
======================================
<table><thead><th>GROWTH FACTOR</th><th>WOUND CELL ORIGIN</th><th>CELLULAR AND BIOLOGIC EFFECTS</th></thead><tr><td>PDGF</td><td>Platelets, macrophages, monocytes, smooth muscle cells, endothelial cells</td><td>| Chemotaxis: fibroblasts, smooth muscle, monocytes, neutrophils Mitogenesis: fibroblasts, smooth muscle cells Stimulation of angiogenesis Stimulation of collagen synthesis Enhance reepithelization Modulate tissue remodeling</td></tr><tr><td>FGF</td><td>Fibroblasts, endothelial cells, keratinocytes, smooth muscle cells, chondrocytes</td><td>| Stimulation of angiogenesis (by stimulation of endothelial cell proliferation and migration) Mitogenesis: mesoderm and neuroectoderm</td></tr><tr><td>HGF</td><td>Fibroblasts</td><td>Stimulates fibroblasts, keratinocytes, chondrocytes, myoblasts Suppresses inflammation, granulation tissue formation, angiogenesis, reepithelialization</td></tr><tr><td>Keratinocyte growth factor</td><td>Keratinocytes, fibroblasts</td><td>Significant homology with FGF; stimulates keratinocytes</td></tr><tr><td>EGF</td><td>Platelets, macrophages, monocytes (also identified in salivary glands, duodenal glands, kidney, and lacrimal glands)</td><td>Stimulates proliferation and migration of all epithelial cell types</td></tr><tr><td>TGF-o</td><td>Keratinocytes, platelets, macrophages</td><td>Homology with EGF; binds to EGF receptor Mitogenic and chemotactic for epidermal and endothelial cells</td></tr><tr><td>TGF-B (three isoforms: B1, B2, B3)</td><td>Platelets, T lymphocytes, macrophages, monocytes, neutrophils, fibroblasts, keratinocytes</td><td>Stimulates angiogenesis Stimulates leukocyte chemotaxis TGF-B1 stimulates wound matrix production (fibronectin, collagen glycosaminoglycans); regulation of inflammation TGF-8, inhibits scar formation</td></tr><tr><td>Insulin-like growth factors (IGF-1, IGF-2)</td><td>Platelets (IGF-1 in high concentrations in liver; IGF-2 in high concentrations in fetal growth); likely the effector of growth hormone action</td><td>Promote protein/extracellular matrix synthesis Increase membrane glucose transport</td></tr><tr><td>Vascular endothelial growth factor</td><td>Macrophages, fibroblasts, endothelial cells, keratinocytes</td><td>Mitogen for endothelial cells (not fibroblasts) Stimulates angiogenesis Proinflammatory</td></tr><tr><td>IL-1</td><td>Macrophages, leukocytes, keratinocytes, fibroblasts</td><td>Proinflammatory Stimulates angiogenesis, reepithelialization, tissue remodeling</td></tr><tr><td>IL-4</td><td>Leukocytes</td><td>Enhances collagen synthesis</td></tr><tr><td>IL-6</td><td>Fibroblasts, endothelial cells, macrophages, keratinocytes</td><td>| Stimulates inflammation, angiogenesis, reepithelialization, collagen deposition, tissue remodeling</td></tr><tr><td>Activin</td><td>Keratinocytes, fibroblasts</td><td>Stimulates granulation tissue formation, keratinocyte differentiation, reepithelialization</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>CLINICAL FEATURES</th><th>INHERITANCE</th><th>BIOCHEMICAL DEFECT</th></thead><tr><td>[</td><td>Skin: soft, hyperextensible, easy bruising, fragile, atrophic scars; hypermobile joints; varicose veins; premature births</td><td>AD</td><td>Not known</td></tr><tr><td>ul</td><td>Similar to type I, except less severe</td><td>AD</td><td>Not known</td></tr><tr><td>ue</td><td>Skin: soft, not hyperextensible, normal scars; small and large joint hypermobility</td><td>AD</td><td>Not known</td></tr><tr><td>[V</td><td>Skin: thin, translucent, visible veins, normal scarring, no hyperextensibility; no joint hypermobility; arterial, bowel, and uterine rupture</td><td>AD</td><td>Type III collagen defect</td></tr><tr><td>V</td><td>Similar to type II</td><td>XLR</td><td>Not known</td></tr><tr><td>VI</td><td>Skin: hyperextensible, fragile, easy bruising; hypermobile joints; hypotonia; kyphoscoliosis</td><td>AR</td><td>Lysyl hydroxylase deficiency</td></tr><tr><td>VIL</td><td>Skin: soft, mild hyperextensibility, no increased fragility; extremely lax joints with dislocations</td><td>| AD</td><td>Type I collagen gene defect</td></tr><tr><td>VIII</td><td>Skin: soft, hyperextensible, easy bruising, abnormal scars with purple discoloration; hypermobile joints; generalized periodontitis</td><td>| AD</td><td>Not known</td></tr><tr><td>[XxX</td><td>Skin: soft, lax; bladder diverticula and rupture; limited pronation and supination; broad clavicle; occipital horns</td><td>=| XLR</td><td>Lysyl oxidase defect with abnormal copper use</td></tr><tr><td>x</td><td>Similar to type II with abnormal clotting studies</td><td>AR</td><td>Fibronectin defect</td></tr><tr><td>TNx</td><td>Hypermobile joints, skin fragility</td><td>AR</td><td>Absence of tenascin X protein</td></tr></table>
======================================
<table><thead><th>TYPE</th><th>CLINICAL FEATURES</th><th>INHERITANCE</th></thead><tr><td>I</td><td>Mild bone fragility, blue sclera</td><td>| Dominant</td></tr><tr><td>IL</td><td>“Prenatal lethal”; crumpled long bones, thin ribs, dark blue sclera</td><td>| Dominant</td></tr><tr><td>Il</td><td>Progressively deforming; multiple fractures; early loss of ambulation</td><td>Dominant/ recessive</td></tr><tr><td>IV</td><td>Mild to moderate bone fragility; normal or gray sclera; mild short stature</td><td>| Dominant</td></tr></table>
======================================
<table><thead><th></th><th></th><th>GI TRACT</th><th>SKIN</th></thead><tr><td rowspan="4">Wound environment</td><td>pH</td><td>Varies throughout GI tract in accordance with local exocrine secretions</td><td>Usually constant except during sepsis or local infection</td></tr><tr><td></td><td>Microorganisms</td><td>| Aerobic and anaerobic, especially in the colon and rectum; problematic if they contaminate the peritoneal cavity</td><td>Skin commensals rarely cause problems; infection usually results from exogenous contamination or hematogenous spread</td></tr><tr><td></td><td>Shear stress</td><td>Intraluminal bulk transit and peristalsis exert distracting forces on the anastomosis</td><td>Skeletal movements may stress the suture line but pain usually acts as a protective mechanism preventing excess movement</td></tr><tr><td></td><td>Tissue oxygenation</td><td>Dependent on intact vascular supply and neocapillary formation</td><td>Circulatory transport of oxygen as well as diffusion</td></tr><tr><td rowspan="3">Collagen synthesis</td><td>Cell type</td><td>Fibroblasts and smooth muscle cells</td><td>Fibroblasts</td></tr><tr><td></td><td>Lathyrogens</td><td>D-Penicillamine has no effect on collagen cross-linking</td><td>Significant inhibition of cross-linking with decreased wound strength</td></tr><tr><td></td><td>Steroids</td><td>Contradictory evidence exists concerning their negative effect on GI healing; increased abscess in the anastomotic line may play a significant role</td><td>Significant decrease in collagen accumulation</td></tr><tr><td>Collagenase activity</td><td>=</td><td>Increased presence throughout GI tract after transection and reanastomosis; during sepsis, excess enzyme may promote dehiscence by decreasing suture-holding capacity of tissue</td><td>| Not as significant a role in cutaneous wounds</td></tr><tr><td>Wound strength</td><td>|—</td><td>Rapid recovery to preoperative level.</td><td>Less rapid than GI tissue</td></tr><tr><td>Scar formation</td><td>| Age</td><td>Definite scarring seen in fetal wound sites</td><td>Usually heals without scar formation in the</td></tr></table>
======================================
<table><thead><th>Cardiac</th><th>Staphylococcus aureus, S. epidermidis</th><th>Cefazolin or Cefuroxime or Vancomycin*</th><th>1-2 g IV? 1.5 g IV’ lgIV</th></thead><tr><td colspan="4">Gastrointestinal</td></tr><tr><td>Esophageal/gastroduodenal</td><td>| Enteric gram-negative bacilli, gram-positive cocci</td><td>| High risk* only: cefazolin®</td><td>12 gIVv?</td></tr><tr><td>Biliary tract</td><td>Enteric gram-negative bacilli, enterococci, clostridia</td><td>| High risk’ only: cefazolin®*</td><td>12 gIVv?</td></tr><tr><td>Colorectal</td><td>Enteric gram-negative bacilli, anaerobes, enterococci</td><td>| Oral: neomycin + erythromycin base’ _| or metronidazole’ Parenteral: cefoxitin? or Cefotetan® or Cefazolin + Metronidazole’ or Ampicillin/sulbactam</td><td>see note 9 1-2 gIV 12gIV 12 gIV? 0.5 gIV 3gIV</td></tr><tr><td>Appendectomy, nonperforated!!</td><td>Same as for colorectal</td><td>Cefoxitin® or cefotetan® or Cefazolin® + Metronidazole</td><td>1-2 gIV 12 gIV? 0.5 gIV</td></tr><tr><td colspan="4">Genitourinary</td></tr><tr><td>Cystoscopy alone</td><td>Enteric gram-negative bacilli, enterococci</td><td>| High risk only’*: ciprofloxacin’? or Trimethoprim-sulfamethoxazole</td><td>500 mg PO or 400 mg IV 1 DS tablet</td></tr><tr><td>Cystoscopy with manipulation or upper tract instrumentation!*</td><td>Enteric gram-negative bacilli, enterococci</td><td>| Ciprofloxacin’? or Trimethoprim-sulfamethoxazole</td><td>500 mg PO or 400 mg IV 1 DS tablet</td></tr><tr><td>Open or laparoscopic surgery’?</td><td>Enteric gram-negative bacilli, enterococci</td><td>| Cefazolin®</td><td>12 gIVv?</td></tr><tr><td colspan="4">Gynecologic and obstetric</td></tr><tr><td>Vaginal, abdominal, or laparoscopic hysterectomy</td><td>Enteric gram-negative bacilli, anaerobes, group B streptococci, enterococci</td><td>Cefazolin® or cefoxitin® or cefotetan® or Ampicillin/sulbactam®””</td><td>| 1-2 g IV 3gIV</td></tr><tr><td>Cesarean section</td><td>Same as for hysterectomy</td><td>Cefazolin®</td><td>1-2 g IV?</td></tr><tr><td>Abortion, surgical</td><td>Same as for hysterectomy</td><td>Doxycycline</td><td>300 mg PO?”</td></tr><tr><td colspan="4">Head and neck surgery</td></tr><tr><td>Incisions through oral or pharyngeal mucosa</td><td>Anaerobes, enteric gram- negative bacilli, S. aureus</td><td>Clindamycin or Cefazolin + Metronidazole or Ampicillin/sulbactam””</td><td>600-900 mg IV 1-2 gIV? 0.5 gIV 3gIV</td></tr><tr><td>Neurosurgery</td><td>S. aureus, S. epidermidis</td><td>Cefazolin</td><td>1-2 gIV?</td></tr><tr><td>Ophthalmic</td><td>S. epidermidis, S. aureus, streptococci, enteric gram-negative bacilli, Pseudomonas spp.</td><td>Gentamicin, tobramycin, ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin or neomycin-gramicidin-polymyxin B OR cefazolin</td><td>Multiple drops topically over 2 to 24 hours 100 mg subconjuctivally</td></tr></table>
======================================
<table><thead><th colspan="4">Antimicrobial prophylaxis for surgery (Continued)</th></thead><thead><th>NATURE OF OPERATION</th><th>COMMON PATHOGENS</th><th>RECOMMENDED ANTIMICROBIALS</th><th>ADULT DOSAGE BEFORE SURGERY?</th></thead><tr><td>Vascular Arterial surgery involving a prosthesis, the abdominal aorta, or a groin incision</td><td>S. aureus, S. epidermidis, enteric gram-negative bacilli</td><td>Cefazolin or | Vancomycin*</td><td>12 gIVv? lgIV</td></tr><tr><td>Lower extremity amputation for ischemia</td><td>S. aureus, S. epidermidis, enteric gram-negative bacilli, clostridia</td><td>Cefazolin or Vancomycin*</td><td>1-2 gIV? lgIV</td></tr></table>
======================================
<table><thead><th></th><th>KELOID</th><th>HYPERTROPHIC SCAR</th></thead><tr><td>Incidence</td><td>Rare</td><td>Frequent</td></tr><tr><td>Ethnic groups</td><td>| African American, Asian, Hispanic</td><td>No predilection</td></tr><tr><td>Prior injury</td><td>Yes</td><td>Yes</td></tr><tr><td>Site predilection</td><td>Neck, chest, ear lobes, shoulders, upper back</td><td>Anywhere</td></tr><tr><td>Genetics</td><td>Autosomal dominant with incomplete penetration</td><td>| No</td></tr><tr><td>Timing</td><td>Symptom-free interval; may appear years after injury</td><td>4-6 weeks post injury</td></tr><tr><td>Symptoms</td><td>Pain, pruritus, hyperesthesia, growth beyond wound margins</td><td>Raised, some pruritus, respects wound confines</td></tr><tr><td>Regression</td><td>No</td><td>Frequent spontaneous</td></tr><tr><td>Contracture</td><td>Rare</td><td>Frequent</td></tr><tr><td>Histology</td><td>Hypocellular, thick, wavy collagen fibers in random orientation</td><td>| Parallel orientation of collagen fibers</td></tr></table>
======================================
<table><tr><td>Desired characteristics of wound dressings</td></tr><tr><td>Promote wound healing (maintain moist environment) Conformability</td></tr><tr><td>Pain control</td></tr><tr><td>Odor control</td></tr><tr><td>Nonallergenic and nonirritating</td></tr><tr><td>Permeability to gas</td></tr><tr><td>Safety</td></tr><tr><td>Nontraumatic removal</td></tr><tr><td>Cost-effectiveness</td></tr><tr><td>Convenience</td></tr></table>
======================================
<table><thead><th>SKIN SUBSTITUTE</th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td>Bioengineered dermal replacement</td><td>Prevents contracture Good prep for graft application</td><td>Limited ability to drive reepithelialization Largely serves as temporary dressing</td></tr><tr><td>Cultured bilayer skin equivalent</td><td>More closely mimics normal anatomy Does not need secondary procedure Easily handled Can be sutured, meshed, etc.</td><td>Cost Short shelf life True engraftment questionable</td></tr></table>
======================================
<table><tr><td colspan="2">APC Gene and Familial Adenomatous Polyposis / 324</td></tr><tr><td colspan="2">PTEN and Cowden Disease / 325</td></tr><tr><td>Viral Carcinogens / 326 Risk</td><td></td></tr><tr><td>Cancer Assessment</td><td>328</td></tr><tr><td>Cancer Screening</td><td>330</td></tr><tr><td>Cancer Diagnosis Cancer Staging</td><td>332 333</td></tr><tr><td>Prognostic and Predictive Tissue Markers / 334 Serum Markers / 335 Circulating Tumor Cells / 336</td><td></td></tr><tr><td>Surgical Approaches to Cancer Therapy</td><td>337</td></tr><tr><td colspan="2">Multidisciplinary Approach to Cancer / 337 Surgical Management of Primary Tumors / 337</td></tr><tr><td>Surgical Management of the Regional Lymph Node Basin / 338</td><td></td></tr></table>
======================================
<table><tr><td colspan="2">Clinical Use of Chemotherapy / 340</td></tr><tr><td>Principles of Chemotherapy / 340</td><td></td></tr><tr><td>Anticancer Agents / 340</td><td></td></tr><tr><td colspan="2">Combination Chemotherapy / 341</td></tr><tr><td>Drug Toxicity / 341</td><td></td></tr><tr><td>Administration of Chemotherapy /</td><td>341</td></tr><tr><td>Hormonal Therapy</td><td>342</td></tr><tr><td>Targeted Therapy</td><td>342</td></tr><tr><td>Immunotherapy</td><td>342</td></tr><tr><td>Gene Therapy</td><td>345</td></tr><tr><td>Mechanisms of Intrinsic and</td><td></td></tr><tr><td>Acquired Drug Resistance</td><td>345</td></tr><tr><td>Radiation Therapy</td><td>346</td></tr><tr><td>Physical Basis of Radiation Therapy</td><td>/ 346</td></tr><tr><td>Biologic Basis of Radiation Therapy Radiation Therapy Planning / 347 Side Effects 348</td><td>/ 346</td></tr><tr><td>/ Cancer Prevention</td><td>348</td></tr><tr><td>Trends in Oncology</td><td>349</td></tr><tr><td>Cancer Screening and Diagnosis /</td><td>349</td></tr></table>
======================================
<table><thead><th></th><th rowspan="2">ESTIMATED NEW CASES 1,688,780</th><th rowspan="2">| ESTIMATED DEATHS 600,920</th><th rowspan="2">Genital system</th><th rowspan="2">ESTIMATED NEW CASES 279,800</th><th rowspan="2">| ESTIMATED | DEATHS 59,100</th></thead><thead><th>All cancers</th><th></th><th></th><th></th><th></th><th></th></thead><tr><td>Oral cavity and pharynx</td><td>49,670</td><td>9700</td><td>Uterine cervix</td><td>12,820</td><td>4210</td></tr><tr><td>Digestive system</td><td>310,440</td><td>157,700</td><td>Uterine corpus</td><td>61,380</td><td>10,920</td></tr><tr><td>Esophagus</td><td>16,940</td><td>15,690</td><td>Ovary</td><td>22,440</td><td>14,080</td></tr><tr><td>Stomach</td><td>28,000</td><td>10,960</td><td>Vulva</td><td>6020</td><td>1150</td></tr><tr><td>Small intestine</td><td>10,190</td><td>1390</td><td>Vagina and other genital, female</td><td>| 4810</td><td>1240</td></tr><tr><td>Colon and rectum</td><td>95,520/ 39,910</td><td>| 50,260°</td><td>Prostate</td><td>161,360</td><td>26,730</td></tr><tr><td>Anus, anal canal, and anorectum.</td><td>8200</td><td>1100</td><td>Testis</td><td>8850</td><td>410</td></tr><tr><td>Liver and intrahepatic bile duct</td><td>40,710</td><td>28,920</td><td>Penis and other genital, male</td><td>2120</td><td>360</td></tr><tr><td>Gallbladder and other biliary</td><td>| 11,740</td><td>3830</td><td>Urinary system</td><td>146,650</td><td>32,190</td></tr><tr><td>Pancreas</td><td>53,670</td><td>43,090</td><td>Urinary bladder</td><td>79,030</td><td>16,870</td></tr><tr><td>Other digestive organs</td><td>5560</td><td>2460</td><td>Kidney and renal pelvis</td><td>63,990</td><td>14,400</td></tr><tr><td>Respiratory system</td><td>243,170</td><td>160,420</td><td>Ureter and other urinary organs</td><td>3630</td><td>920</td></tr><tr><td>Larynx</td><td>13,360</td><td>3660</td><td>Eye and orbit</td><td>3130</td><td>330</td></tr><tr><td>Lung and bronchus</td><td>220,500</td><td>155,870</td><td>Brain and other nervous system</td><td>23,800</td><td>16,700</td></tr><tr><td>Other respiratory organs</td><td>7310</td><td>890</td><td>Endocrine system</td><td>59,250</td><td>3010</td></tr><tr><td>Bones and joints</td><td>3260</td><td>1550</td><td>Thyroid</td><td>56,870</td><td>2010</td></tr><tr><td>Soft tissue (including heart)</td><td>— 12,390</td><td>4990</td><td>Other endocrine</td><td>2380</td><td>1000</td></tr><tr><td>skin (excluding basal and squamous)</td><td>95,360</td><td>13,590</td><td>Lymphoma</td><td>80,500</td><td>21,210</td></tr><tr><td>Melanoma</td><td>87,110</td><td>9730</td><td>Multiple myeloma</td><td>30,280</td><td>12,590</td></tr><tr><td>Other nonepithelial</td><td>8250</td><td>3860</td><td>Leukemia</td><td>62,130</td><td>24,500</td></tr><tr><td>Breast</td><td>255,180</td><td>41,070</td><td>Other and unspecified primary sites®</td><td>33,770</td><td>42,270</td></tr></table>
======================================
<table><tr><td></td><td></td><td></td><td>Females</td><td></td><td></td><td></td></tr><tr><td>Prostate</td><td>161,360</td><td>19%</td><td></td><td>Breast</td><td>252,710</td><td>30%</td></tr><tr><td>Lung &amp; bronchus</td><td>116,990</td><td>14%</td><td></td><td>Lung &amp; bronchus</td><td>105,510</td><td>12%</td></tr><tr><td>Colon &amp; rectum</td><td>71,420</td><td>9%</td><td></td><td>Colon &amp; rectum</td><td>64,010</td><td>8%</td></tr><tr><td>Urinary bladder</td><td>60,490</td><td>7%</td><td></td><td>Uterine corpus</td><td>61,380</td><td>7%</td></tr><tr><td>Melanoma of the skin</td><td>52,170</td><td>6%</td><td></td><td>Thyroid</td><td>42,470</td><td>5%</td></tr><tr><td>Kidney &amp; renal pelvis</td><td>40,610</td><td>5%</td><td></td><td>Melanoma of the skin</td><td>34,940</td><td>4%</td></tr><tr><td>Non-Hodgkin lymphoma</td><td>40,080</td><td>5%</td><td></td><td>Non-Hodgkin lymphoma</td><td>32,160</td><td>4%</td></tr><tr><td>Leukemia</td><td>36,290</td><td>4%</td><td></td><td>Leukemia</td><td>25,840</td><td>3%</td></tr><tr><td>Oral cavity &amp; pharynx</td><td>35,720</td><td>4%</td><td></td><td>Pancreas</td><td>25,700</td><td>3%</td></tr><tr><td>Liver &amp; intrahepatic bile duct</td><td>29,200</td><td>3%</td><td></td><td>Kidney &amp; renal pelvis</td><td>23,380</td><td>3%</td></tr><tr><td>All Sites</td><td>836,150</td><td>100%</td><td></td><td>All Sites</td><td>852,630</td><td>100%</td></tr><tr><td colspan="7">Estimated deaths</td><td colspan="7" rowspan="2">Males Females</td></tr><tr><td colspan="7"></td><td colspan="7"></td></tr><tr><td>Lung &amp; bronchus</td><td>84,590</td><td>27%</td><td></td><td>Lung &amp; bronchus</td><td>71,280</td><td>25%</td></tr><tr><td>Colon &amp; rectum</td><td>27,150</td><td>9%</td><td></td><td>Breast</td><td>40,610</td><td>14%</td></tr><tr><td>Prostate</td><td>26,730</td><td>8%</td><td></td><td>Colon &amp; rectum</td><td>23,110</td><td>8%</td></tr><tr><td>Pancreas</td><td>22,300</td><td>7%</td><td></td><td>Pancreas</td><td>20,790</td><td>7%</td></tr><tr><td>Liver &amp; intrahepatic bile duct</td><td>19,610</td><td>6%</td><td></td><td>Ovary</td><td>14,080</td><td>5%</td></tr><tr><td>Leukemia</td><td>14,300</td><td>4%</td><td></td><td>Uterine corpus</td><td>10,920</td><td>4%</td></tr><tr><td>Esophagus</td><td>12,720</td><td>4%</td><td></td><td>Leukemia</td><td>10,200</td><td>4%</td></tr><tr><td>Urinary bladder</td><td>12,240</td><td>4%</td><td></td><td>Liver &amp; intrahepatic bile duct</td><td>9,310</td><td>3%</td></tr><tr><td>Non-Hodgkin lymphoma</td><td>11,450</td><td>4%</td><td></td><td>Non-Hodgkin lymphoma</td><td>8,690</td><td>3%</td></tr><tr><td>Brain &amp; other nervous system</td><td>9,620</td><td>3%</td><td></td><td>Brain &amp; other nervous system</td><td>7,080</td><td>3%</td></tr><tr><td>All Sites</td><td>318,420</td><td>100%</td><td></td><td>All Sites</td><td>282,500</td><td>100%</td></tr></table>
======================================
<table><thead><th rowspan="2">CANCER TYPE</th><th colspan="3">RELATIVE 5-YEAR SURVIVAL RATES (%)</th></thead><thead><th></th><th>1975-1977</th><th>1987-1989</th><th>2005-2011</th></thead><tr><td>All cancers</td><td>49</td><td>56</td><td>69</td></tr><tr><td>Brain</td><td>22</td><td>29</td><td>35</td></tr><tr><td>Breast (female)</td><td>75</td><td>84</td><td>91</td></tr><tr><td>Uterine cervix</td><td>69</td><td>70</td><td>69</td></tr><tr><td>Colon</td><td>Sl</td><td>61</td><td>69</td></tr><tr><td>Uterine corpus</td><td>87</td><td>83</td><td>83</td></tr><tr><td>Esophagus</td><td>5</td><td>10</td><td>20</td></tr><tr><td>Hodgkin’s disease</td><td>72</td><td>719</td><td>88</td></tr><tr><td>Kidney</td><td>50</td><td>57</td><td>74</td></tr><tr><td>Larynx</td><td>66</td><td>66</td><td>63</td></tr><tr><td>Leukemia</td><td>34</td><td>43</td><td>62</td></tr><tr><td>Liver</td><td>3</td><td>5</td><td>18</td></tr><tr><td>Lung and bronchus</td><td>12</td><td>13</td><td>18</td></tr><tr><td>Melanoma of the skin</td><td>82</td><td>88</td><td>93</td></tr><tr><td>Multiple myeloma</td><td>25</td><td>28</td><td>49</td></tr><tr><td>Non-Hodgkin’s lymphoma</td><td>47</td><td>Sl</td><td>72</td></tr><tr><td>Oral cavity</td><td>53</td><td>54</td><td>66</td></tr><tr><td>Ovary</td><td>36</td><td>38</td><td>46</td></tr><tr><td>Pancreas</td><td>2</td><td>4</td><td>8</td></tr><tr><td>Prostate</td><td>68</td><td>83</td><td>99</td></tr><tr><td>Rectum</td><td>48</td><td>58</td><td>68</td></tr><tr><td>Stomach</td><td>15</td><td>20</td><td>30</td></tr><tr><td>Testis</td><td>83</td><td>95</td><td>97</td></tr><tr><td>Thyroid</td><td>92</td><td>95</td><td>98</td></tr><tr><td>Urinary bladder</td><td>73</td><td>719</td><td>719</td></tr></table>
======================================
<table><thead><th>YMBOL</th><th>NAME</th><th>TUMOR TYPES (GERMLINE MUTATIONS)</th><th>CANCER SYNDROME</th></thead><tr><td>\LK</td><td>anaplastic lymphoma kinase (Ki-1)</td><td>Neuroblastoma</td><td>Familial neuroblastoma</td></tr><tr><td>\PC</td><td>adenomatous polyposis of the colon gene</td><td>Colorectal, pancreatic, desmoid, hepatoblastoma,| glioma, other CNS</td><td>Adenomatous polyposis coli; Turcot syndrome</td></tr><tr><td>\TM</td><td>ataxia telangiectasia mutated</td><td>Leukemia, lymphoma, medulloblastoma, glioma</td><td>Ataxia-telangiectasia</td></tr><tr><td>3LM</td><td>Bloom syndrome</td><td>Leukemia, lymphoma, skin squamous cell, other cancers</td><td>Bloom syndrome</td></tr><tr><td>3MPRIA</td><td>bone morphogenetic protein receptor, type IA</td><td>Gastrointestinal polyps</td><td>Juvenile polyposis</td></tr><tr><td>3RCAL</td><td>familial breast/ovarian cancer gene |</td><td>Breast, ovarian</td><td>Hereditary breast/ovarian cancer</td></tr><tr><td>3RCA2</td><td>familial breast/ovarian cancer gene 2</td><td>Breast, ovarian, pancreatic |</td><td>Hereditary breast/ovarian cancer</td></tr><tr><td>3RIPI</td><td>BRCAI interacting protein C-terminal helicase 1</td><td>| AML, leukemia, breast</td><td>Fanconi anemia J, breast cancer susceptibility</td></tr><tr><td>3UB1B</td><td>BUB1 budding uninhibited by benzimidazoles | homolog beta (yeast)</td><td>Rhabdomyosarcoma</td><td>Mosaic variegated aneuploidy</td></tr><tr><td>“DH1</td><td>cadherin 1, type 1, E-cadherin (epithelial) (ECAD) |</td><td>Gastric, lobular cancer</td><td>Familial gastric carcinoma</td></tr><tr><td>SDK4</td><td>cyclin-dependent kinase 4</td><td>Melanoma</td><td>Familial malignant melanoma</td></tr><tr><td>“DKN2A</td><td>cyclin-dependent kinase inhibitor 2A. (p16[INK4a]) gene</td><td>Melanoma, pancreatic</td><td>Familial malignant melanoma</td></tr><tr><td>“DKN2a(p14) |</td><td>cyclin-dependent kinase inhibitor 2A— pl14ARF protein</td><td>Melanoma, pancreatic</td><td>Familial malignant melanoma</td></tr><tr><td>SHEK2</td><td>CHK2 checkpoint homolog (S pombe)</td><td>Breast</td><td>Familial breast cancer</td></tr><tr><td>&gt;YLD</td><td>familial cylindromatosis gene</td><td>Cylindroma</td><td>Familial cylindromatosis</td></tr><tr><td>DB2</td><td>damage-specific DNA binding protein 2</td><td>Skin basal cell, skin squamous cell, melanoma</td><td>Xeroderma pigmentosum (E)</td></tr><tr><td>JICER1</td><td>dicer 1, ribonuclease type III</td><td>Pleuropulmonary blastoma |</td><td>Familial pleuropulmonary blastoma</td></tr><tr><td>3GFR</td><td>epidermal growth factor receptor (erythroblastic leukemia viral [v-erb-b] oncogene homolog, avian)</td><td>NSCLC</td><td>Familial lung cancer</td></tr><tr><td>ERCC2, 3, 4,5</td><td>excision repair cross-complementing rodent repair deficiency, complementation group</td><td>Skin basal cell, skin squamous cell, melanoma</td><td>Xeroderma pigmentosum (D, B, F, G)</td></tr><tr><td>XT1</td><td>multiple exostoses type | gene</td><td>exostoses, osteosarcoma</td><td>exostoses, osteosarcoma</td></tr><tr><td>“ANCA, C, D2, E, F,G</td><td>Fanconi anemia, complementation group</td><td>AML, leukemia</td><td>Fanconi anemia A, C, D2, E, F,G</td></tr></table>
======================================
<table><thead><th>SYMBOL</th><th>NAME</th><th>TUMOR TYPES (GERMLINE MUTATIONS)</th><th>CANCER SYNDROME</th></thead><tr><td>KIT</td><td>v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog</td><td>GIST, epithelioma</td><td>Familial gastrointestinal stromal tumor</td></tr><tr><td>MADH4</td><td>Homolog of Drosophila Mothers Against Decapentaplegic 4 gene</td><td>Gastrointestinal polyps</td><td>Juvenile polyposis</td></tr><tr><td>MEN1</td><td>multiple endocrine neoplasia type 1 gene</td><td>Parathyroid adenoma, pituitary adenoma, pancreatic islet cell, carcinoid</td><td>Parathyroid adenoma, pituitary adenoma, pancreatic islet cell, carcinoid</td></tr><tr><td>MLH1</td><td>E coli MutL homolog gene</td><td>Colorectal, endometrial, ovarian, CNS</td><td>Hereditary nonpolyposis colorectal cancer, Turcot syndrome</td></tr><tr><td>MPL</td><td>myeloproliferative leukemia virus oncogene, thrombopoietin receptor</td><td>MPD</td><td>Familial essential thrombocythemia</td></tr><tr><td>MSH2</td><td>mutS homolog 2 (E coli)</td><td>colorectal, endometrial, ovarian</td><td>Hereditary non-polyposis colorectal cancer</td></tr><tr><td>MSH6</td><td>mutS homolog 6 (E coli)</td><td>colorectal, endometrial, ovarian</td><td>Hereditary non-polyposis colorectal cancer</td></tr><tr><td>MUTYH</td><td>mutY homolog (E coli)</td><td>Colorectal</td><td>Adenomatous polyposis coli</td></tr><tr><td>NBS1</td><td>Nijmegen breakage syndrome | (nibrin)</td><td>NHL, glioma, medulloblastoma, rhabdomyosarcoma</td><td>Nijmegen breakage syndrome</td></tr><tr><td>NF1</td><td>neurofibromatosis type | gene</td><td>Neurofibroma, glioma</td><td>Neurofibromatosis type |</td></tr><tr><td>NF2</td><td>neurofibromatosis type 2 gene</td><td>Meningioma, acoustic neuroma</td><td>Neurofibromatosis type 2</td></tr><tr><td>PALB2</td><td>partner and localizer of BRCA2</td><td>Wilms tumor, medulloblastoma, AML, breast</td><td>Fanconi anemia N, breast cancer susceptibility</td></tr><tr><td>PHOX2B</td><td>paired-like homeobox 2b</td><td>Neuroblastoma</td><td>Familial neuroblastoma</td></tr><tr><td>PMS1</td><td>PMS1 postmeiotic segregation increased 1 (S cerevisiae)</td><td>Colorectal, endometrial, ovarian</td><td>Hereditary non-polyposis colorectal cancer</td></tr><tr><td>PMS2</td><td>PMS2 postmeiotic segregation increased 2 (S cerevisiae)</td><td>Colorectal, endometrial, ovarian, medulloblastoma, glioma}</td><td>Hereditary nonpolyposis colorectal cancer, Turcot syndrome</td></tr><tr><td>PRKARIA</td><td>protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1)</td><td>Myxoma, endocrine, papillary thyroid</td><td>Carney complex</td></tr><tr><td>PTCH</td><td>Homolog of Drosophila Patched gene</td><td>Skin basal cell, medulloblastoma</td><td>Nevoid basal cell carcinoma syndrome</td></tr><tr><td>PTEN</td><td>phosphatase and tensin homolog gene</td><td>Hamartoma, glioma, prostate, endometrial</td><td>Cowden syndrome, Bannayan- Riley-Ruvalcaba syndrome</td></tr></table>
======================================
<table><thead><th>SYMBOL</th><th>NAME</th><th>TUMOR TYPES (GERMLINE MUTATIONS)</th><th>CANCER SYNDROME</th></thead><tr><td>SDH5</td><td>chromosome 11 open reading frame 79</td><td>Paraganglioma</td><td>Familial paraganglioma</td></tr><tr><td>SHD, B, D</td><td>succinate dehydrogenase complex</td><td>Paraganglioma, pheochromocytoma</td><td>Familial paraganglioma</td></tr><tr><td>SMARCB1</td><td>SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member |</td><td>Malignant rhabdoid</td><td>Rhabdoid predisposition syndrome</td></tr><tr><td>STK 11</td><td>serine/threonine kinase 11 gene (LKB1)</td><td>Jejunal hamartoma, ovarian, testicular, pancreatic</td><td>Peutz-Jeghers syndrome</td></tr><tr><td>SUFU</td><td>suppressor of fused homolog (Drosophila)</td><td>Medulloblastoma</td><td>Medulloblastoma predisposition</td></tr><tr><td>TCF1</td><td>transcription factor 1, hepatic (HNF1)</td><td>Hepatic adenoma, hepatocellular carcinoma</td><td>Familial Hepatic Adenoma</td></tr><tr><td>rPS3</td><td>tumor protein p53</td><td>Breast, sarcoma, adrenocortical carcinoma, glioma, multiple other tumor types</td><td>Li-Fraumeni syndrome</td></tr><tr><td>TSCl</td><td>tuberous sclerosis | gene</td><td>Hamartoma, renal cell</td><td>Tuberous sclerosis 1</td></tr><tr><td>TSC2</td><td>tuberous sclerosis 2 gene</td><td>Hamartoma, renal cell</td><td>Tuberous sclerosis 2</td></tr><tr><td>TSHR</td><td>thyroid stimulating hormone receptor</td><td>Thyroid adenoma</td><td></td></tr><tr><td>VHL</td><td>von Hippel-Lindau syndrome gene</td><td>Renal, hemangioma, pheochromocytoma</td><td>von Hippel-Lindau syndrome</td></tr><tr><td>WRN</td><td>Werner syndrome (RECQL2)</td><td>Osteosarcoma, meningioma, others</td><td>Werner syndrome</td></tr><tr><td>WT1</td><td>Wilms’ tumor | gene</td><td>Wilms’</td><td>Denys-Drash syndrome, Frasier syndrome, Familial Wilms tumor</td></tr><tr><td>XPA, C</td><td>xeroderma pigmentosum, complementation group</td><td>| Skin basal cell, skin squamous cell,</td><td>Xeroderma pigmentosum (AC)</td></tr></table>
======================================
<table><tr><td>4-Aminobipheny]</td><td>Urinary bladder</td><td>Strong</td></tr><tr><td>Benzidine</td><td>Urinary bladder</td><td>Strong</td></tr><tr><td>Dyes metabolized to benzidine</td><td></td><td>Strong*</td></tr><tr><td>4,4’ -Methylenebis(2-chloroaniline)</td><td></td><td>Strong*</td></tr><tr><td>2-Napthylamine</td><td>Urinary bladder</td><td>Strong</td></tr><tr><td>Ortho-toluidine</td><td>Urinary bladder</td><td>Moderate</td></tr><tr><td>Auramine production</td><td>Urinary bladder</td><td>Weak/lack of data’</td></tr><tr><td>Magenta production</td><td>Urinary bladder</td><td>Weak/lack of data</td></tr><tr><td>Benzo[a]pyrene</td><td></td><td>Strong*</td></tr><tr><td>Soot (chimney sweeping)</td><td>Skin, lung</td><td>Moderate</td></tr><tr><td>Coal gasification</td><td>Lung</td><td>Strong</td></tr><tr><td>Coal-tar distillation</td><td>Skin</td><td>Strong</td></tr><tr><td>Coke production</td><td>Lung</td><td>Strong</td></tr><tr><td>Coal-tar pitches (paving, roofing)</td><td>Lung</td><td>Strong</td></tr><tr><td>Aluminum production</td><td>Lung, urinary bladder</td><td>Weak/moderate”*</td></tr><tr><td>Aflatoxins</td><td>Hepatocellular carcinoma</td><td>Strong</td></tr><tr><td>Benzene</td><td>ANLL</td><td>Strong</td></tr><tr><td>Bis (chloromethy])ether/chloromethyl methylether</td><td>| Lung</td><td>Moderate/strong</td></tr><tr><td>1,3-Butadiene</td><td>Haematolymphatic organs</td><td>Strong</td></tr><tr><td>Dioxin (2,3,7,8-TCDD)</td><td>All cancers combined*</td><td>See text</td></tr><tr><td>2,3,4,7,8-Pentachlorodibenzofuran</td><td></td><td>See text*¢</td></tr><tr><td>3,3” ,4,4’ 5-Pentachlorobiphenyl (PCB-126)</td><td></td><td>See text*¢</td></tr><tr><td>Ethylene oxide</td><td></td><td>Strong*</td></tr><tr><td>Formaldehyde</td><td>Nasopharynx Leukemia®</td><td>Strong Moderate</td></tr><tr><td>Sulfur mustard</td><td>Lung</td><td>Strong</td></tr><tr><td>Vinyl chloride</td><td>Hepatic angiosarcoma, hepatocellular carcinoma</td><td>Strong</td></tr><tr><td>[ron and steel founding</td><td>Lung</td><td>Weak/moderate</td></tr><tr><td>Isopropyl alcohol manufacture using strong acids _|</td><td>Nasal cavity</td><td>Weak/lack of data</td></tr><tr><td>Mineral oils</td><td>Skin</td><td>Weak/lack of data</td></tr><tr><td>Occupational exposure as a painter</td><td>Lung, urinary bladder, pleural mesothelioma</td><td>| Strong*</td></tr><tr><td>Rubber-manufacturing industry</td><td>Leukaemia, lymphoma, urinary bladder, lung,* stomach®</td><td>Strong®</td></tr><tr><td>Shale oils</td><td>Skin</td><td>Weak/lack of data</td></tr><tr><td>Strong inorganic acid mists</td><td>Larynx</td><td>Weak/lack of data</td></tr></table>
======================================
<table><thead><th>VIRUS</th><th>PREDOMINANT TUMOR TYPE?</th></thead><tr><td>Hepatitis C virus HIV type 1</td><td>Hepatocellular carcinoma Kaposi’s sarcoma Cervical cancer Non-Hodgkin’s lymphoma</td></tr><tr><td>Human herpes virus 8</td><td>Kaposi’s sarcoma</td></tr><tr><td rowspan="3">Human papillomavirus 16 and 18</td><td>Cervical cancer</td></tr><tr><td></td><td>Penile cancer Oropharyngeal cancer (commonly base of tongue and tonsil)</td></tr><tr><td></td><td>Anal cancer</td></tr><tr><td>Human T-cell lymphotropic viruses</td><td>Adult T-cell leukemia/lymphoma</td></tr><tr><td>Merkel cell polyoma virus</td><td>| Merkel cell carcinoma</td></tr></table>
======================================
<table><thead><th>ONCOGENE</th><th>VIRUS NAME</th><th>ORIGIN</th><th>PROTEIN PRODUCT</th></thead><tr><td>abl</td><td>Abelson murine leukemia virus</td><td>Mouse</td><td>Tyrosine kinase</td></tr><tr><td>fes</td><td>ST feline sarcoma virus</td><td>Cat</td><td>Tyrosine kinase</td></tr><tr><td>Sps</td><td>Fujinami sarcoma virus</td><td>Chicken</td><td>Tyrosine kinase</td></tr><tr><td>Src</td><td>Rous sarcoma virus</td><td>Chicken</td><td>Tyrosine kinase</td></tr><tr><td>erbB</td><td>Avian erythroblastosis virus</td><td>Chicken</td><td>Epidermal growth factor receptor</td></tr><tr><td>fins</td><td>McDonough feline sarcoma virus</td><td>Cat</td><td>Colony-stimulating factor receptor</td></tr><tr><td>kit</td><td>Hardy-Zuckerman 4 feline sarcoma virus</td><td>Cat</td><td>Stem cell factor receptor</td></tr><tr><td>mil</td><td>Avian myelocytoma virus</td><td>Chicken</td><td>Serine/threonine kinase</td></tr><tr><td>mos</td><td>Moloney murine sarcoma virus</td><td>Mouse</td><td>Serine/threonine kinase</td></tr><tr><td>raf</td><td>Murine sarcoma virus 3611</td><td>Mouse</td><td>Serine/threonine kinase</td></tr><tr><td>sis</td><td>Simian sarcoma virus</td><td>Monkey</td><td>Platelet-derived growth factor</td></tr><tr><td>H-ras</td><td>Harvey murine sarcoma virus</td><td>Rat</td><td>GDP/GTP binding</td></tr><tr><td>K-ras</td><td>Kirsten murine sarcoma virus</td><td>Rat</td><td>GDP/GTP binding</td></tr><tr><td>erbA</td><td>Avian erythroblastosis virus</td><td>Chicken</td><td>Transcription factor (thyroid hormone receptor)</td></tr><tr><td>ets</td><td>Avian myeloblastosis virus E26</td><td>Chicken</td><td>Transcription factor</td></tr><tr><td>fos</td><td>FBJ osteosarcoma virus</td><td>Mouse</td><td>Transcription factor (AP1 component)</td></tr><tr><td>jun</td><td>Avian sarcoma virus 17</td><td>Chicken</td><td>Transcription factor (AP1 component)</td></tr><tr><td>myb</td><td>Avian myeloblastosis virus</td><td>Chicken</td><td>Transcription factor</td></tr><tr><td>myc</td><td>MC29 myelocytoma virus</td><td>Chicken</td><td>Transcription factor (NF-«B family)</td></tr></table>
======================================
<table><thead><th>&lt;12</th><th>21</th></thead><tr><td colspan="2">Age at first live birth (years)</td></tr><tr><td colspan="2">Patients with no first-degree relatives with cancer</td></tr><tr><td>&lt;20</td><td>.00</td></tr><tr><td>20-24</td><td>24</td></tr><tr><td>25-29 or nulliparous</td><td>55</td></tr><tr><td>230</td><td>93</td></tr><tr><td colspan="2">Patients with one first degree-relative with cancer</td></tr><tr><td>&lt;20</td><td>.00</td></tr><tr><td>20-24</td><td>2.64</td></tr><tr><td>25-29 or nulliparous</td><td>2.76</td></tr><tr><td>230</td><td>2.83</td></tr><tr><td colspan="2">Patients with 22 first-degree relatives with cancer</td></tr><tr><td>&lt;20</td><td>6.80</td></tr><tr><td>20-24</td><td>5.78</td></tr><tr><td>25-29 or nulliparous</td><td>4.91</td></tr><tr><td>230</td><td>4.17</td></tr><tr><td colspan="2" rowspan="2">Breast biopsies (number) Patients aged &lt;50 y at counseling</td></tr><tr><td colspan="2"></td></tr><tr><td>0</td><td>.00</td></tr><tr><td>1</td><td>-10</td></tr><tr><td>&gt;2</td><td>2.88</td></tr><tr><td colspan="2">Patients aged 250 y at counseling</td></tr><tr><td>0</td><td>.00</td></tr><tr><td>1</td><td>27</td></tr><tr><td>22</td><td>62</td></tr><tr><td colspan="2">Atypical hyperplasia</td></tr><tr><td>No biopsies</td><td>-00</td></tr><tr><td>At least | biopsy, no atypical hyperplasia</td><td>0.93</td></tr><tr><td>No atypical hyperplasia, hyperplasiastatus unknown for at least 1 biopsy</td><td>-00</td></tr><tr><td>Atypical hyperplasia in at least 1 biopsy</td><td>82</td></tr></table>
======================================
<table><tr><td>CANCER SITE</td><td>POPULATION</td><td>TEST OR PROCEDURE</td><td>FREQUENCY</td></tr><tr><td>Breast</td><td>Women age 40 and above</td><td>Mammography</td><td>Women with an average risk of breast cancer should undergo regular screening mammography starting at age 45 years. Women age 45 to 54 years should be screened annually. Women 55 years and older should transition to biennial screening or have the opportunity to continue screening annually. Women should continue screening mammography as long as their overall health is good and they have a life expectancy of 10 years or longer. The ACS does not recommend clinical breast examination for breast cancer screening among average-risk women at any age.</td></tr><tr><td>Cervix</td><td>Women, age 21-65 y</td><td>Pap test and HPV DNA test</td><td>Cervical cancer screening should begin at age 21 y. For women age 21-29 y, screening should be done every 3 y with conventional or liquid-based Pap tests. For women age 30-65 y, screening should be done every 5 y with both the HPV test and the Pap test (preferred), or every 3 y with the Pap test alone (acceptable). Women age &gt;65 y who have had 23 consecutive negative Pap tests or 22 consecutive negative HPV and Pap tests within the last 10 y, with the most recent test occurring within the last 5 y, and women who have had a total hysterectomy should stop cervical cancer screening.</td></tr><tr><td rowspan="4"></td><td rowspan="4"></td><td>sensitivity for cancer FSIG, or</td><td>Every 5 y, starting at age 50 y. FSIG can be performed alone, or consideration can be given to combining FSIG performed every 5 y with a highly sensitive guaiac-based FOBT or FIT</td></tr><tr><td></td><td></td><td>DCBE, or</td><td>performed annually. Every 5 y, starting at age 50 y.</td></tr><tr><td></td><td></td><td>Colonoscopy</td><td>Every 10 y, starting at age 50 y.</td></tr><tr><td></td><td></td><td>CT colonography</td><td>Every 5 yr, starting at age 50 y.</td></tr><tr><td>Endometrial</td><td>Women, at menopause</td><td></td><td>At the time of menopause, women at average risk should be informed about the risks and symptoms of endometrial cancer and strongly encouraged to report any unexpected bleeding or spotting to their physicians.</td></tr><tr><td>Lung</td><td>Current or former smokers age 50-74 in good health with at least a 30 pack/ year history</td><td>LDCT</td><td>Clinicians with access to high-volume, high-quality lung cancer screening and treatment centers should initiate a discussion about lung cancer screening with apparently healthy patients age 55-74 y who have at least a 30 pack-y smoking history, and who currently smoke or have quit within the past 15 y. A process of informed and shared decision-making with a clinician related to the potential benefits, limitations, and harms associated with screening for lung cancer with LDCT should occur before any decision is made to initiate lung cancer screening. Smoking cessation counseling remains a hich priority for clinical attention in discussions with</td></tr></table>
======================================
<table><tr><td>CANCER SITE Prostate</td><td>POPULATION Men, age 250 y</td><td>TEST OR PROCEDURE DRE and PSA</td><td>FREQUENCY Men who have at least a 10-y life expectancy should have an opportunity to make an informed decision with their health care provider about whether to be screened for prostate cancer, after receiving information about the potential benefits, risks, and uncertainties associated with prostate cancer screening. Prostate cancer screening should not occur without an informed decision-making process. Men at average risk should receive this information beginning at age 50 years. Men in higher risk groups should receive this information before age 50 years. Men should either receive this information directly from their health care providers or be referred to reliable and culturally appropriate sources. Patient decision aids are helpful in preparing men to make a decision whether to be tested.</td></tr><tr><td>Cancer-related checkup</td><td>Men and women age 220 y</td><td></td><td>On the occasion of a periodic health examination, the cancer- related checkup should include examination for cancers of the thyroid, testicles, ovaries, lymph nodes, oral cavity, and skin, as well as health counseling about tobacco, sun exposure, diet and nutrition, risk factors, sexual practices, and environmental and occupational exposures.</td></tr></table>
======================================
<table><thead><th>GENERIC NAME</th><th>TRADE NAME</th><th>| TARGET</th><th>FDA-APPROVED INDICATIONS</th></thead><tr><td>Ado-trastuzumab emtansine</td><td>| Kadcyla</td><td>HER2</td><td>Breast cancer</td></tr><tr><td>Axitinib</td><td>Inlyta</td><td>KIT, FDGFRB, VEGFRI1/2/3</td><td>RCC</td></tr><tr><td>Bevacizumab</td><td>Avastin</td><td>VEGF</td><td>Colorectal cancer, lung cancer, glioblastoma, NSCLC RCC</td></tr><tr><td>Bortezomib</td><td>Velcade</td><td>Proteasome</td><td>Myeloma</td></tr><tr><td>Bosutinib</td><td>Bosulif</td><td>ABL</td><td>CML (Philadelphia chromosome+)</td></tr><tr><td>Cabozantinib</td><td>Cometriq</td><td>FLT3, KIT, MET, RET, VEGR2</td><td>Medullary thyroid cancer</td></tr><tr><td>Cetuximab</td><td>Erbitux</td><td>EGFR</td><td>Colorectal cancer (KRAS wild-type) Squamous cell cancer of the head and neck</td></tr><tr><td>Crizotinib</td><td>Xalkori</td><td>ALK (anaplastic lymphoma kinase) and | ROS1 (c-ros oncogene 1) inhibitor</td><td>Non-small cell lung carcinoma</td></tr><tr><td>Dabrafenib</td><td>Tafinolar</td><td>BRAF V600E mutation</td><td>Melanoma</td></tr><tr><td>Dasatinib</td><td>Sprycel</td><td>ABL, src family, KIT, EPHA2, PDGFR-B</td><td>| CML</td></tr><tr><td>Erlotinib</td><td>Tarceva</td><td>EGFR</td><td>NSCLC, Pancreatic cancer</td></tr><tr><td>Gefitinib</td><td>Iressa</td><td>EGFR</td><td>astrocytoma associated with tuberous sclerosis NSCLC with known/previous benefit from gefitinib (limited approval)</td></tr><tr><td>Tbrutinib</td><td>Imbruvica</td><td>Bruton’s Tyrosine Kinase</td><td>Chronic lymphocytic leukemia</td></tr><tr><td>Imatinib</td><td>Gleevec</td><td>KIT, ABL, PDGFR</td><td>CML, GIST (KIT+), Dermatofibrosarcoma protuberans</td></tr><tr><td>Lapatinib</td><td>Tykerb</td><td>EGFR and HER2</td><td>Breast cancer (HER2+)</td></tr><tr><td>Nilotinib</td><td>Tasigna</td><td>ABL</td><td>CML (Philadelphia chromosome+)</td></tr><tr><td>Panitumumab</td><td>Vectibix</td><td>EGFR</td><td>Colorectal cancer (KRAS wild type)</td></tr><tr><td>Pazopanib</td><td>Votrient</td><td>VEGEFR, PDGFR, KIT</td><td>RCC</td></tr><tr><td>Pertuzumab</td><td>Perjeta</td><td>HER2</td><td>Breast cancer (HER+)</td></tr><tr><td>Ponatinib</td><td>Iclusig</td><td>ABL, FGFR1-3, FLT3, VEGFR2</td><td>CML, ALL (Philadelphia chromosome+)</td></tr><tr><td>Regorafenib</td><td>Stivarga</td><td>KIT, PDGFRB, RAF, RET, VEGFR1/2/3 |</td><td>Colorectal cancer, GIST</td></tr><tr><td>Sorafenib</td><td>Nexavar</td><td>VEGEFR, PDGFR, KIT, RAF</td><td>HCC RCC</td></tr><tr><td>Sunitinib</td><td>Sutent</td><td>VEGFR PDGER KIT, Fit-3, RET</td><td>GIST, RCC,</td></tr></table>
======================================
<table><tr><td>ORGAN</td><td>ACUTE CHANGES</td><td>CHRONIC CHANGES</td></tr><tr><td>Skin</td><td>Erythema, wet or dry desquamation, epilation</td><td>Telangiectasia, subcutaneous fibrosis, ulceration</td></tr><tr><td>GI tract</td><td>Nausea, diarrhea, edema, ulceration, hepatitis</td><td>Stricture, ulceration, perforation, hematochezia</td></tr><tr><td>Kidney</td><td>—_—</td><td>Nephropathy, renal insufficiency</td></tr><tr><td>Bladder</td><td>Dysuria</td><td>Hematuria, ulceration, perforation</td></tr><tr><td>Gonads</td><td>Sterility</td><td>Atrophy, ovarian failure</td></tr><tr><td>Hematopoietic tissue</td><td>Lymphopenia, neutropenia, thrombocytopenia</td><td>Pancytopenia</td></tr><tr><td>Bone</td><td>Epiphyseal growth arrest</td><td>Necrosis</td></tr><tr><td>Lung</td><td>Pneumonitis</td><td>Pulmonary fibrosis</td></tr><tr><td>Heart</td><td>—_—</td><td>Pericarditis, vascular damage</td></tr><tr><td>Upper aerodigestive tract</td><td>Mucositis, xerostomia, anosmia</td><td>Xerostomia, dental caries</td></tr><tr><td>Eye</td><td>Conjunctivitis</td><td>Cataract, keratitis, optic nerve atrophy</td></tr><tr><td>Nervous system</td><td>Cerebral edema</td><td>Necrosis, myelitis</td></tr></table>
======================================
<table><tr><td>Background</td><td>355</td></tr><tr><td>Definitions</td><td>355</td></tr><tr><td>History</td><td>356</td></tr><tr><td>Transplant Immunobiology</td><td>357</td></tr><tr><td>Transplant Antigens</td><td>358</td></tr><tr><td>Allorecognition Lymphocyte Activation</td><td>358</td></tr><tr><td>Clinical Rejection</td><td>358</td></tr><tr><td>Clinical Immunosuppression</td><td>358</td></tr><tr><td>Induction</td><td>359</td></tr><tr><td>Depleting Antibodies / 359</td><td></td></tr><tr><td>Maintenance</td><td>359</td></tr><tr><td>Corticosteroids / 359</td><td></td></tr><tr><td>Azathioprine / 360</td><td></td></tr><tr><td colspan="2">Mycophenolate Mofetil / 361</td></tr><tr><td colspan="2">Sirolimus / 361</td></tr><tr><td colspan="2">Cyclosporine / 362</td></tr><tr><td>Tacrolimus / 362</td><td></td></tr><tr><td>Belatacept / 362</td><td></td></tr><tr><td>Humoral Rejection</td><td>362</td></tr><tr><td>Rituximab / 362</td><td></td></tr></table>
======================================
<table><thead><th>Transplant history</th><th></th><th></th><th></th></thead><thead><th>ORGAN</th><th>YEAR</th><th>SURGEON</th><th>LOCATION</th></thead><tr><td>Kidney</td><td>954</td><td>Joseph E. Murray</td><td>Boston, MA</td></tr><tr><td>Liver</td><td>963</td><td>Thomas E. Starzl</td><td>Denver, CO</td></tr><tr><td>Lung</td><td>963</td><td>James D. Hardy</td><td>Jackson, MS</td></tr><tr><td>Pancreas</td><td>966</td><td>Richard C. Lillehei</td><td>Minneapolis, MN</td></tr><tr><td>Heart</td><td>967</td><td>Christiaan N. Barnard</td><td>Cape Town, South Africa</td></tr><tr><td>Small intestine</td><td>967</td><td>Richard C. Lillehei</td><td>Minneapolis, MN</td></tr><tr><td>Heart/lung</td><td>981</td><td>Bruce Reitz</td><td>Stanford, CA</td></tr><tr><td>Multivisceral</td><td>989</td><td>Thomas E. Starzl</td><td>Pittsburgh, PA</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>MECHANISM OF ACTION</th><th>ADVERSE EFFECTS</th><th>CLINICAL USES</th><th>DOSAGE</th></thead><tr><td>Cyclosporine (CSA)</td><td>Binds to cyclophilin Inhibits calcineurin and | IL-2 synthesis</td><td>Nephrotoxicity Tremor Hypertension Hirsutism</td><td>Improved bioavailability of microemulsion form</td><td>Oral dose 5 mg/kg per day (given in two divided doses)</td></tr><tr><td>Tacrolimus (FK506)</td><td>Binds to FKBP Inhibits calcineurin and IL-2 synthesis</td><td>Nephrotoxicity | Hypertension Neurotoxicity GI toxicity (nausea, diarrhea)</td><td>Improved patient and graft survival in (liver) primary immunosuppression and. rescue therapy Used as mainstay of maintenance protocols</td><td>IV 0.015 mg/kg per day as continuous infusio! PO 0.05 mg/kg per day (given every 12 h)</td></tr><tr><td>Mycophenolate mofetil</td><td>| Antimetabolite Inhibits enzyme necessary for de novo purine synthesis</td><td>Leukopenia GI toxicity</td><td>Effective for primary immunosuppression in combination with tacrolimus</td><td>1 g bid PO</td></tr><tr><td>Sirolimus</td><td>Inhibits lymphocyte effects driven by IL-2 | receptor</td><td>Thrombocytopenia Increased serum cholesterol/LDL Poor wound healing</td><td>May allow early withdrawal of steroids and decreased calcineurin doses</td><td>2-4 mg/d, adjusted to trough drug levels</td></tr><tr><td>Corticosteroids</td><td>| Multiple actions Anti-inflammatory Inhibits lymphokine production</td><td>Cushingoid state Glucose intolerance Osteoporosis.</td><td>Used in induction, maintenance, and treatment of acute rejection</td><td>| Varies from milligrams to several grams per day Maintenance doses, 5-10 mg/d</td></tr><tr><td>Azathioprine</td><td>Antimetabolite Interferes with DNA and | RNA synthesis</td><td>Thrombocytopenia Neutropenia Liver dysfunction</td><td>Used in maintenance protocols or if intolerance to mycophenolate mofetil</td><td>| 1-3 mg/kg per day for maintenance</td></tr><tr><td>Belatacept</td><td>T-cell blocker</td><td>Increased risk of bacterial infections</td><td>New drug for maintenance immunosuppression in renal transplants only</td><td>5-10 mg/kg per day infusion</td></tr></table>
======================================
<table><thead><th></th><th>COMMON SIDE EFFECTS</th><th>OTHER MEDICATIONS THAT INCREASE BLOOD LEVELS</th><th>OTHER MEDICATIONS THAT DECREASE BLOOD LEVELS</th><th>OTHER MEDICATIONS THAT POTENTIATE TOXICITY</th></thead><tr><td>Cyclosporine | (CSA)</td><td>Hypertension, nephrotoxicity, hirsutism, neurotoxicity, gingival hyperplasia, hypomagnesemia, hyperkalemia</td><td>| Verapamil, diltiazem, clarithromycin, azithromycin, erythromycin, azole antifungals, protease inhibitors, grapefruit juice</td><td>Isoniazid, carbamazepine, | phenobarbital, phenytoin, rifampin, St. John’s wort</td><td>Nephrotoxicity: ganciclovir, aminoglycosides, NSAIDs, ACE-Is, and ARBs</td></tr><tr><td>Tacrolimus (FK506)</td><td>Hypertension, nephrotoxicity, alopecia, hyperglycemia, neurotoxicity, hypomagnesemia, hyperkalemia</td><td>| Verapamil, diltiazem, clarithromycin, azithromycin, erythromycin, azole antifungals, protease inhibitors, grapefruit juice</td><td>Isoniazid, carbamazepine, | phenobarbital, phenytoin, rifampin, St. John’s wort</td><td>Nephrotoxicity: ganciclovir, aminoglycosides, NSAIDs, ACE-Is, and ARBs</td></tr><tr><td>Sirolimus</td><td>Thrombocytopenia and neutropenia, elevated cholesterol, extremity edema, impaired wound healing</td><td>Verapamil, diltiazem, clarithromycin, azithromycin, erythromycin, azole antifungals, protease inhibitors, grapefruit juice</td><td>Isoniazid, carbamazepine, | _ phenobarbital, phenytoin, rifampin, St. John’s wort</td><td>—</td></tr><tr><td>Mycophenolate mofetil</td><td>Leukopenia, thrombocytopenia, GI upset</td><td>—</td><td>Cholestyramine, antacids</td><td>Bone marrow suppression: valganciclovir, ganciclovir, TMP-SMX</td></tr><tr><td>Corticosteroids</td><td>Hyperglycemia, osteoporosis, cataracts, myopathy, weight gain</td><td>|—</td><td>—</td><td>—</td></tr><tr><td>Azathioprine |</td><td>Leukopenia, anemia, thrombocytopenia, neoplasia, hepatitis, cholestasis</td><td>—</td><td>_—</td><td>Bone marrow suppression: allopurinol, sulfonamides</td></tr></table>
======================================
<table><thead><th>INTERACTIONS</th><th>MEDICATIONS</th></thead><tr><td>Inhibition of metabolism</td><td>Clarithromycin, erythromycin, azole antifungals, diltiazem, verapamil, nicardipine, amiodarone, grapefruit juice, ritonavir, azithromycin</td></tr><tr><td>Induction of metabolism</td><td>Nevirapine, rifampin, St. John’s wort, carbamazepine, phenobarbital, phenytoin, caspofungin</td></tr><tr><td>Hyperkalemia</td><td>Potassium-sparing diuretics, angiotensin- converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), B-blockers, trimethoprim-sulfamethoxazole</td></tr><tr><td>Nephrotoxicity</td><td>Nonsteroidal anti-inflammatory drugs, aminoglycosides, amphotericin, ACE-Is, ARBs</td></tr></table>
======================================
<table><thead><th>Leading causes of intestine</th><th>failure</th></thead><tr><td>CHILDREN</td><td>ADULTS</td></tr><tr><td>Gastroschisis</td><td>Visceral ischemia secondary to SMA/SMV thrombosis</td></tr><tr><td>Midgut volvulus</td><td>Crohn’s disease</td></tr><tr><td>Intestinal atresia</td><td>Trauma</td></tr><tr><td>Necrotizing enterocolitis</td><td>Mesenteric desmoid tumors</td></tr><tr><td>Microvillus involution disease</td><td>Radiation enteritis</td></tr><tr><td>Hirschsprung’s disease</td><td>Massive resection secondary to tumors</td></tr><tr><td>Crohn’s disease</td><td>Chronic intestinal pseudo-obstruction</td></tr><tr><td>Pseudo-obstruction</td><td>Autoimmune enteropathy</td></tr></table>
======================================
<table><tr><td>Medical Care Gone Wrong / 397</td><td></td></tr><tr><td>Unnecessary Medical Care / 398</td><td></td></tr><tr><td>The Science of Patient Safety</td><td>399</td></tr><tr><td>High Reliability Organizations / 399</td><td></td></tr><tr><td>Creating a Culture of Safety</td><td>400</td></tr><tr><td>Assessing an Organization's Safety Culture / 401</td><td></td></tr><tr><td>Teamwork and Communication</td><td>402</td></tr><tr><td>Measuring Teamwork / 402 Communication Tools</td><td>402</td></tr><tr><td colspan="2">Operating Room Briefings (A Surgical Checklist) / 402</td></tr><tr><td colspan="2">Operating Room Debriefings / 403</td></tr></table>
======================================
<table><tr><td>he Joint Commission Universal to Ensure Correct Surgery / 411</td><td>Protocol</td></tr><tr><td>Transparency in Healthcare Public Reporting and Patient Assessment of Care / 412</td><td>412</td></tr><tr><td>Managing Risk / 413 Complications</td><td>415</td></tr><tr><td>Complications in Minor Procedures</td><td>/ 415</td></tr></table>
======================================
<table><thead><th>i61y</th><th>90%</th><th></th><th>87%</th><th></th></thead><tr><td colspan="5">80% AeA</td></tr><tr><td>Jo</td><td>70% uolperoge||oo</td><td></td><td></td><td></td></tr><tr><td>yBiy</td><td>60% yo</td><td></td><td></td><td></td></tr><tr><td>se</td><td></td><td></td><td></td><td>48%</td></tr><tr><td></td><td>50% Ayyenb</td><td></td><td></td><td></td></tr><tr><td colspan="5">40% uoledluNWWOD</td></tr><tr><td></td><td>30% Bulyes</td><td></td><td></td><td></td></tr><tr><td></td><td>20%</td><td></td><td></td><td></td></tr><tr><td>pu</td><td>3 c 10% jusose8q4</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th rowspan="2">CAREGIVER POSITION PERFORMING RATING</th><th colspan="4">CAREGIVER POSITION BEING RATED</th></thead><thead><th></th><th>SURGEON</th><th>ANESTHESIOLOGIST</th><th>NURSE</th><th>CRNA</th></thead><tr><td>Surgeon</td><td>85</td><td>84</td><td>88</td><td>87</td></tr><tr><td>Anesthesiologist</td><td>70</td><td>96</td><td>89</td><td>92</td></tr><tr><td>Nurse</td><td>48</td><td>63</td><td>81</td><td>68</td></tr><tr><td>CRNA</td><td>58</td><td>75</td><td>716</td><td>93</td></tr></table>
======================================
<table><thead><th>1. Coronary artery bypass graft</th><th>2450/100</th></thead><tr><td>2. Percutaneous coronary intervention</td><td>2400/75</td></tr><tr><td>3. Abdominal aortic aneurysm repair</td><td>250/22</td></tr><tr><td>4. Aortic valve replacement</td><td>2120/22</td></tr><tr><td>5. Pancreatic resection</td><td>211/2</td></tr><tr><td>6. Esophagectomy</td><td>213/2</td></tr><tr><td>7. Bariatric surgery</td><td>&gt;100/20</td></tr></table>
======================================
<table><thead><th>PATIENT</th><th>INSTITUTION</th><th>YEAR</th><th>| EVENT</th><th>ROOT CAUSE</th><th>OUTCOME</th></thead><tr><td>Libby Zion</td><td>New York Hospital, New York, NY</td><td>1984</td><td>| Missed allergy to Demerol</td><td>Physician fatigue</td><td>Bell Commission shortened resident work hours</td></tr><tr><td>Betsy Lehman</td><td>| Dana-Farber Cancer Institute, Boston, MA</td><td>1994</td><td>| Chemotherapy overdose</td><td>Lack of medication checks and triggers</td><td>| Fired doctor, three pharmacists, 15 nurses; overhauled safety program</td></tr><tr><td>Josie King</td><td>Johns Hopkins Hospital, Baltimore, MD</td><td>2001</td><td>| Severe dehydration</td><td>| Poor communication</td><td>Increased safety research funding</td></tr><tr><td>Mike Hurewitz</td><td>| Mt. Sinai Hospital, New York, NY</td><td>| 2002</td><td>| Inadequate postoperative care</td><td>Inadequate supervision</td><td>Transplant program shut down until better patient safety safeguards implemented</td></tr></table>
======================================
<table><thead><th>YOUR CARE FROM DOCTORS</th><th colspan="2">YOUR EXPERIENCES IN THIS HOSPITAL</th></thead><thead><th>During this hospital stay, how often did doctors treat you with courtesy and respect?</th><th rowspan="3">10.</th><th>During this hospital stay, did you need help from nurses or other hospital staff in getting to the</th></thead><tr><td>1D Never</td><td></td><td>bathroom or in using a bedpan?</td></tr><tr><td>210 Sometimes</td><td></td><td>‘DO Yes</td></tr><tr><td>8X0 Usually</td><td></td><td>21) No =} If No, Go to Question 12</td></tr><tr><td>41 Always</td><td>11.</td><td>How often did you get help in getting</td></tr><tr><td>During this hospital stay, how often did doctors listen carefully to you?</td><td></td><td>to the bathroom or in using a bedpan as soon as you wanted?</td></tr><tr><td>1D Never</td><td></td><td>‘DO Never</td></tr><tr><td>21 Sometimes</td><td></td><td>21 Sometimes</td></tr><tr><td>81 Usually</td><td></td><td>800 Usually</td></tr><tr><td>41 Always</td><td></td><td>410 Always</td></tr><tr><td>During this hospital stay, how often did doctors explain things in a way</td><td>12.</td><td>During this hospital stay, did you have any pain?</td></tr><tr><td>you could understand?</td><td></td><td>‘DO Yes</td></tr><tr><td>1D Never</td><td></td><td>21] No = If No, Go to Question 15</td></tr><tr><td>210 Sometimes</td><td></td><td></td></tr><tr><td></td><td>13.</td><td>this how often</td></tr><tr><td>3 Usually</td><td></td><td>During hospital stay,</td></tr><tr><td>410 Always</td><td></td><td>did hospital staff talk with you about how much pain you had?</td></tr><tr><td></td><td></td><td>‘1</td></tr><tr><td>THE HOSPITAL ENVIRONMENT</td><td></td><td>Never</td></tr><tr><td></td><td></td><td>21 Sometimes</td></tr><tr><td></td><td></td><td>800</td></tr><tr><td>During this hospital stay, how often were your room and bathroom kept clean?</td><td></td><td>Usually 410 Always</td></tr><tr><td>1D Never</td><td>14.</td><td>During this hospital stay, how often</td></tr><tr><td>2L] Sometimes</td><td></td><td>did hospital staff talk with you about how to treat your pain?</td></tr><tr><td>3 Usually</td><td rowspan="7"></td><td rowspan="7">1D Never 211 Sometimes 3Z0 Usually 41 Always</td></tr><tr><td>410 Always</td><td></td><td></td></tr><tr><td>During this hospital stay, how often was the area around your room quiet at night?</td><td></td><td></td></tr><tr><td>‘DZ Never</td><td></td><td></td></tr><tr><td>210 Sometimes</td><td></td><td></td></tr><tr><td>8X0 Usually</td><td></td><td></td></tr><tr><td>417 Always</td><td></td><td></td></tr></table>
======================================
<table><thead><th>ELECTROLYTE IMBALANCE</th><th>| TOXINS</th><th>TRAUMA</th><th>METABOLIC</th><th>MEDICATIONS</th></thead><tr><td>Sodium</td><td>Ethanol</td><td>Closed head injury</td><td>Thyrotoxicosis</td><td>Aspirin</td></tr><tr><td>Magnesium</td><td>Methanol</td><td>Pain</td><td>Adrenal insufficiency</td><td>B-Blockers</td></tr><tr><td>Calcium</td><td>Venoms and poisons</td><td>Shock</td><td>Hypoxemia</td><td>Narcotics</td></tr><tr><td>Inflammation</td><td>Ethylene glycol</td><td>Psychiatric</td><td>Acidosis</td><td>Antiemetics</td></tr><tr><td>Sepsis</td><td>Carbon monoxide</td><td>Dementia</td><td>Severe anemia</td><td>MAOIs</td></tr><tr><td>AIDS</td><td></td><td>Depression</td><td>Hyperammonemia</td><td>TCAs</td></tr><tr><td>Cerebral abscess</td><td></td><td>ICU psychosis</td><td>Poor glycemic control</td><td>Amphetamines</td></tr><tr><td>Meningitis</td><td></td><td>Schizophrenia</td><td>Hypothermia</td><td>Antiarrhythmics</td></tr><tr><td>Fever/hyperpyrexia</td><td></td><td></td><td>Hyperthermia</td><td>Corticosteroids, anabolic steroids</td></tr></table>
======================================
<table><thead><th>UPPER GI BLEED</th><th>LOWER GI BLEED</th></thead><tr><td>Erosive esophagitis</td><td>Angiodysplasia</td></tr><tr><td>Gastric varices</td><td>Radiation proctitis</td></tr><tr><td>Esophageal varices</td><td>Hemangioma</td></tr><tr><td>Dieulafoy’s lesion</td><td>Diverticulosis</td></tr><tr><td>Aortoduodenal fistula</td><td>Neoplastic diseases</td></tr><tr><td>Mallory-Weiss tear</td><td>Trauma</td></tr><tr><td>Peptic ulcer disease</td><td>Vasculitis</td></tr><tr><td>Trauma</td><td>Hemorrhoids</td></tr><tr><td rowspan="4">Neoplastic disease</td><td>Aortoenteric fistula</td></tr><tr><td></td><td>Intussusception</td></tr><tr><td></td><td>Ischemic colitis</td></tr><tr><td></td><td>Inflammatory bowel disease</td></tr></table>
======================================
<table><thead><th></th><th>FE,,</th><th>|</th><th>OSMOLARITY</th><th>| UR,,</th><th>| ETIOLOGY</th></thead><tr><td>Prerenal</td><td>&lt;1</td><td>| &gt;500</td><td></td><td>&lt;20</td><td>| CHF, cirrhosis</td></tr><tr><td>Intrinsic failure</td><td>|&gt;1 |</td><td>&lt;350</td><td></td><td>&gt;40</td><td>| Sepsis, shock</td></tr></table>
======================================
<table><thead><th>HIV</th><th>1:1.9 million</th></thead><tr><td>HBV?</td><td>1:137,000</td></tr><tr><td>HCV</td><td>1:1 million</td></tr></table>
======================================
<table><thead><th>PROGNOSIS</th><th>MORTALITY (%)</th></thead><tr><td>2 SIRS criteria</td><td>5</td></tr><tr><td>3 SIRS criteria</td><td>10</td></tr><tr><td>4 SIRS criteria</td><td>15-20</td></tr></table>
======================================
<table><thead><th>HYPERTHERMIA</th><th>HYPERPYREXIA</th></thead><tr><td>Environmental</td><td>Sepsis</td></tr><tr><td>Malignant hyperthermia</td><td>Infection</td></tr><tr><td>Neuroleptic malignant syndrome</td><td>Drug reaction</td></tr><tr><td>Thyrotoxicosis</td><td>Transfusion reaction</td></tr><tr><td>Pheochromocytoma</td><td>Collagen disorders</td></tr><tr><td>Carcinoid syndrome</td><td>Factitious syndrome</td></tr><tr><td>Tatrogenic</td><td>Neoplastic disorders</td></tr><tr><td colspan="2">Central/hypothalamic responses</td></tr><tr><td colspan="2">Pulmonary embolism</td></tr><tr><td>Adrenal insufficiency</td><td></td></tr></table>
======================================
<table><thead><th>Introduction</th><th>433</th></thead><tr><td>Arterial Blood Pressure</td><td>434</td></tr><tr><td>Noninvasive Measurement of Arterial Blood Pressure / 434</td><td></td></tr><tr><td>Algorithmic Integrative Monitoring</td><td>436</td></tr><tr><td>Placement of the Pulmonary Artery Catheter</td><td>437</td></tr><tr><td>Hemodynamic Measurements</td><td>438</td></tr><tr><td>Measurement of Cardiac Output by Thermodilution / 439</td><td></td></tr></table>
======================================
<table><thead><th>PARAMETER</th><th>NORMAL RANGE</th></thead><tr><td>CVP</td><td>0-6 mmHg</td></tr><tr><td>PAP</td><td>Varies</td></tr><tr><td>PAOP</td><td>6-12 mmHg</td></tr><tr><td>SvO, (intermittent or continuous)</td><td>65%-10%</td></tr><tr><td>Q, (intermittent or continuous)</td><td>4-6 L/min</td></tr><tr><td>Q,* (intermittent or continuous)</td><td>2.5-3.5 L-min-m2</td></tr><tr><td>RVEF</td><td>&gt;55%</td></tr><tr><td>SV</td><td>40-80 mL</td></tr><tr><td>SVR</td><td>800-1400 dyne-sec-em™&gt;</td></tr><tr><td>SVRI</td><td>1500-2400 dyne-sec-cm™-m</td></tr><tr><td>PVR</td><td>100-150 dyne-sec-em*&gt;</td></tr><tr><td>PVRI</td><td>200-400 dyne-sec-cm™&gt;-m?</td></tr><tr><td>RVEDV</td><td>Variable</td></tr><tr><td>DO,</td><td>400-660 mL-min-!-m~</td></tr><tr><td>vo,</td><td>115-165 mL-min--m2</td></tr><tr><td>ER</td><td>Variable</td></tr><tr><td></td><td>Variable</td></tr></table>
======================================
<table><thead><th>AUTHOR Pearson al?</th><th>STUDY POPULATION “Low risk” patients</th><th>| GROUPS | CVP catheter</th><th>OUTCOMES No differences among groups for mortality</th><th>STRENGTHS/WEAKNESSES _Underpowered (266 total</th></thead><thead><th>Tuman</th><th>vascular surgery Cardiac surgical</th><th>with continuous Sv O, readout (group 3) PAC; CVP</th><th>| &lt; group 3) No differences between groups for</th><th>protocols Large trial (1094 patients);</th></thead><tr><td>et al’? Bender</td><td>patients Vascular surgery</td><td>PAC; CVP</td><td>mortality, length of ICU stay, or significant noncardiac complications No differences between groups for</td><td>different anesthesiologists for different groups Relatively underpowered</td></tr><tr><td>et al Valentine</td><td>patients | Aortic surgery</td><td>PAC +</td><td>mortality, length of ICU stay, or length of hospital stay No difference between groups for</td><td>Relatively underpowered</td></tr><tr><td>et al?</td><td>patients</td><td>hemodynamic optimization in ICU night before surgery; CVP</td><td>mortality or length of ICU stay; significantly higher incidence of postoperative complications in PAC group</td><td></td></tr><tr><td>Sandham et al?®</td><td>| “High risk” major surgery</td><td>| PAC; CVP</td><td>No differences between groups for mortality, length of ICU stay; increased incidence of pulmonary embolism in PAC group</td><td>Largest RCT of PAC utilization; commonly criticized for smaller number of highest risk category patients</td></tr><tr><td>Harvey S| et al?’ PAC-Man Trial</td><td>Medical and surgical ICU patients</td><td>PAC vs no PAC, | with option for alternative CO measuring device in non- PAC group</td><td>No difference in hospital mortality between the 2 groups, increased incidence of complications in the PAC group</td><td>Loose inclusion criteria with lack of a defined treatment protocol for use of PAC data</td></tr><tr><td>Binanay et al”? ESCAPE Trial</td><td>Patients with CHF</td><td>|PAC vsnoPAC</td><td>No difference in hospital mortality between the groups, increased incidence of adverse events in the PAC group</td><td>No formal treatment protocol for PAC-driven therapy</td></tr><tr><td>Wheeler et al? FACTT Trial</td><td>| Patients with ALI</td><td>| PAC vs CVC with a fluid and inotropic management protocol</td><td>No difference in ICU or hospital mortality, or incidence of organ failure between the groups; increased incidence of adverse events in the PAC group</td><td></td></tr></table>
======================================
<table><thead><th>CONDITION</th><th>peak</th><th>plateau</th></thead><tr><td>Decreased compliance of the system (ARDS, abdominal distention, intrinsic PEEP)</td><td>tT</td><td>tT</td></tr><tr><td colspan="3">Increase in airway resistance tT normal (bronchospasm, endotracheal tube obstruction/kinking, or small-caliber endotracheal tube)</td></tr><tr><td>Disconnected circuit</td><td></td><td></td></tr></table>
======================================
<table><tr><td>5-7</td><td>Normal</td></tr><tr><td colspan="2">In the absence of organ dysfunction:</td></tr><tr><td>12-15</td><td>Grade I JAH</td></tr><tr><td>16-20</td><td>Grade II IAH</td></tr><tr><td colspan="2">21-25 Grade III IAH</td></tr><tr><td colspan="2">&gt;25 Grade IV IAH</td></tr><tr><td colspan="2">In the presence of new onset organ dysfunction:</td></tr><tr><td>&gt;20</td><td>ACS</td></tr></table>
======================================
<table><thead><th rowspan="2">BASIC Appendectomy</th><th colspan="2">ADVANCED</th></thead><thead><th></th><th>Nissen fundoplication</th><th>Lymph node dissection</th></thead><tr><td>Cholecystectomy</td><td>| Heller myotomy</td><td>Robotics</td></tr><tr><td>Inguinal hernia repair</td><td>Paraesophageal hernia</td><td>Bariatric</td></tr><tr><td rowspan="7">Enteral access</td><td>Gastrectomy</td><td>Complex abdominal wall reconstruction</td></tr><tr><td></td><td>Lysis of adhesions</td><td>| Esophagectomy</td></tr><tr><td></td><td>Bile duct exploration</td><td>Hepatectomy</td></tr><tr><td></td><td>Colectomy</td><td>Pancreatectomy</td></tr><tr><td></td><td>Splenectomy</td><td>Prostatectomy</td></tr><tr><td></td><td>Adrenalectomy</td><td>Hysterectomy</td></tr><tr><td></td><td>Nephrectomy</td><td></td></tr></table>
======================================
<table><thead><th>MODALITY</th><th>TECHNIQUE</th></thead><tr><td></td><td>Ultrasound</td></tr><tr><td>Fracture Dilate</td><td>Ultrasound Endoscopic biopsy Balloon Balloon</td></tr><tr><td></td><td>Angioplasty Endoscope</td></tr><tr><td>Bypass</td><td>Transvenous intrahepatic portosystemic shunt Surgical (synthetic or autologous conduit)</td></tr><tr><td>Stent</td><td>Self-expanding metal stent Plastic stent</td></tr></table>
======================================
<table><thead><th>INSTRUMENTATION</th><th>BENEFIT TO SURGEON</th></thead><tr><td>Slimline instruments with low-profile design</td><td>Reduces internal and external clashing</td></tr><tr><td>Varied-length instruments</td><td>Reduces extracorporeal clashing</td></tr><tr><td>Longer instruments</td><td>Advantageous for reaching the surgical field</td></tr><tr><td>Articulating (or prebent) instruments</td><td>Restore triangulation</td></tr><tr><td>Small-diameter, low-profile angle scope</td><td>Reduces clashing by providing additional space</td></tr><tr><td>High-definition camera</td><td>Achieves high-quality images for intraoperative visualization</td></tr></table>
======================================
<table><tr><td>YEAR</td><td>INVESTIGATOR</td><td>EVENT</td></tr><tr><td>1865</td><td>Mendel</td><td>Laws of genetics established</td></tr><tr><td>1869</td><td>Miescher</td><td>DNA isolated</td></tr><tr><td>1905</td><td>Garrod</td><td>Human inborn errors of metabolism</td></tr><tr><td>1913</td><td>Sturtevant</td><td>Linear map of genes</td></tr><tr><td>1927</td><td>Muller</td><td>X-rays cause inheritable genetic damage</td></tr><tr><td>1928</td><td>Griffith</td><td>Transformation discovered</td></tr><tr><td>1941</td><td>Beadle and Tatum</td><td>“One gene, one enzyme” concept</td></tr><tr><td>1944</td><td>Avery, MacLeod, McCarty</td><td>DNA as material of heredity</td></tr><tr><td>1950</td><td>McKlintock</td><td>Existence of transposons confirmed</td></tr><tr><td>1953</td><td>Watson and Crick</td><td>Double-helical structure of DNA</td></tr><tr><td>1957</td><td>Benzer and Kornberg</td><td>Recombination and DNA polymerase</td></tr><tr><td>1966</td><td>Nirenberg, Khorana, Holley</td><td>Genetic code determined</td></tr><tr><td>1970</td><td>Temin and Baltimore</td><td>Reverse transcriptase</td></tr><tr><td>1972</td><td>Cohen, Boyer, Berg</td><td>Recombinant DNA technology</td></tr><tr><td>1975</td><td>Southern</td><td>Transfer of DNA fragments from sizing gel to nitrocellulose (Southern blot)</td></tr><tr><td>1977</td><td>Sanger, Maxim, Gilbert</td><td>DNA sequencing methods</td></tr><tr><td>1982</td><td>_</td><td>GenBank database established</td></tr><tr><td>1985</td><td>Mullis</td><td>Polymerase chain reaction</td></tr><tr><td>1986</td><td>_</td><td>Automated DNA sequencing</td></tr><tr><td>1989</td><td>Collins</td><td>Cystic fibrosis gene identified by positional cloning and linkage analysis</td></tr><tr><td>1990</td><td>=</td><td>Human Genome Project initiated</td></tr><tr><td>1997</td><td>Roslin Institute</td><td>Mammalian cloning (Dolly)</td></tr><tr><td>2001</td><td>IHGSC and Celera Genomics</td><td>Draft versions of human genome sequence published</td></tr></table>
======================================
<table><tr><td rowspan="16">irst Base in Codon</td><td>UUU</td><td>Phe |</td><td>[F]</td><td>UCU</td><td>|Ser</td><td>|[S]</td><td>|UAU |</td><td>Tyr</td><td>[Y]</td><td>|UGU</td><td>|Cys</td><td>C)</td><td>U</td><td>Third Base in Codon</td></tr><tr><td></td><td>UUC</td><td>Phe |</td><td>[F]</td><td>UCC</td><td>|Ser</td><td>|[S]</td><td>|UAC</td><td>| Tyr</td><td>[Y]</td><td>|UGC</td><td>|Cys</td><td>C]</td><td>a</td><td></td></tr><tr><td></td><td>UUA</td><td>Leu</td><td>}[L]</td><td>UCA</td><td>|Ser</td><td>|[S]</td><td>|UAA</td><td>|STOP</td><td>|—</td><td>|UGA</td><td>|STOP</td><td>|—</td><td>A</td><td></td></tr><tr><td></td><td>UUG</td><td>Leu</td><td>}[L]</td><td>UCG</td><td>|Ser</td><td>|[S]</td><td>|UAG</td><td>|STOP</td><td>|—</td><td>|UGG</td><td>| Trp</td><td>W)]</td><td>|G</td><td></td></tr><tr><td></td><td>CUU</td><td>Leu</td><td>}[L]</td><td>CCU</td><td>|Pro</td><td>§[P]</td><td>|CAU</td><td>His</td><td>[H]</td><td>|CGU</td><td>| Arg</td><td>R]</td><td>U</td><td></td></tr><tr><td></td><td>CUC</td><td>| Leu }</td><td>[L]</td><td>CCC</td><td>|Pro</td><td>|[P]</td><td>|CAC |</td><td>His</td><td>{[H]</td><td>|CGC</td><td>| Arg</td><td>R]</td><td>a</td><td></td></tr><tr><td></td><td>CUA |</td><td>Leu</td><td>}[L]</td><td>CCA</td><td>|Pro</td><td>|[P]</td><td>|CAA</td><td>| Gln</td><td>[Q]</td><td>|CGA</td><td>|Arg |</td><td>[R]</td><td>A</td><td></td></tr><tr><td></td><td>CUG |</td><td>Leu</td><td>}[L]</td><td>CCG</td><td>|Pro</td><td>|[P]</td><td>|CAG</td><td>| Gln</td><td>[Q]</td><td>|CGG</td><td>| Arg</td><td>R]</td><td>G</td><td></td></tr><tr><td></td><td>AUU</td><td>|Ile</td><td>| [I]</td><td>ACU</td><td>|Thr</td><td>|[T]</td><td>|AAU</td><td>(Asn</td><td>|[N]</td><td>| AGU</td><td>| Ser</td><td>S]</td><td>U</td><td></td></tr><tr><td></td><td>AUC</td><td>|Ile |</td><td>[I]</td><td>ACC</td><td>|Thr</td><td>|[T]</td><td>|AAC</td><td>(Asn</td><td>|[N]</td><td>| AGC</td><td>| Ser</td><td>S]</td><td>a</td><td></td></tr><tr><td></td><td>AUA J</td><td>Ile |</td><td>[I]</td><td>ACA</td><td>|Thr</td><td>|[T]</td><td>|AAA |</td><td>Lys</td><td>[K]</td><td>| AGA</td><td>| Arg</td><td>R]</td><td>A</td><td></td></tr><tr><td></td><td>AUG</td><td>Met</td><td>|[M]</td><td>|ACG</td><td>/Thr</td><td>|[T]</td><td>| AAG |</td><td>Lys</td><td>[K]</td><td>| AGG</td><td>| Arg</td><td>R]</td><td>G</td><td></td></tr><tr><td></td><td>GUU</td><td>| Val</td><td>|[V]</td><td>GCU</td><td>|Ala</td><td>|[A]</td><td>|}|GAU</td><td>|Asp_</td><td>|[D]</td><td>|GGU</td><td>|Gly</td><td>G</td><td>U</td><td></td></tr><tr><td></td><td>GUC</td><td>| Val</td><td>|[V]</td><td>GCC</td><td>|Ala</td><td>|[A]</td><td>|}|GAC</td><td>|Asp_</td><td>|[D]</td><td>| GGC</td><td>|Gly</td><td>[G</td><td>€</td><td></td></tr><tr><td></td><td>GUA</td><td>| Val</td><td>|[V]</td><td>GCA</td><td>|Ala</td><td>|[A]</td><td>|GAA</td><td>| Glu</td><td>[E]</td><td>GGA</td><td>|Gly</td><td>[G</td><td>A</td><td></td></tr><tr><td></td><td>GUG</td><td>Val</td><td>| [V]</td><td>GCG</td><td>|Ala</td><td>[A]</td><td>|GAG</td><td>Glu</td><td>[E]</td><td>GGG</td><td>|Gly</td><td>G</td><td>G</td><td></td></tr></table>
======================================
<table><thead><th></th><th>NORMAL</th><th>DISORDER</th><th>DISEASE</th></thead><tr><td rowspan="4">Early reproductive years (age 15-25 y)</td><td>Lobular development</td><td>Fibroadenoma</td><td>Giant fibroadenoma</td></tr><tr><td></td><td>Stromal development</td><td>Adolescent hypertrophy</td><td>Gigantomastia</td></tr><tr><td></td><td>Nipple eversion</td><td>Nipple inversion</td><td>Subareolar abscess</td></tr><tr><td></td><td></td><td></td><td>Mammary duct fistula</td></tr><tr><td rowspan="4">Later reproductive years (age 25-40 y) Involution 35-55</td><td></td><td>Cyclical changes of menstruation</td><td>Cyclical mastalgia</td><td>Incapacitating mastalgia</td></tr><tr><td></td><td></td><td>Nodularity</td><td></td></tr><tr><td></td><td>Epithelial hyperplasia of</td><td>Bloody nipple discharge</td><td></td></tr><tr><td>pregnancy Lobular involution</td><td></td><td></td></tr><tr><td rowspan="5">(age y)</td><td></td><td>Macrocysts Sclerosing lesions</td><td rowspan="5">Periductal mastitis Epithelial hyperplasia with atypia</td></tr><tr><td></td><td>Duct involution</td><td></td><td></td></tr><tr><td></td><td>Dilatation</td><td>Duct ectasia</td><td></td></tr><tr><td></td><td>Sclerosis</td><td>Nipple retraction</td><td></td></tr><tr><td></td><td>Epithelial turnover</td><td>Epithelial hyperplasia</td><td></td></tr></table>
======================================
<table><tr><td>ABNORMALITY</td><td>RELATIVE RISK</td></tr><tr><td>Nonproliferative lesions of the breast</td><td>No increased risk</td></tr><tr><td>Sclerosing adenosis</td><td>No increased risk</td></tr><tr><td>Intraductal papilloma</td><td>No increased risk</td></tr><tr><td>Florid hyperplasia</td><td>1.5 to 2-fold</td></tr><tr><td>Atypical lobular hyperplasia</td><td>4-fold</td></tr><tr><td>Atypical ductal hyperplasia</td><td>4-fold</td></tr><tr><td>Ductal involvement by cells of atypical ductal hyperplasia</td><td>7-fold</td></tr><tr><td>Lobular carcinoma in situ</td><td>10-fold</td></tr><tr><td>Ductal carcinoma in situ</td><td>10-fold</td></tr></table>
======================================
<table><thead><th>Treatment of recurrent</th><th>subareolar sepsis</th></thead><thead><th>SUITABLE FOR FISTULECTOMY</th><th>SUITABLE FOR TOTAL DUCT EXCISION</th></thead><tr><td>Small abscess localized to one segment</td><td>Large abscess affecting &gt;50% of the areolar circumference</td></tr><tr><td>Recurrence involving the same segment</td><td>Recurrence involving a different segment</td></tr><tr><td>Mild or no nipple inversion</td><td>Marked nipple inversion</td></tr><tr><td>Patient unconcerned about nipple inversion</td><td>Patient requests correction of nipple inversion</td></tr><tr><td>Younger patient</td><td>Older patient</td></tr><tr><td>No discharge from other ducts</td><td>Purulent discharge from other ducts</td></tr><tr><td>No prior fistulectomy</td><td>Recurrence after fistulectomy</td></tr></table>
======================================
<table><thead><th colspan="2">elative risk estimates for the Gail model</th></thead><thead><th>ARIABLE</th><th>RELATIVE</th></thead><tr><td colspan="2">.ge at menarche (years)</td></tr><tr><td>214</td><td>.00</td></tr><tr><td>12-13</td><td>10</td></tr><tr><td>&lt;12</td><td>21</td></tr><tr><td colspan="2">(umber of biopsy specimens/history of</td></tr><tr><td colspan="2">benign breast disease, age &lt;50 y</td></tr><tr><td>0</td><td>00</td></tr><tr><td>1</td><td>-70</td></tr><tr><td>22</td><td>2.88</td></tr><tr><td colspan="2">(umber of biopsy specimens/history of</td></tr><tr><td colspan="2">benign breast disease, age &gt;50 y</td></tr><tr><td>(0)</td><td>.02</td></tr><tr><td>1</td><td>27</td></tr><tr><td>22</td><td>62</td></tr><tr><td colspan="2" rowspan="2">ge at first live birth (years) &lt;20y</td></tr><tr><td colspan="2" rowspan="2">Number of first-degree relatives with</td><td colspan="2"></td></tr><tr><td colspan="2" rowspan="2">history of breast cancer</td><td colspan="2"></td></tr><tr><td colspan="2"></td></tr><tr><td>0</td><td>1.00</td></tr><tr><td>1</td><td>2.61</td></tr><tr><td>22</td><td>6.80</td></tr><tr><td colspan="2">20-24 y Number of first-degree relatives with</td></tr><tr><td colspan="2">history of breast cancer</td></tr><tr><td>0</td><td>1.24</td></tr><tr><td>1</td><td>2.68</td></tr><tr><td>22</td><td>5.78</td></tr><tr><td>25-29 y</td><td></td></tr><tr><td colspan="2">Number of first-degree relatives with</td></tr><tr><td colspan="2">history of breast cancer</td></tr><tr><td>0</td><td>1.55</td></tr><tr><td>1</td><td>2.76</td></tr><tr><td>22</td><td>4.91</td></tr><tr><td colspan="2">&gt;30y</td></tr><tr><td colspan="2">Number of first-degree relatives with</td></tr><tr><td colspan="2">history of breast cancer</td></tr><tr><td>0</td><td>1.93</td></tr><tr><td>1</td><td>2.83</td></tr><tr><td>22</td><td>4.17</td></tr></table>
======================================
<table><thead><th>Sporadic breast cancer</th><th>65%-715%</th></thead><tr><td>Familial breast cancer</td><td>20%-30%</td></tr><tr><td>Hereditary breast cancer</td><td>5%-10%</td></tr><tr><td>BRCAI*</td><td>45%</td></tr><tr><td>BRCA2</td><td>35%</td></tr><tr><td>p53* (Li-Fraumeni syndrome)</td><td>1%</td></tr><tr><td>STK11/LKB1? (Peutz-Jeghers syndrome)</td><td>&lt;1%</td></tr><tr><td>PTEN® (Cowden disease)</td><td>&lt;1%</td></tr><tr><td>MSH2/MLH1? (Muir-Torre syndrome)</td><td>&lt;1%</td></tr><tr><td>ATM? (Ataxia-telangiectasia)</td><td>&lt;1%</td></tr><tr><td>Unknown</td><td>20%</td></tr></table>
======================================
<table><thead><th></th><th>LCIS</th><th>DCIS</th></thead><tr><td>Age (years)</td><td>44-47</td><td>54-58</td></tr><tr><td>Incidence*</td><td>2%-5%</td><td>5%-10%</td></tr><tr><td>Clinical signs</td><td></td><td>Mass, pain, nipple discharge</td></tr><tr><td>Mammographic signs</td><td></td><td>Microcalcifications</td></tr><tr><td>Premenopausal</td><td>2/3</td><td>1/3</td></tr><tr><td>Incidence of synchronous invasive carcinoma</td><td>| 5%</td><td>2% 46%</td></tr><tr><td>Multicentricity</td><td>60%-90%</td><td>| 40%-80%</td></tr><tr><td>Bilaterality</td><td>50%-10%</td><td>| 10%-20%</td></tr><tr><td>Axillary metastasis</td><td>1%</td><td>1%-2%</td></tr><tr><td colspan="3">Subsequent carcinomas:</td></tr><tr><td>Incidence</td><td>25%-35%</td><td>| 25%-70%</td></tr><tr><td>Laterality</td><td>Bilateral</td><td>Ipsilateral</td></tr><tr><td>Interval to diagnosis</td><td>15-20 y</td><td>5-l0y</td></tr><tr><td>Histologic type</td><td>Ductal</td><td>Ductal</td></tr></table>
======================================
<table><thead><th></th><th></th><th>DETERMINING CHARACTERISTICS</th><th></th></thead><tr><td>HISTOLOGIC SUBTYPE</td><td>| NUCLEAR GRADE</td><td>NECROSIS.</td><td>DCIS GRADE</td></tr><tr><td>Comedo</td><td>High</td><td>Extensive</td><td>High</td></tr><tr><td>Intermediate*</td><td>Intermediate</td><td>| Focal or absent</td><td>| Intermediate</td></tr><tr><td>Noncomedo’</td><td>| Low</td><td>Absent</td><td>Low</td></tr></table>
======================================
<table><tr><td>TX</td><td>Primary tumor cannot be assessed</td></tr><tr><td>TO</td><td>No evidence of primary tumor</td></tr><tr><td>Tis (DCIS)* Tis (Paget)</td><td>Ductal carcinoma in situ Paget disease of the nipple NOT associated with invasive carcinoma and/or carcinoma in situ (DCIS) in the</td></tr><tr><td>Tl</td><td>categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted. Tumor &lt;20 in dimension</td></tr><tr><td></td><td>mm greatest</td></tr><tr><td>Timi Tla</td><td>Tumor &lt;1 mm in greatest dimension Tumor &gt;1 but &lt;5 in dimension &gt;1.0—1.9 2</td></tr><tr><td>Tlb</td><td>mm mm greatest (round any measurement mm to mm). Tumor &gt;5 mim but &lt;10 mm in dimension</td></tr><tr><td></td><td>greatest</td></tr><tr><td>Tle</td><td>Tumor &gt;10 mm but &lt;20 mm in greatest dimension</td></tr><tr><td>T2</td><td>Tumor &gt;20 mm but &lt;50 mm in greatest dimension</td></tr><tr><td>T3</td><td>Tumor &gt;50 mm in greatest dimension</td></tr><tr><td></td><td></td></tr><tr><td>T4</td><td>Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not as T4</td></tr><tr><td></td><td>qualify</td></tr><tr><td>T4a</td><td>Extension to the chest wall; invasion or adherence to pectoralis muscle in the absence of invasion of chest wall</td></tr><tr><td></td><td>structures does not qualify as T4</td></tr><tr><td>T4b</td><td>Ulceration and/or ipsilateral macroscopic satellite nodules and/or edema (including peau d’ orange) of the skin that does not meet the criteria for carcinoma</td></tr><tr><td></td><td>inflammatory</td></tr><tr><td>T4c</td><td>Both T4a and T4b are present</td></tr><tr><td>T4d</td><td>carcinoma section “Rules for</td></tr><tr><td></td><td>Inflammatory (see Classification’)</td></tr><tr><td>*Note: Lobular</td><td>carcinoma in situ (LCIS) is a benign entity and is removed from TNM staging in the AJCC Cancer Staging Manual, 8th edition.</td></tr><tr><td>cNX*</td><td>nodes cannot be assessed removed)</td></tr><tr><td>cN1 cN1Imi** cN2</td><td>Metastases to movable ipsilateral Level I, II axillary lymph node(s) Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm) Metastases in ipsilateral Level I, II axillary lymph nodes that are clinically fixed or matted;</td></tr><tr><td>Regional lymph cNO cN2a cN2b cN3</td><td>nodes—Clinical (N) Regional lymph (e.g., previously No regional lymph node metastases (by imaging or clinical examination) or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases Metastases in ipsilateral Level I, II axillary lymph nodes fixed to one another (matted) or to other structures Metastases only in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases Metastases in ipsilateral infraclavicular (Level III axillary) lymph node(s) with or without Level I, II axillary lymph node involvement;</td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td>cN3a</td><td>or in ipsilateral internal mammary lymph node(s) with Level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement</td></tr><tr><td>cN3b</td><td>Metastases in ipsilateral infraclavicular lymph node(s)</td></tr><tr><td colspan="2">cN3c Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s)</td></tr><tr><td>Note: and</td><td>Metastases in ipsilateral supraclavicular lymph node(s) suffixes should be added the N denote confirmation of is sentinel node fine needle</td></tr><tr><td colspan="2">(sn) (f) to category to metast: needle biopsy respectively. *the cNX category is used sparingly in cases where regional lymph nodes have previously been surgically removed or where there is no docu
======================================
mentation of physical examination of the axilla. by biopsy or aspiration/core</td></tr></table>
======================================
<table><tr><td>pNx pNO</td><td>Regional lymph nodes cannot be assessed (e.g., not removed for pathological study or previously removed) No regional lymph node metastasis identified or ITCs only</td></tr><tr><td>pNO(i+)</td><td>ITCs only (malignant cell clusters no larger than 0.2 mm) in regional lymph node(s)</td></tr><tr><td>pNO(mol+)</td><td>Positive molecular findings by reverse transcriptase polymerase chain reaction (RT-PCR); no ITCs detected</td></tr><tr><td>pN1 pNimi</td><td>Micrometastases; or metastases in 1—3 axillary lymph nodes; and/or clinically negative internal mammary node with micrometastases or macrometastases by sentinel lymph node biopsy Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm)</td></tr><tr><td>pN2</td><td>pNla pNlb Metastases in 4—9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases</td></tr><tr><td>pN2a pN2b</td><td>Metastases in 4—9 axillary lymph nodes (at least one tumor deposit larger than 2.0 mm) Metastases in clinically detected internal mammary lymph nodes with or without microscopic confirmation;</td></tr><tr><td></td><td>(Level axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive Level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; in nodes</td></tr><tr><td>pN3a</td><td>or ipsilateral supraclavicular lymph Metastases in 10 or more axillary lymph nodes (at least one tumor deposit larger than 2.0 mm);</td></tr><tr><td>pN3b</td><td>or metastases to the infraclavicular (Level III axillary lymph) nodes pNla or pN2a in the presence of cN2b (positive internal mammary nodes by imaging); in the of</td></tr><tr><td>pN3c Note: (sn) and (f)</td><td>or pN2a presence pNIb Metastases in ipsilateral supraclavicular lymph nodes suffixes should be added to the N category to denote confirmation of metastasis by sentinel node biopsy or FNA/core needle biopsy</td></tr><tr><td colspan="2">respectively, with NO further resection of nodes. Distant metastas: sis</td></tr><tr><td>MO</td><td>(M) No clinical or radiographic evidence of distant metastases*</td></tr></table>
======================================
<table><thead><th>When Tis...</th><th>| And Nis...</th><th>| And M is...</th><th>Then the stage | group is...</th></thead><tr><td>Tis</td><td>NO</td><td>MO</td><td>0</td></tr><tr><td>Tl</td><td>NO</td><td>MO</td><td>JIA</td></tr><tr><td>TO</td><td>Nimi</td><td>MO</td><td>IB</td></tr><tr><td>Tl</td><td>Nimi</td><td>MO</td><td>IB</td></tr><tr><td>TO</td><td>NI</td><td>MO</td><td>TIA</td></tr><tr><td>Tl</td><td>Nl</td><td>MO</td><td>TIA</td></tr><tr><td>T2</td><td>NO</td><td>MO</td><td>TIA</td></tr><tr><td>T2</td><td>Nl</td><td>MO</td><td>IIB</td></tr><tr><td>T3</td><td>NO</td><td>MO</td><td>IIB</td></tr><tr><td>TO</td><td>N2</td><td>MO</td><td>THA</td></tr><tr><td>Tl</td><td>N2</td><td>MO</td><td>THA</td></tr><tr><td>T2</td><td>N2</td><td>MO</td><td>THA</td></tr><tr><td>T3</td><td>Nl</td><td>MO</td><td>THA</td></tr><tr><td>T3</td><td>N2</td><td>MO</td><td>THA</td></tr><tr><td>T4</td><td>NO</td><td>MO</td><td>THB</td></tr><tr><td>T4</td><td>NI</td><td>MO</td><td>THB</td></tr><tr><td>T4</td><td>N2</td><td>MO</td><td>THB</td></tr><tr><td>Any T</td><td>N3</td><td>MO</td><td>THC</td></tr><tr><td>Any T</td><td>Any N</td><td>MI</td><td>IV</td></tr></table>
======================================
<table><thead><th>TUMOR FACTORS</th><th>HOST FACTORS</th></thead><tr><td>Nodal status</td><td>Age</td></tr><tr><td>Tumor size</td><td>Menopausal status</td></tr><tr><td>Histologic/nuclear grade</td><td>Family history</td></tr><tr><td>Lymphatic/vascular invasion</td><td>Previous breast cancer</td></tr><tr><td>Pathologic stage</td><td>Immunosuppression</td></tr><tr><td>Hormone receptor status</td><td>Nutrition</td></tr><tr><td>DNA content (ploidy, S-phase fraction)</td><td>Prior chemotherapy</td></tr><tr><td>Extent of intraductal component</td><td>Prior radiation therapy</td></tr><tr><td>HER2/neu expression</td><td></td></tr></table>
======================================
<table><thead><th></th><th></th><th rowspan="2">{I</th><th rowspan="2">CANCER {II</th><th>STAGE</th><th rowspan="2">jIv</th></thead><thead><th></th><th>oO</th><th></th><th></th><th>III</th><th></th></thead><tr><td>History &amp; physical</td><td>X</td><td>|X</td><td>|X</td><td>|X</td><td>|X</td></tr><tr><td>Complete blood count, platelet count</td><td></td><td></td><td>X</td><td>|X</td><td>|X</td></tr><tr><td>Liver function tests and alkaline phosphatase level</td><td></td><td></td><td>xX</td><td>|X</td><td>|X</td></tr><tr><td>Chest radiograph</td><td></td><td></td><td>X</td><td>|X</td><td>|X</td></tr><tr><td>Bilateral diagnostic mammograms, ultrasound as indicated</td><td>|X</td><td>|X</td><td>|X</td><td>|X</td><td>|X</td></tr><tr><td>Hormone receptor status</td><td>X</td><td>|X</td><td>|X</td><td>|X</td><td>|X</td></tr><tr><td>HER2/neu expression</td><td></td><td>xX</td><td>|X</td><td>|X</td><td>|X</td></tr><tr><td>Bone scan</td><td></td><td></td><td></td><td>xX</td><td>|X</td></tr><tr><td>Abdominal (without or without</td><td></td><td></td><td></td><td>xX</td><td>|X</td></tr></table>
======================================
<table><thead><th>HER-2 NEGATIVE</th><th>HER-2 POSITIVE</th></thead><tr><td>AC &gt; Paclitaxel weekly TAC (T = docetaxel)</td><td>FEC — Paclitaxel + trastuzumab + pertuzumab Paclitaxel + trastuzumab Paclitaxel + trastuzumab + pertuzumab + FEC Docetaxel + trastuzumab + pertuzumab &gt; FEC</td></tr></table>
======================================
<table><thead><th>INFLAMMATORY</th><th>NONINFLAMMATORY</th></thead><tr><td>Dermal lymph vessel invasion is present with or without inflammatory changes.</td><td>Inflammatory changes are present without dermal lymph vessel invasion.</td></tr><tr><td>Cancer is not sharply delineated.</td><td>Cancer is better delineated.</td></tr><tr><td>Erythema and edema frequently involve &gt;33% of the skin over the breast.</td><td>Erythema is usually confined to the lesion, and edema is less extensive.</td></tr><tr><td>Lymph node involvement is present in &gt;75% of cases.</td><td>Lymph nodes are involved in approximately 50% of the cases.</td></tr><tr><td>Distant metastases are more</td><td>Distant metastases are less</td></tr><tr><td>common at the initial</td><td>common at presentation.</td></tr><tr><td>presentation (25% of</td><td></td></tr></table>
======================================
<table><thead><th>T CATEGORY</th><th>| T CRITERIA</th></thead><tr><td>TO</td><td>No primary identified</td></tr><tr><td>Tl</td><td>Tumor 2 cm or smaller in greatest dimension</td></tr><tr><td>T2</td><td>Tumor larger than 2 cm but not larger than 4 cm in greatest dimension</td></tr><tr><td>T3</td><td>Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis</td></tr><tr><td>T4</td><td>Moderately advanced local disease Tumor invades the larynx, extrinsic muscle</td></tr><tr><td></td><td>of tongue, medial pterygoid, hard palate, or mandible or beyond”</td></tr></table>
======================================
<table><thead><th>T CATEGORY</th><th>T CRITERIA</th></thead><tr><td>TX</td><td>Primary tumor cannot be assessed</td></tr><tr><td>Tis</td><td>Carcinoma in situ</td></tr><tr><td>Tl</td><td>Tumor 2 cm or smaller in greatest dimension</td></tr><tr><td>T2</td><td>Tumor larger than 2 cm but not larger than 4 cm in greatest dimension</td></tr><tr><td>T3</td><td>Tumor larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis</td></tr><tr><td>T4</td><td>Moderately advanced or very advanced local disease</td></tr><tr><td>T4a</td><td>Moderately advanced local disease Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible*</td></tr><tr><td>T4b</td><td>Very advanced local disease Tumor invades lateral pterygoid muscle, pterygoid plates, lateral nasopharynx, or skull base or encases carotid artery</td></tr></table>
======================================
<table><thead><th>T CATEGORY</th><th>T CRITERIA</th></thead><tr><td>TX</td><td>Primary tumor cannot be assessed</td></tr><tr><td>Tis</td><td>Carcinoma in situ</td></tr><tr><td>Tl</td><td>Tumor &lt;2 cm, &lt;5 mm depth of invasion (DOI) DOL is depth of invasion and not tumor thickness.</td></tr><tr><td>T2</td><td>Tumor &lt;2 cm, DOI &gt;5 mm and &lt;10 mm or tumor &gt;2 cm but &lt;4 cm, and DOI &lt;10 mm</td></tr><tr><td>T3</td><td>Tumor &gt;4 cm or any tumor with DOI &gt;10 mm but &lt;20 mm</td></tr><tr><td>T4</td><td>Moderately advanced or very advanced local disease</td></tr><tr><td>T4a</td><td>Moderately advanced local disease Tumor invades adjacent structures only (e.g., through cortical bone of the mandible or maxilla, or involves the maxillary sinus or skin of the face) or extensive tumor with bilateral tongue involvement and/or DOI &gt;20 mm. Note: Superficial erosion of bone/tooth socket (alone) by a gingival primary is not sufficient to classify a tumor as T4.</td></tr><tr><td>T4b</td><td>Very advanced local disease Tumor invades masticator space, pterygoid plates, or skull base and/or encases the internal carotid artery</td></tr></table>
======================================
<table><thead><th>Clinical N oropharyngeal</th><th>category for non-HPV-associated (p16-negative) cancer</th></thead><thead><th>N CATEGORY</th><th>N CRITERIA</th></thead><tr><td>NX</td><td>Regional lymph nodes cannot be assessed</td></tr><tr><td>NO</td><td>No regional lymph node metastasis</td></tr><tr><td>NI</td><td>Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)</td></tr><tr><td>N2</td><td>Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)</td></tr><tr><td>N2a</td><td>Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in</td></tr><tr><td>N2b</td><td>greatest dimension and ENE(—) Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)</td></tr><tr><td>N2c</td><td>Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(—)</td></tr><tr><td>N3</td><td>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+)</td></tr><tr><td>N3a</td><td>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(—)</td></tr><tr><td>N3b</td><td>Metastasis in any node(s) and clinically overt ENE(+)</td></tr></table>
======================================
<table><thead><th>N CATEGORY</th><th>N CRITERIA</th></thead><tr><td>NX</td><td>Regional lymph nodes cannot be assessed</td></tr><tr><td>NO</td><td>No regional lymph node metastasis</td></tr><tr><td>NI</td><td>Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension ENE(—)</td></tr><tr><td>N2</td><td>Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-)</td></tr><tr><td>N2a</td><td>Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension, and ENE(-)</td></tr><tr><td>N2b</td><td>Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension, and ENE(-)</td></tr><tr><td>N2c</td><td>Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-)</td></tr><tr><td>N3</td><td>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in any node(s) and clinically overt ENE(+)</td></tr><tr><td>N3a N3b</td><td>Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(—) Metastasis in node(s) and clinically overt</td></tr><tr><td>ENE = extranodal</td><td>any ENE(+) extension.</td></tr></table>
======================================
<table><thead><th>FLAP</th><th>BLOOD SUPPLY</th><th>CHARACTERISTICS</th><th>COMMON DEFECTS</th></thead><tr><td>Radial forearm</td><td>Radial artery</td><td>Thin, pliable, long pedicle</td><td>Partial and hemiglossectomy, floor of mouth, buccal defects</td></tr><tr><td>Anterolateral thigh</td><td>Descending branch of lateral femoral circumflex artery</td><td>Thicker adipose than radial forearm, can have myocutaneous (most common) or septocutaneous perforators</td><td>Hypopharynx, external neck/ facial skin, extended hemiglossectomy/total glossectomy</td></tr><tr><td>Lateral arm</td><td>Posterior radial collateral artery</td><td>Outstanding color match for facial skin, resists ptosis, diminutive pedicle</td><td>Parotid, temporal bone, external face and neck skin</td></tr><tr><td>Rectus</td><td>Deep inferior epigastric artery</td><td>Thick adipose tissue for large volume defects, long pedicle, poor external skin color match</td><td>Total glossectomy, skull base</td></tr><tr><td>Latissimus dorsi</td><td>Thoracodorsal artery</td><td>Large surface area of muscle, requires semi-lateral position, can be difficult for two-team harvest</td><td>Extensive scalp and skull base defects</td></tr><tr><td>Fibula osseocutaneous</td><td>Peroneal artery</td><td>Excellent bone stock and length, long pedicle, thin skin paddle</td><td>Segmental mandible and maxilla</td></tr><tr><td>Scapula osseocutaneous</td><td>Circumflex scapular artery</td><td>Less bone length compared to fibula, large scapular or parascapular skin paddles ideal for large composite defects</td><td>Segmental mandible and maxilla defects with extensive soft tissue components</td></tr><tr><td>Radial forearm osseocutaneous</td><td>Radial artery</td><td>Long pedicle, diminutive bone stock</td><td>Partial mandible defects, orbit</td></tr><tr><td>Iliac crest</td><td>Deep circumflex iliac artery</td><td>Up to 16 cm of bone available, limited soft tissue, significant donor site morbidity</td><td>Segmental mandible defects with small intraoral component and large external skin component</td></tr></table>
======================================
<table><thead><th></th><th>Segments</th><th></th></thead><tr><td colspan="3">1. Apical 6. Superior</td></tr><tr><td colspan="3">2. Posterior Medial Basal *</td></tr><tr><td>3. Anterior</td><td></td><td>Anterior Basal</td></tr><tr><td>4. Lateral</td><td></td><td>Lateral Basal</td></tr><tr><td>5. Medial</td><td></td><td>Posterior Basal</td></tr></table>
======================================
<table><thead><th></th><th>INVASIVE MUCINOUS ADENOCARCINOMA (FORMERLY MUCINOUS BAC)</th><th>NONMUCINOUS AIS/MIA/LPA (FORMERLY NONMUCINOUS BAC)</th></thead><tr><td>Female</td><td>49/84 (58%)&gt;120-12</td><td>101/140 (72%)52120-123</td></tr><tr><td>Smoker</td><td>39/87 (45% )°%120-122.124</td><td>75/164 (46%)52:120-122,124</td></tr><tr><td rowspan="2">Radiographic appearance</td><td>Majority consolidation; air bronchogram!”&gt;</td><td>Majority ground-glass attenuation?35658.103,129-134</td></tr><tr><td></td><td>Frequent multifocal and multilobar presentation®®!7!78</td><td></td></tr><tr><td>Cell type</td><td>Mucin-filled, columnar, and/or goblet**5%!2513</td><td>Type II pneumocyte and/or Clara cel]5°52!75:135</td></tr><tr><td colspan="3">Phenotype</td></tr><tr><td>CK7</td><td>Mostly positive (~88%)*455-36139</td><td>Positive (~98%)*5455136139</td></tr><tr><td>CK20</td><td>Positive (~54%)#5455.136-139</td><td>Negative (~5%)5#55136:139</td></tr><tr><td>TTF-1</td><td>Mostly negative (~17%)#5455:!20.137-139</td><td>Positive (~67%)*5455.120.137-139</td></tr><tr><td colspan="3">Genotype</td></tr><tr><td>KRAS mutation</td><td>Frequent (~76%)*5594121127.140-144</td><td>Some (~13%)#55121127.140-144</td></tr><tr><td>EGFR mutation</td><td>Almost none (~3)#55!2/-127.140-142</td><td>Frequent (~45%)55!21:127.140-142</td></tr></table>
======================================
<table><tr><td>Estimated new cases</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>Males</td><td>Females</td><td></td><td></td></tr><tr><td>Prostate</td><td>161,360</td><td></td><td></td><td>Breast</td><td></td></tr><tr><td>Lung &amp; bronchus</td><td>116,990</td><td></td><td></td><td>Lung &amp; bronchus</td><td></td></tr><tr><td>Colon &amp; rectum</td><td>71,420</td><td></td><td></td><td>Colon &amp; rectum</td><td></td></tr><tr><td>Urinary bladder</td><td>60,490</td><td></td><td></td><td>Uterine corpus</td><td></td></tr><tr><td>Melanoma of the skin</td><td>52,170</td><td></td><td></td><td>Thyroid</td><td></td></tr><tr><td>Kidney &amp; renal pelvis</td><td>40,610</td><td></td><td></td><td>Melanoma of the skin</td><td></td></tr><tr><td>Non-Hodgkin lymphoma</td><td>40,080</td><td></td><td></td><td>Non-Hodgkin lymphoma</td><td>32,160</td></tr><tr><td>Leukemia</td><td>36,290</td><td></td><td></td><td>Leukemia</td><td>25,840</td></tr><tr><td>Oral cavity &amp; pharynx</td><td>35,720</td><td></td><td></td><td>Pancreas</td><td>25,700</td></tr><tr><td>Liver &amp; intrahepatic bile duct</td><td>29,200</td><td></td><td></td><td>Kidney &amp; renal pelvis</td><td>23,380</td></tr><tr><td>All Sites</td><td>836,150</td><td></td><td></td><td>All Sites</td><td>852,630</td></tr><tr><td colspan="6">Estimated deaths</td><td colspan="6" rowspan="2">Males Females</td></tr><tr><td colspan="6"></td></tr><tr><td>Lung &amp; bronchus</td><td></td><td></td><td></td><td>Lung &amp; bronchus</td><td></td></tr><tr><td>Colon &amp; rectum</td><td></td><td></td><td></td><td>Breast</td><td></td></tr><tr><td>Prostate</td><td></td><td></td><td></td><td>Colon &amp; rectum</td><td></td></tr><tr><td>Pancreas</td><td></td><td>{}</td><td></td><td>Pancreas</td><td></td></tr><tr><td>Liver &amp; intrahepatic bile duct</td><td></td><td></td><td></td><td>Ovary</td><td></td></tr><tr><td>Leukemia</td><td></td><td></td><td></td><td>Uterine corpus</td><td></td></tr><tr><td>Esophagus</td><td></td><td></td><td></td><td>Leukemia</td><td></td></tr><tr><td>Urinary bladder</td><td></td><td></td><td></td><td>Liver &amp; intrahepatic bile duct</td><td></td></tr><tr><td>Non-Hodgkin lymphoma</td><td></td><td></td><td></td><td>Non-Hodgkin lymphoma</td><td></td></tr><tr><td>Brain &amp; other nervous system</td><td></td><td></td><td></td><td>Brain &amp; other nervous system</td><td></td></tr><tr><td>All Sites</td><td>318,420</td><td></td><td></td><td>All Sites</td><td>282,500</td></tr></table>
======================================
<table><thead><th>Relative risk of lung cancer in</th><th>smokers</th><th></th></thead><tr><td>SMOKING CATEGORY</td><td></td><td>RELATIVE RISK</td></tr><tr><td>Never smoked</td><td></td><td>1.0</td></tr><tr><td>Currently smoke</td><td></td><td>15.8-16.3</td></tr><tr><td colspan="3">Formerly smoked</td></tr><tr><td colspan="3">Years of abstinence</td></tr><tr><td>1-9</td><td></td><td>5.9-19.5</td></tr><tr><td>10-19</td><td></td><td>2.0-6.1</td></tr><tr><td>&gt;20</td><td></td><td>1.9-3.7</td></tr></table>
======================================
<table><thead><th>RISK FACTOR</th><th>RISK ESTIMATE (95% CI)</th><th>COMMENTS</th><th>REFERENCE</th></thead><tr><td rowspan="4">Environmental tobacco smoke</td><td>| 1.19 (90% CI: 1.04-1.35)</td><td>Meta-analysis of 11 U.S. studies of spousal | exposure (females only)</td><td>225</td></tr><tr><td></td><td>1.21 (1.13-1.30)</td><td>Meta-analysis of 44 case-control studies worldwide of spousal exposure</td><td>226</td></tr><tr><td></td><td>1.22 (1.13-1.33)</td><td>Meta-analysis of 25 studies worldwide of | workplace exposure</td><td>226</td></tr><tr><td></td><td>1.24 (1.18-1.29)</td><td>Meta-analysis of 22 studies worldwide of | workplace exposure</td><td>227</td></tr><tr><td rowspan="2">Residential radon</td><td>8.4% (3.0%-15.8%) per 100 Bq m3 increase | in measured radon</td><td>Meta-analysis of 13 European studies</td><td>228</td></tr><tr><td></td><td>11% (0%-28%) per 100 Bq m?</td><td>Meta-analysis of 7 North American studies |</td><td>229</td></tr><tr><td>Cooking oil vapors</td><td>2.12 (1.81-2.47)</td><td>Meta-analysis of 7 studies from China and | Taiwan (females who never smoked)</td><td>230</td></tr><tr><td rowspan="4">Indoor coal and wood _| burning Genetic factors:</td><td>2.66 (1.39-5.07)</td><td>Meta-analysis of 7 studies from China and | Taiwan (both sexes)</td><td>230</td></tr><tr><td></td><td>1.22 (1.04-1.44)</td><td>Large case-control study (2861 cases and | 3118 controls) from Eastern and Central Europe (both sexes)</td><td>231</td></tr><tr><td></td><td>2.5 (1.5-3.6)</td><td>Large case-control study (1205 cases and | 1541 controls) from Canada (significant</td><td>232</td></tr><tr><td></td><td>1.51 (1.11-2.06)</td><td>for women only) Meta-analysis of 28 case-control, 17 cohort, and 7 twin studies</td><td>| 233</td></tr><tr><td rowspan="5">family history, CYPIAI Ie462Val polymorphism, RCO! ess</td><td></td><td>| 2.99 (1.51-5.91)</td><td>Meta-analysis of 14 case-control studies of | Caucasian never smokers</td><td>234</td></tr><tr><td></td><td>2.04 (1.17-3.54)</td><td>Meta-analysis of 21 case-control studies | of Caucasian and Asian never smokers (significant for Caucasians only)</td><td>235</td></tr><tr><td></td><td>No association</td><td>Meta-analysis of 13 case-control studies</td><td>236</td></tr><tr><td></td><td>No association overall; reduced risk 0.65 (0.46-0.83) with Arg194Trp polymorphism and 0.56 (0.36—0.86) with Arg280His for heavy smokers</td><td>Large case-control study from Europe (2188 cases and 2198 controls)</td><td>237</td></tr><tr><td>Increased risk for never smokers 1.3 (1.0-1.8) and decreased risk for heavy smokers 0.5 (0.3-1.0) with Arg299GIn</td><td>Large case-control study from the United States (1091 cases and 1240 controls)</td><td>238</td></tr><tr><td>Viral factors: HPV 16 and 18</td><td>10.12 (3.88—26.4) for never smoking women &gt;60 y</td><td>Case-control study (141 cases, 60 controls) | from Taiwan of never smoking women</td><td>239</td></tr></table>
======================================
<table><thead><th>SURVIVAL</th><th>COMPLETE RESECTION (%)</th><th>INCOMPLETE RESECTION (%)</th></thead><tr><td>5 years</td><td>36</td><td>13</td></tr><tr><td>10 years</td><td>26</td><td>7</td></tr><tr><td>15 years</td><td>22</td><td>—_—</td></tr></table>
======================================
<table><tr><td>CATEGORY</td><td>SYMPTOM</td><td>CAUSE</td></tr><tr><td rowspan="5">Pulmonary symptoms</td><td>Cough</td><td>Bronchus irritation or compression</td></tr><tr><td></td><td>Dyspnea</td><td>Airway obstruction or compression</td></tr><tr><td></td><td>Wheezing</td><td>&gt;50% airway obstruction</td></tr><tr><td></td><td>Hemoptysis</td><td>Tumor erosion or irritation</td></tr><tr><td></td><td>Pneumonia</td><td>Airway obstruction</td></tr><tr><td>Nonpulmonary thoracic</td><td>| Pleuritic pain |</td><td>Parietal pleural irritation or invasion</td></tr><tr><td rowspan="5"></td><td>pain Radicular chest pain</td><td>Intercostal nerve involvement</td></tr><tr><td></td><td>Pancoast’s syndrome</td><td>Stellate ganglion, chest wall, brachial plexus involvement</td></tr><tr><td></td><td>Hoarseness</td><td>Recurrent laryngeal nerve involvement</td></tr><tr><td></td><td>Swelling of head and arms</td><td>Bulky involved mediastinal lymph nodes</td></tr><tr><td></td><td></td><td>Medially based right upper lobe tumor</td></tr></table>
======================================
<table><thead><th></th><th>PRIMARY TUMOR</th><th>METASTATIC DISEASE</th><th>FUNCTIONAL ASSESSMENT</th></thead><tr><td rowspan="3">History</td><td>Pulmonary</td><td>Weight loss</td><td>Ability to walk up two flights of stairs</td></tr><tr><td></td><td>Nonpulmonary thoracic</td><td>| Malaise</td><td>Ability to walk on a flat surface indefinitely</td></tr><tr><td></td><td>Paraneoplastic</td><td>New bone pain Neurologic signs or symptoms Skin lesions</td><td></td></tr><tr><td rowspan="3">Physical examination</td><td rowspan="3">Voice</td><td>Supraclavicular node palpation</td><td>Accessory muscle usage</td></tr><tr><td></td><td></td><td>Skin examination</td><td>Air flow by auscultation</td></tr><tr><td></td><td></td><td>Neurologic examination</td><td>Force of cough</td></tr><tr><td>Radiographic examination</td><td>Chest CT</td><td>Chest CT, PET</td><td>Chest CT: tumor anatomy, atelectasis</td></tr><tr><td rowspan="2">Tissue analysis</td><td>Bronchoscopy</td><td>Bone scan, head MRI, abdominal CT</td><td>Quantitative perfusion scan</td></tr><tr><td></td><td>Transthoracic needle aspiration and biopsy</td><td>Bronchoscopic lymph node FNA Endoscopic ultrasound Mediastinoscopy Biopsy of suspected metastasis</td><td></td></tr><tr><td>Other</td><td>Thoracoscopy</td><td></td><td>Pulmonary function tests (FEV,, DLco, O, consumption)</td></tr></table>
======================================
<table><tr><td>0 cm (pure lepidic adenocarcinoma &lt;3 cm total size)</td><td>Tla if &lt;2 cm; T1b if &gt;2-3 cm_|</td><td>Tis (AIS)</td></tr><tr><td>&lt;0.5 cm invasive size (lepidic predominant adenocarcinoma &lt;3 cm total size)</td><td>| Tlaif &lt;2 cm; Tlbif&gt;2-3cm</td><td>| T1lmi</td></tr><tr><td>&lt;lcm</td><td>Tla</td><td>Tla</td></tr><tr><td>&gt;1-2 cm</td><td>Tla</td><td>Tlb</td></tr><tr><td>&gt;2-3 cm</td><td>Tlb</td><td>Tle</td></tr><tr><td>&gt;3-4 cm</td><td>T2a</td><td>T2a</td></tr><tr><td>&gt;4—-5 cm</td><td>T2a</td><td>T2b</td></tr><tr><td>&gt;5-7 cm</td><td>T2b</td><td>T3</td></tr><tr><td>&gt;7 cm</td><td>T3</td><td>T4</td></tr><tr><td>Bronchus &lt;2 cm from carina</td><td>T3</td><td>T2</td></tr><tr><td>Total atelectasis/pneumonitis</td><td>T3</td><td>T2</td></tr><tr><td>Invasion of diaphragm</td><td>T3</td><td>T4</td></tr><tr><td>Invasion of mediastinal pleura</td><td>T3</td><td>=</td></tr><tr><td colspan="3">N component</td></tr><tr><td>No assessment, no involvement, or involvement of regional lymph nodes</td><td>NX, NO, N1, N2, N3</td><td>No change</td></tr><tr><td colspan="3">M component</td></tr><tr><td>Metastases within the thoracic cavity</td><td>Mla</td><td>Mla</td></tr><tr><td>Single extrathoracic metastasis</td><td>Mlb</td><td>Mlb</td></tr><tr><td>Multiple extrathoracic metastases</td><td>Mlb</td><td>Mic</td></tr></table>
======================================
<table><thead><th>T</th><th>PRIMARY TUMOR</th></thead><tr><td>TX</td><td>Primary tumor cannot be assessed, or tumor proven by the presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy</td></tr><tr><td>TO</td><td>No evidence of primary tumor</td></tr><tr><td>Tis</td><td>Carcinoma in situ Squamous cell carcinoma in situ (SCIS) Adenocarcinoma in situ (AIS); adenocarcinoma with pure lepidic pattern, &lt;3 cm in greatest dimension</td></tr><tr><td>Tl</td><td>Tumor &lt;3 cm in greatest dimension, surrounded by lung or visceral pleura, without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)</td></tr><tr><td>Tlmi_</td><td>| Minimally invasive adenocarcinoma: adenocarcinoma (&lt;3 cm in greatest dimension) with a predominantly lepidic pattern and &lt;5 mm invasion in greatest dimension</td></tr><tr><td>Tla</td><td>Tumor &lt;1 cm in greatest dimension. A superficial, spreading tumor of any size whose invasive component is limited to the bronchial wall and may extend proximal to the main bronchus also is classified as T1a, but these tumors are uncommon.</td></tr><tr><td>Tlb</td><td>Tumor &gt;1 cm but &lt;2 cm in greatest dimension</td></tr><tr><td>Tle</td><td>Tumor &gt;2 cm but &lt;3 cm in greatest dimension</td></tr><tr><td>T2</td><td>Tumor &gt;3 cm but &lt;5 cm or having any of the following features: e Involves the main bronchus regardless of distance to the carina, but without involvement of the carina e Invades visceral pleura (PL1 or PL2) e Associated with atelectasis or obstructive pneumonitis that extends to the hilar region, involving part or all of the lung T2 tumors with these features are classified as T2a if &lt;4 cm or if the size cannot be determined and T2b if &gt;4 cm but &lt;5 cm.</td></tr></table>
======================================
<table><tr><td>T2a</td><td>Tumor &gt;3 cm but &lt;4 cm in greatest dimension</td></tr><tr><td>T2b</td><td>Tumor &gt;4 cm but &lt;5 cm in greatest dimension</td></tr><tr><td>T3</td><td>Tumor &gt;5 cm but &lt;7 cm in greatest dimension or directly invading any of the following: parietal pleura (PL3), chest wall (including superior sulcus tumors), phrenic nerve, parietal pericardium; or separate tumor nodule(s) in the same lobe as the primary</td></tr><tr><td>T4</td><td>Tumor &gt;7 cm or tumor of any size invading one or more of the following: diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina; separate tumor nodule(s) in an ipsilateral lobe different from that of the primary</td></tr><tr><td>N</td><td>REGIONAL LYMPH NODE</td></tr><tr><td>NX</td><td>Regional lymph nodes cannot be assessed</td></tr><tr><td>NO</td><td>No regional lymph node metastasis</td></tr><tr><td>N1</td><td>Metastasis in ipsilateral peribronchial and/or ipsilateral hilar lymph nodes and intrapulmonary nodes, including involvement by direct extension</td></tr><tr><td>N2</td><td>Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)</td></tr><tr><td>N3</td><td>Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node(s)</td></tr><tr><td>M</td><td>DISTANT METASTASIS</td></tr><tr><td>MO</td><td>No distant metastasis</td></tr><tr><td>M1</td><td>Distant metastasis</td></tr><tr><td>Mla</td><td>Separate tumor nodule(s) in a contralateral lobe; tumor with pleural or pericardial nodules or malignant pleural or pericardial effusion. Most pleural (pericardial) effusions with lung cancer are a result of the tumor. In a few patients, however, multiple microscopic examinations of pleural (pericardial) fluid are negative for tumor, and the fluid is nonbloody and not an exudate. If these elements and clinical judgment dictate that the effusion is not related to the tumor, the effusion should be excluded as a staging descriptor.</td></tr><tr><td>Mlb</td><td>Single extrathoracic metastasis in a single organ (including involvement of a single nonregional node)</td></tr><tr><td>Mic</td><td>Multiple extrathoracic metastases in a single organ or in multiple organs</td></tr></table>
======================================
<table><tr><td rowspan="3">T1/MO</td><td></td><td>No</td><td>N1</td><td>N2</td><td>N3</td></tr><tr><td></td><td>Tla</td><td>TA</td><td>IIB</td><td>INA</td><td>IIB</td></tr><tr><td></td><td>Tlb</td><td>TA2</td><td>IIB</td><td>INA</td><td>IIB</td></tr><tr><td></td><td>Tle</td><td>TA3</td><td>IIB</td><td>INA</td><td>IIB</td></tr><tr><td rowspan="2">T2/M0O</td><td>T2a</td><td>IB</td><td>IB</td><td>INA</td><td>IIB</td></tr><tr><td></td><td>T2b</td><td>TA</td><td>IIB</td><td>INA</td><td>IIB</td></tr><tr><td>T3/MO</td><td></td><td>IIB</td><td>INA</td><td>IB</td><td>TIC</td></tr><tr><td>T4/MO</td><td></td><td>THA</td><td>TIA</td><td>IB</td><td>TIC</td></tr><tr><td rowspan="3">TX/M1</td><td>Mla</td><td>IVA</td><td>IVA</td><td>IVA</td><td>IVA</td></tr><tr><td></td><td>Mlb</td><td>IVA</td><td>IVA</td><td>IVA</td><td>IVA</td></tr><tr><td></td><td>Mic</td><td>IVB</td><td>IVB</td><td>IVB</td><td>IVB</td></tr></table>
======================================
<table><thead><th>STUDY</th><th>DEATHS/TOTAL</th></thead><tr><td colspan="2">VO5 ng, 10-15 mL/kg per minute</td></tr><tr><td>Smith et al!</td><td>1/6 (33%)</td></tr><tr><td>Bechard and Wetstein!””</td><td>0/15 (0%)</td></tr><tr><td>Olsen et al!®</td><td>1/14 (7.1%)</td></tr><tr><td>Walsh et al!”</td><td>1/5 (20%)</td></tr><tr><td>Bolliger et al?</td><td>2/17 (11.7%)</td></tr><tr><td>Markos et al?°!</td><td>1/11 (9.1%)</td></tr><tr><td>Wang et al???</td><td>0/12 (0%)</td></tr><tr><td>Win et al?</td><td>2/16 (12.5%)</td></tr><tr><td>Total</td><td>8/96 (8.3%)</td></tr><tr><td colspan="2">VOsmax &lt;10 mL/kg per minute</td></tr><tr><td>Bechard and Wetstein!””</td><td>2/7 (29%)</td></tr><tr><td>Olsen et al!®</td><td>3/11 (27%)</td></tr><tr><td>Holden et al?</td><td>2/4 (50%)</td></tr><tr><td>Markos et al?°!</td><td>0/5 (0%)</td></tr><tr><td>Total</td><td>7/27 (26%)</td></tr></table>
======================================
<table><thead><th>log</th><th></th><th>SEGMENTECTOMY</th><th>LOBECTOMY</th><th></th><th>HAZARD RATIO</th></thead><thead><th>[HAZARD RATIO]</th><th>SE</th><th>TOTAL</th><th>TOTAL</th><th>WEIGHT</th><th>RANDOM, 95%</th></thead><tr><td>-0,315</td><td>0,3495</td><td>74</td><td>132</td><td>3,3%</td><td>0,73 [0,37,1,45.</td></tr><tr><td>-0,21</td><td>0,29081</td><td>32</td><td>32</td><td>4,8%</td><td>0,81 [0,46, 1,43</td></tr><tr><td>0,332</td><td>0,2104</td><td>4240</td><td>11520</td><td>9,2%</td><td>239 [0,92, 2,1</td></tr><tr><td>0,368</td><td>0,2157</td><td>122</td><td>125</td><td>8,7%</td><td>44 [0,95, 2,2</td></tr><tr><td>0,1989</td><td>0,2806</td><td>32</td><td>77</td><td>5,1%</td><td>,22 [0,70, 2,1</td></tr><tr><td>—0,08338</td><td>0,50765</td><td>31</td><td>55</td><td>1,6%</td><td>0,92 [0,34, 2,49</td></tr><tr><td>0,131</td><td>0,4158</td><td>54</td><td>147</td><td>2,3%</td><td>14 [0,50, 2,58</td></tr><tr><td>-0,2357</td><td>0,21683</td><td>106</td><td>78</td><td>8,6%</td><td>0,79 [0,52,</td></tr><tr><td>0,1011</td><td>0,5732</td><td>46</td><td>77</td><td>1,2%</td><td>,11 [0,36, 3,40</td></tr><tr><td>0,0773</td><td>0,4385</td><td>74</td><td>159</td><td>2,1%</td><td>208 [0,46, 2,55</td></tr><tr><td>0,46</td><td>0,2482</td><td>102</td><td>117</td><td>6,6%</td><td>258 [0,97, 2,58</td></tr><tr><td>—1,0435</td><td>0,7071</td><td>17</td><td>17</td><td>0,8%</td><td>0,35 [0,09,</td></tr><tr><td>0,239</td><td>1</td><td>38</td><td>289</td><td>0,4%</td><td>.27 [0,18, 9,02</td></tr><tr><td>-0,1165</td><td>0,7168</td><td>68</td><td>104</td><td>0,8%</td><td>0,89 [0,22, 3,63</td></tr><tr><td>—0,1632</td><td>0,3595</td><td>67</td><td>273</td><td>3,1%</td><td>0,85 [0,42,</td></tr><tr><td>—0,02</td><td>0,2569</td><td>119</td><td>1051</td><td>6,1%</td><td>0,98 [0,59,</td></tr><tr><td>0,3148</td><td>0,4184</td><td>113</td><td>131</td><td>2,3%</td><td>237 (0,60, 3,11</td></tr><tr><td>1,0402</td><td>0,91581</td><td>49</td><td>150</td><td>0,5%</td><td>2,83 [0,47,17,0.</td></tr><tr><td>0,2852</td><td>1,6735</td><td>56</td><td>178</td><td>0,1%</td><td>33 [0,05, 35,3</td></tr><tr><td>—0,0202</td><td>0,25</td><td>43</td><td>95</td><td>6,5%</td><td>0,98 [0,60,</td></tr><tr><td>—0,7133</td><td>0,3087</td><td>98</td><td>383</td><td>4,3%</td><td>0,49 [0,27, 0,90</td></tr><tr><td>0,5481</td><td>0,5</td><td>66</td><td>103</td><td>1,6%</td><td>+73 (0,65, 4,61</td></tr><tr><td>—0,6162</td><td>0,89796</td><td>20</td><td>57</td><td>0,5%</td><td>0,54 [0,09, 3,14</td></tr><tr><td>0,19886</td><td>0,73469</td><td>90</td><td>124</td><td>0,8%</td><td>»22 [0,29, 5,15</td></tr><tr><td>0,3001</td><td>0,4056</td><td>153</td><td>277</td><td>2,5%</td><td>235 [0,61 , 2,9!</td></tr><tr><td>0,239</td><td>0,27562</td><td>162</td><td>2599</td><td>5,3%</td><td>,27 (0,74, 2,18</td></tr><tr><td>—0,1625</td><td>0,19388</td><td>39</td><td>81</td><td>10,8%</td><td>0,85 [0,58, 1,24</td></tr></table>
======================================
<table><thead><th>STAGE</th><th>5-YEAR SURVIVAL (%)</th><th>ABSOLUTE | BENEFIT (%)</th><th>NEW 5-YEAR | SURVIVAL (%)</th></thead><tr><td>IA</td><td>75</td><td>4</td><td>719</td></tr><tr><td>IB</td><td>55</td><td>6</td><td>61</td></tr><tr><td>IIA</td><td>50</td><td>7</td><td>S7</td></tr><tr><td>IIB</td><td>40</td><td>7</td><td>47</td></tr><tr><td>THA</td><td>15-35</td><td>6-7</td><td>21-42</td></tr><tr><td>TB</td><td>5-10</td><td>3-5</td><td>8-15</td></tr></table>
======================================
<table><thead><th>)</th><th>NO. OF PATIENTS (STAGE III)</th><th>CHEMOTHERAPY</th><th>RESPONSE RATE (%)</th><th>| PCR (%)</th><th>COMPLETE | RESECTION</th><th>PFS</th><th>os</th><th>5-YEAI</th></thead><tr><td rowspan="3">5</td><td>60 (60)</td><td>Mitomycin Tfosfamide Cisplatin</td><td>60</td><td>4</td><td>85%</td><td>12 vs. 5 mo (DFS; P = .006)</td><td>22 vs. 10 mo (P = .005)</td><td>16% v</td></tr><tr><td></td><td>60 (60)</td><td>Cyclophosphamide Etoposide Cisplatin</td><td>| 35</td><td>NR</td><td>39% vs. 31%</td><td>| Not reached vs. 9 mo (P= .006) |</td><td>64 vs. 11 mo (P = .008)</td><td>56% v</td></tr><tr><td></td><td>27 (27)</td><td>Etoposide Cisplatin</td><td>62</td><td>8</td><td>85% vs. 86%</td><td>| 12.7 vs. 5.8 mo (P = .083)</td><td>28.7 vs. 15.6 mo (P= .095)</td><td>|NR</td></tr><tr><td>P</td><td>62 (62)</td><td>Cisplatin Vindesine</td><td>28</td><td>0</td><td>65% vs. 77%</td><td>|NR</td><td>17 vs. 16 mo (P = .5274)</td><td>10% v</td></tr><tr><td>1?</td><td>| 519 (80)</td><td>Platinum based?</td><td>49</td><td>4</td><td>82% vs. 80%</td><td>|NR</td><td>54 vs. 55 mo (P = .86)</td><td>44% v</td></tr><tr><td>al™</td><td>| 355 (167)</td><td>Mitomycin Tfosfamide Cisplatin</td><td>64</td><td>11</td><td>92% vs. 86%</td><td>| 26.7 vs. 12.9 mo (P = .033)</td><td>37 vs. 26 mo (P = .15)</td><td>43.9%</td></tr><tr><td>faa</td><td>354 (113)¢</td><td>Carboplatin Paclitaxel</td><td>41</td><td>NR</td><td>94% vs. 89%</td><td>| 33 vs. 21 mo (P = .07)</td><td>75 vs. 46 mo (P = .19)</td><td>50% v</td></tr><tr><td>al’</td><td>| 90 (NR)</td><td>Paclitaxel Carboplatin</td><td>46</td><td>0</td><td>79% vs. 70%</td><td>|NR</td><td>34.4 vs. 22.5 mo (NS)</td><td>36% v</td></tr><tr><td>1°?</td><td>| 274 (274)</td><td>Docetaxel</td><td>28</td><td>NR</td><td>71% vs. 16%*</td><td>|9 vs. 7.6 mo (NS)</td><td>14.8 vs. 12.6 mo (NS)</td><td>NR</td></tr></table>
======================================
<table><thead><th>CONDITION</th><th>EXAMPLES</th></thead><tr><td>Pulmonary compromise</td><td>Poor FEV ,/Dico, heavy smoking, sleep apnea, recent pneumonia</td></tr><tr><td>Cardiac dysfunction</td><td>Congestive heart failure, severe coronary artery disease, recent myocardial infarction, valvular disease</td></tr><tr><td>Extrathoracic malignancy</td><td>Solitary brain metastasis from lung cancer, deep pulmonary metastases requiring lobectomy</td></tr><tr><td>Poor physical performance</td><td>Performance status equivalent to a Zubrod score of 2 or 3, morbid obesity</td></tr><tr><td>condition Advanced age</td><td>erythematosus, osteomyelitis Age &gt;70 years</td></tr><tr><td>Vascular problems</td><td>Aneurysm, severe peripheral vascular disease</td></tr><tr><td>Recent or impending major operation</td><td>Urgent abdominal operation, joint replacement requiring use of crutches, need for contralateral</td></tr><tr><td>Psychological/ neurologic conditions</td><td>thoracotomy Substance abuse, poor command following, pain syndromes</td></tr><tr><td>Immunosuppression/ impaired wound healing</td><td>— Recent transplantation, diabetes</td></tr><tr><td>Abbreviations: DLco = forced expiratory volume</td><td>carbon monoxide diffusion capacity; FEV, = in 1 second.</td></tr></table>
======================================
<table><thead><th>PULMONARY</th><th>EXTRAPULMONARY</th><th>TATROGENIC</th></thead><tr><td>Bronchiectasis</td><td>Mitral stenosis</td><td></td></tr><tr><td>Tuberculosis</td><td>Medications</td><td></td></tr><tr><td>Lung abscess</td><td></td><td></td></tr><tr><td>Pneumonia</td><td></td><td></td></tr><tr><td>Pulmonary parenchymal disease Bronchitis Cavitary fungal infection (e.g., aspergilloma) Lung parasitic infection (ascariasis, schistosomiasis, paragonimiasis) Pulmonary neoplasm Pulmonary infarction or embolism Trauma Arteriovenous malformation Pulmonary vasculitis Pulmonary endometriosis Wegener’s granulomatosis</td><td>Congestive heart failure Coagulopathy</td><td>Intrapulmonary catheter</td></tr></table>
======================================
<table><thead><th></th><th>N</th><th>HAZARD RATIO</th><th>95% CI</th><th>P VALUE</th></thead><tr><td>Gender Male Female</td><td>3937 4113</td><td>Reference group 0.897</td><td>Reference group 0.843-0.955</td><td>Reference group 001</td></tr><tr><td>Age 50 years 51-70 years &gt;70 years</td><td>1837 3099 3114</td><td>Reference group 131 538</td><td>Reference group .026-1.247 -395-1.697</td><td>Reference group 013, &lt;.001</td></tr><tr><td>Race Caucasian Non-Caucasian</td><td>7152 898</td><td>Reference group 212</td><td>Reference group .093-1.344</td><td>Reference group &lt;.001</td></tr><tr><td>Histologic type Fibrosarcoma MFH Liposarcoma LMS/GIST</td><td>489 2529 1534 3498</td><td>Reference group 281 0.894 -204</td><td>Reference group .097-1.495 0.759-1.054 -033-1.403</td><td>Reference group 002 182 018</td></tr><tr><td>Location Head and neck Trunk Extremity Retroperitoneum</td><td>576 4054 2474 946</td><td>Reference group 255 .003 276</td><td>Reference group -096-1.438 0.875-1.151 .093-1.489</td><td>Reference group 001 960 002</td></tr><tr><td>Stage Localized Regional Distant</td><td>5006 1724 1320</td><td>Reference group 575 2.897</td><td>Reference group 458-1.702 2.660-3.155</td><td>Reference group &lt;.001 &lt;.001</td></tr><tr><td>Surgical treatment Yes No</td><td>6754 1296</td><td>Reference group 562</td><td>Reference group .443-1.691</td><td>Reference group &lt;.001</td></tr><tr><td>Radiation therapy Yes No</td><td>2175 5875</td><td>Reference group ASI</td><td>Reference group .070-1.239</td><td>Reference group &lt;.001</td></tr><tr><td>Chemotherapy Yes No</td><td>1062 6988</td><td>Reference group 0.909</td><td>Reference group 0.829-0.996</td><td>Reference group 041</td></tr></table>
======================================
<table><thead><th>Classification of sarcomas by</th><th>therapeutic response</th></thead><thead><th>TUMOR TYPE</th><th>CHEMOTHERAPY SENSITIVITY</th></thead><tr><td>Osteosarcoma</td><td>+</td></tr><tr><td>Rhabdomyosarcoma</td><td>+</td></tr><tr><td>Primitive neuroectodermal tumor</td><td>+</td></tr><tr><td>Ewing’s sarcoma</td><td>+</td></tr><tr><td>Malignant fibrous histiocytoma</td><td>+</td></tr><tr><td>Fibrosarcoma</td><td>+</td></tr><tr><td>Liposarcoma</td><td>+</td></tr><tr><td>Synovial sarcoma</td><td>+</td></tr></table>
======================================
<table><tr><td>ANTERIOR</td><td>VISCERAL</td><td>PARAVERTEBRAL</td></tr><tr><td>COMPARTMENT</td><td>| COMPARTMENT</td><td>SULCI</td></tr><tr><td>Thymoma</td><td>Enterogenous cyst</td><td>| Neurilemoma- schwannoma</td></tr><tr><td>Germ cell tumor</td><td>Lymphoma</td><td>Neurofibroma</td></tr><tr><td>Lymphoma</td><td>Pleuropericardial | cyst</td><td>Malignant schwannoma</td></tr><tr><td>Lymphangioma</td><td>| Mediastinal granuloma</td><td>Ganglioneuroma</td></tr><tr><td>Hemangioma |</td><td>Lymphoid hamartoma</td><td>Ganglioneuroblastoma</td></tr><tr><td>Lipoma</td><td>Mesothelial cyst</td><td>Neuroblastoma</td></tr><tr><td>Fibroma</td><td>Neuroenteric cyst |</td><td>Paraganglioma</td></tr><tr><td>Fibrosarcoma _</td><td>Paraganglioma</td><td>Pheochromocytoma</td></tr><tr><td>Thymic cyst</td><td>Pheochromocytoma</td><td>| Fibrosarcoma</td></tr><tr><td>Parathyroid adenoma</td><td>Thoracic duct cyst</td><td>| Lymphoma</td></tr></table>
======================================
<table><thead><th>Mediastinal tumors in</th><th>children</th><th></th></thead><thead><th>TUMOR TYPE</th><th>PERCENTAGE OF TOTAL</th><th>LOCATION</th></thead><tr><td>Neurogenic tumors</td><td>40</td><td>Posterior</td></tr><tr><td>Lymphomas</td><td>18</td><td>Anterior/middle</td></tr><tr><td>Cysts</td><td>18</td><td>All</td></tr><tr><td>Germ cell tumors</td><td>11</td><td>Anterior</td></tr><tr><td>Mesenchymal tumors</td><td>9</td><td>All</td></tr><tr><td>Thymomas</td><td>Rare</td><td>Anterior</td></tr></table>
======================================
<table><thead><th>Mediastinal tumors in</th><th>adults</th><th></th></thead><thead><th>TUMOR TYPE</th><th>PERCENTAGE OF TOTAL</th><th>LOCATION</th></thead><tr><td>Neurogenic tumors</td><td>21</td><td>Posterior</td></tr><tr><td>Cysts</td><td>20</td><td>All</td></tr><tr><td>Thymomas</td><td>19</td><td>Anterior</td></tr><tr><td>Lymphomas</td><td>13</td><td>Anterior/middle</td></tr><tr><td>Germ cell tumors</td><td>11</td><td>Anterior</td></tr><tr><td>Mesenchymal tumors</td><td>7</td><td>All</td></tr><tr><td>Endocrine tumors</td><td>6</td><td>Anterior/middle</td></tr></table>
======================================
<table><thead><th>DIAGNOSIS</th><th>HISTORY AND PHYSICAL FINDINGS</th><th>COMPARTMENT LOCATION OF MASS</th></thead><tr><td>Lymphoma</td><td>Night sweats, weight loss, fatigue, extrathoracic adenopathy, elevated erythrocyte sedimentation rate or C-reactive protein level, leukocytosis</td><td>Any compartment</td></tr><tr><td>Thymoma with myasthenia gravis</td><td>Fluctuating weakness, early fatigue, ptosis, diplopia</td><td>Anterior</td></tr><tr><td>Mediastinal granuloma</td><td>Dyspnea, wheezing, hemoptysis</td><td>Visceral (middle)</td></tr><tr><td>Germ cell tumor</td><td>Male gender, young age, testicular mass, elevated levels of human chorionic gonadotropin and/or o.-fetoprotein</td><td>Anterior</td></tr></table>
======================================
<table><tr><td>RADIOPHARMACEUTICAL,</td><td></td><td></td></tr><tr><td>RADIONUCLIDE, OR</td><td></td><td>DISEASE OF</td></tr><tr><td>RADIOCHEMICAL</td><td>LABEL</td><td>INTEREST</td></tr><tr><td>Iodine</td><td>By, Si</td><td>Retrosternal goiter, thyroid cancer</td></tr><tr><td>Monoclonal antibodies</td><td>a, He</td><td>NSCLC, colon and breast cancer, prostate cancer metastases</td></tr><tr><td>Octreotide</td><td>Tn</td><td>Amine precursor uptake decarboxylation tumors: carcinoid, gastrinoma, insulinoma, small cell lung cancer, pheochromocytoma, glucagonoma, medullary thyroid carcinoma, paraganglioma</td></tr><tr><td>Gallium</td><td>"Ga</td><td>Lymphoma, NSCLC, melanoma</td></tr><tr><td>Sestamibi</td><td>Se</td><td>Medullary thyroid carcinoma, nonfunctional papillary or follicular thyroid carcinoma, Hiirthle cell thyroid carcinoma, parathyroid adenoma or carcinom</td></tr><tr><td>Thallium</td><td>201T]</td><td>See sestamibi</td></tr><tr><td>MIBG</td><td>yy, By</td><td>Pheochromocytoma, neuroblastoma; see also octreotide</td></tr><tr><td>Fluorodeoxyglucose</td><td>nek</td><td>General oncologic imaging, breast and colon cancer, melanoma</td></tr></table>
======================================
<table><thead><th>Table 19-30</th><th></th></thead><tr><td>Masaoka</td><td>staging system for thymoma</td></tr><tr><td>Stage I</td><td>Encapsulated tumor with no gross or microscopic evidence of capsular invasion</td></tr><tr><td>Stage II</td><td>Gross capsular invasion or invasion into the mediastinal fat or pleura or microscopic capsular invasion</td></tr><tr><td>Stage III</td><td>Gross invasion into the pericardium, great vessels, or lung</td></tr><tr><td>Stage IVA</td><td>Pleural or pericardial dissemination</td></tr><tr><td>Stage IVB</td><td>Lymphogenous or hematogenous metastasis</td></tr></table>
======================================
<table><thead><th>TUMOR ORIGIN</th><th>BENIGN</th><th>MALIGNANT</th></thead><tr><td>Nerve sheath</td><td>Neurilemoma, neurofibroma, melanotic schwannoma, granular cell tumor</td><td>Neurofibrosarcoma</td></tr><tr><td>Ganglion cell</td><td>Ganglioneuroma</td><td>Ganglioneuroblastoma, neuroblastoma</td></tr><tr><td>Paraganglionic cell</td><td>Chemodectoma, pheochromocytoma</td><td>Malignant chemodectoma, malignant pheochromocytoma</td></tr></table>
======================================
<table><thead><th>CAUSE</th><th>ANNUAL INCIDENCE</th><th>TRANSUDATE</th><th>EXUDATE</th></thead><tr><td>Congestive heart failure</td><td>500,000</td><td>Yes</td><td>No</td></tr><tr><td>Pneumonia</td><td>300,000</td><td>No</td><td>Yes</td></tr><tr><td>Cancer</td><td>200,000</td><td>No</td><td>Yes</td></tr><tr><td>Pulmonary embolus</td><td>150,000</td><td>Sometimes</td><td>Sometimes</td></tr><tr><td>Viral disease</td><td>100,000</td><td>No</td><td>Yes</td></tr><tr><td>Coronary artery bypass surgery</td><td>60,000</td><td>No</td><td>Yes</td></tr><tr><td>Cirrhosis with ascites</td><td>50,000</td><td>Yes</td><td>No</td></tr></table>
======================================
<table><thead><th>PRIMARY SITE OR TUMOR TYPE</th><th>NO. OF MALE PATIENTS</th><th>PERCENTAGE OF MALE PATIENTS</th></thead><tr><td>Lung</td><td>140</td><td>49.1</td></tr><tr><td>Lymphoma/leukemia</td><td>60</td><td>21.1</td></tr><tr><td>Gastrointestinal tract</td><td>20</td><td>7.0</td></tr><tr><td>Genitourinary tract</td><td>17</td><td>6.0</td></tr><tr><td>Melanoma</td><td>4</td><td>1.4</td></tr><tr><td>Miscellaneous less common tumors</td><td>10</td><td>3.5</td></tr><tr><td>Primary site unknown</td><td>31</td><td>10.9</td></tr><tr><td>Total</td><td>285</td><td>100.0</td></tr></table>
======================================
<table><tr><td>PRIMARY SITE OR TUMOR TYPE</td><td>NO. OF FEMALE PATIENTS</td><td>PERCENTAGE OF FEMALE PATIENTS</td></tr><tr><td>Breast</td><td>70</td><td>37.4</td></tr><tr><td>Female genital tract</td><td>38</td><td>20.3</td></tr><tr><td>Lung</td><td>28</td><td>15.0</td></tr><tr><td>Lymphoma</td><td>14</td><td>8.0</td></tr><tr><td>Gastrointestinal tract</td><td>8</td><td>43</td></tr><tr><td>Melanoma</td><td>6</td><td>3.2</td></tr><tr><td>Urinary tract</td><td>2</td><td>11</td></tr><tr><td>Miscellaneous less common tumors</td><td>3</td><td>1.6</td></tr><tr><td>Primary site unknown</td><td>| 17</td><td>9.1</td></tr><tr><td>Total</td><td>187</td><td>100.0</td></tr></table>
======================================
<table><thead><th>Composition of chyle</th><th></th></thead><thead><th>COMPONENT</th><th>AMOUNT (PER 100 ML)</th></thead><tr><td>Total fat</td><td>0.4-5 g</td></tr><tr><td>Total cholesterol</td><td>65-220 mg</td></tr><tr><td>Total protein</td><td>2.21-5.9 g</td></tr><tr><td>Albumin</td><td>1.1-4.1 g</td></tr><tr><td>Globulin</td><td>1.1-3.1 g</td></tr><tr><td>Fibrinogen</td><td>16-24 g</td></tr><tr><td>Sugars</td><td>48-200 g</td></tr><tr><td>Electrolytes</td><td>Similar to levels in plasma</td></tr><tr><td colspan="2">Cellular elements</td></tr><tr><td>Lymphocytes</td><td>400-6800/mm?</td></tr><tr><td>Erythrocytes</td><td>50-600/mm'</td></tr><tr><td>Antithrombin globulin</td><td>&gt;25% of plasma concentration</td></tr><tr><td>Prothrombin</td><td>&gt;25% of plasma concentration</td></tr><tr><td>Fibrinogen</td><td>&gt;25% of plasma concentration</td></tr></table>
======================================
<table><thead><th></th><th>MESOTHELIOMA</th><th>| ADENOCARCINOMA</th></thead><tr><td>Immunohistochemical results</td><td></td><td></td></tr><tr><td>Carcinoembryonic | antigen</td><td>Negative</td><td>Positive</td></tr><tr><td>Vimentin</td><td>Positive</td><td>Negative</td></tr><tr><td>Low molecular weight cytokeratins</td><td>Positive</td><td>Negative</td></tr><tr><td>Electron microscopic features</td><td>Long, sinuous villi</td><td>Short, straight villi with fuzzy glycocalyx</td></tr></table>
======================================
<table><tr><td colspan="2">The Great Ormond Street Score (GOSE)</td></tr><tr><td colspan="2">GOSE Score: Area of RA + aRA/Area of RV + LA + LV</td></tr><tr><td>GOSE Score</td><td>Mortality (%)</td></tr><tr><td>1</td><td>8</td></tr><tr><td>2</td><td>8</td></tr><tr><td>3</td><td>100</td></tr><tr><td>4</td><td>100</td></tr></table>
======================================
<table><tr><td>Cardiac Assessment Clinical Evaluation / 801</td><td>801</td></tr><tr><td colspan="2">History / 801</td></tr><tr><td colspan="2">Physical Examination / 803</td></tr><tr><td>Cardiac Risk Assessment in Noncardiac Surgery Patients / 804</td><td></td></tr><tr><td>Diagnostic Studies / 804</td><td></td></tr><tr><td>Extracorporeal Perfusion History / 807 Technique / 807 Adverse Effects / 808 Myocardial Protection / 808</td><td>807</td></tr><tr><td>Coronary Artery Disease</td><td>808</td></tr><tr><td>History / 808</td><td></td></tr><tr><td colspan="2">Etiology and Pathogenesis / 809</td></tr><tr><td>Risk Factors and Prevention / 809</td><td></td></tr><tr><td>Clinical Manifestations / 809</td><td></td></tr><tr><td>Preoperative Evaluation / 809</td><td></td></tr><tr><td>Coronary Artery Bypass Grafting</td><td>809</td></tr><tr><td>Indications / 809</td><td></td></tr><tr><td colspan="2">Percutaneous Coronary Intervention vs.</td></tr></table>
======================================
<table><thead><th>CLASS</th><th>| DESCRIPTION</th></thead><tr><td>I</td><td>Physical activity not limited by symptoms: fatigue, palpitations, or dyspnea.</td></tr><tr><td>IL</td><td>Comfortable at rest. Slight limitation of physical activity. Fatigue, palpitations, or dyspnea with ordinary physical activity.</td></tr><tr><td>Il</td><td>Comfortable at rest. Marked limitation of physical activity. Fatigue, palpitations, or dyspnea with less than ordinary physical activity.</td></tr><tr><td>IV</td><td>Inability to carry out any physical activity. Symptoms may be present at rest and increase with activity.</td></tr></table>
======================================
<table><thead><th>CLASS</th><th>DESCRIPTION</th></thead><tr><td></td><td>Ordinary physical activity (walking, climbing stairs) does not cause angina. Angina occurs with strenuous, rapid, or prolonged exertion during work or recreation.</td></tr><tr><td>Il</td><td>Slight limitation of ordinary activity. Angina occurs with climbing stairs rapidly, walking uphill in the wind, under emotional stress, in the cold, or after meals. Walking more than 2 blocks or climbing one flight of stairs causes angina.</td></tr><tr><td>Il</td><td>Marked limitation of ordinary physical activity (climbing a flight of stairs or walking 1 to 2 blocks at a normal pace).</td></tr><tr><td>IV</td><td>Inability to carry out any physical activity without discomfort. Angina may be present at rest.</td></tr></table>
======================================
<table><thead><th>NUMBER OF RISK</th><th></th></thead><tr><td>FACTORS?</td><td>RECOMMENDATION</td></tr><tr><td>0</td><td>Proceed with planned surgery.</td></tr><tr><td>1-2</td><td>Control HR and proceed with planned surgery or pursue further testing if it will change management.</td></tr><tr><td>3-5</td><td>Pursue further testing if it will advance management.</td></tr></table>
======================================
<table><thead><th>ANATOMY</th><th>CLASS OF RECOMMENDATION</th><th>LEVEL OF EVIDENCE</th></thead><tr><td>- LM</td><td>I</td><td></td></tr><tr><td>¢ 3-vessel +/— proximal LAD</td><td>I</td><td></td></tr><tr><td>* 2-vessel + proximal LAD</td><td>I</td><td>DADs</td></tr><tr><td rowspan="2">* 2-vessel — proximal LAD</td><td>Ila — with extensive ischemia</td><td></td></tr><tr><td></td><td>IIb — without extensive ischemia</td><td></td></tr><tr><td>¢ Multivessel disease with DM</td><td>Ila (CABG preferred over PCI)</td><td></td></tr><tr><td>¢ Proximal LAD only</td><td>Ila — with LITA for long-term benefit</td><td></td></tr><tr><td>¢ 1-vessel — proximal LAD</td><td>Il — Harm</td><td>RWaDDWwr</td></tr><tr><td rowspan="2">¢ LV dysfunction</td><td>Ila — LVEF 35%-50%</td><td></td></tr><tr><td></td><td>Ilb — LVEF &lt;35% without LM disease</td><td></td></tr><tr><td>¢ Survivor of ischemia-mediated VT</td><td>I</td><td></td></tr></table>
======================================
<table><tr><td>ANATOMY ASSOCIATED SYMPTOMS</td><td>CLASS OF RECOMMENDATION</td><td>LEVEL OF EVIDENCE</td></tr><tr><td>Unacceptable angina with presence of 21 stenoses amenable to revascularization despite medical treatment</td><td>I</td><td>A</td></tr><tr><td>Complex 3-vessel CAD +/— proximal LAD involvement</td><td>Ila (CABG preferred over PCI)</td><td>B</td></tr><tr><td>Unacceptable angina with presence of 21 stenoses amenable to revascularization but medical treatment is not possible</td><td>Ila</td><td></td></tr><tr><td>Previous CABG with 21 stenoses associated with ischemia and angina despite medical treatment</td><td>IIb</td><td></td></tr></table>
======================================
<table><thead><th>Classification of cardiac</th><th>murmurs</th><th></th></thead><thead><th>MURMUR</th><th>CONDITION</th><th>MECHANISM/ETIOLOGY</th></thead><tr><td></td><td></td><td>SYSTOLIC MURMURS</td></tr><tr><td>Holosystolic (pansystolic)</td><td>| VSD</td><td>Flow between chambers that have widely different pressures throughout systole</td></tr><tr><td>Mid-systolic (systolic ejection)</td><td>High flow rate, MS, MR, TS, TI</td><td>Often crescendo-decrescendo in configuration; occur as blood is ejected int the left and right ventricular outflow tracts</td></tr><tr><td>Early systolic</td><td>Early TI, acute MR</td><td>Less common</td></tr><tr><td>Mid to late systolic</td><td>MR, MVP</td><td>Soft to moderate high-pitched murmurs at the LV apex; often due to apical tethering and malcoaptation of MV leaflets; an associated click indicates prolapse of the MV leaflets</td></tr><tr><td colspan="3">DIASTOLIC MURMURS</td></tr><tr><td>Early high-pitched</td><td>AL, PR</td><td>Generally decrescendo in configuration; occur when the associated ventricular pressure drops sufficiently below that of the outflow tract</td></tr><tr><td>Mid-diastolic</td><td>MS, TS, PDA*, VSD*, ASD*</td><td>Due to a relative disproportion between valve orifice size and diastolic blood flow volume; seen in normal MV and TV with increased diastolic blood flow associated with these conditions*</td></tr><tr><td>Presystolic</td><td>MS, TS</td><td>Occur during the period of ventricular filling that follows atrial contraction (i.e., only occur in sinus rhythm)</td></tr><tr><td colspan="3">CONTINUOUS MURMURS</td></tr><tr><td></td><td>PDA</td><td>Uncommon, due to shunts that persist through the end of systole and the some or all of diastole</td></tr></table>
======================================
<table><thead><th>INTERVENTION</th><th>EFFECT</th></thead><tr><td>Respiration</td><td>Right-sided murmurs increase with inspiration. Left-sided murmurs increase with expiration.</td></tr><tr><td>Valsalva maneuver</td><td>Most murmurs decrease in length and intensity. The murmur of HCM becomes louder, and the murmur of MVP becomes louder and longer.</td></tr><tr><td>Exercise</td><td>Benign flow murmurs and murmurs caused by stenotic valves become louder with isotonic and isometric exercise. The murmurs of MR, VSD, and AI also increase with isometric exercise.</td></tr><tr><td>Positional changes</td><td>Most murmurs decrease with standing; the murmur of HCM becomes louder, and the murmur of MVP becomes louder and longer. Brisk squatting and passive leg raising increases most murmur: the murmurs of HCM and MVP diminish.</td></tr><tr><td>Postventricular premature beat or atrial fibrillation</td><td>Benign flow murmurs and stenosis at the semilunar valves increase in intensity following a ventricular premature beat or a long cycle length in atrial fibrillation. Systolic murmurs of atrioventricular valve regurgitation do not change.</td></tr><tr><td>Pharmacologic interventions</td><td>The initial hypotensive phase following inhalation of amy] nitrate decreases the murmurs of MR, VSD, and AI, and increases the murmur of AS. The later tachycardic phase following inhalation of amy] nitrate increases right-sided murmurs and the murmur of MS. The response in MVP is biphasic (softer then louder than control).</td></tr><tr><td>Transient arterial occlusion</td><td>Transient external compression of the upper extremity increases the murmurs of MR, VSD, and AI.</td></tr></table>
======================================
<table><tr><td>INDICATOR</td><td>MILD</td><td>MODERATE</td><td>SEVERE</td></tr><tr><td>Mean gradient (mmHg)*</td><td>&lt;5</td><td>5-10</td><td>&gt;10</td></tr><tr><td>Pulmonary artery systolic pressure (mmHg)</td><td>&lt;30</td><td>30-50</td><td>&gt;50</td></tr><tr><td>Valve area (cm?)</td><td>&gt;1.5</td><td>1.0-1.5</td><td>&lt;1.0</td></tr></table>
======================================
<table><tr><td>QUALITATIVE</td><td>MILD</td><td>MODERATE</td><td>SEVERE</td></tr><tr><td>Angiographic grade</td><td>1+</td><td>2+</td><td>3+</td></tr><tr><td>Color Doppler jet area</td><td>Small, central jet (&lt;4 cm? or &lt;20% left atrial area)</td><td>More than mild criteria, but no severe criteria present</td><td>Vena contracta width &gt;0.7 cm with large central jet (area &gt;40% of left atrial area) or with a wall-impinging jet of any size, swirling in left atrium</td></tr><tr><td>Doppler vena contracta width (cm)</td><td>&lt;0.3</td><td>0.3-0.69</td><td>20.7</td></tr></table>
======================================
<table><thead><th>Regurgitant volume (ml per beat)</th><th>| &lt;30</th><th>30-59</th><th>260</th></thead><tr><td>fraction (%)</td><td>&lt;30</td><td></td><td>250</td></tr><tr><td>Regurgitant</td><td></td><td>30-49</td><td></td></tr></table>
======================================
<table><tr><td>Left atrial size</td><td>Enlarged</td></tr><tr><td>Left ventricular size</td><td>Enlarged</td></tr></table>
======================================
<table><thead><th>CLINICAL SETTING</th><th>CLASS OF RECOMMENDATION</th><th>LEVEL OF EVIDENCE</th></thead><tr><td colspan="3">Balloon Valvotomy for Mitral Stenosis</td></tr><tr><td>¢ Symptomatic patients (NYHA II, III, IV) with moderate or severe MS and favorable valve morphology, without left atrial thrombus or moderate to severe MR</td><td></td><td>A</td></tr><tr><td>« Asymptomatic patients with moderate or severe MS, favorable valve morphology, and pulmonary hypertension (PASP &gt;50 mmHg at rest, &gt; 60 mmHg with exercise), without left atrial thrombus or moderate to severe MR</td><td></td><td>€</td></tr><tr><td>¢ Symptomatic patients (NYHA III, IV) with moderate or severe MS and favorable valve morphology, who are high risk or not candidates for surgery</td><td></td><td></td></tr><tr><td>« Asymptomatic patients with moderate or severe MS, favorable valve morphology, and new onset atrial fibrillation, without left atrial thrombus or moderate to severe MR</td><td></td><td></td></tr><tr><td>* Symptomatic patients (NYHA II, III, [1V) with MV area &gt; 1.5 cm’ if there is evidence of hemodynamically significant MS (PASP &gt;60 mmHg, PAWP 225 mmHg, mean MV gradient &gt;15 mmHg during exercise)</td><td></td><td></td></tr><tr><td>¢ Symptomatic patients (NYHA III, IV) with moderate or severe MS and favorable valve morphology, as an alternative to surgery</td><td></td><td></td></tr><tr><td>¢ Patients with mild MS ¢ Patients with moderate to severe MR or left atrial thrombus</td><td></td><td></td></tr><tr><td colspan="3">Surgery for Mitral Stenosis*</td></tr><tr><td>¢ Symptomatic patients (NYHA III, IV) with moderate or severe MS when: Balloon valvotomy is unavailable Balloon valvotomy is contraindicated due to thrombus or MR</td><td></td><td></td></tr><tr><td>Valve morphology is not favorable for balloon valvotomy ¢ Symptomatic patients with moderate to severe MS who also have moderate to severe MR</td><td></td><td></td></tr><tr><td>¢ Mildly symptomatic patients (NYHA I, II) with severe MS and severe pulmonary hypertension (PASP &gt;60 mmHg)</td><td></td><td></td></tr><tr><td>¢ Asymptomatic patients with moderate or severe MS and recurrent embolic events while</td><td></td><td></td></tr><tr><td>receiving adequate anticoagulation, when the likelihood of successful MVr is high ¢ MVr in the setting of mild MS</td><td></td><td></td></tr><tr><td>¢ Closured commissurotomy in the setting of MVr; open commissurotomy should be performed</td><td></td><td></td></tr><tr><td colspan="3">Surgery for Mitral Regurgitation*</td></tr><tr><td>¢ Symptomatic patients with acute severe MR</td><td></td><td></td></tr><tr><td>¢ Symptomatic patients (NYHA II, III, IV) with chronic severe MR without LV dysfunction (LVEF &lt;0.30) and/or end-systolic dimension &gt;55 mm</td><td></td><td></td></tr><tr><td>¢ Asymptomatic patients with chronic severe MR and mild to moderate LV dysfunction (LVEF 0.30-0.60) and/or end-systolic dimension 240 mm</td><td></td><td></td></tr><tr><td>« Asymptomatic patients with chronic severe MR and preserved LV function (LVEF &gt;0.60, end-systolic dimension &lt;40 mm), when the likelihood of successful MVr is &gt;90%</td><td></td><td></td></tr><tr><td>« Asymptomatic patients with chronic severe MR, preserved LV function, and 1) New onset atrial fibrillation, 2) Pulmonary hypertension (PASP &gt;50 mmHg at rest, &gt;60 mmHg with exercise)</td><td>Ila</td><td></td></tr></table>
======================================
<table><tr><td>INDICATOR</td><td>MILD</td><td>MODERATE</td><td>SEVERE</td></tr><tr><td>Jet velocity (m per s)</td><td>&lt;30</td><td>3.0-4.0</td><td>&gt;40</td></tr><tr><td>Mean gradient (mmHg)*</td><td>&lt;25</td><td>25-40</td><td>&gt;4.0</td></tr><tr><td>Valve area (cm?)</td><td>&gt;15</td><td>1.0-1.5</td><td>&lt;1.0</td></tr><tr><td>Valve area index (cm? per m’)</td><td></td><td></td><td>&lt;0.6</td></tr></table>
======================================
<table><tr><td>Regurgitant volume (ml per beat)</td><td>&lt;30</td><td>30-59</td><td>60</td></tr><tr><td rowspan="2">Regurgitant fraction (%) Regurgitant orifice area (cm?)</td><td>&lt;30</td><td>30-49</td><td>250</td></tr><tr><td></td><td>&lt;0.1</td><td>0.1-0.29</td><td>20.3</td></tr></table>
======================================
<table><tr><td>Bridge to surgery in hemodynamically unstable patients with AS at high risk for AVR</td><td>| IIb</td><td>€</td></tr><tr><td>Palliation in adult patients with AS, who are not candidates for AVR</td><td>| IIb</td><td>Cc</td></tr><tr><td>Alternative to AVR in adult patients with AS</td><td>Il- Harm</td><td>B</td></tr></table>
======================================
<table><thead><th>¢ Alternative to AVR in adult patients with AS</th><th>Il — Harm</th><th></th></thead><tr><td colspan="3">Surgery for Aortic Stenosis</td></tr><tr><td>¢ Symptomatic patients with severe AS</td><td></td><td></td></tr><tr><td>Severe AS in the setting of 1) Concomitant CABG 2) Concomitant valvular or aortic surgery LV</td><td></td><td></td></tr><tr><td>3) systolic dysfunction (LVEF &lt;0.50) Moderate AS in the setting of 1) Concomitant CABG</td><td>Ila</td><td></td></tr><tr><td>2) Concomitant valvular or aortic surgery « Asymptomatic patients with severe AS and ¢ Abnormal response to exercise ¢ High likelihood of rapid progression ¢ High likelihood of delay if surgery is withheld until time of symptom onset</td><td>IIb</td><td></td></tr><tr><td>¢ Expected operative mortality &lt;1.0% ¢ Mild AS in patients undergoing CABG, when there is high likelihood of rapid progression</td><td></td><td></td></tr><tr><td>¢ AVR for prevention of sudden death in asymptomatic patients with AS without any of the</td><td></td><td></td></tr><tr><td>findings above</td><td></td><td></td></tr><tr><td colspan="3">Surgery for Aortic Insufficiency</td></tr><tr><td colspan="3">¢ Symptomatic patients with severe Al</td></tr><tr><td>« Asymptomatic patients with chronic severe AI in the setting of 1) Concomitant CABG 2) Concomitant valvular or aortic surgery 3) LV systolic dysfunction (LVEF &lt;0.50)</td><td></td><td>BIRBAN</td></tr><tr><td>« Asymptomatic patients with severe AI, normal LV systolic function (LVEF &gt;0.50), but severe LV dilatation (end-diastolic dimension &gt;75 mm, end-systolic dimension &gt;55 mm)</td><td></td><td></td></tr><tr><td>Moderate AI in the setting of 1) Concomitant CABG 2) Concomitant surgery on the ascending aorta</td><td>IIb</td><td></td></tr><tr><td>« Asymptomatic patients with severe AI, normal LV systolic function at rest (LVEF &gt;0.50), and LV dilatation (end-diastolic dimension 270 mm, end-systolic dimension 250 mm) in the setting of 1) Progressive LV dilatation 2) Declining exercise tolerance 3) Abnormal hemodynamic responses to exercise</td><td>IIb</td><td></td></tr><tr><td>¢ Asymptomatic patients with mild, moderate, or severe AI and normal LV systolic function (LVEF 30.50), when the degree of LV dilatation is not moderate or severe (end-diastolic dimension &lt;70 mm, end-systolic dimension &lt;50 mm)</td><td>Il — Harm</td><td></td></tr></table>
======================================
<table><thead><th>CLINICAL SETTING</th><th>CLASS OF RECOMMENDATION |</th><th>LEVEL OF EVIDENCE</th></thead><tr><td colspan="3">Surgery for Tricuspid Valve Disease</td></tr><tr><td>¢ TVr for severe TI in patients with MV disease requiring MV surgery</td><td>I</td><td>B</td></tr><tr><td>¢ TVR or annuloplasty for severe symptomatic primary TI</td><td>Ila</td><td>Cc</td></tr><tr><td>¢ TVR for severe TI secondary to diseased/abnormal TV leaflets not amenable to annuloplasty or TVr</td><td>| la</td><td>€</td></tr><tr><td>¢ Annuloplasty for less than severe TI in patients undergoing MV surgery in the setting of 1) Pulmonary hypertension 2) Tricuspid annular dilatation</td><td>IIb</td><td>Cc</td></tr><tr><td>¢ TVR or annuloplasty is not indicated in asymptomatic patients with TI, a normal MV, and a PASP &lt;60 mmHg</td><td>Il — Harm</td><td>Cc</td></tr><tr><td>e TVR or annuloplasty is not indicated in patients with mild primary TI</td><td>Iti — Harm</td><td>Cc</td></tr></table>
======================================
<table><tr><td>* Moderate MR, undergoing CABG, if mitral repair is feasible</td><td>Ila</td><td>€</td></tr><tr><td>¢ Severe MR, symptomatic patients, LVEF &lt;30%, candidate for revascularization</td><td>Ila</td><td>€</td></tr><tr><td colspan="3">Chronic Functional MR (ESC and ACC/AHA Guidelines)</td></tr><tr><td>* Chronic severe MR due to LV dysfunction, EF &lt;30%, persistent NYHA class III-IV, symptoms despite optimal medical therapy</td><td>IIb</td><td>Cc</td></tr></table>
======================================
<table><thead><th colspan="2">Anatomic complications of aortic dissection and their associated symptoms and signs</th></thead><tr><td>ANATOMIC MANIFESTATION</td><td>SYMPTOMS AND SIGNS</td></tr><tr><td>Aortic valve insufficiency</td><td>Dyspnea Murmur Pulmonary rales Shock</td></tr><tr><td>Coronary malperfusion</td><td>Chest pain with characteristics of angina Nausea/vomiting Shock Ischemic changes on electrocardiogram Elevated cardiac enzymes</td></tr><tr><td>Pericardial tamponade</td><td>Dyspnea Jugular venous distension Pulsus paradoxus Muffled cardiac tones Shock Low-voltage electrocardiogram</td></tr><tr><td>Subclavian or iliofemoral artery malperfusion</td><td>Cold, painful extremity Extremity sensory and motor deficits Peripheral pulse deficit</td></tr><tr><td>Carotid artery malperfusion</td><td>Syncope Focal neurologic deficit (transient or persistent) Carotid pulse deficit Coma</td></tr><tr><td>Spinal malperfusion</td><td>Paraplegia Incontinence</td></tr><tr><td>Mesenteric malperfusion</td><td>Nausea/vomiting Abdominal pain</td></tr><tr><td>Renal malperfusion</td><td>Oliguria or anuria</td></tr></table>
======================================
<table><tr><td>Grading</td><td>scales for</td><td>peripheral</td><td>pulses</td><td></td></tr><tr><td></td><td>TRADITIONAL SCALE</td><td></td><td></td><td>BASIC SCALE</td></tr><tr><td>4+</td><td>Normal</td><td></td><td>2+</td><td>Normal</td></tr><tr><td>3+</td><td>Slightly reduced</td><td></td><td>1+</td><td>Diminished</td></tr><tr><td>2+</td><td>Markedly reduced</td><td></td><td>0</td><td>Absent</td></tr><tr><td>1+</td><td>Barely palpable</td><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>DEGREE OF STENOSIS (%)</td><td>ICA PSV (CM/S)</td><td>ICA/CCA PSV RATIO</td><td>ICA EDV (CM/S)</td><td>PLAQUE ESTIMATE (%)?</td></tr><tr><td>Normal</td><td>&lt;125</td><td>&lt;2.0</td><td>&lt;40</td><td></td></tr><tr><td>&lt;50</td><td>&lt;125</td><td>&lt;2.0</td><td>&lt;40</td><td>&lt;50</td></tr><tr><td>50-69</td><td>125-230</td><td>2.0-4.0</td><td>40-100</td><td>250</td></tr><tr><td>270 to less than near occlusion</td><td>&gt;230</td><td>&gt;4.0</td><td>&gt;100</td><td>250</td></tr><tr><td rowspan="2">Near occlusion Total occlusion</td><td>High, low, or not detected</td><td>| Variable</td><td>Variable</td><td>Visible</td></tr><tr><td></td><td>Not detected</td><td>Not applicable</td><td>Not detected</td><td>Visible, no lumen</td></tr></table>
======================================
<table><thead><th>Conditions qualifying patients as high surgical risk</th><th>for carotid endarterectomy</th></thead><tr><td>ANATOMIC FACTORS</td><td>PHYSIOLOGIC FACTORS</td></tr><tr><td>¢ High carotid bifurcation (above C2 vertebral body) ¢ Low common carotid artery (below clavicle) * Contralateral carotid occlusion ¢ Restenosis of ipsilateral prior carotid endarterectomy ¢ Previous neck irradiation ¢ Prior radical neck dissection</td><td>« Age 280 years ¢ Left ventricular ejection fraction &lt;30% ¢ New York Heart Association class III/IV congestive heart failure ¢ Unstable angina: Canadian Cardiovascular Society class III/IV angina pectoris ¢ Recent infarction</td></tr><tr><td>* Contralateral laryngeal nerve palsy ¢ Presence of tracheostomy</td><td>myocardial ¢ Clinically significant cardiac disease (congestive heart failure, abnormal stress test, or need for coronary revascularization) ¢ Severe chronic obstructive pulmonary disease ¢ End-stage renal disease on dialysis</td></tr></table>
======================================
<table><thead><th>MECHANISM</th><th>NAME OF EPD</th><th>PORE SIZE (uM)</th></thead><tr><td>Distal balloon occlusion</td><td>PercuSurge Guard Wire, Export catheter (Medtronic)</td><td></td></tr><tr><td>Distal filter</td><td>Angioguard (Cordis)</td><td>100</td></tr><tr><td></td><td>Accunet (Abbott)</td><td>150</td></tr><tr><td></td><td>Emboshield (Abbott)</td><td>140</td></tr><tr><td></td><td>FilterWire (Boston Scientific)</td><td>| 110</td></tr><tr><td></td><td>SpiderRx (EV3)</td><td>&lt;100</td></tr><tr><td>Flow reversal*</td><td>| Parodi Neuro Protection (Gore)</td><td></td></tr><tr><td colspan="3">*Clinical trial (EMPIRE) in United States.</td></tr><tr><td colspan="3">= not applicable.</td></tr></table>
======================================
<table><tr><td>NAME OF STENT</td><td>MANUFACTURER</td><td>CELL DESIGN</td><td>TAPERED STENT</td><td>DELIVERY SYSTEM SIZE (FRENCH)</td></tr><tr><td>Acculink</td><td>Abbott</td><td>Open</td><td>Yes</td><td>6</td></tr><tr><td>Exact</td><td>Abbott</td><td>Closed</td><td>Yes</td><td>6</td></tr><tr><td>NexStent</td><td>Boston Scientific</td><td>Closed</td><td>Self-tapering</td><td>5</td></tr><tr><td>Protégé RX</td><td>EV3</td><td>Open</td><td>Yes</td><td>6</td></tr><tr><td>Precise RX</td><td>Cordis</td><td>Open</td><td>No</td><td>6</td></tr><tr><td>Exponent</td><td>Medtronic</td><td>Open</td><td>No</td><td>6</td></tr></table>
======================================
<table><thead><th>DESCRIPTION</th><th>DIAMETER OF AORTA (CM)</th><th>ESTIMATED ANNUAL RISK OF RUPTURE (%)</th><th>ESTIMATED 5-YEAR RISK OF RUPTURE (%)?</th></thead><tr><td>Normal aorta</td><td>2-3</td><td>0</td><td>0 (unless AAA develops)</td></tr><tr><td>Small AAA</td><td>4-5</td><td>1</td><td>5-10</td></tr><tr><td>Moderate AAA</td><td>5-6</td><td>2-5</td><td>30-40</td></tr><tr><td>Large AAA</td><td>6-7</td><td>3-10</td><td>&gt;50</td></tr><tr><td>Very large AAA</td><td>&gt;7</td><td>&gt;10</td><td>Approaching 100</td></tr></table>
======================================
<table><thead><th>Neck length (mm)</th><th>&gt;15</th></thead><tr><td>Neck diameter (mm)</td><td>&gt;18, &lt;32</td></tr><tr><td>Aortic Neck angle (degrees)</td><td>&lt;60</td></tr><tr><td>Neck mural calcification (% circumference)</td><td>&lt;50</td></tr><tr><td>Neck luminal thrombus (% circumference)</td><td>&lt;50</td></tr><tr><td>Common iliac artery diameter (mm)</td><td>Between 8 and 20</td></tr><tr><td>Common iliac artery length (mm)</td><td>&gt;20</td></tr><tr><td>External iliac artery diameter (mm)</td><td>&gt;7</td></tr></table>
======================================
<table><thead><th>Endoleak classification</th><th></th></thead><tr><td>CLASSIFICATION</td><td>DESCRIPTION</td></tr><tr><td>Type I endoleak</td><td>Attachment site leak</td></tr><tr><td>Type Ilendoleak</td><td>| Side branch leak caused by lumbar or inferior mesenteric arteries</td></tr><tr><td>Type Il endoleak</td><td>— Junctional leak (of overlapping endograft components) and graft fabric defect</td></tr><tr><td>Type IV endoleak</td><td>Endograft fabric porosity leak</td></tr></table>
======================================
<table><tr><td>Table 23-11</td><td></td><td></td></tr><tr><td colspan="3">Renal duplex diagnostic criteria</td></tr><tr><td>RENAL ARTERY</td><td>RENAL ARTERY</td><td></td></tr><tr><td>DIAMETER REDUCTION</td><td>PSV</td><td>RAR</td></tr><tr><td>Normal</td><td>&lt;180 cm/s</td><td>&lt;3.5</td></tr><tr><td>&lt;60%</td><td>2180 cm/s</td><td>&lt;3.5</td></tr><tr><td>260%</td><td>2180 cm/s</td><td>23.5</td></tr><tr><td>Occlusion</td><td>No signal</td><td>No signal</td></tr></table>
======================================
<table><thead><th rowspan="2">AUTHOR |</th><th rowspan="2">YEAR</th><th rowspan="2">PATIENT | NO.</th><th rowspan="2">| TECHNICAL | SUCCESS (%)</th><th rowspan="2">FOLLOW-UP | (MONTHS)</th><th colspan="2">RENAL INSUFFICIENCY (%)</th><th colspan="2">RENOVASCULAR | HYPERTENSION (%)</th><th rowspan="2">COMPLICATION | (%)</th><th rowspan="2">| RESTENOSIS (%)</th></thead><thead><th></th><th></th><th></th><th></th><th></th><th>|STABLE</th><th>|IMPROVED</th><th>| CURED</th><th>| IMPROVED</th><th></th><th></th></thead><tr><td>Iannone</td><td>1996</td><td>| 63</td><td>99</td><td>10</td><td>45</td><td>36</td><td>4</td><td>35</td><td>13</td><td>14</td></tr><tr><td>Harden”</td><td>1997</td><td>| 32</td><td>100</td><td>6</td><td>34</td><td>34</td><td></td><td>|N/A</td><td>3</td><td>1B</td></tr><tr><td>Blum!</td><td>1997</td><td>| 68</td><td>100</td><td>27</td><td></td><td>|N/A</td><td>16</td><td>62</td><td>0</td><td>in</td></tr><tr><td>White!</td><td>1997</td><td>| 100</td><td>99</td><td>6</td><td></td><td>|20</td><td></td><td>|N/A</td><td>2</td><td>19</td></tr><tr><td>Shannon?</td><td>| 1998</td><td>| 21</td><td>100</td><td>9</td><td>29</td><td>B</td><td></td><td>|N/A</td><td>9</td><td>0</td></tr><tr><td>Rundback"!</td><td>1998</td><td>| 45</td><td>94</td><td>17</td><td></td><td>|N/A</td><td></td><td>|N/A</td><td>9</td><td>25</td></tr><tr><td>Dorros!®</td><td>1998</td><td>| 163</td><td>100</td><td>48</td><td></td><td>|N/A</td><td>3</td><td>51</td><td>mm</td><td></td></tr><tr><td>Henry</td><td>1999</td><td>|210</td><td>99</td><td>25</td><td></td><td>|29</td><td>19</td><td>61</td><td>3</td><td>9</td></tr><tr><td>Bush!”</td><td>2001</td><td>| 73</td><td>89</td><td>20</td><td>2</td><td>38</td><td>13</td><td>61</td><td>12</td><td>16</td></tr></table>
======================================
<table><thead><th></th><th></th><th>CATEGORY</th><th></th></thead><thead><th>DESCRIPTION</th><th>VIABLE</th><th>THREATENED</th><th>IRREVERSIBLE</th></thead><tr><td>Clinical description</td><td>Not immediately threatened</td><td>Salvageable if promptly treated</td><td>Major tissue loss, amputation unavoidable</td></tr><tr><td>Capillary return</td><td>Intact</td><td>Intact, slow</td><td>Absent (marbling)</td></tr><tr><td>Muscle weakness</td><td></td><td>Mild, partial</td><td>Profound, paralysis (rigor)</td></tr><tr><td>Sensory loss</td><td></td><td>Mild, incomplete</td><td>Profound anesthetic</td></tr><tr><td>Arteriovenous Doppler finding</td><td>Audible</td><td>Inaudible or audible</td><td>Inaudible</td></tr></table>
======================================
<table><thead><th></th><th>LOCATION OF PAIN OR DISCOMFORT</th><th>CHARACTERISTIC DISCOMFORT</th><th>ONSET RELATIVE TO EXERCISE</th><th>EFFECT OF REST</th><th>EFFECT OF BODY POSITION</th><th>OTHER CHARACT</th></thead><tr><td>ion (calf)</td><td>Calf muscles</td><td>Cramping pain</td><td>After same degree of exercise</td><td>Quickly relieved</td><td></td><td>Reproducible</td></tr><tr><td>npartment 3</td><td>| Calf muscles</td><td>Tight, bursting pain</td><td>| After much exercise (e.g., jogging)</td><td>Subsides very slowly |</td><td>Relief speeded by elevation</td><td>Typically heavy athletes</td></tr><tr><td>idication</td><td>| Entire leg, but usually worse in thigh and groin</td><td>Tight, bursting pain</td><td>| After walking</td><td>Subsides slowly</td><td>Relief speeded by elevation</td><td>History of iliofe venous throm venous conge</td></tr><tr><td>ion (e.g., disk)</td><td>Radiates down leg, usually posteriorly</td><td>| Sharp lancinating | pain</td><td>Soon, if not immediately after onset</td><td>| Not quickly relieved (also often present at rest)</td><td>| Relief may be aided by adjusting back position</td><td>History of back</td></tr><tr><td>ic Baker’s</td><td>| Behind knee, down | calf</td><td>Swelling, soreness, tenderness</td><td>With exercise</td><td>Present at rest</td><td></td><td>Not intermittent</td></tr><tr><td>ion (hip, tock)</td><td>Hip, thigh, buttocks</td><td>| Aching discomfort, weakness</td><td>| After same degree of exercise</td><td>Quickly relieved</td><td></td><td>Reproducible</td></tr><tr><td></td><td>Hip, thigh, buttocks</td><td>| Aching discomfort</td><td>After variable degree of exercise</td><td>| Not quickly relieved (and may be present at rest)</td><td>| More comfortable sitting, weight taken off legs</td><td>Variable, may r activity level, changes</td></tr><tr><td>ion</td><td>Hip, thigh, buttocks (follows dermatome)</td><td>| Weakness more than pain</td><td>| After walking or standing for same length of time</td><td>Relieved by stopping only if position changed</td><td>| Relief by lumbar spine flexion (sitting or stooping forward) pressure</td><td>| Frequent history problems, pre increased intr pressure</td></tr><tr><td>ion (foot)</td><td>Foot, arch</td><td>Severe deep pain and numbness</td><td>| After same degree of exercise</td><td>Quickly relieved</td><td></td><td>Reproducible</td></tr><tr><td>tory</td><td>Foot, arch</td><td>Aching pain</td><td>After variable degree of exercise</td><td>| Not quickly relieved (and may be</td><td>| May be relieved by not bearing weight</td><td>| Variable, may r activity level</td></tr></table>
======================================
<table><thead><th colspan="2">FONTAINE CLASSIFICATION</th><th colspan="3">RUTHERFORD CLASSIFICATION</th></thead><thead><th>STAGE</th><th>CLINICAL</th><th>GRADE</th><th>CATEGORY</th><th>CLINICAL</th></thead><tr><td>I</td><td>Asymptomatic</td><td>0</td><td>0</td><td>Asymptomatic</td></tr><tr><td>Ila</td><td>Mild claudication</td><td>I</td><td>1</td><td>Mild claudication</td></tr><tr><td rowspan="2">IIb</td><td>Moderate to severe claudication</td><td>I</td><td>2</td><td>Moderate claudication</td></tr><tr><td></td><td></td><td>I</td><td>3</td><td>Severe claudication</td></tr><tr><td>Il</td><td>Ischemic rest pain</td><td>I</td><td>4</td><td>Ischemic rest pain</td></tr><tr><td rowspan="2">IV</td><td></td><td>Ulceration or gangrene</td><td>Il</td><td>5</td><td>Minor tissue loss</td></tr><tr><td></td><td>Il</td><td>6</td><td>Major tissue loss</td></tr></table>
======================================
<table><thead><th></th><th>ANTERIOR COMPARTMENT</th><th>LATERAL COMPARTMENT</th><th></th><th>SUPERFICIAL POSTERIOR COMPARTMENT</th><th>DEEP POSTERIOR COMPARTMENT</th></thead><tr><td>Muscles</td><td>_ Tibialis anterior Extensor digitorum longus Peroneus tertius Extensor hallucis longus Extensor digitorum brevis Extensor hallucis brevis</td><td>Peroneus longus _| Peroneus brevis</td><td></td><td>Gastrocnemius Plantaris Soleus</td><td>Tibialis posterior Flexor digitorum longus Flexor hallucis longus</td></tr><tr><td>Artery</td><td>Anterior tibial artery</td><td>Anterior and posterior tibial branches of the popliteal artery</td><td></td><td></td><td>Posterior tibial artery Peroneal artery</td></tr><tr><td>Nerve</td><td>Deep peroneal nerve</td><td>Superficial peroneal nerve</td><td></td><td></td><td>Tibial nerve</td></tr></table>
======================================
<table><tr><td>GRADE</td><td>| CATEGORY |</td><td>CLINICAL DESCRIPTION</td><td>OBJECTIVE CRITERIA</td></tr><tr><td rowspan="2">0</td><td>0</td><td>Asymptomatic—no hemodynamically significant occlusive disease</td><td>Normal treadmill or reactive hyperemia test</td></tr><tr><td></td><td>1</td><td>Mild claudication</td><td>Able to complete treadmill exercise*; AP after exercise &gt;50 mmHg but at least 20 mmHg lower than resting value</td></tr><tr><td rowspan="2">I</td><td>2</td><td>Moderate claudication</td><td>Between categories | and 3</td></tr><tr><td></td><td>3</td><td>Severe claudication</td><td>Cannot complete standard treadmill exercise* and AP after exercise &lt;50 mmHg</td></tr><tr><td>mr</td><td>4</td><td>Ischemic rest pain</td><td>Resting AP &lt;40 mmHg, flat or barely pulsatile ankle or metatarsal PVR; TP &lt;30 mmHg</td></tr><tr><td rowspan="2">rr</td><td>5</td><td>Minor tissue loss—nonhealing ulcer, focal gangrene with diffuse pedal ischemia</td><td>Resting AP &lt;60 mmHg, ankle or metatarsal PVR flat or barely pulsatile; TP &lt;40 mmHg</td></tr><tr><td></td><td>6</td><td>Major tissue loss—extending above TM level, functional foot no longer salvageable</td><td>| Same as category 5</td></tr></table>
======================================
<table><thead><th>NEUROPATHIC ULCER</th><th>ISCHEMIC ULCER</th></thead><tr><td>Painless</td><td>Painful</td></tr><tr><td>Normal pulses</td><td>Absent pulses</td></tr><tr><td>Regular margins, typically punched-out appearance</td><td>Irregular margin</td></tr><tr><td>Often located on plantar surface of foot</td><td>Commonly located on toes, glabrous margins</td></tr><tr><td>Presence of calluses</td><td>Calluses absent or infrequent</td></tr><tr><td>Loss of sensation, reflexes, and vibration</td><td>Variable sensory findings</td></tr><tr><td>Increased in blood flow (arteriovenous shunting)</td><td>Decreased in blood flow</td></tr><tr><td>Dilated veins</td><td>Collapsed veins</td></tr><tr><td>Dry, warm foot</td><td>Cold foot</td></tr><tr><td>Bony deformities</td><td>No bony deformities</td></tr><tr><td>Red or hyperemic in</td><td>Pale and cyanotic in</td></tr><tr><td>appearance</td><td>appearance</td></tr></table>
======================================
<table><thead><th>INTERVENTION</th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td>Angioplasty</td><td>¢ Easy to use ¢ Broad range of applications</td><td>¢ Failure in long lesions, calcified lesions, and disease at multiple levels</td></tr><tr><td>Balloon- expandable stent</td><td>* Overcomes arterial recoil from angioplasty Useful in treatment of flow-limiting dissection</td><td>¢ Crushability can lead to restenosis ¢ Poor distal runoff can result in stent thrombosis ¢ Limited data</td></tr><tr><td>Self-expanding stent</td><td>¢ Vessel conformability and wall apposition prevent kinking and crushing of stent</td><td>| * Limited sizes ¢ Limited data; multicenter trials under way</td></tr><tr><td>Bioabsorbable stent</td><td>* Overcomes arterial recoil from angioplasty ¢ Absorbed long term to prevent risk of stent thrombosis</td><td>¢ Limited data; multicenter trials under way</td></tr><tr><td>Cryoplasty</td><td>¢ Reduces the risk of flow-limiting dissection, therefore reducing the need for stent implantation</td><td>¢ Short-term results of a multicenter trial are promising; however, long-term data are limited</td></tr><tr><td>Cutting balloon</td><td>Useful in anastomotic segments of bypass grafts and in-stent restenosis where “watermelon seeding” can prevent adequate expansion of plaque</td><td>¢ Limited data</td></tr><tr><td>Mechanical atherectomy</td><td>¢ Allows for debulking of plaque without the need for stent implantation in most cases ¢ Allows for removal of plaque for histologic analysis</td><td>¢ Limited use in areas of heavy calcification ¢ No large, randomized, prospective trial comparing this technique to angioplasty and stenting</td></tr><tr><td>Laser</td><td>¢ Useful in acute thrombotic and chronic total occlusions</td><td>¢ Minimal data in infrapopliteal arteries ¢ Need adjunctive treatment with angioplasty, stenting, or atherectomy</td></tr></table>
======================================
<table><tr><td>Angiographic</td><td>classification of Takayasu's arteritis</td></tr><tr><td>TYPE</td><td>VESSEL INVOLVEMENT</td></tr><tr><td>Type I</td><td>Branches from the aortic arch</td></tr><tr><td>Type Ila</td><td>| Ascending aorta, aortic arch and its branches</td></tr><tr><td>Type IIb</td><td>| Ascending aorta, aortic arch and its branches, thoracic descending aorta</td></tr><tr><td>Type III</td><td>| Thoracic descending aorta, abdominal aorta, and/ or renal arteries</td></tr><tr><td>Type IV</td><td>| Abdominal aorta and/or renal arteries</td></tr><tr><td>Type V</td><td>Combined features of types Ib and IV</td></tr></table>
======================================
<table><thead><th colspan="2">Classification of popliteal entrapment syndrome</th></thead><thead><th>TYPE</th><th>DESCRIPTION</th></thead><tr><td>I</td><td>Popliteal artery is displaced medially around a normal medial head of the gastrocnemius</td></tr><tr><td>I</td><td>Medial head of gastrocnemius, which arises lateral to popliteal artery</td></tr><tr><td>Il</td><td>Popliteal artery is compressed by an accessory slip of muscle from medial head of gastrocnemius</td></tr><tr><td>IV</td><td>Entrapment by a deeper popliteus muscle</td></tr><tr><td>Vv</td><td>Any of the above plus popliteal vein entrapment</td></tr><tr><td>VI</td><td>Functional entrapment</td></tr></table>
======================================
<table><tr><td>Table 24-1</td><td></td></tr><tr><td colspan="2">Possible signs of superficial venous abnormalities</td></tr><tr><td colspan="2">Tortuosity</td></tr><tr><td colspan="2">Varicosity</td></tr><tr><td colspan="2">Venous saccule</td></tr><tr><td colspan="2">Distended subdermal venules (corona phlebectatica)</td></tr><tr><td colspan="2">Distended intradermal venules (spider angiomata)</td></tr><tr><td>Warmth, erythema, tenderness (superficial</td><td>thrombophlebitis)</td></tr></table>
======================================
<table><thead><th>LEVEL OF RISK</th><th>APPROXIMATE DVT RISK WITHOUT THROMBOPROPHYLAXIS (%)</th><th>SUGGESTED THROMBOPROPHYLAXIS OPTIONS</th></thead><tr><td>Very low risk General or abdominopelvic surgery</td><td>&lt;0.5% (Rogers score &lt;7; Caprini score 0)</td><td>No specific thromboprophylaxis Early ambulation</td></tr><tr><td>Low risk General or abdominopelvic surgery</td><td>~1.5% (Rogers score 7-10; Caprini score 1-2)</td><td>Mechanical prophylaxis</td></tr><tr><td>Moderate risk General or abdominopelvic surgery</td><td>~3.0% (Rogers score &gt;10; Caprini score 3-4)</td><td>LMWH (at recommended doses), LDUH, or mechanical prophylaxis</td></tr><tr><td>High bleeding risk</td><td></td><td>Mechanical prophylaxis</td></tr><tr><td>High risk General or abdominopelvic surgery</td><td>~6% (Caprini score 25)</td><td>LMWH (at recommended doses), fondaparinux and mechanical prophylaxis</td></tr><tr><td>High bleeding risk General or abdominopelvic surgery for cancer</td><td></td><td>Mechanical thromboprophylaxis Extended-duration LMWH (4 weeks)</td></tr></table>
======================================
<table><thead><th>CLINICAL SUBGROUP</th><th>DURATION</th></thead><tr><td>First episode DVT/transient risk/surgery</td><td>VKA or LMWH for 3 months</td></tr><tr><td>First episode DVT/ unprovoked</td><td>VKA or LMWH for 3 months Consider for long-term therapy if: ¢ Proximal DVT ¢ Minimal bleeding risk ¢ Stable coagulation monitoring</td></tr><tr><td>Distal DVT/unprovoked ¢ Symptomatic ¢ Asymptomatic and no risk factors for progression Second episode DVT/</td><td>VKA for 3 months Serial imaging in 2 weeks, if progression VKA for 3 months VKA for extended therapy</td></tr><tr><td>unprovoked DVT and cancer</td><td>LMWH for extended therapy over VKA</td></tr></table>
======================================
<table><tr><td>Operation type other than endocrine</td><td></td></tr><tr><td colspan="2">Respiratory and hernia</td></tr><tr><td>Thoracoabdominal aneurysm,</td><td></td></tr><tr><td>embolectomy/thrombectomy,</td><td></td></tr><tr><td>venous reconstruction, and</td><td></td></tr><tr><td colspan="2">endovascular repair</td></tr><tr><td>Aneurysm</td><td>HL</td></tr><tr><td>Mouth, palate</td><td></td></tr><tr><td>Stomach, intestines</td><td></td></tr><tr><td>Integument</td><td>NWR</td></tr><tr><td>ASA, physical status classification 3,4, or 5 2 Female sex</td><td></td></tr><tr><td></td><td></td></tr><tr><td>Work RVU &gt;17</td><td></td></tr><tr><td>Preoperative serum sodium &gt;145 mmol/L Transfusion &gt;4 units packed RBCs in 72 hours before operation Ventilator dependent</td><td></td></tr><tr><td>One point for each of these conditions</td><td></td></tr><tr><td>Wound class (clean/contaminated) Preoperative hematocrit &lt;38% Preoperative bilirubin &gt;1 mg/dL Dyspnea Albumin &lt;3.5 mg/dL Emergency</td><td></td></tr><tr><td></td><td></td></tr></table>
======================================
<table><tr><td>1 POINT</td><td>2 POINTS</td><td>3 POINTS</td><td>5 POINTS</td></tr><tr><td>Age 41-60</td><td>Age 61-74</td><td>Age 275</td><td>Stroke (&lt;1 month)</td></tr><tr><td>Minor surgery</td><td>Arthroscopic surgery</td><td>History of VTE</td><td>Elective arthroplasty</td></tr><tr><td>BMI &gt;25 kg/m?</td><td>Major open surgery (&gt; 45 minutes)</td><td>Family history of VTE</td><td>Hip, pelvis, or leg fracture</td></tr><tr><td>Swollen legs</td><td>Laparoscopic surgery (&gt; 45 minutes)</td><td>Factor V Leiden</td><td>Acute spinal cord injury (&lt;1 month)</td></tr><tr><td>Varicose veins</td><td>Malignancy</td><td>Prothrombin 20210A</td><td></td></tr><tr><td>Pregnancy or postpartum</td><td>Confined to bed (&gt;72 hours)</td><td>Lupus anticoagulant</td><td></td></tr><tr><td>History of unexplained or recurrent spontaneous abortion</td><td>Immobilizing plaster cast</td><td>Anticardiolipin antibody</td><td></td></tr><tr><td>Oral contraceptives of hormone replacement</td><td>Central venous access</td><td>Elevated serum homocysteine</td><td></td></tr><tr><td>Sepsis (&lt;1 month)</td><td></td><td>Heparin-induced thrombocytopenia</td><td></td></tr><tr><td>Serious lung disease, including pneumonia (&lt;1 month)</td><td></td><td>Other congenital or acquired thrombophilia</td><td></td></tr><tr><td colspan="4">Abnormal pulmonary function test</td></tr><tr><td colspan="4">Acute myocardial infarction</td></tr><tr><td colspan="4">Congestive heart failure</td></tr><tr><td>History of inflammatory bowel disease</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th></th><th rowspan="2">MEDIAN |</th><th colspan="2">PERCENTILE</th></thead><thead><th></th><th></th><th>2.5</th><th>97.5</th></thead><tr><td>Pressure (mmHg)</td><td>13</td><td>5.8</td><td>27.7</td></tr><tr><td>Overall length (cm)</td><td>| 3.6</td><td>2.1</td><td>5.6</td></tr><tr><td>Abdominal length (cm)</td><td>2</td><td>0.9</td><td>47</td></tr><tr><td></td><td>MEAN</td><td>MEAN - 2 SD|</td><td>MEAN + 2 SD</td></tr><tr><td>Pressure (mmHg)</td><td>13.84 4.6</td><td>| 4.6</td><td>23.0</td></tr><tr><td>Overall length (cm)</td><td>|3.7+0.8 |</td><td>2.1</td><td>5.3</td></tr><tr><td>Abdominal length (cm)</td><td>2.2+0.8</td><td>| 0.6</td><td>3.8</td></tr></table>
======================================
<table><thead><th>Normal values for</th><th>esophageal</th><th>exposure to pH</th><th rowspan="2">&lt;4 (n = 50) 95%</th></thead><thead><th>COMPONENT</th><th>MEAN</th><th>SD</th><th></th></thead><tr><td>Total time</td><td>1.51</td><td>1.36</td><td>4.45</td></tr><tr><td>Upright time</td><td>2.34</td><td>2.34</td><td>8.42</td></tr><tr><td>Supine time</td><td>0.63</td><td>1.0</td><td>3.45</td></tr><tr><td>No. of episodes</td><td>19.00</td><td>12.76</td><td>46.90</td></tr><tr><td>No. &gt;5 min</td><td>0.84</td><td>1.18</td><td>3.45</td></tr><tr><td>Longest episode</td><td>6.74</td><td>7.85</td><td>19.80</td></tr></table>
======================================
<table><thead><th>pH THRESHOLD</th><th>95TH PERCENTILE</th></thead><tr><td>&lt;l</td><td>14.2</td></tr><tr><td>&lt;2</td><td>17.37</td></tr><tr><td>&lt;3</td><td>14.10</td></tr><tr><td>&lt;4</td><td>14.72</td></tr><tr><td>&lt;5</td><td>15.76</td></tr><tr><td>&lt;6</td><td>12.76</td></tr><tr><td>&gt;7</td><td>14.90</td></tr><tr><td>&gt;8</td><td>8.50</td></tr></table>
======================================
<table><thead><th>PARAMETER</th><th>MEDIAN VALUE</th><th>| 2.5TH | PERCENTILE</th><th>97.5TH | PERCENTILE</th></thead><tr><td>Pressure (mmHg)</td><td>13</td><td>5.8</td><td>27.7</td></tr><tr><td>Overall length (cm)</td><td>3.6</td><td>2.1</td><td>5.6</td></tr><tr><td>Abdominal length (cm)</td><td>| 2</td><td>0.9</td><td>47</td></tr></table>
======================================
<table><thead><th>COMPLICATION</th><th>|NO.</th><th>STRUCTURALLY — NORMAL |SPHINCTER (%)</th><th>| STRUCTURALLY DEFECTIVE | SPHINCTER (%)</th></thead><tr><td>Erosive esophagitis</td><td>59 47</td><td>58 23</td><td>42 TT</td></tr><tr><td>Stricture</td><td>19</td><td>11</td><td>89</td></tr><tr><td>Barrett’s esophagus</td><td>25</td><td>0</td><td>100</td></tr><tr><td>Total</td><td>150</td><td></td><td></td></tr></table>
======================================
<table><thead><th>AUTHOR</th><th>YEAR</th><th>NO. OF | PATIENTS</th><th>% EXCELLENT TO GOOD | RESPONSE</th><th>| MEAN FOLLOW-UP, YEARS</th></thead><tr><td>Starnes</td><td>1984</td><td>|8</td><td>75</td><td>2</td></tr><tr><td>Williamson</td><td>| 1990</td><td>| 37</td><td>92</td><td>3</td></tr><tr><td>DeMeester</td><td>| 1990</td><td>| 35</td><td>77</td><td>3</td></tr><tr><td>McDonald</td><td>| 1996</td><td>| 113</td><td>82.2</td><td>6.5</td></tr><tr><td>Ortiz</td><td>1996</td><td>| 32</td><td>90.6</td><td>5</td></tr></table>
======================================
<table><thead><th rowspan="2">REASON</th><th colspan="3">AUTHOR, PROCEDURE (NV)</th></thead><thead><th></th><th>ELLIS, MYOTOMY ONLY (N = 81)</th><th>GOULBOURNE, MYOTOMY ONLY (N = 65)</th><th>MALTHANER, MYOTOMY + ANTIREFLUX (N = 22)</th></thead><tr><td>Reflux</td><td>4%</td><td>5%</td><td>18%</td></tr><tr><td>Inadequate myotomy</td><td>2%</td><td>_</td><td>9%</td></tr><tr><td>Megaesophagus</td><td>2%</td><td>=</td><td>=</td></tr><tr><td>Poor emptying</td><td>4%</td><td>3%</td><td>_</td></tr><tr><td>Persistent chest pain</td><td>1%</td><td>=</td><td>=</td></tr></table>
======================================
<table><tr><td colspan="3">TX</td><td colspan="11">Primary tumor cannot be assessed.</td></tr><tr><td>TO</td><td></td><td colspan="2" rowspan="2">No</td><td colspan="11">evidence of primary tumor.</td></tr><tr><td colspan="13">Tis</td><td colspan="11" rowspan="2">High-grade dysplasia. propria, muscularis mucosae, or submucosa.</td><td colspan="2"></td></tr><tr><td>Tl</td><td></td><td colspan="3">Tumor invades lamina</td><td colspan="11"></td></tr><tr><td>Tla</td><td></td><td colspan="11" rowspan="2">Tumor invades lamina propria or muscularis mucosae. Tumor invades submucosa.</td></tr><tr><td>Tlb</td><td></td><td colspan="11"></td></tr><tr><td>T2</td><td></td><td colspan="6">Tumor invades muscularis propria.</td><td colspan="10"></td></tr><tr><td>T3</td><td colspan="3"></td><td colspan="11" rowspan="6">Tumor Resectable Unresectable Regional</td><td colspan="3">Tumor invades adventitia.</td></tr><tr><td>T4</td><td></td><td colspan="4"></td><td colspan="11"></td><td colspan="9" rowspan="6">invades adjacent structures. tumor invading pleura, pericardium, or diaphragm. tumor invading other adjacent structures, such as aorta, vertebral body, trachea, etc. lymph cannot be assessed. in 1-2 regional lymph nodes.</td></tr><tr><td>T4a</td><td colspan="3"></td><td colspan="11"></td><td colspan="9"></td></tr><tr><td>T4b</td><td></td><td colspan="11"></td><td colspan="9"></td></tr><tr><td>NX</td><td></td><td colspan="3">nodes</td><td colspan="11"></td><td colspan="9"></td></tr><tr><td>NO</td><td></td><td colspan="4">No regional lymph node metastasis.</td><td colspan="11"></td><td colspan="9"></td></tr><tr><td>NI</td><td colspan="3">Metastases</td><td colspan="9"></td></tr><tr><td>N2</td><td></td><td></td><td colspan="4">Metastases in 3-6 regional</td><td></td><td></td><td>lymph nodes.</td><td></td><td></td><td></td></tr><tr><td>N3</td><td></td><td></td><td colspan="3">Metastases in 27 regional distant</td><td></td><td></td><td></td><td>lymph nodes.</td><td></td><td></td><td></td></tr><tr><td>MO</td><td colspan="3">No</td><td>metastasis.</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3"></td><td></td><td>SQUAMOUS</td><td></td><td></td><td></td><td>CELL CARCINOMA</td><td></td><td></td><td></td></tr><tr><td>Clinical</td><td colspan="3" rowspan="3">(CTNM)</td><td></td><td></td><td>T3</td><td>NO</td><td>MO</td><td>GX IIB</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3"></td><td></td><td></td><td></td><td></td><td></td><td>___Lower/upper/middle</td><td></td><td></td><td></td></tr><tr><td></td><td colspan="3"></td><td></td><td></td><td>T3</td><td>NO</td><td>MO</td><td>Any Location X IB</td><td></td><td></td><td></td></tr><tr><td>When</td><td></td><td>And</td><td></td><td>And</td><td>Then the</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>eT is...</td><td></td><td colspan="2" rowspan="2">cN is... Ne</td><td>Mis...</td><td>stage group is...</td><td>1</td><td>ND</td><td>wo</td><td>An An tla</td><td></td><td></td><td></td></tr><tr><td>is</td><td></td><td colspan="2"></td><td></td><td>0</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>nl</td><td></td><td>NOI</td><td></td><td>mao MD</td><td>u</td><td>T2.</td><td>NI</td><td>MO</td><td>Any Any MA</td><td></td><td></td><td></td></tr><tr><td>T2</td><td></td><td>NO-1</td><td></td><td>MO</td><td>tt</td><td>T2</td><td>N2</td><td>MO</td><td>Any Any 1B</td><td></td><td></td><td></td></tr><tr><td>T3</td><td></td><td colspan="3">NO MO</td><td>I</td><td>T3 T4a</td><td>NI-2 NO-1</td><td>MO MO</td><td>Any Any 1B Any = Any TUB</td><td></td><td></td><td></td></tr><tr><td>T3 T1-3</td><td></td><td>NI N2</td><td></td><td>MO MO</td><td>Tl Tl</td><td>T4a T4b</td><td>N2 NO-2</td><td>MO MO</td><td>Any~ Any IVA Any ~= Any IVA</td><td></td><td></td><td></td></tr><tr><td>T4</td><td></td><td>NO-2</td><td></td><td>MO</td><td>IVA</td><td></td><td>N3</td><td>MO</td><td>AnyT Any Any IVA</td><td><
======================================
/td><td></td><td></td></tr><tr><td>Any T</td><td></td><td colspan="2" rowspan="2">NB Any N</td><td>MO</td><td>IVA</td><td></td><td></td><td>MI</td><td>AnyT AnyN Any ~ Any IVB</td><td></td><td></td><td></td></tr><tr><td>Any T</td><td></td><td colspan="2"></td><td>MI</td><td>IVB</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pathological</td><td></td><td colspan="3">(pTNM)</td><td></td><td colspan="3" rowspan="2"></td><td colspan="3"></td><td colspan="3"></td><td>Postneoadjuvant Therapy (ypTNM)</td><td></td></tr><tr><td>When</td><td colspan="3">And And And =</td><td colspan="2">And</td><td colspan="4" rowspan="2"></td><td>Then the stage | When yp And yp And Then the stage</td><td></td></tr><tr><td colspan="4" rowspan="2">pTis... pNis... Mis... Gis... Tis NO</td><td>location is...</td><td>group is...</td><td></td><td colspan="4"></td><td>Tis... Nis... Mis... group is...</td><td></td></tr><tr><td colspan="4"></td><td colspan="2">MO</td><td>Any</td><td>0</td><td>TO-2</td><td></td><td>NO</td><td>MO I</td><td></td><td></td><td></td></tr><tr><td>Tla</td><td>NO</td><td>MO</td><td>Gl</td><td>Any</td><td>IA</td><td>73</td><td></td><td colspan="2" rowspan="2"></td><td>NO MO I</td><td></td><td></td></tr><tr><td>Tla</td><td>NO</td><td colspan="2">MO G2-3</td><td>Any</td><td>IB</td><td>TO-2</td><td></td><td colspan="2"></td><td>NI MO THA</td><td></td><td></td></tr><tr><td>Tla</td><td>NO</td><td>MO</td><td colspan="2">GX Any</td><td>IA</td><td>73</td><td></td><td colspan="2"></td><td>NI Mo IB</td><td></td><td></td></tr><tr><td>Tlb</td><td>NO</td><td>MO MO.</td><td>GI-3 any</td><td>An ay</td><td>IB</td><td>TO-3</td><td></td><td>N2</td><td>MO TB</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>Pathological</th><th>(pTNM)</th><th></th><th></th><th></th><th>T4a</th><th>NO-1</th><th colspan="2">MO</th><th>Any</th><th>IMB</th></thead><tr><td>When</td><td>And</td><td>And</td><td>And</td><td>Then the stage</td><td>T4a</td><td>N2</td><td colspan="2">MO</td><td>Any</td><td>IVA</td></tr><tr><td>pT is...</td><td>pNis...</td><td>Mis...</td><td>Gis...</td><td>group is...</td><td>T4b</td><td>NO-2</td><td colspan="2" rowspan="2">MO</td><td>Any</td><td>IVA</td></tr><tr><td>Tis</td><td>0</td><td>MO</td><td></td><td></td><td>Any T</td><td>N3</td><td colspan="2" rowspan="2">MO MI</td><td colspan="2"></td><td>Any</td><td>IVA</td></tr><tr><td>Tla</td><td></td><td>MO</td><td>Gl</td><td></td><td>Any T</td><td>Any N</td><td colspan="2"></td><td>Any</td><td>IVB</td></tr><tr><td>Tla</td><td>BPNEFENSOKFCCSCSCSCSCSCSCS</td><td>MO</td><td>Gx</td><td></td><td colspan="3" rowspan="2">Postneoadjuvant Therapy (ypTNM)</td><td></td><td colspan="2"></td></tr><tr><td>Tla</td><td></td><td>MO</td><td>G2</td><td></td><td colspan="3"></td><td></td><td colspan="2"></td></tr><tr><td>Tlb</td><td></td><td>MO</td><td>G12</td><td></td><td>When yp</td><td>And yp</td><td colspan="2">And</td><td></td><td>Then the stage</td></tr><tr><td>Tlb</td><td></td><td>MO</td><td>Gx</td><td></td><td>Tis... TO-2</td><td>Nis... NO</td><td></td><td>Mis... MO</td><td colspan="2">group is...</td></tr><tr><td>Tl</td><td></td><td>MO</td><td>G3</td><td></td><td>T3</td><td>NO</td><td></td><td>MO</td><td colspan="2"></td></tr><tr><td>T2</td><td></td><td>MO</td><td>G12</td><td></td><td>TO-2</td><td>NI</td><td></td><td>MO</td><td></td><td></td></tr><tr><td>T2</td><td></td><td>MO</td><td>G3</td><td></td><td>T3</td><td>NI</td><td></td><td>MO</td><td colspan="2"></td></tr><tr><td>T2</td><td></td><td>MO</td><td>Gx</td><td></td><td>TO-3</td><td>N2</td><td></td><td>MO</td><td colspan="2"></td></tr><tr><td>Tl</td><td></td><td>MO</td><td>Any</td><td></td><td>T4a</td><td>NO</td><td></td><td>MO</td><td colspan="2"></td></tr><tr><td>T3</td><td></td><td>MO</td><td>Any</td><td></td><td>T4a</td><td>N1-2</td><td colspan="2">MO</td><td></td><td></td></tr><tr><td>Tl</td><td></td><td>MO</td><td>Any</td><td></td><td>T4a</td><td>NX</td><td></td><td>MO</td><td></td><td></td></tr><tr><td>T2</td><td></td><td>MO</td><td>Any</td><td></td><td>T4b</td><td>NO-2</td><td></td><td>MO</td><td colspan="2"></td></tr><tr><td>T2</td><td></td><td>MO</td><td>Any</td><td></td><td>Any T</td><td>N3</td><td></td><td>MO</td><td colspan="2"></td></tr><tr><td>T3</td><td></td><td>MO</td><td>Any</td><td></td><td>Any T</td><td>Any N</td><td></td><td>MI</td><td colspan="2"></td></tr></table>
======================================
<table><tr><td>GRADE</td><td>| DEFINITION</td><td>INCIDENCE AT DIAGNOSIS (%)</td></tr><tr><td>I</td><td>Eating normally</td><td>11</td></tr><tr><td>IL</td><td>Requires liquids with meals</td><td>21</td></tr><tr><td>Il</td><td>Able to take semisolids but unable to take any solid food</td><td>30</td></tr><tr><td>IV</td><td>Able to take liquids only</td><td>40</td></tr><tr><td>v</td><td>Unable to take liquids, but able to swallow saliva</td><td>| 7</td></tr><tr><td>VI</td><td>Unable to swallow saliva</td><td>12</td></tr></table>
======================================
<table><thead><th>YEAR ACTIVATED</th><th>TREATMENT SCHEDULE | | (RADIOTHERAPY)</th><th>TREATMENT SCHEDULE (CHEMOTHERAPY)</th><th>CONCURRENT OR SEQUENTIAL</th><th>| TUMOR TYPE</th><th>SAMPLE | SIZE</th><th>MEDIAN FOLLOW- UP (MO)</th></thead><tr><td colspan="7">Chemoradiotherapy</td></tr><tr><td>983</td><td>35 Gy, 1.75 Gy/ fraction over 4 wk</td><td>Two cycles: cisplatin 20 mg/m? d 1-5; | bleomycin 5 mg/m? d 1-5</td><td>Sequential</td><td>| SCC</td><td>78</td><td>18*</td></tr><tr><td>986</td><td>40 Gy, 2 Gy/fraction | over 4 wk</td><td>Two cycles: cisplatin 100 mg/m*d1; | 5-fluorouracil 1000 mg/m? d 1-4</td><td>Concurrent</td><td>| SCC</td><td>69</td><td>12"</td></tr><tr><td>988</td><td>20 Gy, 2 Gy/fraction | over 12d</td><td>Two cycles: cisplatin 100 mg/m? d1; | 5-fluorouracil 600 mg/m? d 2-5, 22-25</td><td>Sequential</td><td>| SCC</td><td>86</td><td>123</td></tr><tr><td>989</td><td>45 Gy, 1.5 Gy/fraction over 3 wk</td><td>| Two cycles: cisplatin 20 mg/m? d 1-5; | 5-fluorouracil 300 mg/m? d 1-21; vinblastine 1 mg/m? d 1-4</td><td>Concurrent</td><td>| SCC and adenocarcinoma</td><td>100</td><td>98</td></tr><tr><td>989</td><td>37 Gy, 3.7 Gy/fraction over 2 wk</td><td>| Two cycles: cisplatin 80 mg/m? d 0-2 |</td><td>Sequential</td><td>| SCC</td><td>293</td><td>55</td></tr><tr><td>990</td><td>40 Gy, 2.7 Gy/fraction over 3 wk</td><td>| Two cycles: cisplatin 75 mg/m? d 7; 5-fluorouracil 15 mg/kg d 1-5</td><td>Concurrent</td><td>Adenocarcinoma |</td><td>113</td><td>24</td></tr><tr><td>990</td><td>40 Gy, 2.7 Gy/fraction over 3 wk</td><td>| Two cycles: cisplatin 75 mg/m? d 7; 5-fluorouracil 15 mg/kg d 1-5</td><td>Concurrent</td><td>SCC</td><td>61</td><td>10</td></tr><tr><td>994</td><td>35 Gy, 2.3 Gy/fraction over 3 wk</td><td>| One cycle: cisplatin 80 mg/m? d 1; 5-fluorouracil 800 mg/m? d 2-5</td><td>Concurrent</td><td>SCC and adenocarcinoma</td><td>256</td><td>65</td></tr><tr><td>2006</td><td>50.4 Gy, 1.8 Gy/ fraction over 5.6 wk</td><td>Two cycles: cisplatin 60 mg/m? d 1; 5-fluorouracil 1000 mg/m? d 3-5</td><td>Concurrent</td><td>| SCC and adenocarcinoma</td><td>56</td><td>60</td></tr><tr><td>999</td><td>45.6 Gy, 1.2 Gy/ fraction over 28 d</td><td>Two cycles: cisplatin 60 mg/m? d 1; 5-fluorouracil 1000 mg/m? d 3-5</td><td>Concurrent</td><td>SCC</td><td>101</td><td>25</td></tr><tr><td colspan="7">Chemotherapy</td></tr><tr><td>982</td><td>=</td><td>Two cycles: cisplatin 120 mg/m?d1; | vindesine 3 mg/m? d 1, 8; bleomycin 10 U/m? d 3-6</td><td>—</td><td>SCC</td><td>39</td><td>20</td></tr><tr><td>983</td><td>=</td><td>Two cycles: cisplatin 20 mg/m? d 1-5; bleomycin 5 mg/m? d 1-5</td><td>| —</td><td>SCC</td><td>106</td><td>18°</td></tr><tr><td>988°</td><td>=</td><td>Three cycles: cisplatin 20 mg/m? d 1-5; 5-fluorouracil 1000 mg/m? d 1-5</td><td>| —</td><td>SCC</td><td>46</td><td>715</td></tr><tr><td>988</td><td>=</td><td>Two cycles: cisplatin 100 mg/m?d1; | bleomycin 10 mg/m? d 3-8; vinblastine 3 mg/m? d 1, 8</td><td>—</td><td>SCC</td><td>46</td><td>17°</td></tr><tr><td>989</td><td>=</td><td>Two cycles: cisplatin 100 mg/m? d1; | 5-fluorouracil 1000 mg/m? d 1-5</td><td>—</td><td>SCC</td><td>147</td><td>17</td></tr><tr><td>990</td><td>=</td><td>Two cycles: cisplatin 80 mg/m? d 1; etoposide 200 mg/m? d 1-5</td><td>=</td><td>SCC</td><td>160</td><td>198</td></tr><tr><td>990</td><td>=</td><td>Three cycles: cisplatin 100 mg/m? 1; 5-fluorouracil 1000 mg/m? days 1-5</td><td>=</td><td>SCC and adeno-carcinoma</td><td>467</td><td>56</td></tr></table>
======================================
<table><thead><th>RISK GROUP</th><th>2-Y SURVIVAL RATE (%)</th><th>|CONTROL | (%)</th><th>EXPECTED 2-Y | TREATED? (%)</th><th>MORTALITY | ARR (%)</th><th>| NNT</th></thead><tr><td>High</td><td>Chemoradiotherapy 20</td><td>80</td><td>64.8</td><td>15.2</td><td>|7</td></tr><tr><td>Medium</td><td>| 35</td><td>65</td><td>52.7</td><td>12.3</td><td>|8</td></tr><tr><td>Low</td><td>50</td><td>50</td><td>40.5</td><td>95</td><td>10</td></tr><tr><td colspan="6">Chemotherapy</td></tr><tr><td>High</td><td>20</td><td>80</td><td>72.0</td><td>12.0</td><td>8</td></tr><tr><td>Medium</td><td>| 35</td><td>65</td><td>58.5</td><td>65</td><td>| 15</td></tr><tr><td>Low</td><td>50</td><td>50</td><td>45.0</td><td>5.0</td><td>20</td></tr></table>
======================================
<table><thead><th>INSTITUTION</th><th>YEAR</th><th>NO. OF PATIENTS</th><th>REGIMEN</th><th>COMPLETE PATHOLOGIC RESPONSE (%)</th><th>SURVIVAL</th></thead><tr><td>MD Anderson</td><td>1990</td><td>35</td><td>P, E, 5-FU</td><td>3</td><td>42% at 3 y</td></tr><tr><td>SLMC</td><td>1992</td><td>18</td><td>P, S-FU, RT</td><td>17</td><td>40% at 3 y</td></tr><tr><td>Vanderbilt</td><td>1993</td><td>39</td><td>P, E, 5-FU, RT</td><td>19</td><td>47% at 4y</td></tr><tr><td>Michigan</td><td>1993</td><td>21</td><td>P, VBL, 5-FU, RT</td><td>24</td><td>34% at Sy</td></tr><tr><td>MGH</td><td>1994</td><td>16</td><td>P, 5-FU</td><td>0</td><td>42% at4y</td></tr><tr><td>MGH</td><td>1994</td><td>22</td><td>E, A,P</td><td>5</td><td>58% at 2y</td></tr></table>
======================================
<table><tr><td>Location of caustic injury (n = 62)</td><td></td></tr><tr><td>Pharynx</td><td>10%</td></tr><tr><td>Esophagus</td><td>10%</td></tr><tr><td>Upper</td><td>15%</td></tr><tr><td>Middle</td><td>65%</td></tr><tr><td>Lower</td><td>2%</td></tr><tr><td>Whole</td><td>18%</td></tr><tr><td>Stomach</td><td>20%</td></tr><tr><td>Antral</td><td>91%</td></tr><tr><td>Whole</td><td>9%</td></tr><tr><td>Both stomach and esophagus</td><td>14%</td></tr></table>
======================================
<table><thead><th colspan="2">Historic milestones in gastric surgery</th><th rowspan="2">DATE</th><th rowspan="2">EVENT</th></thead><thead><th>DATE</th><th>EVENT</th><th></th><th></th></thead><tr><td>350 B.c.—</td><td>Existence of gastric ulceration was</td><td>1886</td><td>Heineke performs pyloroplasty.</td></tr><tr><td>201 A.D.</td><td>acknowledged by Diocles of Carystos (350 | B.c.), Celsus, and Galen (131-201 a.p.).</td><td>1888 1892</td><td>Mikulicz performs similar operation. Jaboulay describes bypassing the intact pylorus</td></tr><tr><td>363</td><td>Guy de Chauliac describes closure of gastric wound.</td><td>1902</td><td>with gastroduodenostomy. Finney from Baltimore describes pyloroplasty</td></tr><tr><td>586</td><td>Marcellus Donatus of Mantua describes gastric ulcer</td><td></td><td>technique. Different of</td></tr><tr><td>600-1700</td><td>at autopsy. Reports of surgeons cutting stomach to remove foreign bodies.</td><td>1891-1913</td><td>techniques gastrostomy are described by Witzel (1891), Stamm (1894), and Janeway (1913).</td></tr><tr><td>688</td><td>Muralto describes duodenal ulcer at autopsy. |</td><td>1920-1950</td><td>Subtotal gastrectomy grows popular as an</td></tr><tr><td>737</td><td>Morgagni describes both gastric and duodenal</td><td></td><td>operation for peptic ulcer. Von Haberer and</td></tr><tr><td>833</td><td>ulcer at autopsy. William Beaumont reports data recorded during his care of Alexis St. Martin who developed a gastric fistula from left</td><td rowspan="2">1943</td><td>Finsterer proponents. Dragstedt and Owen describe transthoracic truncal vagotomy to treat peptic ulcer disease. By the early 1950s, it is well recognized that</td></tr><tr><td>869</td><td>quadrant musket wound. Maury reportedly performs feeding gastrostomy to palliate esophageal stricture</td><td></td><td>some patients developed gastric stasis after this procedure, and transabdominal truncal vagotomy and drainage (pyloroplasty or</td></tr><tr><td></td><td>following consultation with Samuel D. Gross.</td><td></td><td>gastrojejunostomy) become a standard ulcer operation.</td></tr><tr><td>875 879</td><td>Sidney Jones in London publishes the first successful gastrostomy for feeding. Paen performed distal gastrectomy and</td><td>1952</td><td>Farmer and Smithwick describe good results with truncal vagotomy and hemigastrectomy for peptic ulcer.</td></tr><tr><td>880</td><td>gastroduodenostomy. The patient died Sd | later. Rydygier resected a distal gastric cancer, and</td><td>1953</td><td>Edwards and Herrington (Nashville) describe truncal vagotomy and antrectomy for peptic ulcer.</td></tr><tr><td>880</td><td>the patient died 12 h later. Billroth resects distal gastric cancer and</td><td>1955</td><td>Zollinger and Ellison describe the eponymous syndrome.</td></tr><tr><td></td><td>performs gastroduodenostomy (Billroth I). | Patient Therese Heller recovers and survives 4 mo.</td><td>1957</td><td>Griffith and Harkins (Seattle) describe parietal cell vagotomy (highly selective vagotomy) for the elective treatment of peptic ulcer disease.</td></tr><tr><td>881</td><td>Anton Wolfler performs loop gastrojejunostomy to palliate an obstructing distal gastric cancer.</td><td>1980-2000</td><td>Japanese surgeons and other surgical groups from East Asia demonstrate that more aggressive lymphadenectomy may improve</td></tr><tr><td>884</td><td>Rydygier reports an unsuccessful gastrojejunostomy for benign gastric outlet | obstruction.</td><td>1990-current</td><td>survival in patients with gastric cancer. | Evolving role of laparoscopic techniques in the treatment of surgical gastric disease.</td></tr><tr><td>885</td><td>(Billroth II) for gastric cancer. Billroth performs a successful distal gastrectomy and gastrojejunostomy</td><td>1995-current 2000-current</td><td>| Dramatic increase in bariatric operations. | Development of natural orifice translumenal endoscopic surgery, such as transgastric appendectomy and peroral pyloromyotomy. Development of robo
======================================
tic gastrectomy.</td></tr></table>
======================================
<table><tr><td>CELL TYPE</td><td>DISTINCTIVE ULTRASTRUCTURAL FEATURES</td><td>MAJOR FUNCTIONS</td></tr><tr><td>Surface-foveolar mucous cells</td><td>Apical stippled granules up to | um in diameter</td><td>Production of neutral glycoprotein and bicarbonate to form a gel on the gastric luminal surface; neutralization of hydrochloric acid*</td></tr><tr><td>Mucous neck cell</td><td>Heterogeneous granules 1—2 um in diameter dispersed throughout the cytoplasm</td><td>Progenitor cell for all other gastric epithelial cells; glycoprotein production; production of pepsinogens I and II</td></tr><tr><td>Oxyntic (parietal) cell</td><td>Surface membrane invaginations (canaliculi); tubulovesicle structures; numerous mitochondria</td><td>Production of hydrochloric acid; production of intrinsic factor; production of bicarbonate</td></tr><tr><td>Chief cell</td><td>Moderately dense apical granules up to 2 um in diameter; prominent supranuclear Golgi apparatus; extensive basolateral granular endoplasmic reticulum</td><td>Production of pepsinogens I and II, and of lipase</td></tr><tr><td>Cardiopyloric mucous cell Endocrine cells</td><td>Mixture of granules like those in mucous neck and chief cells; extensive basolateral granular endoplasmic reticulum See Figure 26-11</td><td>| Production of glycoprotein; production of pepsinogen II</td></tr></table>
======================================
<table><thead><th>Drugs that accelerate</th><th>gastric emptying</th><th></th></thead><thead><th>AGENT</th><th>TYPICAL ADULT DOSE</th><th>MECHANISM OF ACTION</th></thead><tr><td>Metoclopramide</td><td>10 mg PO four times a day</td><td>Dopamine antagonist</td></tr><tr><td>Erythromycin</td><td>250 mg PO four times a day</td><td>Motilin agonist</td></tr><tr><td>Domperidone</td><td>10 mg PO four times a day</td><td>Dopamine antagonist</td></tr></table>
======================================
<table><thead><th rowspan="2">STUDY?</th><th>THERAPIES</th><th rowspan="2">USED STUDY DRUGS</th><th colspan="2">CLINICAL UPPER GI EVENTS*</th><th rowspan="2">COMPLICATED | CONTROL</th><th rowspan="2">U PPER GI EVENTS? STUDY DRUG</th></thead><thead><th></th><th>NSAID CONTROL</th><th></th><th>CONTROL</th><th>STUDY DRUG</th><th></th><th></th></thead><tr><td>MUCOSA |</td><td>NSAIDs (n = 4439)</td><td>Misoprostol 200 ug four times a day + NSAID (n = 4404)</td><td>3.1%</td><td>1.6%</td><td>5%</td><td>0.7%</td></tr><tr><td rowspan="2">CLASS</td><td>Ibuprofen 800 mg three times a day, diclofenac 75 mg twice a day (n = 3987)</td><td>Celecoxib 400 mg twice a day (n = 3995)</td><td>3.5%</td><td>2.1%</td><td>5%</td><td>0.8%</td></tr><tr><td></td><td></td><td></td><td>(No aspirin®: 2.9%)</td><td>| 1.4%</td><td>3%</td><td>0.4%</td></tr><tr><td>VIGOR</td><td>Naproxen 500 mg twice a _| day (n = 4047)</td><td>Rofecoxib 50 mg four times a day (n = 4029)</td><td>4.5%</td><td>2.1%</td><td>4%</td><td>0.6%</td></tr></table>
======================================
<table><tr><td>AT PRESENTATION</td><td>POINTS</td></tr><tr><td colspan="2">Systolic blood pressure</td></tr><tr><td>100-109 mmHg</td><td>eS</td></tr><tr><td>90-99 mmHg</td><td>WN</td></tr><tr><td>&lt;90 mmHg</td><td></td></tr><tr><td colspan="2">Blood urea nitrogen</td></tr><tr><td>6.5-7.9 mmol/L</td><td>wid</td></tr><tr><td>8.0-9.9 mmol/L</td><td></td></tr><tr><td>10.0-24.9 mmol/L</td><td>Dif</td></tr><tr><td>225 mmol/L</td><td></td></tr><tr><td colspan="2">Hemoglobin for men</td></tr><tr><td>12.0-12.9 g/dL</td><td></td></tr><tr><td>10.0-11.9 g/dL</td><td></td></tr><tr><td>&lt;10.0 g/dL</td><td></td></tr><tr><td colspan="2">Hemoglobin for women</td></tr><tr><td>10.0-11.9 g/dL</td><td></td></tr><tr><td>&lt;10.0 g/dL</td><td></td></tr><tr><td colspan="2">Other variables at presentation</td></tr><tr><td>Pulse 2100 beats/min</td><td></td></tr><tr><td>Melena</td><td>Niele</td></tr><tr><td>Syncope</td><td></td></tr><tr><td>Hepatic disease</td><td>NN</td></tr><tr><td>Cardiac failure</td><td></td></tr></table>
======================================
<table><thead><th></th><th></th><th>VARIABLE</th><th>POINTS</th></thead><tr><td></td><td></td><td>&lt;60 y</td><td>0</td></tr><tr><td></td><td>SCORE</td><td>60-79 y</td><td>1</td></tr><tr><td></td><td></td><td>280 y</td><td>2</td></tr><tr><td>SCORE</td><td>ROCKALL</td><td>Shock Heart rate &gt;100 beats/min</td><td>1</td></tr><tr><td></td><td></td><td>Systolic blood pressure &lt;100 mmHg</td><td>2</td></tr><tr><td>ROCKALL</td><td>CLINICAL</td><td>Coexisting illness Ischemic heart disease, congestive heart failure, other major illness | Renal failure, hepatic failure, metastatic cancer</td><td>2 3</td></tr><tr><td>COMPLETE</td><td></td><td>Endoscopic diagnosis No lesions observed, Mallory-Weiss syndrome Peptic ulcer, erosive disease, esophagitis Cancer of the upper GI tract</td><td>0 1 2</td></tr><tr><td></td><td></td><td>Endoscopic stigmata of recent hemorrhage Clean base ulcer, flat pigmented spot Blood in upper GI tract, active bleeding, visible vessel, clot</td><td>0 2</td></tr></table>
======================================
<table><thead><th>Clinical results</th><th>of surgery</th><th>for duodenal</th><th>ulcer</th></thead><tr><td>Operative mortality rate (%)</td><td>0</td><td>&lt;l</td><td>1</td></tr><tr><td>Ulcer recurrence rate (%)</td><td>5-15</td><td>5-15</td><td>&lt;2</td></tr><tr><td colspan="4">Dumping (%)</td></tr><tr><td>Mild</td><td>&lt;5</td><td>10</td><td>10-15</td></tr><tr><td>Severe</td><td>0</td><td>1</td><td>1-2</td></tr><tr><td colspan="4">Diarrhea (%)</td></tr><tr><td>Mild</td><td>&lt;5</td><td>25</td><td>20</td></tr><tr><td>Severe</td><td>0</td><td>2</td><td>1-2</td></tr></table>
======================================
<table><thead><th>INDICATION</th><th>| DUODENAL</th><th>GASTRIC</th></thead><tr><td>Obstruction |</td><td>3.Patch,V+D_ 1.HSV + GJ 2V+A</td><td>| 3. Distal gastrectomy 1. Biopsy; HSV + GJ 2. Distal</td></tr><tr><td>Intractability/</td><td>| 1. HSV°</td><td>gastrectomy” 1. HSV and wedge</td></tr><tr><td>nonhealing</td><td>| 2. V + D</td><td>excision</td></tr></table>
======================================
<table><tr><td>Table 26-13 Differential diagnosis of intractability or ulcer disease</td></tr><tr><td>peptic Cancer</td></tr><tr><td>Gastric</td></tr><tr><td>Pancreatic</td></tr><tr><td>Duodenal</td></tr><tr><td>Persistent Helicobacter pylori infection</td></tr><tr><td>Tests may be false-negative</td></tr><tr><td>Consider empiric treatment</td></tr><tr><td>Noncompliant patient</td></tr><tr><td>prescribed Surreptitious use of NSAIDs</td></tr><tr><td>Motility disorder</td></tr></table>
======================================
<table><thead><th colspan="3">Genetic abnormalities in gastric cancer</th></thead><thead><th>ABNORMALITIES</th><th>GENE</th><th>APPROXIMATE FREQUENCY %</th></thead><tr><td>Deletion/suppression</td><td>ps3</td><td>60-70</td></tr><tr><td></td><td>FHIT</td><td>60</td></tr><tr><td></td><td>APC</td><td>50</td></tr><tr><td></td><td>DCC</td><td>50</td></tr><tr><td></td><td>E-cadherin</td><td>\&lt;5</td></tr><tr><td rowspan="8">Amplification/overexpression</td><td>| HGF/SF</td><td>60</td></tr><tr><td></td><td>VEGF</td><td>50</td></tr><tr><td></td><td>c-met</td><td>45</td></tr><tr><td></td><td>AIB-1</td><td>40</td></tr><tr><td></td><td>B-catenin</td><td>25</td></tr><tr><td></td><td>k-sam</td><td>20</td></tr><tr><td></td><td>ras</td><td>10-15</td></tr><tr><td></td><td>c-erb B-2</td><td>5-7</td></tr><tr><td>Microsatellite instability</td><td></td><td>25-40</td></tr><tr><td>DNA aneuploidy</td><td></td><td>60-75</td></tr></table>
======================================
<table><thead><th>Type 0-I (protruding)*</th><th>Polypoid tumors</th></thead><tr><td>Type 0-II (superficial)</td><td>Tumors with or without minimal elevation or depression relative to the surrounding mucosa</td></tr><tr><td>Type 0-Ila</td><td>Slightly elevated tumors. (superficial elevated)</td></tr><tr><td>Type 0-IIb</td><td>Tumors without elevation or depression (superficial flat)</td></tr><tr><td>Type 0-IIc</td><td>Slightly depressed tumors (superficial depressed)</td></tr><tr><td>Type 0-III (excavated)</td><td>Tumors with deep depression</td></tr></table>
======================================
<table><thead><th rowspan="2">STAGE</th><th colspan="3">AJCC 8TH EDITION</th></thead><thead><th></th><th>T</th><th>N</th><th>M</th></thead><tr><td>IA</td><td>Tl</td><td>NO</td><td>MO</td></tr><tr><td rowspan="2">IB</td><td>T2</td><td>NO</td><td>MO</td></tr><tr><td></td><td>Tl</td><td>NI</td><td>MO</td></tr><tr><td rowspan="3">IIA</td><td>T3</td><td>NO</td><td>MO</td></tr><tr><td></td><td>T2</td><td>NI</td><td>MO</td></tr><tr><td></td><td>T</td><td>N2</td><td>MO</td></tr><tr><td rowspan="4">IIB</td><td>T4a</td><td>NO</td><td>MO</td></tr><tr><td></td><td>T3</td><td>NI</td><td>MO</td></tr><tr><td></td><td>T2</td><td>N2</td><td>MO</td></tr><tr><td></td><td>T</td><td>N3a</td><td>MO</td></tr><tr><td rowspan="5">THA</td><td></td><td>T4b</td><td>NI</td><td>MO</td></tr><tr><td></td><td>T4a</td><td>NI</td><td>MO</td></tr><tr><td></td><td>T4a</td><td>N2</td><td>MO</td></tr><tr><td></td><td>T3</td><td>N2</td><td>MO</td></tr><tr><td>T2</td><td>N3a</td><td>MO</td></tr><tr><td rowspan="6">IB</td><td>T4b</td><td>NI</td><td>MO</td></tr><tr><td></td><td>T4b</td><td>N2</td><td>MO</td></tr><tr><td></td><td>T4a</td><td>N3a</td><td>MO</td></tr><tr><td></td><td>T3</td><td>N3a</td><td>MO</td></tr><tr><td></td><td>T2</td><td>N3b</td><td>MO</td></tr><tr><td></td><td>T</td><td>N3b</td><td>MO</td></tr><tr><td rowspan="4">ite</td><td></td><td>T4b</td><td>N3a</td><td>MO</td></tr><tr><td>T4b</td><td>N3b</td><td>MO</td></tr><tr><td></td><td>T4a</td><td>N3b</td><td>MO</td></tr><tr><td></td><td>T3</td><td>N3b</td><td>MO</td></tr><tr><td>IV</td><td>Any T</td><td>Any N</td><td>M1</td></tr></table>
======================================
<table><thead><th></th><th>MARUYAMA (JAPAN), 1971-1985</th><th>AMERICAN |COLLEGE OF SURGEONS, _ 1982-1987</th><th>MEMORIAL | SLOAN | KETTERING, 1985-1994</th></thead><tr><td>No. patients</td><td>3176</td><td>18,365</td><td>675</td></tr><tr><td>Stage I</td><td>91%</td><td>50%</td><td>84%</td></tr><tr><td>Stage II</td><td>72%</td><td>29%</td><td>61%</td></tr><tr><td>Stage III</td><td>44%</td><td>13%</td><td>29%</td></tr><tr><td>Stage IV</td><td>9%</td><td>3%</td><td>25%</td></tr><tr><td>Operative mortality</td><td>1%</td><td>1%</td><td>3%</td></tr></table>
======================================
<table><thead><th>AUTHORS</th><th>NUMBER OF PATIENTS</th><th>TYPE OF SURGERY</th><th>POSTOPERATIVE COMPLICATIONS</th><th>POSTOPERATIVE MORTALITY</th><th>5 YEAR SURVIVAL</th></thead><tr><td rowspan="2">Bonenkamp et al.</td><td>711</td><td>DiI</td><td>25</td><td>4</td><td>45</td></tr><tr><td></td><td></td><td>D2</td><td>43</td><td>10</td><td>47</td></tr><tr><td rowspan="2">Cuschieri et al.</td><td>400</td><td>DiI</td><td>28</td><td>6.5</td><td>35</td></tr><tr><td></td><td></td><td>D2</td><td>46</td><td>13</td><td>33</td></tr><tr><td rowspan="2">Degiuli et al.</td><td>267</td><td>DI</td><td>12</td><td>3</td><td></td></tr><tr><td></td><td></td><td>D2</td><td>17.9</td><td>2.2</td><td></td></tr></table>
======================================
<table><thead><th>CLASSIFICATION</th><th>PRINCIPAL CUTOFF POINTS</th><th>| ADDITIONAL CUTOFF POINTS?</th></thead><tr><td>Normal range</td><td>18.50-24.99</td><td>18.50-22.99 23.00-24.99</td></tr><tr><td>Overweight</td><td>225.00</td><td>225.00</td></tr><tr><td>Preobese</td><td>25.00-29.99</td><td>25.00-27.49 27.50-29.99</td></tr><tr><td>Obese</td><td>230.00</td><td>230.00</td></tr><tr><td>Obese class I</td><td>30.00-34.99</td><td>30.00-32.49 32.50-34.99</td></tr><tr><td>Obese class IL</td><td>35.00-39.99</td><td>35.00-37.49 37.50-39.99</td></tr><tr><td>Obese class III</td><td>| 240.00</td><td>&gt;40.00</td></tr></table>
======================================
<table><tr><td>FACTOR</td><td>CRITERIA</td></tr><tr><td>Weight (adults)</td><td>BMI 240 kg/m? with no comorbid conditions BMI 235 kg/m? with obesity-associated comorbidity</td></tr><tr><td>Weight loss history</td><td>Failure of previous nonsurgical attempts at weight reduction, including nonprofessional programs</td></tr><tr><td>Commitment</td><td>Expectation that patient will adhere to postoperative care Follow-up visits with physician(s) and team members Recommended medical management, including use of dietary supplements Instructions regarding any recommended procedures or tests</td></tr><tr><td>Contraindications/ exclusions</td><td>Prohibitive surgical risk, ASA IV Reversible endocrine or other disorders that can cause obesity Current drug or alcohol misuse Uncontrolled, severe psychiatric illness Uncontrolled, severe bulimia Lack of comprehension of risks, benefits, expected outcomes, alternatives, and lifestyle changes</td></tr></table>
======================================
<table><tr><td colspan="4">Lipid Elevated HDL Reduced triglycerides Elevated HDL Reduction in triglycerides not Elevated HDL Reduced triglycerides</td></tr><tr><td>Glucose homeostasis</td><td>Reduced total cholesterol, LDL Improved fasting blood glucose and insulin sensitivity, prior to</td><td>as dramatic as LRYGB or SG Improvements are slower and not as dramatic as after SG or</td><td>Improved fasting blood glucose and insulin sensitivity, prior to</td></tr><tr><td>Role of gastric restriction</td><td>weight loss Has not yet been directly tested</td><td>LRYGB Failure of band leads to less</td><td>weight loss Gastric restriction is not the</td></tr><tr><td></td><td></td><td>gastric restriction and less loss</td><td>critical factor preventing</td></tr><tr><td>Gastric emptying</td><td>Few published studies</td><td>weight No overall change in gastric emptying rate; Emptying rate of proximal pouch created by band is enhanced</td><td>hyperphagia Most papers show increase</td></tr><tr><td>Energy expenditure</td><td>Controversial</td><td>Not reported</td><td>Unchanged, but only reported in one study</td></tr><tr><td>Leptin</td><td>Circulating leptin levels lower than expected for body weight Changes to leptin sensitivity not tested</td><td>Plasma leptin reduced, as expected for body weight; Changes to leptin sensitivity not tested</td><td>Circulating leptin levels lower than expected for body weight; Body weight changes not driven by changes to leptin sensitivity</td></tr><tr><td>Ghrelin</td><td>Reduced total ghrelin; Controversial, but no change in acyl-ghrelin levels</td><td>Increased circulating ghrelin</td><td>Reduced total ghrelin; Contro- versial, but no change in acyl-ghrelin levels</td></tr><tr><td></td><td>No change</td><td>No change</td><td>Not measured</td></tr><tr><td>GLP=1 (postprandial)</td><td>Weight loss-independent postprandial increase</td><td>Increased circulating GLP-1 but much less than RYGB or SG</td><td>Weight loss-independent increase comparable to LRYGB</td></tr><tr><td>PYY (postprandial)</td><td>Increased postprandial PYY levels; Reduced body weight loss in PYY knockout mice</td><td>No change</td><td>Increased postprandial PYY levels, comparable to levels after LRYGB</td></tr><tr><td>Bile acids</td><td>Increased plasma bile acids</td><td>Not reported</td><td>Increased plasma bile acids</td></tr></table>
======================================
<table><tr><td>RECOMMENDATION</td><td>LAGB</td><td>SG</td><td>LRYGB</td><td>BPD/DS</td></tr><tr><td>Bone density (DXA)* at 2 years</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>24 hour urinary calcium excretion at 6 months and annually</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Vitamin B,, annually (methylmalonic acid and homocysteine optional) then every 3—6 months if supplemented</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr><tr><td>Folic acid (red blood cell folic acid optional), iron studies, vitamin D, intact parathyroid hormone</td><td></td><td></td><td>Yes</td><td>Yes</td></tr><tr><td>Vitamin A initially and every 6-12 months thereafter</td><td></td><td></td><td>Optional</td><td>Yes</td></tr><tr><td>Copper, zinc, and selenium evaluation with specific findings</td><td></td><td></td><td>Yes</td><td>Yes</td></tr><tr><td>Thiamine evaluation with specific findings</td><td>Yes</td><td>Yes</td><td>Yes</td><td>Yes</td></tr></table>
======================================
<table><thead><th rowspan="2">OUTCOME?</th><th rowspan="2">ALL</th><th colspan="4">SURGICAL PROCEDURE</th></thead><thead><th></th><th></th><th>LRYGB</th><th>SG</th><th>LAGB</th><th>BPD/DS</th></thead><tr><td>% Mortality 30-day</td><td>&lt;1.0%</td><td>0.3-0.5%</td><td>0.11%</td><td>0.05%</td><td>1.1%</td></tr><tr><td>% Morbidity 30-day</td><td>NA, depends on procedure</td><td>| 12-21%</td><td>3-6%</td><td>24%</td><td>27-33%</td></tr><tr><td>% Total body weight loss (TBWL)</td><td>NA, depends on procedure</td><td>| 31-36%</td><td>25-30%</td><td>13-22%</td><td>36-38%</td></tr><tr><td>% Excess body weight loss (EBWL)</td><td>| NA, depends on procedure</td><td>| 48-77% (mean, 68%)</td><td>49-81%</td><td>29-50%</td><td>&gt;70%</td></tr><tr><td>% Diabetes remission</td><td>71%</td><td>60-80%</td><td>60%</td><td>35%</td><td>75%</td></tr><tr><td>% Dyslipidemia’ remission</td><td>10%</td><td>63-91%</td><td>72-82%</td><td>78%</td><td>80%</td></tr><tr><td>% Hypertension remission</td><td>62%</td><td>61-81%</td><td>60-92%</td><td>43%</td><td>60%, few reports</td></tr><tr><td>% Sleep apnea remission®</td><td>84%</td><td>80%</td><td>80%</td><td>68%</td><td>80%</td></tr></table>
======================================
<table><thead><th></th><th>STUDY DESIGN</th><th>POPULATIONS AND | | PROCEDURES</th><th>FOLLOW-UP DURATION</th><th>PUBLISHED OUTCOMES</th><th>MORTALITY AND SURVIVAL</th><th>LIMITATI</th></thead><tr><td>al,!°°!_| Me 2012 Obese study</td><td>Prospective observational with matched controls</td><td>2010 Surgical cases (13% RYGB; 19% banding; 68% VBG) and 2037 matched controls</td><td>| 10-20 years, depending on the report</td><td>Surgery was associated with: greater weight loss at 2 years (-23% vs. 0%) and at 20 y (-18% vs. -1%)16; greater remission of T2DM after 2 y (OR for remission, 8.4; P &lt;.001) and 10 y (OR, 3.5; P &lt;.001); lower incidence of T2DM (HR, 0.17; P &lt;.001)</td><td>Bariatric surgery treatment: 16 years, 29% lower risk of death from any cause (hazard ratio 0.71, 0.54 to 0.92; P= 0.01) vs. usual care; common causes of death: myocardial infarction (AR, 0.71; P = .02), stroke (HR, 0.66; P = .008), and cancer (in women only; HR, 0.58; P &lt;.001)</td><td>| Not rando include proced that are in use; patients single little diversi</td></tr><tr><td>| 8 ah study)</td><td>Retrospective observational with matched controls</td><td>7925 RYGB cases and 7925 weight-matched controls</td><td>Mean, 7.1 years</td><td>Only mortality outcomes reported</td><td>Bariatric surgery treatment: average 7.1 years post treatment, 40% reduction in all cause mortality (hazard ratio HR 0.60, 0.45 to 0.67; P &lt;0.001), 49% (HR 0.51, 0.36 to 0.73; P &lt;0.001), and 92% (HR 0.08, 0.01 to 0.47; P = 0.005), cardiovascular mortality, and T2DM mortality, respectively</td><td>Not randq matchi on self; height from license include RYGB patients single</td></tr><tr><td>203204 17 esity</td><td>| Prospective observational with two matched control groups|</td><td>418 RYGB cases; | 417 bariatric- surgery seekers who did not undergo operation (control 1); 321 population- based matched controls (control 2)</td><td>6 years, 12 years</td><td>6 years: RYGB group lost 27.7% body weight compared with 0.2% weight gain in control group | and 0% change in control group 2; T2DM remission in 62% of RYGB patients and 8% and 6% in each of the control groups (P &lt;.001); incident T2DM was observed in 2% of RYGB patients but 17% and 15% of each of the control groups at 6 years (P &lt;.001); surgery associated with greater improvements in blood pressure, cholesterol, and</td><td>Deaths at 6 years: 12 (2.8%), 14 (3.3%), and 3 (0.93%) for bariatric surgery, control 1, and control 2, respectively</td><td>Not rando include} RYGB patients single</td></tr></table>
======================================
<table><thead><th></th><th></th><th></th><th>12 years: RYGB 26.9% body weight loss, 2.0% and 0.9% in control groups 1, 2, respectively; T2DM remission in 51% RYGB group; odds ratio for the incidence T2DM 0.08 (95% CI, 0.03 to 0.24) for RYGB vs. control group 1 and 0.09 (95% CI, 0.03 to 0.29) RYGB vs. control group 2 (P &lt;0.001 for both comparisons); RYGB group had higher remission rates and lower incidence rates of hypertension and dyslipidemia than did control group 1 (P &lt;0.05 for all comparisons).</th><th></th></thead><tr><td>observational with matched controls</td><td>2500 surgical cases and their matched controls</td><td></td><td>(95% CI, 19.5%-37.6%) of their baseline weight at 10 years, whereas nonsurgical matches lost 7.3% (95% CI, 1.4%-13.3%) of their baseline weight at 10 years. Patients undergoing RYGB lost 21% (95% Cl, 11%-31%) more of their baseline weight at 10 years than nonsurgical matches. A total of 405 of 564 patients undergoing RYGB (71.8%) had more than 20% body weight loss and 224 of 564 (39.7%) had more than 30% estimated weight loss at 10 years. At 4 years, patients undergoing LRYGB lost 27.5% (95% CI, 23.8%-31.2%) of their baseline weight, patients undergoing LAGB lost 10.6% (95% CI, 0.6%-20.6%), and patients undergoing SG lost 17.8% (95% Cl, 9.7%-25.9%). Surgery was not significantly associated with lower health expenditures 3 years after the procedure, in first study.</td><td>surgery not significantly associated with reduced mortality. Later study, at the end of 14 years, 263 deaths in the surgical group (mean follow-up, 6.9 years) and 1277 deaths in control group (mean follow-up, 6.6 years). Mortality rates were 2.4% at 1 year, 6.4% at 5 years, and 13.8% at 10 years for surgical patients; for matched control patients, 1.7% at 1 year, 10.4% at 5 years, and 23.9% at 10 years. Significantly lower mortality after 1 to S years (HR, 0.45 [95% Cl, 0.36-0.56]) and 5 to 14 years (HR, 0.47 [95% CI, 0.39-0.58]).</td></tr></table>
======================================
<table><thead><th></th><th>STUDY DESIGN</th><th>POPULATIONS AND | | PROCEDURES</th><th>FOLLOW-UP DURATION</th><th>PUBLISHED OUTCOMES</th><th>MORTALITY AND SURVIVAL</th><th>LIMITATI!</th></thead><tr><td>et 109, 17 inal nt of Surgery</td><td>Prospective observational</td><td>4776 in LABS-1, 30 day safety study and 2458 in LABS-2, effectiveness study (70.7% RYGB; 24.8% LAGB; and 5% other procedures)</td><td>30 days, 3 years, 7 years</td><td>| 3 year: 31.5% for RYGB and 15.9% for LAGB; T2DM remission in 67.5% of RYGB cases and 28.6% for LAGB; incidence of T2DM was 0.9% after RYGB and 3.2% after LAGB. Dyslipidemia remission in 61.9% RYGB cases and 27.1% AGB cases; HTN remission in 38.2% RYGB cases and 17.4% AGB cases; other procedures’ results not reported 7 year: 28.4% for RYGB and 14.9% for LAGB; T2DM remission in 60.2% of RYGB cases and 20.3% for LAGB</td><td>30 days: 0.3% overall; 0% LAGB, 0.2% LRYGB, and 2.1% open RYGB. 3 years: 0.9 per 300 person-years for} TYGB and 0.8 per 300 person- years for LAGB, i.e., number of events if 100 people were followed for 3 years 7 years: 3.7 per 700 person-years for RYGB and 2.7 per 700 person years for LAGB, i.e., number of events if 100 people were followed for 7 years</td><td>Not rand lacks control primar! and LA proced follow- (&gt;80% but son in-pers</td></tr><tr><td>P 2013 esearch</td><td>1. Retrospective observational</td><td>| 4434 RYGB cases | with T2DM</td><td>Median, 3.1 years</td><td>68% of patients (95% CI, 66-70) experienced an initial T2DM remission within 5 years after RYGB; among these, 35.1% (95% Cl, 32-38) redeveloped T2DM within 5 years;</td><td>Not reported</td><td>1. Not rar lacks control only R proced</td></tr><tr><td></td><td>2. Retrospective observational with matched controls</td><td>| 1395 cases; 72% | RYGB, 2% SG, 4% LAGB, 13% other</td><td>2 years</td><td>median duration of T2DM remission, 8.3 years Bariatric cases higher T2DM remission rates [73.7% (95% CI: 70.6, 76.5)] vs. controls [6.9% (95%CI: 6.9, 7.1)]. Bariatric cases lower relapse rates T2DM than controls (adjusted HR: 0.19; 95% Cl: 0.15-0.23)</td><td>No higher risk of death in control vs. bariatric within 2 years (adjusted HR = 0.54; 95% CI: 0.22 to 1.23).</td><td>2. Not rat electro record numbe</td></tr><tr><td>oe chigan Surgery tive)</td><td>Prospective observational</td><td>8847 to 35,477, varies depending on publication</td><td>30 days to | 3 years, varies) depending on publication</td><td>Complication rates for SG (6.3%) were significantly lower than for RYGB (10.0%; P &lt;.001) but higher than LAGB (2.4%; P &lt;.001). Excess body weight loss at 1 year was 13% lower for SG (60%) than for RYGB (69%; P &lt;.001) but was 77% higher for SG than for LAGB (34%; P &lt;.001).</td><td>Not reported</td><td>Not rand lacks control froma</td></tr></table>
======================================
<table><thead><th>STUDY</th><th>BMI (kg/m*), % OF PATIENTS</th><th>| DESIGN</th><th>NO. OF PATIENTS RANDOMIZED</th><th>FOLLOW-UP | (MONTHS)</th><th>| REMISSION CRITERIA*</th><th>OUTCOME (REMISSION OR CHANGE IN HbA,,)</th></thead><tr><td>Dixon”</td><td>&lt;35, 22%</td><td>LAGB vs. control</td><td>60</td><td>24</td><td>HbA,, &lt;6.2%</td><td>73% vs. 13%, P &lt;0.001</td></tr><tr><td>Schauer?®:*46252</td><td>&lt;35, 36%</td><td>RYGB vs. SG vs. control</td><td>50</td><td>60</td><td>HbA,, &lt;6.0%</td><td>22% vs. 15% vs. 0, P&lt;0.05</td></tr><tr><td>Mingrone”*?</td><td>&gt;35, 100%</td><td>RYGB vs. BPD vs. control</td><td>60</td><td>60</td><td>HbA,, &lt;6.5%</td><td>42% vs. 68% vs. 0, P= 0.003</td></tr><tr><td>Ikramuddin *°747</td><td>| &lt;35, 59%</td><td>RYGB vs. control</td><td>20</td><td>24</td><td>HbA, , &lt;6%</td><td>44% vs. 9%, P &lt;0.001</td></tr><tr><td>Liang”*</td><td>&lt;35, 100%</td><td>RYGB vs. control</td><td>01</td><td>12</td><td>HbA, , &lt;6.5%**</td><td>| 90% vs. 0 vs. 0, P &lt;0.0001</td></tr><tr><td>Halperin*?</td><td>&lt;35, 34%</td><td>RYGB vs. control</td><td>38</td><td>12</td><td>HbA,, &lt;6.5%</td><td>58% vs. 16%, P=0.03</td></tr><tr><td>Courcoulas***°</td><td>&lt;35, 43%</td><td>RYGB vs. LAGB vs. control</td><td>69</td><td>36</td><td>HbA,, &lt;6.5%</td><td>40% vs. 29% vs. 0 P=0.004</td></tr><tr><td>Wentworth?”</td><td>&lt;30, 100%</td><td>LAGB vs. control</td><td>51</td><td>24</td><td>Fasting blood glucose &lt;7.0 mmol/L</td><td>52% vs. 8%, P=0.001</td></tr><tr><td>Parikh?!</td><td>&lt;35, 100%</td><td>Bariatric surgery (RYGB, LAGB, SG) vs. control</td><td>57</td><td>6</td><td>HbA, , &lt;6.5%</td><td>65% vs. 0, P=0.0001</td></tr><tr><td>Ding®</td><td>&lt;35, 34%</td><td>LAGB vs. control</td><td>45</td><td>12</td><td>HbA,, &lt;6.5%***</td><td>33% vs. 23%, P=0.46</td></tr><tr><td>Cummings*!</td><td>&lt;35, 25%</td><td>RYGB vs. control</td><td>| 43</td><td>12</td><td>HbA, , &lt;6.0%</td><td>60% vs. 5.9%, P=0.002</td></tr></table>
======================================
<table><thead><th rowspan="2">ration) [Follow-Up; HbA,, end point]</th><th colspan="2">Surgery</th><th rowspan="2">Medical/Lifestyle Glyc.Endp.</th><th rowspan="2">N</th><th rowspan="2">Weight</th><th rowspan="2">_ Peto, Fixed, 95% Cl</th><th rowspan="2"></th></thead><thead><th></th><th>Glyc.Endp.</th><th>N</th><th></th><th></th><th></th><th></th><th></th></thead><tr><td>(RYGB/LAGB/SG) [6 mo; &lt;6.5% off meds] (18)</td><td>13</td><td>20</td><td>0</td><td>24</td><td>4.5%</td><td>21.15 [5.85, 76.51</td><td></td></tr><tr><td>2014 (RYGB/LAGB) [12 mo; &lt;6.5% off meds] (14)</td><td>18</td><td>4</td><td>0</td><td>17</td><td>5.1%</td><td>7.51 (2.24, 25.21</td><td></td></tr><tr><td>LAGB) [12 mo; &lt;6.5%] (22)</td><td>6</td><td>18</td><td>5</td><td>22</td><td>3.9%</td><td>1.68 [0.42, 6.66</td><td></td></tr><tr><td>14 (RYGB) [12 mo; &lt;6.5% off meds] (15)</td><td>11419</td><td></td><td>3</td><td>19</td><td>4.4%</td><td>5.82 [1.59, 21.39</td><td></td></tr><tr><td>2013 (RYGB) [12 mo; &lt;7.0%] (13)</td><td>28</td><td>«57</td><td>11</td><td>57)</td><td>12.5%</td><td>3.72 [1.72, 8.04</td><td></td></tr><tr><td>(RYGB) [12 mo; &lt;7.0% off meds] (16)</td><td>2831</td><td></td><td>0</td><td>70</td><td>8.4%</td><td>86.76 [33.89, 222.08</td><td></td></tr><tr><td>12 (RYGB/SG) [12 mo; &lt;6.0%] (12)</td><td>34-99</td><td></td><td>0</td><td>41</td><td>10.4%</td><td>6.39 [2.74, 14.88</td><td></td></tr><tr><td>2016 (RYGB) [12 mo; &lt;6.5% off meds] (23)</td><td>9</td><td>15</td><td>1</td><td>17</td><td>3.4%</td><td>11.48 [2.63, 50.13</td><td></td></tr><tr><td>(LAGB) [24 mo; &lt;6.2% off meds] (10)</td><td>22</td><td>29</td><td>4</td><td>26</td><td>6.7%</td><td>10.83 [3 .79, 30.96</td><td></td></tr><tr><td>2015 (RYGB) [24 mo; &lt;7.0%] (21)</td><td>26</td><td>©6660</td><td>8</td><td>59</td><td>11.8%</td><td>4.25 [1.92, 9.38</td><td></td></tr><tr><td>012 (RYGB/BPD) [24 mo; &lt;6.5% off meds] (11)</td><td>34</td><td>40</td><td>0</td><td>20</td><td>6.4%</td><td>30.08 [10.28, 88.06</td><td></td></tr><tr><td>2014 (LAGB) [24 mo; &lt;7.0%] (17)</td><td>12</td><td>23</td><td>2</td><td>25</td><td>4.9%</td><td>8.11 [2.37, 27.84</td><td></td></tr><tr><td>2015 (RYGB/LAGB) [36 mo; &lt;6.5% off meds] (24)</td><td>14</td><td>37</td><td>0</td><td>14</td><td>4.0%</td><td>6.44 [1.65, 25.21</td><td></td></tr><tr><td>14 (RYGB/SG) [36 mo; &lt;6.0%] (19)</td><td>27</td><td>«97</td><td>0</td><td>40</td><td>8.7%</td><td>5.73 [2.28, 14.42</td><td></td></tr><tr><td>015 (RYGB/BPD) [60 mo; &lt;6.5% off meds] (20)</td><td>19</td><td>38</td><td>0</td><td>15</td><td>4.9%</td><td>8.44 [2.46, 29.01</td><td></td></tr><tr><td>ts Model</td><td></td><td>624</td><td></td><td>466</td><td>100.0%</td><td>8.45 [6.44, 11.10]</td><td></td></tr><tr><td colspan="8">ity: Chi? = 45 .43, df = 14 (P &lt; 0.0001); I? = 69%</td></tr><tr><td>rall effect: Z = 15.36 (P &lt; 0.00001)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>0.001</td></tr></table>
======================================
<table><tr><td>\gents that stimulate absorption or inhibit secretion of</td><td>water</td></tr><tr><td colspan="2">Aldosterone</td></tr><tr><td colspan="2">Glucocorticoids</td></tr><tr><td colspan="2">Angiotensin</td></tr><tr><td colspan="2">Norepineprhine</td></tr><tr><td colspan="2">Epinephrine</td></tr><tr><td colspan="2">Dopamine</td></tr><tr><td colspan="2">Somatostatin</td></tr><tr><td colspan="2">Neuropeptide Y</td></tr><tr><td colspan="2">Peptide YY</td></tr><tr><td colspan="2">Enkephalin</td></tr><tr><td colspan="2">\gents that simulate secretion or inhibit absorption of water</td></tr><tr><td>Secretin</td><td></td></tr><tr><td>Bradykinin</td><td></td></tr><tr><td colspan="2">Prostaglandins</td></tr><tr><td colspan="2">Acetylcholine</td></tr><tr><td colspan="2">Atrial natriuretic factor</td></tr><tr><td colspan="2">Vasopressin</td></tr><tr><td colspan="2">Vasoactive intestinal peptide</td></tr><tr><td colspan="2">Bombesin</td></tr><tr><td colspan="2">Substance P</td></tr><tr><td colspan="2">Serotonin</td></tr><tr><td colspan="2">Neurotensin</td></tr><tr><td>Histamine</td><td></td></tr></table>
======================================
<table><thead><th>HORMONE</th><th>SOURCE?</th><th>| ACTIONS</th></thead><tr><td>Somatostatin</td><td>Dcell</td><td>Inhibits gastrointestinal secretion, motility, and splanchnic perfusion</td></tr><tr><td>Secretin</td><td>S cell</td><td>Stimulates exocrine pancreatic secretion, stimulates intestinal secretion</td></tr><tr><td>Cholecystokinin |</td><td>I cell</td><td>Simulates pancreatic exocrine secretion, simulates gallbladder emptying, inhibits sphincter of Oddi contraction</td></tr><tr><td>Motilin</td><td>Meell |</td><td>Simulates intestinal motility</td></tr><tr><td>Peptide YY</td><td>Lcell</td><td>Inhibits intestinal motility and secretion</td></tr><tr><td>Glucagon-like | Peptide 2</td><td>L cell</td><td>Stimulates intestinal epithelial proliferation</td></tr><tr><td>Neurotensin</td><td>N cell</td><td>Stimulates pancreatic and biliary secretion, inhibits small bowel motility, stimulates intestinal mucosal growth</td></tr></table>
======================================
<table><tr><td>TUMOR TYPE</td><td>CELL OF ORIGIN</td><td>FREQUENCY?</td><td>PREDOMINANT SITE</td></tr><tr><td>Adenocarcinoma</td><td>Epithelial cell</td><td>35-50%</td><td>Duodenum</td></tr><tr><td>Carcinoid</td><td>Enterochromaffin cell</td><td>20-40%</td><td>Tleum</td></tr><tr><td>Lymphoma</td><td>Lymphocyte</td><td>10-15%</td><td>Tleum</td></tr><tr><td>GIST</td><td>Interstitial cell of Cajal</td><td>10-15%</td><td>-</td></tr></table>
======================================
<table><thead><th></th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td>Fecal occult blood testing (FOBT)</td><td>Ease of use and noninvasive Low cost Good sensitivity with repeat testing</td><td>May not detect most polyps Low specificity Colonoscopy required for positive result Poor compliance with serial testing Three successive stools required</td></tr><tr><td>Fecal immunohistochemical test (FIT)</td><td>Ease of use and noninvasive Low cost More sensitive and specific than FOBT Only one stool sample required</td><td>May not detect most polyps Colonoscopy required for positive result</td></tr><tr><td>Multitarget stool DNA</td><td>Ease of use and noninvasive More sensitive than FIT</td><td>May not detect most polyps Colonoscopy required for positive result Less specific than FIT</td></tr><tr><td>Sigmoidoscopy</td><td>Examines colon most at risk Very sensitive for polyp detection in left colon Does not require full bowel preparation (enemas only)</td><td>Invasive Uncomfortable Slight risk of perforation or bleeding May miss proximal lesions Colonoscopy required if polyp identified</td></tr><tr><td>Colonoscopy</td><td>Examines entire colon Highly sensitive and specific Therapeutic</td><td>Most invasive Uncomfortable and requires sedative Requires bowel preparation Risk of perforation or bleeding Costly</td></tr><tr><td>Double-contrast barium enema</td><td>Examines entire colon Good sensitivity for polyps &gt;1 cm Examines entire colon</td><td>Requires bowel preparation Less sensitivity for polyps &lt;1 cm May miss lesions in the sigmoid colon Colonoscopy required for positive result</td></tr><tr><td>Computed tomography colonography (virtual colonoscopy)</td><td>Noninvasive Sensitivity may be as good as colonoscopy</td><td>Requires bowel preparation Insensitive for small polyps Minimal experience and data</td></tr></table>
======================================
<table><thead><th>POPULATION</th><th>INITIAL AGE</th><th>RECOMMENDED SCREENING TEST</th></thead><tr><td>Average risk</td><td>S0y</td><td>Annual FOBT or Flexible sigmoidoscopy every 5 y or Annual FOBT and flexible sigmoidoscopy every 5 y or Air-contrast barium enema every 5 y or Colonoscopy every 10 y</td></tr><tr><td>Adenomatous polyps</td><td>S0y</td><td>Colonoscopy at first detection; then colonoscopy in 3 y If no further polyps, colonoscopy every 5 y If polyps, colonoscopy every 3 y Annual colonoscopy for &gt;5 adenomas</td></tr><tr><td>Colorectal cancer</td><td>At diagnosis</td><td>Pretreatment colonoscopy; then at 12 mo after curative resection; then colonoscopy after 3 y; then colonoscopy every 5 y, if no new lesions</td></tr><tr><td>Ulcerative colitis, Crohn’s colitis</td><td>At diagnosis; then after 8 y for pancolitis, after 15 y for left-sided colitis</td><td>Colonoscopy with multiple biopsies every 1-2 y</td></tr><tr><td>FAP</td><td>10-12 y</td><td>Annual flexible sigmoidoscopy Upper endoscopy every 1-3 y after polyps appear</td></tr><tr><td>Attenuated FAP</td><td>20 y</td><td>Annual flexible sigmoidoscopy Upper endoscopy every 1-3 y after polyps appear</td></tr><tr><td>HNPCC</td><td>20-25 y</td><td>Colonoscopy every 1-2 y Endometrial aspiration biopsy every 1-2 y</td></tr><tr><td>Familial colorectal cancer first-degree relative</td><td>40 y or 10 y before the age of the youngest affected relative</td><td>Colonoscopy every 5 y Increase frequency if multiple family members are affected, especially before 50 y</td></tr></table>
======================================
<table><thead><th>TNM Staging of colorectal</th><th colspan="3">carcinoma DEFINITION</th></thead><tr><td colspan="4">Tumor Stage (T)</td></tr><tr><td>TX</td><td colspan="3">Primary tumor cannot be assessed</td></tr><tr><td>TO</td><td colspan="3">No evidence of primary tumor</td></tr><tr><td>Tis</td><td colspan="3" rowspan="2">Carcinoma in situ, intramucosal carcinoma (involvement of lamina propria with no extension through muscularis mucosae) Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis propria)</td></tr><tr><td>Tl</td><td colspan="3"></td></tr><tr><td>T2</td><td colspan="3">Tumor invades the muscularis</td></tr><tr><td>T3</td><td colspan="3">propria Tumor invades the muscularis into pericolorectal tissues</td></tr><tr><td>T4</td><td>through Tumor invades the visceral</td><td>propria invades</td><td></td></tr><tr><td>T4a</td><td colspan="3">peritoneum or or adheres to adjacent organ or structure Tumor invades through the visceral peritoneum (including gross perforation of the bowel through tumor and</td></tr><tr><td></td><td>continuous invasion of tumor</td><td>through areas of inflammation</td><td>to the surface of the visceral peritoneum)</td></tr><tr><td colspan="4" rowspan="3">T4b Nodal Stage (N) NX nodes be assessed</td><td colspan="3" rowspan="2">Tumor directly invades or adheres to adjacent organs or structures</td></tr><tr><td colspan="4"></td><td colspan="3"></td></tr><tr><td colspan="4"></td></tr><tr><td></td><td colspan="3">Regional lymph cannot</td></tr><tr><td>NO NI</td><td colspan="3">No regional lymph node metastasis One to three regional lymph nodes are positive (tumor in lymph nodes measuring 20.2 mm), or any</td></tr><tr><td></td><td colspan="3">number of tumor deposits are present and all identifiable lymph nodes are negative</td></tr><tr><td>Nla</td><td colspan="3">One regional lymph node is positive</td></tr><tr><td>Nlb</td><td colspan="3" rowspan="2">Two or three regional lymph nodes are positive</td></tr><tr><td></td><td colspan="3"></td></tr><tr><td>Nic</td><td colspan="3" rowspan="2">No regional lymph nodes are positive, but there are tumor deposits in the e subserosa</td></tr><tr><td></td><td colspan="3">© mesentery © or nonperitonealized pericolic, or perirectal/mesorectal tissues.</td><td colspan="3"></td></tr><tr><td>N2</td><td colspan="3">Four or more regional nodes are positive</td></tr><tr><td>N2a</td><td>Four to six regional lymph</td><td colspan="2" rowspan="2">nodes are positive nodes are positive</td><td colspan="2"></td></tr><tr><td>N2b</td><td>Seven or more regional lymph</td></tr><tr><td>Distant Metastasis (M)</td><td></td><td></td><td></td></tr><tr><td colspan="4" rowspan="2">MO No distant metastasis by imaging, etc.; no evidence of tumor in distant sites or organs (This category is not assigned by pathologists.)</td><td colspan="3" rowspan="2"></td></tr><tr><td colspan="4"></td><td colspan="3"></td></tr><tr><td>MI</td><td colspan="3">Metastasis to one or more distant sites or organs or peritoneal metastasis is identified</td></tr><tr><td>Mla</td><td colspan="3">Metastasis to one site or organ is identified without peritoneal metastasis</td></tr><tr><td>Mlb</td><td colspan="3">Metastasis to two or more sites or organs is identified without peritoneal metastasis</td></tr><tr><td>Mic</td><td>Metastasis to the peritoneal</td><td>surface is identified alone or</td><td>with other site or organ metastases</td></tr><tr><td colspan="4">STAGE T N M</td></tr><tr><td>0</td><td>Tis</td><td>NO</td><td>MO</td></tr><tr><td>I</td><td>T1, T2</td><td colspan="2">NO MO</td></tr><tr><td>IIA</td><td>T3</td><td>NO</td><td>MO</td></tr><tr><td>IIB</td><td>T4a</td><td>NO</td><td>MO</td></tr><tr><td>ite</td><td>T4b</td><td>NO</td><td>MO</td></tr><tr><td>THA</td><td>T1-T2</td><td>NI/NIc</td><td>MO</td></tr><tr><td>THA</td><td>Tl</td><td colspan="2">N2a MO</td></tr></table>
======================================
<table><thead><th></th><th>RUE POSITIVE LIKELIHOOD RATIO</th><th>95% CONFIDENCE INTERVAL</th><th>TRUE NEGATIVE LIKELIHOOD RATIO</th><th>95% CONFIDENCE INTERVAL</th></thead><tr><td>Duration of symptoms (hours) &gt;9 &gt;12 &gt;24 &gt;48</td><td>O1 0.96 0.65 0.49</td><td>0.97-1.05 0.90-1.04 0.47-0.90 0.36-0.67</td><td>0.94 1.19 1.47 1.20</td><td>0.62-1.42 0.87-1.63 1.14-1.90 1.08-1.34</td></tr><tr><td>Fever</td><td>64</td><td>0.89-3.01</td><td>0.61</td><td>0.49-0.77</td></tr><tr><td>Gastrointestinal dysfunction Anorexia Nausea Vomiting</td><td>27 15S 63</td><td>-14-1.41 .04-1.36 45-1.84</td><td>0.59 0.72 0.75</td><td>0.45-0.77 0.57-0.91 0.69-0.80</td></tr><tr><td>Pain Pain migration</td><td>2.06</td><td>.63-2.60</td><td>0.52</td><td>0.40-0.69</td></tr><tr><td>Psoas sign Rebound Percussion tenderness Guarding Rigidity</td><td>2.31 99 2.86 2.48 2.96</td><td>36-3.91 -61-2.45 954.21 -60-3.84 2.43-3.59</td><td>0.85 0.39 0.49 0.57 0.86</td><td>0.76-0.95 0.32-0.48 0.37-0.63 0.48-0.68 0.72-1.02</td></tr><tr><td>Temperature (degrees centigrade) &gt;37.7 &gt;38.5</td><td>1.57 1.87</td><td>0.90-2.76 0.66-5.32</td><td>0.65 0.89</td><td>0.31-1.36 0.71-1.12</td></tr><tr><td>White blood cells (10°/L) 210 215</td><td>4.20 7.20</td><td>2.11-8.35 4.31-12.00</td><td>0.20 0.66</td><td>0.10-0.41 0.56-0.78</td></tr><tr><td>C-reactive protein (mg/L) &gt;10 &gt;20</td><td>1.97 2.39</td><td>1.58-2.45 1.67-3.41</td><td>0.32 0.47</td><td>0.20-0.51 0.28-0.81</td></tr></table>
======================================
<table><thead><th></th><th></th><th colspan="5">AUTHOR</th><th rowspan="2">SUMMAR</th></thead><thead><th></th><th></th><th>TERASAWA</th><th>WESTON</th><th>DORIA</th><th>AL-KHAYAL</th><th>VAN RANDEN</th><th></th></thead><tr><td></td><td></td><td>2004</td><td>2005</td><td>2006</td><td>2007</td><td>2008</td><td></td></tr><tr><td>es</td><td></td><td>22</td><td>21</td><td>57</td><td>25</td><td>6</td><td></td></tr><tr><td rowspan="3">nts</td><td>CT US Total</td><td>1172 1516 2688</td><td>NR NR 5039</td><td>NR NR 13697</td><td>NR NR 13046</td><td>NR NR 671</td><td></td></tr><tr><td></td><td>CT US</td><td>94% (CI: 91%-95%) 86% (Cl: 83%-88%)</td><td>97% (CI: 95%-98%) 87% (Cl: 85%-89%)</td><td>94% (Cl: 92%-97%) 88% (Cl: 86%-90%)</td><td>93% (Cl: 92%-95%) 84% (Cl: 82%-85%)</td><td>| 91% (CI: 84%-95%) | 78% (CI: 67%-86%)</td><td>| CT more than U five m</td></tr><tr><td></td><td>CT US</td><td>95% (CI: 93%-96%) 81% (Cl: 78%-84%)</td><td>95% (CI: 93%-96%) 93% (CI: 92%-94%)</td><td>94% (Cl: 94%-96%) 93% (Cl: 90%-96%)</td><td>93 (Cl: 92%-94%) 96 (CL: 95%—-96%)</td><td>90% (CI: 85%-94%) 83% (Cl: 76%-88%)</td><td>| CT more US in meta-2</td></tr><tr><td>dictive</td><td>CT US</td><td>NR NR</td><td>94% (CI: 92%-95%) 89% (Cl: 87%-90%)</td><td>NR NR</td><td>90% (CI: 89%-92%) 90% (CI: 89%-91%)</td><td>|NR |NR</td><td>CT has si positiv value meta-2</td></tr><tr><td rowspan="2">edictive</td><td>|CT US</td><td>NR NR</td><td>97% (CI: 96%-98%) 92% (CI:91%-93%)</td><td>NR NR</td><td>96% (CI: 95%-97%) 93% (CI: 92%-94%)</td><td>|NR |NR</td><td>CT has si negati’ value meta-2</td></tr><tr><td></td><td>CT US</td><td>NR NR</td><td>NR NR</td><td>NR NR</td><td>94% (CI: 93%-94%) 92% (CI: 92%-96%)</td><td>|NR |NR</td><td>CT is mo in the</td></tr></table>
======================================
<table><thead><th>Ovarian Torsion</th><th>Conservative management with detorsion and</th></thead><tr><td>Crohn’s terminal ileitis</td><td>oophoropexy Appendectomy if base uninflamed</td></tr><tr><td>Meckel’s diverticulitis</td><td>Segmental small bowel resection and primary anastomosis</td></tr><tr><td>Appendiceal Mass</td><td>Laparoscopic appendectomy/ ileocecectomy without capsular disruption or spillage and retrieval in a bag</td></tr></table>
======================================
<table><thead><th>LESION</th><th>PERITONEAL DISEASE AT DIAGNOSIS</th><th>PROGNOSIS</th><th>TREATMENT</th></thead><tr><td>Low-grade appendiceal mucinous neoplasm (LAMN)</td><td>Confined to the appendix</td><td>Excellent-curative</td><td>Negative margin appendectomy, rarely need ileocecectomy</td></tr><tr><td>LAMN</td><td>Peri-appendiceal Acellular mucin dissecting through the wall (t4a) or adjacent organs (t4b)</td><td>Excellent-low risk of | recurrence</td><td>Negative margin appendectomy, resection o} acellular mucin</td></tr><tr><td>LAMN</td><td>Peri-appendiceal Epithelial cells dissecting through the wall (t4a) or adjacent organs (t4b)</td><td>Excellent-high risk of | recurrence</td><td>Negative margin appendectomy, peritoneal surveillance with second look laparoscopy vs. HIPEt</td></tr><tr><td>LAMN</td><td>Distant epithelial cells or acellular mucin (Mla) Low grade mucinous carcinoma peritonei</td><td>Excellent-high risk of recurrence</td><td>Negative margin appendectomy, omentectomy, HIPEC</td></tr><tr><td>High-grade appendiceal mucinous neoplasm (HAMN-rare)</td><td>Management is identical to a LAMN prognosis.</td><td>with risk stratification as shown</td><td>above but slightly worse</td></tr><tr><td>Mucinous adenocarcinoma</td><td>| Confined to the appendix</td><td>Very Good</td><td>Right hemicolectomy</td></tr><tr><td>Mucinous adenocarcinoma |</td><td>Peritoneal Dissemination High grade mucinous carcinoma peritonei with or without signet ring cells</td><td>Well Differentiated-Very good Moderately differentiated —Good Poorly differentiated/signet ring cell histology: 10 year survival of 10-20%</td><td>Cytoreductive surgery and HIPEC, with systemic chemotherapy for high grac histologies</td></tr><tr><td>Adenocarcinoma (non- mucinous, including goblet cell histology)</td><td>Management identical to the mucinous chemotherapy</td><td>histologies, with more extensive</td><td>use of systemic</td></tr><tr><td>Serrated Adenoma (rare)</td><td>Confined to appendix</td><td>Excellent-curative</td><td>Appendectomy</td></tr><tr><td>Adenoma (rare)</td><td>Confined to appendix</td><td>Excellent-curative</td><td>Appendectomy</td></tr></table>
======================================
<table></table>
======================================
<table><thead><th>Child-Turcotte-Pugh</th><th>(CTP)</th><th>score</th><th></th></thead><thead><th>VARIABLE</th><th>1 POINT</th><th>| 2 POINTS</th><th>3 POINTS</th></thead><tr><td>Bilirubin level</td><td>&lt;2 mg/dL</td><td>| 2-3 mg/dL</td><td>| &gt;3 mg/dL</td></tr><tr><td>Albumin level</td><td>&gt;3.5 g/dL</td><td>| 2.8- 3.5 g/dL</td><td>&lt;2.8 g/dL</td></tr><tr><td>International normalized ratio</td><td>&lt;17</td><td>1.7-2.2</td><td>&gt;2.2</td></tr><tr><td>Encephalopathy</td><td></td><td>Controlled</td><td>| Uncontrolled</td></tr><tr><td>Ascites</td><td></td><td>Controlled</td><td>| Uncontrolled</td></tr><tr><td colspan="4">Child-Turcotte-Pugh class</td></tr><tr><td colspan="4">Class A = 5-6 points</td></tr><tr><td colspan="4">Class B = 7-9 points</td></tr></table>
======================================
<table><thead><th>Treatment options for liver cancer</th></thead><tr><td>Hepatic resection</td></tr><tr><td>Liver transplantation</td></tr><tr><td>Ablation techniques</td></tr><tr><td>Radiofrequency ablation</td></tr><tr><td>¢ Ethanol ablation</td></tr><tr><td>* Cryoablation</td></tr><tr><td>* Microwave ablation</td></tr><tr><td>Regional liver therapies</td></tr><tr><td>¢ Chemoembolization/embolization</td></tr><tr><td>* Hepatic artery pump chemoperfusion</td></tr><tr><td>¢ Internal radiation therapy (yttrium-90 internal radiation)</td></tr><tr><td>External-beam radiation therapy</td></tr><tr><td>* Stereotactic radiosurgery (CyberKnife, Trilogy,</td></tr><tr><td>¢ Intensity-modulated radiation therapy</td></tr><tr><td>Systemic chemotherap:</td></tr></table>
======================================
<table><tr><td>OLDER HEPATIC RESECTION TERMINOLOGY</td><td>| BRISBANE 2000 HEPATIC RESECTION TERMINOLOGY</td></tr><tr><td rowspan="3">Caudate lobectomy</td><td>Left lateral sectionectomy or bisegmentectomy (II, IID) Right posterior sectionectomy (VI, VII) Caudate lobectomy segmentectomy (1)</td></tr><tr><td></td><td>ALTERNATIVE “SECTOR” TERMINOLOGY</td></tr><tr><td></td><td>Right sectorectomy Right posterior sectorectomy or right lateral sectorectomy Left medial sectorectomy or left paramedian sectorectomy (bisegmentectomy, TI, IV)</td></tr></table>
======================================
<table><tr><td colspan="2">ENZYME</td><td>SUBSTRATE</td><td rowspan="2">PRODUCT Glucose, maltose, maltotriose,</td></tr><tr><td>Carbohydrate Amylase (active)</td><td></td><td>Starch, glycogen</td><td></td></tr><tr><td colspan="4"></td></tr><tr><td>Protein Endopeptidases Trypsinogen (inactive) Chymotrypsinogen Chymotrypsin</td><td>Trypsin (active) (inactive) “2 Trypsin</td><td>Cleave bonds between amino acids</td><td>dextrins | Amino acids, dipeptides</td></tr><tr><td colspan="4">Enterokinase —“““““_»</td></tr><tr><td colspan="4">(active)</td></tr><tr><td>Proelastase (inactive) Exopeptidases Procarboxy peptidase</td><td>A&amp;B (inactive) Elastase (active) Trypsin Enterokinase</td><td>Cleave amino acids from end of peptide chains</td><td></td></tr><tr><td colspan="4">—“““""</td></tr><tr><td colspan="4"></td></tr><tr><td colspan="4">Carboxypeptidase A&amp;B (active)</td></tr><tr><td colspan="4"></td></tr><tr><td>Fat Pancreatic lipase (active) Phospholipase A2 (inactive) Phospholipase A2</td><td>—"" —»</td><td>Triglycerides Phospholipase</td><td>2-Monoglycerides, fatty acids</td></tr><tr><td colspan="4">(active)</td></tr><tr><td>Cholesterol esterase</td><td></td><td>Neutral lipids</td><td></td></tr></table>
======================================
<table><thead><th>HORMONES</th><th>ISLET CELL</th><th>FUNCTIONS</th></thead><tr><td>Insulin</td><td>Beta</td><td>Decreases gluconeogenesis, glycogenolysis, fatty acid breakdown, and ketogenesis Increased glycogenesis, protein synthesis and glucose uptake</td></tr><tr><td>Glucagon</td><td>Alpha</td><td>Opposite effects of insulin; increases hepatic glycogenolysis and gluconeogenesis</td></tr><tr><td>Somatostatin</td><td>Delta</td><td>Inhibits secretion and action of all pancreatic and gut peptides, inhibits cell growth</td></tr><tr><td>Pancreatic Polypeptide</td><td>PP or F</td><td>Inhibits pancreatic exocrine secretion and facilitates hepatic action of insulin</td></tr><tr><td>Amylin (IAPP)</td><td>Beta</td><td>Counter-regulates insulin secretion and function</td></tr><tr><td>Pancreastatin</td><td>Beta</td><td>Decreases insulin and somatostatin secretion, increases glucagon secretion, decreases exocrine secretion</td></tr><tr><td>Ghrelin</td><td>Epsilon</td><td>Decreases insulin secretion and action</td></tr><tr><td>Peptide YY (PYY)</td><td>not known</td><td>Increases insulin secretion and beta cell srowth</td></tr></table>
======================================
<table><tr><td>PARAMETER</td><td>TYPE 1</td><td>TYPE 2</td><td>TYPE 3C</td></tr><tr><td></td><td>IDDM</td><td>NIDDM</td><td>Pancreatogenic</td></tr><tr><td>Ketoacidosis</td><td>Common</td><td>Rare</td><td>Rare</td></tr><tr><td>Hyperglycemia</td><td>Severe</td><td>Usually mild</td><td>Mild</td></tr><tr><td>Hypoglycemia</td><td>Common</td><td>Rare</td><td>Common</td></tr><tr><td>Peripheral insulin sensitivity</td><td>Normal or increased</td><td>Decreased</td><td>Increased</td></tr><tr><td>Hepatic insulin sensitivity</td><td>Normal</td><td>Normal or decreased</td><td>Decreased</td></tr><tr><td>Insulin levels</td><td>Low</td><td>High</td><td>Low</td></tr><tr><td>Glucagon levels</td><td>Normal or high</td><td>Normal or high</td><td>Low</td></tr><tr><td>PP levels</td><td>Normal or low (late)</td><td>High</td><td>Low</td></tr><tr><td>GIP levels</td><td>Normal or low</td><td>Normal or high</td><td>Low</td></tr><tr><td>GLP-1 levels</td><td>Normal</td><td>Normal or high</td><td>Normal or high</td></tr><tr><td>Typical age of onset</td><td>Childhood or adolescence</td><td>Adulthood</td><td>Any</td></tr></table>
======================================
<table><thead><th colspan="5">Local complications of acute pancreatitis</th><th rowspan="3">CONTENT</th></thead><tr><td></td><td>ACUTE (&lt;4 WEEKS, NO DEFINED</td><td>WALL)</td><td>CHRONIC (&gt;4 WEEKS,</td><td>D EFINED WALL)</td></tr><tr><td></td><td>NO INFECTION</td><td>INFECTION</td><td>NO INFECTION</td><td>INFECTION</td></tr><tr><td>Fluid</td><td>Acute pancreatic fluid collection (APFC)</td><td>Infected APFC</td><td>| Pseudocyst</td><td>Infected pseudocyst</td></tr><tr><td>Solid + fluid</td><td>| Acute necrotic collection (ANC)</td><td>Infected ANC</td><td>Walled off necrosis (WON)</td><td>| Infected WON</td></tr></table>
======================================
<table><thead><th></th><th>0</th><th>1</th><th>2</th><th>3</th><th>4</th></thead><tr><td>Respiration (PaO,FIO,) (mmHg)</td><td>&gt;400</td><td>&lt;400</td><td>&lt;300</td><td>&lt;200 with respiratory | support</td><td>&lt;100 with respiratory support</td></tr><tr><td>Coagulation Platelets (x10' per pL)</td><td>&gt;150</td><td>&lt;150</td><td>&lt;100</td><td>&lt;50</td><td>&lt;20</td></tr><tr><td>Liver Bilirubin (umol/L)</td><td>&lt;20</td><td>20-32</td><td>33-101</td><td>102-204</td><td>&gt;204</td></tr><tr><td>Cardiovascular Hypotension</td><td>No hypotension</td><td>| MAP &lt;70 | mmHg</td><td>Dopamine &lt;5 or dobutamine (any dose)*)</td><td>Dopamine &gt;5 or epi | —&lt;0.1* or norepi &lt;0.1*}</td><td>Dopamine &gt;15 or epi — &gt;0.1* or norepi &gt;0.1*</td></tr><tr><td>Central nervous system Glasgow coma score</td><td>15</td><td>13-14</td><td>10-12</td><td>6-9</td><td>&lt;6</td></tr><tr><td>Kidney Creatinine (umol/L) or urine output</td><td>| &lt;110</td><td>110-170 |</td><td>171-299</td><td>300-440 or &lt;500 mL/day</td><td>&gt;440 or &lt;200 mL/day</td></tr></table>
======================================
<table><thead><th>At admission</th><th>During the initial 48 h</th></thead><tr><td>Age &gt;55 y</td><td>Hematocrit fall &gt;10 points</td></tr><tr><td>WBC &gt;16,000/mm?</td><td>BUN elevation &gt;5 mg/dL</td></tr><tr><td>Blood glucose &gt;200 mg/dL</td><td>| Serum calcium &lt;8 mg/dL</td></tr><tr><td>Serum LDH &gt;350 IU/L</td><td>Arterial PO, &lt;60 mmHg</td></tr><tr><td>Serum AST &gt;250 U/dL</td><td>Base deficit &gt;4 mEq/L</td></tr><tr><td></td><td>Estimated fluid</td></tr><tr><td></td><td>sequestration &gt;6 L</td></tr></table>
======================================
<table><thead><th>At admission</th><th>During the initial 48 h</th></thead><tr><td>Age &gt;70 y</td><td>Hematocrit fall &gt;10 points</td></tr><tr><td>WBC &gt;18,000/mm?</td><td>BUN elevation &gt;2 mg/dL</td></tr><tr><td>Blood glucose &gt;220 mg/dL</td><td>Serum calcium &lt;8 mg/dL</td></tr><tr><td>Serum LDH &gt;400 IU/L</td><td>Base deficit &gt;5 mEq/L</td></tr><tr><td>Serum AST &gt;250 U/dL</td><td>Estimated fluid</td></tr><tr><td></td><td>sequestration &gt;4 L</td></tr></table>
======================================
<table><tr><td>Determinant Based Classification (2012)</td><td>Revised Atlanta Classification (2013)</td></tr><tr><td>Mild</td><td>No local complication</td></tr><tr><td>No systemic complication</td><td>No local complication</td></tr><tr><td colspan="2">No systemic complication</td></tr><tr><td>Moderate</td><td>Sterile local complication and/or</td></tr><tr><td>Transient organ failure</td><td>Local or systemic complications without persistent organ failure or exacerbation of preexisting</td></tr><tr><td></td><td>comorbidity</td></tr><tr><td>Severe</td><td>infected local complication or</td></tr><tr><td>Persistent organ failure</td><td>Persistent organ failure (single or multiple)</td></tr><tr><td rowspan="2">Critical Persistent organ failure</td><td>Infected local complication and</td></tr><tr><td></td><td></td></tr></table>
======================================
<table><thead><th>RAC</th><th>Mild</th></thead><tr><td>(No OF, No LC)</td><td>Moderately severe</td></tr><tr><td>(TOF and/or LC)</td><td>Severe</td></tr><tr><td colspan="2">(POF)</td></tr><tr><td>DBC</td><td>Mild</td></tr><tr><td>(No OF, No LC)</td><td>Moderate</td></tr><tr><td>(TOF and/or SN)</td><td>Severe</td></tr><tr><td>(POF or IN)</td><td>Critical</td></tr><tr><td colspan="2">(POF and IN)</td></tr><tr><td>MDBC Excluded</td><td>Group |</td></tr><tr><td>(TOF and/or SN)</td><td>Group 2</td></tr><tr><td>(IN without POF)</td><td>Group 3</td></tr><tr><td>(POF without IN)</td><td>Group 4</td></tr><tr><td>(POF and IN)</td><td></td></tr></table>
======================================
<table><tr><td>CLASSIFICATION</td><td>ERCP FINDINGS</td><td>CT AND US FINDINGS</td></tr><tr><td>Normal</td><td>No abnormal SBDs</td><td>Normal gland size, shape; homogeneous parenchyma</td></tr><tr><td>Equivocal</td><td>MPD normal</td><td>One of the following: less than three abnormal SBDs; MPD 2-4 mm; gland enlarged more than two times normal size; heterogeneous parenchyma</td></tr><tr><td>Mild</td><td>MPD normal</td><td>Two or more of the following: less than three abnormal SBDs; MPD 2-4 mm; slight gland enlargement; heterogeneous parenchyma</td></tr><tr><td rowspan="2">Moderate</td><td>MPD changes</td><td>Small cysts &lt;10 mm; MPD irregularity</td></tr><tr><td></td><td>SBD changes</td><td>Focal acute pancreatitis; increased echogenicity of MPD walls; gland-contour irregularity</td></tr><tr><td>Severe</td><td>Any of the above changes plus one or more of the following: cysts &lt;10 mm; intraductal filling defects; calculi; MPD obstruction or stricture; severe MPD irregularity; contiguous organ invasion</td><td>—_—</td></tr></table>
======================================
<table><thead><th>Duct size &gt;3 mm</th><th>Ductal dilation</th></thead><tr><td>Tortuous pancreatic duct</td><td>Ductal irregularity</td></tr><tr><td>Intraductal echogenic foci</td><td>Stones or calcification</td></tr><tr><td>Echogenic duct wall</td><td>Ductal fibrosis</td></tr><tr><td>Side-branch ectasia</td><td>Periductal fibrosis</td></tr><tr><td colspan="2">Parenchymal changes</td></tr><tr><td>Inhomogeneous echo pattern</td><td>| Edema</td></tr><tr><td>Reduced echogenic foci (1-3 mm)</td><td>Edema</td></tr><tr><td>Enhanced echogenic foci</td><td>Calcifications</td></tr><tr><td>Prominent interlobular septae</td><td>| Fibrosis</td></tr><tr><td>Lobular outer gland margin _|</td><td>Fibrosis, glandular atrophy</td></tr><tr><td>Large, echo-poor cavities (&gt;5 mm)</td><td>Pseudocyst</td></tr></table>
======================================
<table><tr><td>GRADE</td><td>MAIN PANCREATIC DUCT</td><td>SIDE BRANCHES</td></tr><tr><td>Normal</td><td>Normal</td><td>Normal</td></tr><tr><td>Suggestive</td><td>| Normal</td><td>&lt;3 Abnormal</td></tr><tr><td>Mild</td><td>Normal</td><td>23 Abnormal</td></tr><tr><td>Moderate</td><td>Abnormal</td><td>&gt;3 Abnormal</td></tr><tr><td>Severe</td><td>Abnormal plus at least one of the following: large cavity, duct obstruction, dilation or duct irregularity, intraductal filing defects</td><td></td></tr></table>
======================================
<table><thead><th>TERM</th><th>DEFINITION</th></thead><tr><td>Peripancreatic fluid collection</td><td>| A collection of enzyme-rich pancreatic juice that occurs early in the course of acute pancreatitis, or that forms after a pancreatic duct leak; located in or near the pancreas; it lacks a well-organized wall of granulation or fibrous tissue</td></tr><tr><td>Early pancreatic (sterile)</td><td>| A focal or diffuse area of nonviable pancreatic parenchyma, typically</td></tr><tr><td>necrosis</td><td>occupying &gt;30% of the gland and containing liquefied debris and fluid</td></tr><tr><td>Late pancreatic (sterile)</td><td>| An organized collection of sterile necrotic debris and fluid with a well-defined margin or wall within the normal</td></tr><tr><td>necrosis</td><td>domain of the pancreas</td></tr><tr><td>Acute pseudocyst</td><td>A collection of pancreatic juice enclosed within a perimeter of early granulation tissue, usually as a consequence of acute pancreatitis that has occurred within the preceding 3-4 wk</td></tr><tr><td>Chronic pseudocyst</td><td>A collection of pancreatic fluid surrounded by a wall of normal granulation and fibrous tissue, usually persisting for &gt;6 wk</td></tr><tr><td>Pancreatic abscess</td><td>Any of the above in which gross purulence (pus) is present, with bacterial or fungal organisms documented to be present</td></tr></table>
======================================
<table><thead><th></th><th>WITH HEAD</th><th>WITHOUT HEAD</th></thead><tr><td>Daily severe pain</td><td>67</td><td>40</td></tr><tr><td>Cholestasis</td><td>46</td><td>11</td></tr><tr><td>Duodenal obstruction</td><td>30</td><td>7</td></tr><tr><td>Diabetes mellitus</td><td>18</td><td>30</td></tr><tr><td>Vascular involvement</td><td>15</td><td>8</td></tr></table>
======================================
<table><thead><th>PRODUCT</th><th>FORMULATION</th><th>MANUFACTURER</th><th>LIPASE CONTENT (USP)/PILL OR CAPSULE</th></thead><tr><td>Zenpep</td><td>Enteric-coated porcine</td><td>Aptalis</td><td>3000, 5000, 10,000, 15,000, 20,000</td></tr><tr><td>Creon</td><td>Enteric-coated porcine</td><td>Abbott</td><td>3000, 6000, 12,000, 24,000</td></tr><tr><td>Pancreaze</td><td>Enteric-coated porcine</td><td>Ortho-McNeil-Janssen</td><td>4200, 10,500, 16,800, 21,000</td></tr><tr><td>Pertzye</td><td>Enteric-coated porcine mixed with bicarbonate granules</td><td>Digestive Care</td><td>8000, 16,000</td></tr><tr><td>Ultresa</td><td>Enteric-coated porcine</td><td>Aptalis</td><td>13,800, 20,700, 23,000</td></tr><tr><td>Viokace</td><td>Tablet non-enteric-coated porcine</td><td>Aptalis</td><td>10,440, 20,880</td></tr></table>
======================================
<table><thead><th>TREATMENT GROUP</th><th>24-MONTH EVALUATION</th></thead><tr><td>Operated (n = 47)</td><td>Mild to moderate 48 (87%); severe 6 (13%)</td></tr><tr><td>Nonoperated (n = 36)</td><td>Mild to moderate 8 (22%); severe 28 (78%)</td></tr></table>
======================================
<table><thead><th>TX</th><th>Tumor cannot be assessed</th></thead><tr><td>Tl</td><td>Tumor limited to the pancreas,* &lt;2 cm</td></tr><tr><td>T2</td><td>Tumor limited to the pancreas,* 2-4 cm</td></tr><tr><td>T3</td><td>Tumor limited to the pancreas,* &gt;4 cm; or tumor invading the duodenum or common</td></tr><tr><td></td><td>bile duct</td></tr><tr><td rowspan="2">T4</td><td>Tumor invading adjacent organs (stomach,</td></tr><tr><td></td><td>spleen, colon, adrenal gland) or the wall of large vessels (celiac axis or the superior mesenteric artery)</td></tr></table>
======================================
<table><thead><th>NX</th><th>Regional lymph nodes cannot be assessed</th></thead><tr><td>NO</td><td>No regional lymph node involvement</td></tr><tr><td>NI</td><td>Regional lymph node involvement</td></tr></table>
======================================
<table><tr><td>MO</td><td>No distant</td><td>metastasis</td><td></td></tr><tr><td>MI</td><td>Distant</td><td>metastasis</td><td></td></tr><tr><td>Mla</td><td>Metastasis</td><td>confined to liver</td><td></td></tr><tr><td>Mlb</td><td>Metastases (e.g.,</td><td>in at least one lung, ovary, nonregional peritoneum, bone)</td><td>extrahepatic site lymph node,</td></tr><tr><td>Mic</td><td>Both</td><td>hepatic and extrahepatic</td><td>metastases</td></tr><tr><td>TUMOR</td><td>NODE</td><td>METASTASIS</td><td>STAGE</td></tr><tr><td>Tl</td><td>NO</td><td>MO</td><td>I</td></tr><tr><td>T2</td><td>NO</td><td>MO</td><td>I</td></tr><tr><td>T3</td><td>NO</td><td>MO</td><td>I</td></tr><tr><td>T4</td><td>NO</td><td>MO</td><td>Il</td></tr><tr><td>Any T</td><td>NI</td><td>MO</td><td>Il</td></tr><tr><td>Any T</td><td>Any N</td><td>M1</td><td>IV</td></tr></table>
======================================
<table><thead><th>DISEASE/CONDITION</th><th>INDICATIONS FOR SPLENECTOMY</th><th>RESPONSE TO SPLENECTOMY</th></thead><tr><td>Essential thrombocythemia</td><td>Only for advanced disease (i.e., transformation to myeloid metaplasia or AML) with severe symptomatic splenomegaly</td><td>Relief of abdominal pain and early satiety</td></tr><tr><td>Glucose-6-phosphate dehydrogenase deficiency (G6PD)</td><td>Excessive transfusion requirements; failure of medical therapy (controversial)</td><td>May be curative</td></tr><tr><td>Hereditary spherocytosis</td><td>Hemolytic anemia, recurrent transfusions, intractable leg ulcers</td><td>Improves or eliminates anemia</td></tr><tr><td>Idiopathic thrombocytopenic purpura (ITP)</td><td>Failure of medical therapy, recurrent disease</td><td>75%-85% rate of long-term response</td></tr><tr><td>Polycythemia vera</td><td>Only for advanced disease (i.e., transformation to myeloid metaplasia or AML) with severe symptomatic splenomegaly</td><td>Relief of abdominal pain and early satiety</td></tr><tr><td>Pyruvate kinase deficiency</td><td>Only in severe cases, recurrent transfusions</td><td>Decreased transfusion requirement, palliative only</td></tr><tr><td>Sickle cell disease</td><td>History of acute sequestration crisis, splenic symptoms, or infarction (consider concomitant cholecystectomy)</td><td>Palliative, variable response</td></tr><tr><td>Thalassemia</td><td>Excessive transfusion requirements, symptomatic splenomegaly, infarction, or hypersplenism</td><td>Diminished transfusion requirements, relief of symptoms</td></tr><tr><td>Thrombotic thrombocytopenic purpura (TTP)</td><td>Excessive plasma exchange requirement</td><td>Typically curative</td></tr><tr><td>Warm-antibody autoimmune hemolytic anemia</td><td>Failure of medical (steroid) therapy</td><td>60%-80% response rate, recurrences common</td></tr></table>
======================================
<table><tr><td>Acute myeloid leukemia (AML)</td><td>Intolerable symptomatic splenomegaly</td><td>Relief of abdominal pain and early satiety</td></tr><tr><td>Chronic lymphocytic leukemia (CLL)</td><td>Cytopenias and anemia</td><td>75% response rate</td></tr><tr><td>Chronic myelogenous leukemia (CML)</td><td>Symptomatic splenomegaly</td><td>Relief of abdominal pain and early satiety</td></tr><tr><td>Chronic myelomonocytic leukemia (CMML)</td><td>Symptomatic splenomegaly</td><td>Relief of abdominal pain and early satiety</td></tr><tr><td>Myelofibrosis (agnogenic myeloid metaplasia)</td><td>Severe symptomatic splenomegaly</td><td>76% clinical response at 1 y, high risk of hemorrhagic, thrombotic, and infectious complications (26%)</td></tr><tr><td>Hairy cell leukemia</td><td>Severe symptomatic splenomegaly, severe transfusion requirements; failure of medical therapy</td><td>Curative</td></tr><tr><td>Hodgkin’s lymphoma</td><td>Surgical staging in selected cases</td><td>Varied</td></tr><tr><td>Non-Hodgkin’s lymphoma</td><td>Cytopenias, symptomatic splenomegaly</td><td>Improved complete blood count values, relief of symptoms</td></tr><tr><td>Metastatic tumor of the spleen (most commonly breast, lung, and melanoma)</td><td>If symptomatic, or as part of cancer treatment</td><td>Varied</td></tr><tr><td>Primary tumor of the spleen</td><td>For diagnosis and treatment of cancer</td><td>Varied</td></tr></table>
======================================
<table><thead><th>DISEASE/CONDITION</th><th>INDICATIONS FOR SPLENECTOMY</th><th>RESPONSE TO SPLENECTOMY</th></thead><tr><td>Abscess of the spleen</td><td>Multiloculated, or failure of conservative measures for unilocular</td><td>Curative</td></tr><tr><td>Amyloidosis</td><td>Symptomatic splenomegaly</td><td>Improves symptoms; does not correct underlying disease</td></tr><tr><td>Felty’s syndrome</td><td>Neutropenia</td><td>80% durable response rate</td></tr><tr><td>Gaucher’s disease</td><td>Hypersplenism</td><td>Improves cytopenias; does not correct underlying disease</td></tr><tr><td>Niemann-Pick disease</td><td>Symptomatic splenomegaly</td><td>Improves symptoms; does not correct underlying disease</td></tr><tr><td>Portal/sinistral hypertension</td><td>Splenic vein thrombosis, symptomatic splenomegaly</td><td>Palliative</td></tr><tr><td>Sarcoidosis</td><td>Hypersplenism or symptomatic splenomegaly</td><td>Improves symptoms and cytopenias; does not correct underlying disease</td></tr><tr><td>Splenic artery aneurysm</td><td>Best for distal lesions near splenic hilum</td><td>Curative</td></tr><tr><td>Symptomatic nonparasitic cysts</td><td>Partial splenectomy for small cysts; unroofing for large cysts</td><td>Curative</td></tr><tr><td>Symptomatic parasitic cysts</td><td>Therapy of choice</td><td>Curative; exercise caution not to spill cyst contents</td></tr><tr><td>Wandering spleen</td><td>Abdominal pain or splenomegaly (venous congestion)</td><td>Curative</td></tr><tr><td>Traumatic rupture</td><td>Grades 4/5, or failure of conservative management of lower grades</td><td>Curative</td></tr></table>
======================================
<table><thead><th>Difficulty Score</th><th></th></thead><thead><th colspan="2">Age</th></thead><thead><th>&lt;40 years</th><th>0</th></thead><tr><td>40-60 years</td><td>1</td></tr><tr><td>260 years</td><td>2</td></tr><tr><td colspan="2">Gender</td></tr><tr><td>Female</td><td>0.5</td></tr><tr><td>Male</td><td>1</td></tr><tr><td colspan="2">Pathology group</td></tr><tr><td>ITP</td><td>0.5</td></tr><tr><td>Other benign</td><td>1</td></tr><tr><td>Malignant</td><td>2</td></tr><tr><td colspan="2">Spleen weight*</td></tr><tr><td>&lt;400 gr</td><td></td></tr><tr><td>400-1000 gr</td><td></td></tr><tr><td>&gt;1000 gr</td><td></td></tr><tr><td colspan="2">Difficulty grade</td></tr><tr><td>Low</td><td>&lt;4</td></tr><tr><td>Medium</td><td>46</td></tr><tr><td>High</td><td>26</td></tr></table>
======================================
<table><thead><th colspan="5">Outcome after splenectomy</th></thead><thead><th>OUTCOME VARIABLE</th><th>STUDIES (N)</th><th>PATIENTS (NN)</th><th>POOLED RESULTS AND CI</th><th>P</th></thead><tr><td>Mortality</td><td>38</td><td>2914</td><td>-0.01 (0-02, 0)</td><td>1</td></tr><tr><td colspan="5">Complications</td></tr><tr><td>Pooled</td><td>38</td><td>2914</td><td>-0.11 (0.16, -0.05)</td><td>&lt;.00001</td></tr><tr><td>Minor</td><td>36</td><td>2914</td><td>—0.03 (-0.05, -0.01)</td><td>13</td></tr><tr><td>Severe</td><td>36</td><td>2745</td><td>-0.07 (-0.11, -0.03)</td><td>&lt;.00001</td></tr><tr><td>Thrombosis</td><td>35</td><td>2695</td><td>—0.01 (-0.02, 0.01)</td><td>1</td></tr><tr><td>Organ injury</td><td>34</td><td>2639</td><td>0.01 (-0, 0.02)</td><td>1</td></tr><tr><td>Acces. spleen</td><td>29</td><td>2135</td><td>0.02 (-0.01, 0.05)</td><td>87</td></tr><tr><td>Operative time</td><td>18</td><td>1370</td><td>57.4 min (43.3, 71.4)</td><td>&lt;.00001</td></tr><tr><td>Blood loss</td><td>10</td><td>759</td><td>—41 mL (-87, 4.71)</td><td>&lt;.00001</td></tr><tr><td>Length of stay</td><td>20</td><td>1566</td><td>—2.48 d (—2.89, -2.07)</td><td>&lt;.00001</td></tr></table>
======================================
<table><thead><th></th><th>ITP (N = 151)</th><th>TTP (N= 7)</th><th>ANEMIA (N = 40)</th><th>MALIGNANCY (N = 28)</th></thead><tr><td>OR time (min)</td><td>128</td><td>146</td><td>149</td><td>165</td></tr><tr><td>EBL (mL)</td><td>137</td><td>96</td><td>116</td><td>238</td></tr><tr><td>LOS (days)</td><td>2.2</td><td>3.0</td><td>2.2</td><td>2.6</td></tr><tr><td>Conversions from LS to OS</td><td>3 (2%)</td><td>1 (14%)</td><td>1 3%)</td><td>1 (4%)</td></tr><tr><td>Complications</td><td>14 (9%)</td><td>0</td><td>1 3%)</td><td>3 (11%)</td></tr></table>
======================================
<table><thead><th>HISTOLOGIC SUBTYPES</th><th>NO.</th><th>%</th></thead><tr><td>Liposarcoma</td><td>188</td><td>15</td></tr><tr><td>Leiomyosarcoma</td><td>148</td><td>12</td></tr><tr><td>Unclassified sarcoma</td><td>140</td><td>1</td></tr><tr><td>Synovial sarcoma</td><td>125</td><td>10</td></tr><tr><td>Malignant peripheral nerve sheath tumor</td><td>72</td><td>6</td></tr><tr><td>Rhabdomyosarcoma</td><td>60</td><td>5</td></tr><tr><td>Fibrosarcoma</td><td>38</td><td>3</td></tr><tr><td>Ewing sarcoma</td><td>25</td><td>2</td></tr><tr><td>Angiosarcoma</td><td>25</td><td>2</td></tr><tr><td>Osteosarcoma</td><td>14</td><td>1</td></tr><tr><td>Epithelioid sarcoma</td><td>14</td><td>1</td></tr><tr><td>Chondrosarcoma</td><td>13</td><td>1</td></tr><tr><td>Clear cell sarcoma</td><td>12</td><td>1</td></tr><tr><td>Alveolar soft part sarcoma</td><td></td><td>1</td></tr><tr><td>Malignant hemangiopericytoma</td><td></td><td>0.4</td></tr></table>
======================================
<table><thead><th colspan="3">Fusion transcripts in soft tissue sarcoma</th></thead><thead><th>DIAGNOSIS</th><th>CHROMOSOMAL ABNORMALITY</th><th>GENES INVOLVED</th></thead><tr><td>Alveolar thabdomyosarcoma _</td><td>t(2;13)(q35;q14) | t(1;13)(p36;q14)</td><td>PAX3-FKHR PAX7-FKHR</td></tr><tr><td>Alveolar soft part sarcoma</td><td>t(X317)(p11.2;q25)</td><td>| TFE3-ASPL</td></tr><tr><td>Angiomatoid fibrous histiocytoma</td><td>t(12;16)(q13;pl1)</td><td>| FUS-ATFI1</td></tr><tr><td>Clear cell sarcoma</td><td>t(12;22)(q13;q12)</td><td>| EWS-ATF1</td></tr><tr><td>Congenital fibrosarcoma/ congenital mesoblastic nephroma</td><td>t(12;15)(p13;q25)</td><td>| ETV6-NTRK3</td></tr><tr><td>Dermatofibrosarcoma</td><td>t(17;22)(q22;q13)</td><td>| PDFGB-</td></tr><tr><td>protuberans Desmoplastic small</td><td>t(11;22)(p13;q12)</td><td>COLIAI | EWS-WT1</td></tr><tr><td>round cell tumor</td><td></td><td></td></tr><tr><td>Endometrial stromal</td><td>t(7;17)(p15;q21)</td><td>JAZF1-JJAZ1</td></tr><tr><td>sarcoma</td><td></td><td></td></tr><tr><td>Ewing’s sarcoma/ peripheral primitive | neuroectodermal tumor</td><td>t(11;22)(q24;q12) t(21;22)(q22;q12) t(7;22)(p22;q12) t(17;22)(q12;q12) t(2;22)(q33;q12) t(16;21)(p11;q22)</td><td>| EWS-FLII | EWS-ERG EWS-ETV1 | EWS-FEV | EWS-EIAF | FUS-ERG</td></tr><tr><td>Low-grade fibromyxoid | sarcoma</td><td>t(7;16)(q33;p1 LS</td><td>FUS-CREB312</td></tr><tr><td>Inflammatory myofibroblastic tumor</td><td>t(1;2)(q22;p23) t(2;19)(p23;p13) t(2;17)(p23;q23)</td><td>TPM3-ALK | TPM4-ALK CLTC-ALK</td></tr><tr><td>Myxoid liposarcoma</td><td>t(12;16)(q13;pl1) t(12;22)(q13;q12)</td><td>| TLS-CHOP | EWS-CHOP</td></tr><tr><td>Myxoid chondrosarcoma</td><td>t(9;22)(q22;q12) t(9;15)(q22;q21) t(9;17)(q22;q11)</td><td>EWS-CHN TFC12-CHN | TAF2N-CHN</td></tr><tr><td>Synovial sarcoma</td><td>t(x;18)(pl1;q11)</td><td>SSX1-SYT SSX2-SYT SSX4-SYT</td></tr></table>
======================================
<table><thead><th>Inguinal hernia prevalence</th><th>by age</th><th></th><th></th><th></th><th></th><th></th></thead><thead><th>AGE (Y)</th><th>25-34</th><th>35-44</th><th>45-54</th><th>55-64</th><th>65-74</th><th>75+</th></thead><tr><td>Current prevalence (%)</td><td>12</td><td>15</td><td>20</td><td>26</td><td>29</td><td>34</td></tr><tr><td>Lifetime prevalence (%)</td><td>15</td><td>19</td><td>28</td><td>34</td><td>40</td><td>47</td></tr></table>
======================================
<table><thead><th>Type I</th><th>Indirect hernia; internal abdominal ring normal; typically in infants, children, small adults</th></thead><tr><td>Type IL</td><td>Indirect hernia; internal ring enlarged without impingement on the floor of the inguinal canal; does not extend to the scrotum</td></tr><tr><td>Type IIIA</td><td>| Direct hernia; size is not taken into account</td></tr><tr><td>Type IIIB</td><td>| Indirect hernia that has enlarged enough to encroach upon the posterior inguinal wall; indirect sliding or scrotal hernias are usually placed in this category because they are commonly associated with extension to the direct space; also includes pantaloon hernias</td></tr><tr><td>Type IIIC</td><td>| Femoral hernia</td></tr><tr><td>Type IV</td><td>Recurrent hernia; modifiers A—-D are sometimes added, which correspond to indirect, direct, femoral, and mixed, respectively</td></tr></table>
======================================
<table><thead><th>Differential diagnosis of</th><th>hyperthyroidism</th></thead></table>
======================================
<table><tr><td>PRIMARY (INCREASED TSH LEVELS)</td><td>SECONDARY (DECREASED TSH LEVELS)</td><td>TERTIARY</td></tr><tr><td>Hashimoto’s thyroiditis</td><td>Pituitary tumor</td><td>| Hypothalamic insufficiency</td></tr><tr><td>RAI therapy for Graves’ disease</td><td>Pituitary resection or ablation</td><td>Resistance to thyroid hormone</td></tr><tr><td>Postthyroidectomy</td><td></td><td></td></tr><tr><td colspan="3">Excessive iodine intake</td></tr><tr><td colspan="3">Subacute thyroiditis</td></tr><tr><td colspan="3">Medications: antithyroid drugs, lithium</td></tr><tr><td>Rare: iodine deficiency, dyshormogenesis</td><td></td><td></td></tr></table>
======================================
<table><thead><th colspan="2">Etiology of nontoxic goiter</th></thead><thead><th>CLASSIFICATION</th><th>SPECIFIC ETIOLOGY</th></thead><tr><td>Endemic</td><td>Iodine deficiency, dietary goitrogens (cassava, cabbage)</td></tr><tr><td>Medications</td><td>Todide, amiodarone, lithium</td></tr><tr><td>Thyroiditis</td><td>Subacute, chronic (Hashimoto’s)</td></tr><tr><td>Familial</td><td>Impaired hormone synthesis from enzyme defects</td></tr><tr><td>Neoplasm</td><td>Adenoma, carcinoma</td></tr><tr><td>Resistance to thyroid hormone</td><td></td></tr></table>
======================================
<table><thead><th>SYNDROME</th><th>GENE</th><th>MANIFESTATION</th><th>THYROID TUMOR</th></thead><tr><td>Cowden’s syndrome</td><td>PTEN</td><td>Intestinal hamartomas, benign and malignant breast tumors</td><td>FTC, rarely PTC and Hiirthle cell tumors</td></tr><tr><td>FAP</td><td>APC</td><td>Colon polyps and cancer, duodenal neoplasms, desmoids</td><td>PTC cribriform growth pattern</td></tr><tr><td>Werner’s syndrome</td><td>WRN</td><td>Adult progeroid syndrome</td><td>PTC, FTC, anaplastic cancer</td></tr><tr><td>Carney complex type 1</td><td>PRKARIa</td><td>Cutaneous and cardiac myxomas, breast and adrenal tumors</td><td>PTC, FTC</td></tr><tr><td>McCune-Albright syndrome</td><td>GNASI</td><td>Polyostotic fibrous dysplasia, endocrine abnormalities, café-au-lait spots</td><td>PTC clear cell</td></tr><tr><td>DICER | syndrome</td><td></td><td>Pleuropulmonary blastoma, cystic nephroma, ovarian sex cord-stromal tumors</td><td>Multinodular goiter, thyroid cancer</td></tr></table>
======================================
<table><thead><th>GENE</th><th>FUNCTION</th><th>TUMOR</th></thead><tr><td colspan="3">Oncogenes</td></tr><tr><td>RET</td><td>Membrane receptor with tyrosine kinase activity</td><td>Sporadic and familial MTC, PTC (RET/PTC rearrangements)</td></tr><tr><td>MET</td><td>Same</td><td>Overexpressed in PTC</td></tr><tr><td>TRKI</td><td>Same</td><td>Activated in some PTC</td></tr><tr><td>TSH-R</td><td>Linked to heterotrimeric G protein</td><td>Hyperfunctioning adenoma</td></tr><tr><td>Gso (gsp)</td><td>Signal transduction molecule (GTP binding)</td><td>Hyperfunctioning adenoma, follicular adenoma</td></tr><tr><td>Ras</td><td>Signal transduction protein</td><td>Follicular adenoma and carcinoma, PTC</td></tr><tr><td>PAX8/PPARy1</td><td>Oncoprotein</td><td>Follicular adenoma, follicular carcinoma</td></tr><tr><td>B-Raf (BRAF)</td><td>Signal transduction</td><td>PTC, tall cell and poorly differentiated, anaplastic</td></tr><tr><td>CTNNBI (B-catenin)</td><td>Signal transduction</td><td>Upregulated in poorly differentiated and anaplastic cancers</td></tr><tr><td>TERT promoter</td><td>Chromosome integrity</td><td>Mutated in thyroid cancers including PTC, FTC and anaplastic cancers</td></tr><tr><td colspan="3">Tumor suppressors</td></tr><tr><td>ps3</td><td>Cell cycle regulator, arrests cells in G,, induces apoptosis</td><td>Dedifferentiated PTC, FTC, anaplastic cancers</td></tr><tr><td>plo</td><td>Cell cycle regulator, inhibits cyclin- dependent kinase</td><td>Thyroid cancer cell lines</td></tr><tr><td>PTEN</td><td>Protein tyrosine phosphatase</td><td>Follicular adenoma and carcinoma</td></tr><tr><td colspan="3">Other genetic alterations</td></tr><tr><td>microRNA</td><td>Small, noncoding RNA</td><td>Specific types upregulated in papillary and some follicular carcinomas</td></tr></table>
======================================
<table><thead><th>DIAGNOSIS AGE</th><th>TUMOR</th><th>NODE</th><th>METASTASIS</th><th>STAGE</th></thead><tr><td>&lt;55 years</td><td>Any T</td><td>Any N</td><td>MO</td><td>I</td></tr><tr><td>&lt;55 years</td><td>Any T</td><td>Any N</td><td>MI</td><td>II</td></tr><tr><td>&gt;55 years</td><td>Tl</td><td>NO/NX</td><td>MO</td><td>I</td></tr><tr><td>&gt;55 years</td><td>Tl</td><td>NI</td><td>MO</td><td>I</td></tr><tr><td>&gt;55 years</td><td>T2</td><td>NO/NX</td><td>MO</td><td>I</td></tr><tr><td>&gt;55 years</td><td>T2</td><td>NI</td><td>MO</td><td>I</td></tr><tr><td>&gt;55 years</td><td>T3a/T3b</td><td>Any N</td><td>MO</td><td>I</td></tr><tr><td>&gt;55 years</td><td>T4a</td><td>Any N</td><td>MO</td><td>TL</td></tr><tr><td>&gt;55 years</td><td>T4b</td><td>Any N</td><td>MO</td><td>IVA</td></tr><tr><td>&gt;55 years</td><td>Any T</td><td>Any N</td><td>MI</td><td>IVB</td></tr><tr><td colspan="5">MEDULLARY THYROID CANCER</td></tr><tr><td>TUMOR</td><td>NODE</td><td>METASTASIS</td><td>STAGE</td><td></td></tr><tr><td>Tl</td><td>NO</td><td>MO</td><td>I</td><td></td></tr><tr><td>T2</td><td>NO</td><td>MO</td><td>I</td><td></td></tr><tr><td>3}</td><td>NO</td><td>MO</td><td>I</td><td></td></tr><tr><td>T1-3</td><td>Nla</td><td>MO</td><td>TL</td><td></td></tr><tr><td>T4a</td><td>Any N</td><td>MO</td><td>IVA</td><td></td></tr><tr><td>T1-3</td><td>Nlb</td><td>MO</td><td>IVA</td><td></td></tr><tr><td>T4b</td><td>Any N</td><td>MO</td><td>IVB</td><td></td></tr><tr><td>Any T</td><td>Any N</td><td>MI</td><td>IVC</td><td></td></tr><tr><td colspan="5">ANAPLASTIC CANCER</td></tr><tr><td>TUMOR</td><td>NODE</td><td>METASTASIS</td><td>STAGE</td><td></td></tr><tr><td>T1-T3a</td><td>NO/NX</td><td>MO</td><td>IVA</td><td></td></tr><tr><td>T1-T3a</td><td>NI</td><td>MO</td><td>IVB</td><td></td></tr><tr><td>T3b</td><td>Any N</td><td>MO</td><td>IVB</td><td></td></tr><tr><td>T4</td><td>Any N</td><td>MO</td><td>IVB</td><td></td></tr><tr><td>Any T</td><td>Any N</td><td>MI</td><td>IVC</td><td></td></tr></table>
======================================
<table><tr><td>Bone marrow suppression (200 mCi)</td><td>Anaplastic thyroid cancer Gastric cancer Hepatocellular cancer Lung cancer Breast cancer (&gt;1000 mCi) Bladder cancer Hypoparathyroidism</td></tr></table>
======================================
<table><thead><th>Clinical and genetic features</th><th>of medullary thyroid cancer syndromes</th><th></th></thead><tr><td>SYNDROME</td><td>MANIFESTATIONS</td><td>RET MUTATIONS</td></tr><tr><td>MEN2A</td><td>MTC, pheochromocytoma, primary hyperparathyroidism, lichen planus amyloidosis</td><td>Exon 10—codons 609, 611, 618, 620 Exon 11—codon 634 (more commonly associated with pheochromocytoma and primary hyperparathyroidism)</td></tr><tr><td>MEN2B</td><td>MTC, pheochromocytoma, Marfanoid habitus, mucocutaneous ganglioneuromatosis</td><td>Exon 16—codon 918</td></tr><tr><td>Familial MTC</td><td>MTC</td><td>Codons 609, 611, 618, 620, and 634 Codons 768, 790, 791, or 804 (rare)</td></tr><tr><td>MEN2A and Hirschsprung’s disease</td><td>| MTC, pheochromocytoma, primary hyperparathyroidism, Hirschsprung’s disease</td><td>Codons 609, 618, 620</td></tr></table>
======================================
<table><thead><th>SERUM TESTS</th><th>ALTERATION</th></thead><tr><td>Calcium</td><td>Increased, except in normocalcemic primary hyperparathyroidism</td></tr><tr><td>Intact PTH</td><td>Increased or inappropriately high</td></tr><tr><td>Chloride</td><td>Increased or high normal</td></tr><tr><td>Phosphate</td><td>Decreased or low normal</td></tr><tr><td>Chloride-to-phosphate ratio</td><td>Increased (usually &gt;33)</td></tr><tr><td>Magnesium</td><td>Unchanged or decreased (in patients with osteitis fibrosa cystica)</td></tr><tr><td>Uric acid</td><td>Normal or increased</td></tr><tr><td>Alkaline phosphatase</td><td>Normal or increased (in the presence of high turnover bone disease)</td></tr><tr><td>Acid-base status</td><td>Mild hyperchloremic metabolic acidosis</td></tr><tr><td>Calcium-to-creatinine clearance ratio</td><td>Generally &gt;0.02 (vs. &lt;0.01 in FHH) but there are exceptions</td></tr><tr><td>1,25-dihydroxy vitamin D</td><td>Normal or increased</td></tr><tr><td colspan="2">Urine tests</td></tr><tr><td>24-h urinary calcium</td><td>Normal or increased</td></tr></table>
======================================
<table><thead><th>STUDY</th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td colspan="3">Preoperative, noninvasive</td></tr><tr><td>Sestamibi-technetium- 99m scan</td><td>Allows planar and SPECT imaging</td><td>False-positive tests due to thyroid neoplasms, lymphadenopathy</td></tr><tr><td rowspan="2">Ultrasound</td><td>Identification of juxta- and intrathyroidal tumors</td><td>False-positive results due to thyroid nodules, cysts, lymph nodes, esophageal lesions</td></tr><tr><td></td><td>Relatively inexpensive</td><td>False-negatives result from substernal, ectopic, and undescended tumors</td></tr><tr><td>CT scan</td><td>Localization of ectopic (mediastinal) glands</td><td>_| Not useful for juxta- or intrathyroidal glands False-positive results from lymph nodes Relatively high cost Radiation exposure Requires IV contrast Interference from shoulders and metallic clips</td></tr><tr><td rowspan="3">MRI scan</td><td></td><td>Localization of ectopic tumors</td><td>Expensive</td></tr><tr><td></td><td>No radiation exposure</td><td>False-positive results from lymph nodes and thyroid nodules</td></tr><tr><td>No IV contrast</td><td>Cannot be used in claustrophobic patients</td></tr><tr><td>Four-dimensional CT scan</td><td>Structural and functional information</td><td>Similar to CT scan</td></tr><tr><td colspan="3">Preoperative, invasive</td></tr><tr><td>FNAB</td><td>Can distinguish parathyroid tumor from lymphadenopathy using PTH assay</td><td>Experienced cytologist needed</td></tr><tr><td rowspan="3">Angiogram</td><td>Provides a road map for selective venous sampling</td><td>Expensive</td></tr><tr><td></td><td>Treatment of mediastinal tumors by embolization</td><td>Experienced radiologist needed</td></tr><tr><td></td><td></td><td>Neurologic complications</td></tr><tr><td>Venous sampling</td><td>Useful to lateralize tumor in equivocal cases or negative localization studies</td><td>Expensive, experienced radiologist needed</td></tr><tr><td colspan="3">Intraoperative</td></tr><tr><td>PTH assay</td><td>Immediate confirmation of tumor removal</td><td>Expensive</td></tr></table>
======================================
<table><thead><th>MEDICATION</th><th>DOSAGE AND ADMINISTRATION</th><th>MECHANISM, ONSET OF ACTION, | AND DURATION</th><th>SIDE EFFECTS</th></thead><tr><td>Bisphosphonates (pamidronate, zolendronic acid preferred in patients with malignancy due to rapid action)</td><td>60-90 mg IV over 4-24 h</td><td>Inhibits osteoclastic bone resorption; rapid onset, 2-3 d</td><td>| May cause local pain and swelling, low-grade fever, lymphopenia, electrolyte abnormalities, osteonecrosis of the jaw in some patients (iv use)</td></tr><tr><td>Calcitonin</td><td>4 IU/kg SC/IM</td><td>Inhibits osteoclast function, augments renal calcium excretion; onset of action in hours; but short lived, therefore not useful as sole therapy</td><td>Transient nausea and vomiting, abdominal cramps, flushing, and local skin reaction</td></tr><tr><td>Mithramycin (plicamycin)</td><td>25 ug/kg/d IV for 3-4 d</td><td>Inhibits osteoclasts RNA secretion; rapid onset of action (12 h); peaks at 48-72 h and lasts days to several weeks</td><td>| May cause renal, hepatic, and hematologic complications, nausea and vomiting</td></tr><tr><td>Gallium nitrate</td><td>200 mg/m? BSA/d IV for 5 d</td><td>Reduces urinary calcium excretion; onset of action delayed (5-7 d)</td><td>Nephrotoxicity, nausea, vomiting, hypotension, anemia, hypophosphatemia</td></tr><tr><td>Glucocorticoids</td><td>Hydrocortisone 100 mg IV q8h</td><td>Delayed onset of action (7-10 d); useful for hematologic malignancies, sarcoidosis, vitamin D intoxication, hyperthyroidism</td><td>Hypertension, hyperglycemia</td></tr><tr><td>Calcimimetics (cinacalcet)</td><td>Up to 90 mg 3 0 4 times per day</td><td>Useful in patients with parathyroid carcinoma and patients with chronic renal failure</td><td>Gastrointestinal complaints, hypotension, hypocalcemia</td></tr></table>
======================================
<table><thead><th>FUNCTION/SYSTEM</th><th>EFFECTS</th></thead><tr><td>Glucose metabolism</td><td>Increased hepatic glycogen deposition, gluconeogenesis, decreased muscle glucose uptake and metabolism</td></tr><tr><td>Protein metabolism</td><td>Decreased muscle protein synthesis, increased catabolism</td></tr><tr><td>Fat metabolism</td><td>Increased lipolysis in adipose tissue</td></tr><tr><td>Connective tissue</td><td>Inhibition of fibroblasts, loss of collagen, thinning of skin, striae formation</td></tr><tr><td>Skeletal system</td><td>Inhibition of bone formation, increased osteoclast activity, potentiate the action of PTH</td></tr><tr><td>Immune system</td><td>Increases circulation of polymorphonuclear cells; decreases numbers of lymphocytes, monocytes, and eosinophils; reduces migration of inflammatory</td></tr><tr><td>Cardiovascular system</td><td>cells to sites of injury Increases cardiac output and peripheral vascular tone</td></tr><tr><td>Renal system</td><td>Sodium retention, hypokalemia, hypertension via mineralocorticoid effect, increased glomerular filtration via glucocorticoid effects</td></tr><tr><td>Endocrine system</td><td>Inhibits TSH synthesis and release, decreased TBG levels, decreased conversion of T, to T,</td></tr><tr><td colspan="2">PTH = parathyroid hormone; T, = 3,5’ ,3-triiodothyronine; T, = thyroxine; TBG = thyroxine-binding globulin; TSH = thyroid-</td></tr></table>
======================================
<table><thead><th>RECEPTOR</th><th>TISSUE</th><th>FUNCTION</th></thead><tr><td rowspan="7">a,</td><td>Blood vessels</td><td>Contraction</td></tr><tr><td></td><td>Gut</td><td>Decreased motility, increased sphincter tone</td></tr><tr><td></td><td>Pancreas</td><td>Decreased insulin and glucagon release</td></tr><tr><td></td><td>Liver</td><td>Glycogenolysis, gluconeogenesis</td></tr><tr><td></td><td>Eyes</td><td>Pupil dilation</td></tr><tr><td></td><td>Uterus</td><td>Contraction</td></tr><tr><td></td><td>Skin</td><td>Sweating</td></tr><tr><td rowspan="2">a,</td><td>Synapse (sympathetic)</td><td>Inhibits norepinephrine release</td></tr><tr><td></td><td>Platelet</td><td>Aggregation</td></tr><tr><td rowspan="4">B,</td><td>Heart</td><td>Chronotropic, inotropic</td></tr><tr><td></td><td>Adipose tissue</td><td>Lipolysis</td></tr><tr><td></td><td>Gut</td><td>Decreased motility, increased sphincter tone</td></tr><tr><td></td><td>Pancreas</td><td>Increased insulin and glucagon release</td></tr><tr><td rowspan="2">B,</td><td>Blood vessels</td><td>Vasodilation</td></tr><tr><td></td><td>Bronchioles</td><td>Dilation</td></tr></table>
======================================
<table><thead><th>Features of</th><th>Cushing’s syndrome</th></thead><tr><td>SYSTEM</td><td>MANIFESTATION</td></tr><tr><td>General</td><td>Weight gain—central obesity, buffalo hump, supraclavicular fat pads</td></tr><tr><td>Integumentary</td><td>Hirsutism, plethora, purple striae, acne, ecchymosis</td></tr><tr><td>Cardiovascular</td><td>Hypertension</td></tr><tr><td>Musculoskeletal</td><td>| Generalized weakness, osteopenia</td></tr><tr><td>Neuropsychiatric</td><td>| Emotional lability, psychosis, depression</td></tr><tr><td>Metabolic</td><td>Diabetes or glucose intolerance, hyperlipidemia</td></tr><tr><td>Renal</td><td>Polyuria, renal stones</td></tr><tr><td>Gonadal</td><td>Impotence, decreased libido, menstrual irregularities</td></tr></table>
======================================
<table><thead><th colspan="4">TNM Staging for adrenocortical cancer</th></thead><thead><th>TUMOR</th><th>NODE</th><th>METASTASIS</th><th>STAGE</th></thead><tr><td>Tl</td><td>NO</td><td>MO</td><td>I</td></tr><tr><td>T2</td><td>NO</td><td>MO</td><td>I</td></tr><tr><td>Tl</td><td>NI</td><td>MO</td><td>Hl</td></tr><tr><td>T2</td><td>NI</td><td>MO</td><td>Hl</td></tr><tr><td>T3</td><td>Any N</td><td>MO</td><td>Il</td></tr><tr><td>T4</td><td>Any N</td><td>MO</td><td>Il</td></tr><tr><td>Any T</td><td>Any N</td><td>MI</td><td>IV</td></tr></table>
======================================
<table><thead><th>FUNCTIONING LESIONS</th><th>NONFUNCTIONING LESIONS</th></thead><tr><td>Benign</td><td>Benign</td></tr><tr><td>Aldosteronoma</td><td>Cortical adenoma</td></tr><tr><td>Cortisol-producing</td><td>Myelolipoma</td></tr><tr><td>adenoma</td><td>Cyst</td></tr><tr><td>Sex steroid—producing</td><td>Ganglioneuroma</td></tr><tr><td>adenoma Pheochromocytoma</td><td>Hemorrhage</td></tr><tr><td></td><td>Malignant</td></tr><tr><td>Adrenocortical cancer</td><td>Metastasis</td></tr><tr><td>Malignant pheochromocytoma</td><td>Adrenocortical cancer</td></tr></table>
======================================
<table><thead><th>PRIMARY</th><th>SECONDARY</th></thead><tr><td>Autoimmune (autoimmune polyglandular disease types I and II)</td><td>Exogenous glucocorticoid therapy</td></tr><tr><td>Infectious—TB, fungi, CMV, HIV</td><td>Bilateral adrenalectomy</td></tr><tr><td>Hemorrhage—spontaneous (Waterhouse-Friderichsen syndrome) and secondary to stress, trauma, infections, coagulopathy, or anticoagulants</td><td>Pituitary or hypothalamic tumors</td></tr><tr><td>Metastases</td><td>Pituitary hemorrhage (postpartum Sheehan’s</td></tr><tr><td>Infiltrative disorders—</td><td>syndrome) Trans-sphenoidal resection of</td></tr><tr><td>amyloidosis, hemochromatosis Adrenoleukodystrophy</td><td>pituitary tumor</td></tr><tr><td colspan="2">Congenital adrenal hyperplasia</td></tr><tr><td>Drugs—ketoconazole, metyrapone, aminoglutethimide, mitotane</td><td></td></tr></table>
======================================
<table><thead><th rowspan="2">Nutritional surgical patient</th><th colspan="2">requirements for the pediatric</th></thead><thead><th></th><th>CALORIES</th><th>PROTEIN</th></thead><tr><td>AGE</td><td>(kcal/kg/d)</td><td>(gram/kg/d)</td></tr><tr><td>0-6 months</td><td>100-120</td><td>2</td></tr><tr><td>1-3 years</td><td>100</td><td>12)</td></tr><tr><td>4—6 years</td><td>90</td><td>1</td></tr><tr><td>7-10 years</td><td>70</td><td>1</td></tr><tr><td>11-14 years</td><td>55</td><td>1</td></tr><tr><td>15-18 years</td><td>45</td><td>1</td></tr></table>
======================================
<table><thead><th colspan="5">Formulas for pediatric surgical neonates</th></thead><thead><th>FORMULA</th><th>kcal/mL</th><th>PROTEIN (g/mL)</th><th>FAT (g/mL)</th><th>CARBOHYDRATE (g/mL)</th></thead><tr><td>Human milk</td><td>0.67</td><td>0.011</td><td>0.04</td><td>0.07</td></tr><tr><td colspan="5">Milk-based formula</td></tr><tr><td>Enfamil 20</td><td>0.67</td><td>0.015</td><td>0.038</td><td>0.069</td></tr><tr><td>Similac 20</td><td>0.67</td><td>0.015</td><td>0.036</td><td>0.072</td></tr><tr><td colspan="5">Soy-based formula</td></tr><tr><td>Prosobee</td><td>0.67</td><td>0.02</td><td>0.036</td><td>0.07</td></tr><tr><td>Isomil</td><td>0.67</td><td>0.018</td><td>0.037</td><td>0.068</td></tr><tr><td colspan="5">Special formula</td></tr><tr><td>Pregestimil</td><td>67</td><td>019</td><td>028</td><td>091</td></tr><tr><td>Alimentum</td><td>67</td><td>019</td><td>038</td><td>.068</td></tr><tr><td colspan="5">Preterm</td></tr><tr><td>Enfamil Premature</td><td>80</td><td>024</td><td>041</td><td>089</td></tr></table>
======================================
<table><thead><th>STAGE</th><th>SITES</th><th>T</th><th>SIZE</th><th>N</th><th>M</th></thead><tr><td>1</td><td>Orbit, nonparameningeal head and neck, genitourinary (other than kidney, bladder, and prostate), and biliary</td><td>Tl or T2</td><td>aorb</td><td>Any N</td><td>MO</td></tr><tr><td></td><td>Bladder/prostate, extremity, cranial parameningeal, other</td><td>Tl or T2</td><td>a</td><td>NO or NX</td><td>MO</td></tr><tr><td rowspan="2"></td><td rowspan="2">Bladder/prostate, extremity, cranial parameningeal, other</td><td rowspan="2">Tl or T2</td><td>a</td><td>N1</td><td>MO</td></tr><tr><td></td><td></td><td></td><td>b</td><td>Any N</td><td>MO</td></tr><tr><td>4</td><td>All</td><td>TlorT2</td><td>aorb</td><td>Any N</td><td>MI</td></tr></table>
======================================
<table><tr><td>GRADE</td><td>DESCRIPTION</td><td>MANAGEMENT</td></tr><tr><td>1</td><td>Contusion or nonenlarging subcapsular perirenal hematoma</td><td>Generally managed conservatively.</td></tr><tr><td>2</td><td>Perinephric hematoma without obvious parenchymal laceration on CT, or a &lt;1 cm laceration into the cortex of the kidney</td><td>| Generally managed conservatively in a stable patient.</td></tr><tr><td>3</td><td>&gt;I1 cm laceration into the cortex without involvement of the collecting system</td><td>| Generally managed conservatively in a stable patient.</td></tr><tr><td>4</td><td>A deep laceration into the collecting system with evidence of urinary extravasation on CT, ora segmental renal artery or vein injury with contained hematoma, or partial vessel laceration, or vessel thrombosis</td><td>Can be observed expectantly in the stable patient, but may require subsequent urgent or delayed repair. Renal artery embolization may be an option for those who fail conservative therapy.</td></tr><tr><td>5</td><td>Renal pedicle injury or multiple deep renal lacerations (“shattered kidney”)</td><td>| Patients often require surgical exploration, but stable patients with only parenchymal injury may be safely treated conservatively.</td></tr></table>
======================================
<table><thead><th>ISSUE</th><th>ELEMENTS TO EXPLORE</th><th>ASSOCIATED ISSUES</th></thead><tr><td>Menstrual history</td><td>Age at menarche, menopause. Bleeding pattern, postmenopausal bleeding, spotting between periods. Any medications (warfarin, heparin, aspirin, herbals, others) or personal or family history that might lead to prolonged bleeding times</td><td>Identifies abnormal patterns related to endocrine, structural, infectious, and oncologic etiologies</td></tr><tr><td>Obstetrical history</td><td>Number of pregnancies, dates, type of deliveries, pregnancy loss, abortion, complications</td><td>Identifies predisposing pregnancy for GTD, possible surgical complications</td></tr><tr><td>Sexual history</td><td>Partners, practices, protection; pregnancy intention</td><td>Guide the assessment of patient risk, risk-reduction strategies, the determination of necessary testing, and the identification of anatomical sites from which to collect specimens for STD testing</td></tr><tr><td>Infectious diseases</td><td>Sexually transmitted diseases and treatment and/or testing for these</td><td>Also need to explore history of other GI diseases that may mimic STD (Crohn’s, diverticulitis)</td></tr><tr><td>Contraceptive history</td><td>Present contraception if appropriate, prior use, type and duration</td><td>Concurrent pregnancy with procedure or complications ¢ contraceptives</td></tr><tr><td>Cytologic screening</td><td>Frequency, results (normal, prior abnormal Pap), any prior surgery or diagnoses, HPV testing history</td><td>Prolonged intervals increase risk of cervical cancer Relationship to anal, vaginal, vulvar cancers</td></tr><tr><td>Prior gynecologic surgery</td><td>Type (laparoscopy, vaginal, abdominal); diagnosis (endometriosis? ovarian cysts? tubo-ovarian abscess?); actual pathology if possible</td><td>Assess present history against this background (for example, granulosa cell pathology, is it now recurrent?)</td></tr><tr><td>Pain history</td><td>Site, location, relationship (with urination, with menses, with intercourse at initiation or deep penetration, with bowel movements), referral</td><td>Assesses relationship to other organ systems, and potential involvement of these with process. Common examples presenting as pelvic pain, ureteral stone, endometriosis with bowel</td></tr></table>
======================================
<table><tr><td></td><td>BACTERIAL VAGINOSIS</td><td colspan="2">VULVOVAGINAL CANDIDIASIS | TRICHOMONIASIS</td></tr><tr><td>Pathogen</td><td>Anaerobic organisms</td><td>Candida albicans</td><td>Trichomonas vaginalis</td></tr><tr><td>% of vaginitis</td><td>40</td><td>30</td><td>20</td></tr><tr><td>pH</td><td>&gt;4.5</td><td>&lt;4.5</td><td>&gt;4.5</td></tr><tr><td>Signs and symptoms</td><td>Malodorous, adherent discharge</td><td>White discharge, vulvar erythema, pruritus, dyspareunia</td><td>Malodorous purulent discharge, vulvovaginal erythema, dyspareunia</td></tr><tr><td>Wet mount</td><td>Clue cells</td><td>Pseudohyphae or budding yeasts in 40% of cases</td><td>Motile trichomonads</td></tr><tr><td>KOH mount</td><td></td><td>Pseudohyphae or budding yeasts in 70% of cases</td><td></td></tr><tr><td>Amine test</td><td>+</td><td>=</td><td>=</td></tr><tr><td>Treatment</td><td>Metronidazole 500 mg twice _| a day for 7 d or 2 g single dose, metronidazole or clindamycin vaginal cream</td><td>Oral fluconazole 150 mg single | dose, vaginal antifungal preparations</td><td>Metronidazole 2 g single dose and treatment of partner</td></tr></table>
======================================
<table><thead><th></th><th>HERPES</th><th>SYPHILIS</th><th>CHANCROID</th><th>LYMPHOGRANULOMA | VENEREUM</th><th>GRANULOMA INGUINALE (DONOVANOSIS)</th></thead><tr><td>Pathogen</td><td>HSV type 2 and less commonly HSV type 1</td><td>| Treponema palladium</td><td>| Haemophilus ducreyi</td><td>| Chlamydia trachomatis L1-L3</td><td>Calymmato- bacterium granulomatis</td></tr><tr><td>Incubation period</td><td>2-7 days</td><td>2-4 weeks (1-12 weeks)</td><td>1-14 days</td><td>3 days—6 weeks</td><td>1-4 weeks (up to 6 months)</td></tr><tr><td>Primary lesion</td><td>| Vesicle</td><td>Papule</td><td>Papule or pustule</td><td>Papule, pustule, or | vesicle</td><td>Papule</td></tr><tr><td>Number of lesions</td><td>Multiple, may coalesce</td><td>Usually one</td><td>Usually multiple, may coalesce</td><td>Usually one</td><td>Variable</td></tr><tr><td>Diameter (mm)</td><td>1-2</td><td>5-15</td><td>2-20</td><td>2-10</td><td>Variable</td></tr><tr><td>Edges</td><td>Erythematous</td><td>Sharply demarcated, | elevated, round, or oval</td><td>Undermined, ragged, | irregular</td><td>Elevated, round, or oval</td><td>Elevated, irregular</td></tr><tr><td>Depth</td><td>Superficial</td><td>Superficial or deep</td><td>Excavated</td><td>Superficial or deep |</td><td>Elevated</td></tr><tr><td>Base</td><td>Serous, erythematous</td><td>Smooth, nonpurulent |</td><td>Purulent</td><td>Variable</td><td>Red and rough (“beefy”)</td></tr><tr><td>Induration</td><td></td><td>Firm</td><td>Soft</td><td>Occasionally firm |</td><td>Firm</td></tr><tr><td>Pain</td><td>Common</td><td>Unusual</td><td>Usually very tender</td><td>Variable</td><td>Uncommon</td></tr><tr><td>Lymph- adenopathy</td><td>Firm, tender, often | bilateral</td><td>Firm, nontender, bilateral</td><td>Tender, may suppate, | usually unilateral</td><td>Tender, may suppurate, loculated, usually unilateral</td><td>Pseudo-adenopathy</td></tr><tr><td>Treatment</td><td>acyclovir (ACV) 400 mg POI three} times a day for 7-10 days for primary infection and 400 mg PO _s three times a day for 5 days ‘or episodic management</td><td>Primary, secondary, and early latent (&lt;I year): benzathine| PCN-G 2.4 million UIMx1 Late latent (&gt;1 year) and latent of unknown duration: benzathine PCN-G 2.4 million units IM| every week x 3</td><td>azithromycin | g po or ceftriaxone 250 mg IM x1 OR Ciprofloxacin 500 mg po twice a day for 3 days Erythromycin base 500 mg po three times a day for 7 days</td><td>Doxycycline 100 mg | po twice a day x 21 days OR | Erythromycin base 500 mg po four times a day for 21 days</td><td>Doxycycline 100 mg po twice a day for 3 weeks until all lesions have healed</td></tr><tr><td>Suppression</td><td>acyclovir 400 mg po twice a day ‘or those with</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>IA |</td><td>Tumor confined to the vulva or perineum, &lt;2 cm in size with stromal invasion &lt;1 mm, negative nodes</td></tr><tr><td>1B</td><td>| Tumor confined to the vulva or perineum, &gt;2 cm in size or with stromal invasion &gt;1 mm, negative nodes</td></tr><tr><td>I</td><td>Tumor of any size with adjacent spread (1/3 lower urethra, 1/3 lower vagina, anus), negative nodes</td></tr><tr><td>INA</td><td>| Tumor of any size with positive inguino-femoral lymph nodes (i) 1 lymph node metastasis 25 mm (ii) 1-2 lymph node metastasis(es) of &lt;5 mm</td></tr><tr><td>IIIB</td><td>| (i) 2 or more lymph nodes metastases &gt;5 mm (ii) 3 or more lymph nodes metastases &lt;5 mm.</td></tr><tr><td>IlIC</td><td>| Positive node(s) with extracapsular spread</td></tr><tr><td>IVA</td><td>| (i) Tumor invades other regional structures (2/3 upper urethra, 2/3 upper vagina), bladder mucosa, rectal mucosa, or fixed to pelvic bone (ii) Fixed or ulcerated inguino-femoral lymph nodes</td></tr><tr><td>IVB</td><td>| Any distant metastasis including pelvic lymph nodes</td></tr></table>
======================================
<table><tr><td>FIGO</td><td>staging of vaginal carcinoma</td></tr><tr><td>0</td><td>Carcinoma in situ; intraepithelial neoplasia grade 3</td></tr><tr><td>I</td><td>Tumor limited to the vaginal wall</td></tr><tr><td>IL</td><td>Tumor has involved the subvaginal tissue but has not extended to the pelvic wall</td></tr><tr><td>Ill</td><td>| Tumor extends to the pelvic wall</td></tr><tr><td>IV__|</td><td>Tumor has extended beyond the true pelvis or has involved the mucosa of the bladder or rectum</td></tr><tr><td>IVA</td><td>| Tumor invades bladder and/or rectal mucosa and/or direct extension beyond the true pelvis</td></tr><tr><td>IVB</td><td>Distant metastasis</td></tr></table>
======================================
<table><thead><th>STAGE</th><th>DESCRIPTION</th><th>OPTIONS FOR MANAGEMENT</th></thead><tr><td></td><td>Carcinoma in situ</td><td>Adenocarcinoma in situ: simple hysterectomy, may be followed for fertility preservation if all margins negative on cone Squamous cell carcinoma in situ: local excision with LEEP or cone or laser ablation</td></tr><tr><td>I</td><td>Confined to the cervix Al: Confined to the cervix, diagnosed only by microscopy with invasion of &lt;3 mm in depth and lateral spread &lt;7 mm A2: Confined to the cervix, diagnosed with microscopy with invasion of &gt;3 mm and &lt;5 mm with lateral spread &lt;7 mm BI: Clinically visible lesion or greater than A2, &lt;4 cm in greatest dimension B2: Clinically visible lesion, &gt;4 cm in greatest dimension</td><td>Al and some A2: fertility preservation through large cone followed by close monitoring, followed by hysterectomy | B1 and B2: radical hysterectomy or chemoradiation; radical trachelectomy with uterine preservation for childbearing is under investigation for highly selected patients with small lesions</td></tr><tr><td>IL</td><td>A1: Involvement of the upper two-thirds of the vagina, without parametrial invasion, &lt;4 cm in greatest dimension A2: &gt;4 cm in greatest dimension B: Parametrial involvement</td><td>For some IIA radical hysterectomy may be considered | IIA and B: chemoradiation is preferred</td></tr><tr><td>Il</td><td>A. Involvement of the lower third of the vagina B. Involvement of a parametria to the sidewall or obstruction of one or both ureters on imaging</td><td>Chemoradiation</td></tr><tr><td>IV</td><td>A. Local involvement of the bladder or rectum B. Distant metastases</td><td>A. Chemoradiation B. Chemotherapy with palliative radiation as indicated</td></tr></table>
======================================
<table><tr><td>2009</td><td>International Federation of Gynecology and</td></tr><tr><td>Obstetrics</td><td>staging of carcinoma of the uterine corpus</td></tr><tr><td>IA</td><td>Tumor confined to the uterus, no or &lt;¥2 myometrial invasion</td></tr><tr><td>IB</td><td>Tumor confined to the uterus, &gt;/2 myometrial invasion</td></tr><tr><td>Il</td><td>Cervical stromal invasion, but not beyond uterus</td></tr><tr><td>1A |</td><td>Tumor invades serosa or adnexa</td></tr><tr><td>IB</td><td>Vaginal and/or parametrial involvement</td></tr><tr><td>I1C1 _</td><td>Pelvic-node involvement</td></tr><tr><td></td><td>Para-aortic involvement</td></tr></table>
======================================
<table><tr><td>OVARIAN CANCER SYMPTOM INDEX</td><td>ACOG GUIDELINES FOR REFERRAL OF PREMENOPAUSAL WOMEN WITH MASS SUSPICIOUS FOR OVCA</td><td>ACOG GUIDELINES FOR REFERRAL OF POSTMENOPAUSAL WOMEN WITH MASS SUSPICIOUS FOR OVCA</td></tr><tr><td>Development of, change in, and/or persistence in:</td><td>1 or more of:</td><td>1 or more of:</td></tr><tr><td>Bloating</td><td>CA-125 &gt;200 U/mL</td><td>Elevated CA-125</td></tr><tr><td>Pelvic or abdominal pain</td><td>Ascites</td><td>Ascites</td></tr><tr><td>Difficulty eating or feeling full quickly</td><td>Evidence of abdominal or distant metastasis</td><td>Nodular or fixed pelvic mass</td></tr><tr><td>Urinary symptoms of urgency or frequency</td><td>Family history of 1 or more first degree relatives with ovarian or breast cancer</td><td>Evidence of abdominal or distant metastasis Family history of one or more first-degree relatives with ovarian or breast cancer</td></tr></table>
======================================
<table><thead><th>I</th><th>Tumor confined to ovaries or fallopian tube(s)</th><th>Tl</th></thead><tr><td>IA</td><td>Tumor limited to one ovary (capsule intact) or fallopian tube No tumor on ovarian or fallopian tube surface No malignant cells in the ascites or peritoneal washings</td><td>Tla</td></tr><tr><td>IB</td><td>Tumor limited to both ovaries (capsules intact) or fallopian tubes No tumor on ovarian or fallopian tube surface No malignant cells in the ascites or peritoneal washings</td><td>Tlb</td></tr><tr><td>Ic</td><td>Tumor limited to one or both ovaries or fallopian tubes, with any of the following: IC1 Surgical spill intraoperatively IC2 Capsule ruptured before surgery or tumor on ovarian or fallopian tube surface IC3 Malignant cells present in the ascites or peritoneal washings</td><td>Tle</td></tr><tr><td>IL</td><td>Tumor involves one or both ovaries or fallopian tubes with pelvic extension (below pelvic brim) or peritoneal cancer (Tp)</td><td>|T2</td></tr><tr><td>IIA</td><td>Extension and/or implants on the uterus and/or fallopian tubes/and/or ovaries</td><td>T2a</td></tr><tr><td>IIB</td><td>Extension to other pelvic intraperitoneal tissues</td><td>T2b</td></tr><tr><td>Il</td><td>Tumor involves one or both ovaries, or fallopian tubes, or primary peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph nodes</td><td>T3</td></tr><tr><td>IA</td><td>Metastasis to the retroperitoneal lymph nodes with or without microscopic peritoneal involvement beyond the pelvis</td><td>T1, T2, T3aN1</td></tr><tr><td>IAI</td><td>Positive retroperitoneal lymph nodes only (cytologically or histologically proven)</td><td></td></tr><tr><td>INA1(i)</td><td>Metastasis &lt;10 mm in greatest dimension (note this is tumor dimension and not lymph node dimension)</td><td>T3a/T3aN1</td></tr><tr><td>TINA 1 (ii)</td><td>Metastasis &gt;10 mm in greatest dimension</td><td></td></tr><tr><td>INA 2</td><td>Microscopic extrapelvic (above the pelvic brim) peritoneal involvement with or without positive retroperitoneal lymph nodes</td><td>T3a/T3aN1</td></tr><tr><td>TB</td><td>Macroscopic peritoneal metastases beyond the pelvic brim &lt;2 cm in greatest dimension, with or without metastasis to the retroperitoneal lymph nodes</td><td>| T3b/T3bN1</td></tr><tr><td>Ic</td><td>Macroscopic peritoneal metastases beyond the pelvic brim &gt;2 cm in greatest dimension, with or without metastases to the retroperitoneal nodes (Note 1)</td><td>| T3c/T3cN1</td></tr><tr><td rowspan="2">IV</td><td></td><td>Distant metastasis excluding peritoneal metastases</td><td></td></tr><tr><td>Stage IV A: Pleural effusion with positive cytology Stage IV B: Metastases to extra-abdominal organs (including inguinal lymph nodes and lymph nodes outside of abdominal cavity) (Note 2)</td><td>Any T, any N, | M1</td></tr></table>
======================================
<table><thead><th>FEATURE</th><th>SCORE 0</th><th>SCORE 2</th></thead><tr><td>Peritoneal carcinomatosis</td><td>Carcinomatosis involving a limited area (along the paracolic gutter or the pelvic peritoneum) and surgically removable by peritonectomy</td><td>Unresectable massive peritoneal involvement as well as with a miliary pattern of distribution</td></tr><tr><td>Diaphragmatic disease</td><td>No infiltrating carcinomatosis and no nodules confluent with the most part of the diaphragmatic surface</td><td>Widespread infiltrating carcinomatosis or nodules confluent with the most part of the diaphragmatic surface</td></tr><tr><td>Mesenteric disease</td><td>No large infiltrating nodules and no involvement of the root of the mesentery as would be indicated by limited movement of the various intestinal segments</td><td>Large infiltrating nodules or involvement of the root of the mesentery indicated by limited movement of the various intestinal segments</td></tr><tr><td>Omental disease</td><td>No tumor diffusion observed along the omentum up to the large stomach curvature</td><td>Tumor diffusion observed along the omentum up to the large stomach curvature</td></tr><tr><td>Bowel infiltration</td><td>No bowel resection was assumed and no miliary carcinomatosis on the ansae observed</td><td>Bowel resection assumed or miliary carcinomatosis on the ansae observed</td></tr><tr><td>Stomach infiltration</td><td>No obvious neoplastic involvement of the gastric wall</td><td>Obvious neoplastic involvement of the gastric wall</td></tr><tr><td>Liver metastases</td><td>No surface lesions</td><td>Any surface lesion</td></tr></table>
======================================
<table><tr><td>Guidelines for secondary</td><td>therapy of epithelial</td><td>ovarian cancer</td></tr><tr><td>Progression on therapy</td><td>Platinum-refractory</td><td>No value of secondary debulking unless remediating complication such as bowel obstruction Non-platinum-based chemotherapy Consider clinical trial</td></tr><tr><td>Progression within 6 months of completion of primary therapy</td><td>Platinum-resistant</td><td>No value of secondary debulking unless remediating complication such as bowel obstruction Non-platinum-based chemotherapy consider adding bevacizumab Consider clinical trial</td></tr><tr><td>Progression after 6 months post completion of primary therapy</td><td>Platinum-sensitive</td><td>Consider secondary debulking if greater than 12 months interval Consider platinum +/— taxane +/— bevacizumab, +/— pegylated liposomal doxorubicin, +/— gemcitabine Consider maintenance PARP inhibitor Consider clinical trial</td></tr></table>
======================================
<table><thead><th></th><th>0</th><th>1</th><th>2</th><th>4</th></thead><tr><td>Age</td><td>&lt;40</td><td>&gt;40</td><td>=</td><td>=</td></tr><tr><td>Antecedent pregnancy</td><td>| Mole</td><td>Abortion</td><td>Term</td><td></td></tr><tr><td>Interval from index pregnancy, months</td><td>&lt;4</td><td>46</td><td>7-12</td><td>&gt;12</td></tr><tr><td>Pretreatment hCG mIU/mL</td><td>&lt;10°</td><td>&gt;10*-10*</td><td>&gt;10*-10°</td><td>&gt;10°</td></tr><tr><td>Largest tumor size including uterus, cm</td><td>-</td><td>3-4</td><td>&gt;5</td><td>-</td></tr><tr><td>Site of metastases including uterus</td><td>Lung</td><td>Spleen, kidney</td><td>Gastrointestinal tract</td><td>Brain, liver</td></tr><tr><td>Number of metastases identified</td><td>| —</td><td>14</td><td>5-8</td><td>&gt;8</td></tr><tr><td>Previous failed chemotherapy</td><td>=</td><td>=</td><td>Single drug</td><td>Two or more drugs</td></tr></table>
======================================
<table><thead><th>Motor</th><th>scoring system</th></thead><tr><td>GRADE</td><td>DESCRIPTION</td></tr><tr><td>0</td><td>No muscle contraction</td></tr><tr><td>1</td><td>Visible muscle contraction without movement across the joint</td></tr><tr><td>2</td><td>Movement in the horizontal plane, unable to overcome gravity</td></tr><tr><td>3</td><td>Movement against gravity</td></tr><tr><td>4</td><td>Movement against some resistance</td></tr><tr><td>5</td><td>Normal strength</td></tr></table>
======================================
<table><tr><td>MOTOR RESPONSE</td><td></td><td>VERBAL RESPONSE</td><td></td><td>EYE-OPENING RESPONSE</td><td></td></tr><tr><td>Obeys commands</td><td></td><td>Oriented</td><td></td><td>Opens spontaneously</td><td></td></tr><tr><td>Localizes to pain</td><td></td><td>Confused</td><td>wlaAln</td><td>Opens to speech</td><td></td></tr><tr><td>Withdraws from pain</td><td>WIAD</td><td>Inappropriate words</td><td></td><td>Opens to pain</td><td>PISCE</td></tr><tr><td>Flexor posturing</td><td></td><td>Unintelligible sounds</td><td></td><td>No eye opening</td><td></td></tr><tr><td>Extensor posturing</td><td></td><td>No sounds</td><td>ely</td><td></td><td></td></tr><tr><td>No movement</td><td>FN</td><td></td><td></td><td></td><td></td></tr></table>
======================================
<table><tr><td>% OF INTRACRANIAL HEMORRHAGES</td><td>LOCATION</td><td>CLASSIC SYMPTOMS</td></tr><tr><td>50</td><td>Basal ganglia (putamen, globus pallidus), internal capsule</td><td>Contralateral hemiparesis</td></tr><tr><td>15</td><td>Thalamus</td><td>Contralateral hemisensory loss</td></tr><tr><td>10-20</td><td>Cerebral white matter (lobar)</td><td>Depends on location (weakness, numbness, partial loss of visual field)</td></tr><tr><td>10-15</td><td>Pons</td><td>Hemiparesis; may be devastating</td></tr><tr><td>10</td><td>Cerebellum</td><td>Lethargy or coma due to brain stem compression and/or hydrocephalus</td></tr><tr><td>1-6</td><td>Brain stem (excluding pons)</td><td>Often devastating</td></tr></table>
======================================
<table><thead><th>Prevalence of</th><th>cerebral aneurysm by location</th></thead><tr><td>PREVALENCE</td><td>ANEURYSM LOCATION (VERNACULAR NAME)</td></tr><tr><td>Anterior circulation 85%</td><td>30% Anterior communicating artery (A-Comm) 25% Posterior communicating artery (P-Comm)</td></tr><tr><td></td><td>20% Middle cerebral artery bifurcation 10% Other</td></tr><tr><td>Posterior circulation 15%</td><td>10% Basilar artery, most frequently at the basilar tip 5% Vertebral artery, usually at the posterior inferior cerebellar artery</td></tr></table>
======================================
<table><thead><th>The Hunt-Hess hemorrhage</th><th>clinical grading system for subarachnoid</th></thead><thead><th>HUNT-HESS GRADE</th><th>CLINICAL PRESENTATION</th></thead><tr><td>0</td><td>Asymptomatic; unruptured aneurysm</td></tr><tr><td>1</td><td>Awake; asymptomatic or mild headache; mild nuchal rigidity</td></tr><tr><td>2</td><td>Awake; moderate to severe headache, cranial nerve palsy (e.g., cranial nerve III or IV), nuchal rigidity</td></tr><tr><td>3</td><td>Lethargic; mild focal neurologic deficit (e.g., pronator drift)</td></tr><tr><td>4</td><td>Stuporous; significant neurologic deficit (e.g., hemiplegia)</td></tr><tr><td>5</td><td>Comatose; posturing</td></tr></table>
======================================
<table><thead><th>Cervical</th><th>disc herniations and</th><th>symptoms by level</th><th></th><th></th><th></th></thead><thead><th>LEVEL</th><th>FREQUENCY (%)</th><th>ROOT INJURED</th><th>REFLEX</th><th>WEAKNESS</th><th>NUMBNESS</th></thead><tr><td>C4-C5</td><td>2</td><td>CS</td><td>_</td><td>Deltoid</td><td>Shoulder</td></tr><tr><td>C5-C6</td><td>19</td><td>C6</td><td>Biceps</td><td>Biceps brachii</td><td>Thumb</td></tr><tr><td>C6-C7</td><td>69</td><td>C7</td><td>Triceps</td><td>Wrist extensors (wrist drop)</td><td>Second and third digits</td></tr><tr><td>C7-Tl</td><td>10</td><td>C8</td><td>=</td><td>Hand intrinsics</td><td>Fourth and fifth digits</td></tr></table>
======================================
<table><thead><th rowspan="2">Lumbar disc LEVEL</th><th>herniations and</th><th>symptoms by level</th><th></th><th></th><th></th></thead><thead><th></th><th>FREQUENCY (%)</th><th>ROOT INJURED</th><th>REFLEX</th><th>WEAKNESS</th><th>NUMBNESS</th></thead><tr><td>L3-L4</td><td>5</td><td>L4</td><td>Patellar</td><td>Quadriceps</td><td>Anterior thigh</td></tr><tr><td>L4-L5</td><td>45</td><td>LS</td><td>_</td><td>Tibialis anterior (foot drop)</td><td>Great toe</td></tr><tr><td>L5-S1</td><td>50</td><td>SI</td><td>Achilles</td><td>Gastrocnemius</td><td>Lateral foot</td></tr></table>
======================================
<table><thead><th>Distal posterior</th><th>Parosteal osteosarcoma</th></thead><tr><td rowspan="2">Distal anterior</td><td>Periosteal osteosarcoma, periosteal</td></tr><tr><td></td><td>myositis ossificans</td></tr></table>
======================================
<table></table>
======================================
<table><tr><td>Anterior</td><td>Metastatic, myeloma, Paget’s disease, vascular malformation, giant cell tumor</td></tr><tr><td>Posterior</td><td>Osteoid osteoma, osteoblastoma; aneurysmal bone cyst</td></tr></table>
======================================
<table><thead><th>STAGE</th><th>FINDINGS</th><th>TREATMENT</th></thead><tr><td>I</td><td>Increased fluid in sheath, mainly a serous exudate</td><td>| Catheter irrigation</td></tr><tr><td>IL Il</td><td>Purulent fluid, granulomatous synovium Necrosis of the</td><td>Minimal invasive drainage + indwelling catheter irrigation Extensive debridement</td></tr><tr><td></td><td>tendon, pulleys, or tendon sheath</td><td>open and possible amputation</td></tr></table>
======================================
<table><thead><th></th><th></th><th>STSG (thick)</th><th></th></thead><tr><td>Dermal content</td><td></td><td></td><td>+++</td></tr><tr><td>1° contraction</td><td></td><td></td><td>+++</td></tr><tr><td>2° contraction</td><td></td><td></td><td>+</td></tr><tr><td>Engraftment</td><td></td><td></td><td>+</td></tr><tr><td>Durability</td><td>+</td><td></td><td>+++</td></tr><tr><td>Pigmentation</td><td>+44</td><td></td><td>+</td></tr><tr><td>Resist desiccation</td><td></td><td></td><td>+++</td></tr><tr><td>Recipient bed</td><td></td><td></td><td>+44</td></tr><tr><td>Appearance</td><td></td><td></td><td></td></tr></table>
======================================
<table><thead><th>CLASSIFICATION</th><th>| VASCULAR SUPPLY</th><th>EXAMPLE</th></thead><tr><td>Type I</td><td>One vascular pedicle</td><td>Gastrocnemius</td></tr><tr><td>Type II</td><td>Dominant and minor pedicles (the flap cannot survive based only on the minor pedicles)</td><td>Gracilis</td></tr><tr><td>Type Ill</td><td>Two dominant pedicles</td><td>| Rectus abdominis</td></tr><tr><td>Type IV</td><td>Segmental pedicles</td><td>Sartorius</td></tr><tr><td>Type V</td><td>One dominant pedicle _ with secondary segmental pedicles (the flap can survive based only on the secondary pedicles)</td><td>Pectoralis major</td></tr></table>
======================================
<table><thead><th>CLASSIFICATION</th><th>| VASCULAR SUPPLY</th><th>EXAMPLE</th></thead><tr><td>Type A</td><td>Direct cutaneous vessel that penetrates the fascia</td><td>Temporoparietal fascial flap</td></tr><tr><td>Type B</td><td>Septocutaneous vessel that penetrates the fascia</td><td>Radial artery forearm flap</td></tr><tr><td></td><td>penetrates the fascia</td><td>myocutaneous flap</td></tr></table>
======================================
<table><tr><td>Table 45-3</td><td></td></tr><tr><td colspan="2">Classification of craniofacial anomalies”?</td></tr><tr><td colspan="2">1. Clefts</td></tr><tr><td>2. Synostoses</td><td></td></tr><tr><td>3. Atrophy—hypoplasia</td><td></td></tr><tr><td>4. Hypertrophy—hyperplasia—neoplasia</td><td></td></tr></table>
======================================
<table><thead><th>Classification of</th><th>vascular</th><th>malformations</th></thead><tr><td>SLOW FLOW</td><td></td><td>FAST FLOW</td></tr><tr><td>Capillary malformations Venous malformations Lymphatic malformations</td><td></td><td>Arteriovenous malformations</td></tr></table>
======================================
<table><tr><td colspan="2">Classification of CMN’s</td></tr><tr><td>PROJECTED ADULT DIAMETER</td><td>CMN CLASSIFICATION</td></tr><tr><td>&lt;1.5cm</td><td>Small</td></tr><tr><td>21.5 cm and &lt;11 cm</td><td>Medium</td></tr><tr><td>211 cm and &lt;20 cm</td><td>Large</td></tr><tr><td>&gt;20 cm</td><td>Giant</td></tr></table>
======================================
<table><thead><th colspan="2">Some reconstructive options for the diabetic foot</th></thead><thead><th>AREA OF DEFECT</th><th>| RECONSTRUCTIVE OPTIONS</th></thead><tr><td>Forefoot</td><td>V-Y advancement Toe island flap Single toe amputation Lisfranc’s amputation</td></tr><tr><td>Midfoot</td><td>V-Y advancement Toe island flap Medial plantar artery flap Free tissue transfer Transmetatarsal amputation</td></tr><tr><td>Hindfoot</td><td>Lateral calcaneal artery flap Reversed sural artery flap Medial plantar artery flap + flexor digitorum brevis Abductor hallucis muscle flap Abductor digiti minimi muscle flap Free tissue transfer Syme’s amputation</td></tr><tr><td>Foot dorsum</td><td>Supramalleolar flap Reversed sural artery flap Thinner free flaps (e.g., temporoparietal fascia, radial forearm, groin, thinned anterolateral thigh flaps)</td></tr></table>
======================================
<table><thead><th>ANESTHETIC</th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td>Nitrous Oxide</td><td>| No odor, taste, or pungency Rapid uptake and elimination Analgesic effect Minimal cardiovascular depression Minimal biotransformation Inexpensive</td><td>Airspace expansion Increased nausea and vomiting Inhibits methionine synthase Environmental pollutant Supports combustion</td></tr><tr><td>Isoflurane</td><td>Good muscle relaxation Bronchodilation Stable heart rate Inexpensive</td><td>Slow uptake and elimination</td></tr><tr><td>Sevoflurane</td><td>Rapid uptake and elimination Not pungent</td><td>Breakdown to compound A in circuit More expensive than isoflurane</td></tr><tr><td>Desflurane</td><td>Rapid uptake and elimination Very low biotransformation</td><td>Airway irritant Requires electric/ heated vaporizer | Expensive</td></tr></table>
======================================
<table><thead><th>AGENT</th><th>TYPE</th><th>INTUBATING DOSE</th><th>| CONSIDERATIONS</th></thead><tr><td>Succinylcholine</td><td>Depolarizer</td><td>1 mg/kg</td><td>Can cause severe hyperkalemia Contraindicated in burns, denervating conditions Excessive or prolonged use can lead to phase II block</td></tr><tr><td>Rocuronium</td><td>Nondepolarizer</td><td>0.6 mg/kg 1.2 mg/kg for RSI</td><td>Primarily hepatic metabolism | Can be reversed with suggamadex or acetylcholinesterase inhibitor</td></tr><tr><td>Vecuronium</td><td>Nondepolarizer</td><td>0.1 mg/kg</td><td>Primarily hepatic metabolism Can be reversed with suggamadex or acetylcholinesterase inhibitor</td></tr><tr><td>Cisatracurium</td><td>Nondepolarizer</td><td>0.1 mg/kg</td><td>Hoffman degradation Can be reversed with an acetylcholinesterase inhibitor</td></tr></table>
======================================
<table><tr><td>TYPE OF MONITOR</td><td>WHAT IS MEASURED</td><td>INVASIVENESS</td><td>POTENTIAL FOR COMPLICATIONS</td></tr><tr><td>Physical examination</td><td>Heart sounds, breath sounds, pulse, color, mental status, etc</td><td>| Noninvasive</td><td>-</td></tr><tr><td>Pulse oximetry</td><td>Arterial oxygen saturation</td><td>Noninvasive</td><td>-</td></tr><tr><td>Arterial catheter</td><td>Blood pressure, acid/base status</td><td>Invasive</td><td>are</td></tr><tr><td>Noninvasive blood pressure measurement</td><td>Blood pressure</td><td>Noninvasive</td><td>+/-</td></tr><tr><td>Electrocardiography</td><td>Cardiac rhythm, rate, ST segments</td><td>Noninvasive</td><td>=</td></tr><tr><td>Capnography</td><td>Ventilatory, circulatory status</td><td>Noninvasive</td><td>-</td></tr><tr><td>Electroenceophalogram, bispectral index, etc</td><td>| Brain function, depth of anesthesia</td><td>Noninvasive</td><td>+/-</td></tr><tr><td>Temperature probe</td><td>Body temperature</td><td>Noninvasive to invasive</td><td>+/-</td></tr><tr><td>Central venous pressure, pulmonary artery pressure</td><td>Cardiac function, volume status</td><td>Invasive</td><td>+4+</td></tr><tr><td>Transesophageal echocardiogram</td><td>Cardiac function, volume status</td><td>Invasive</td><td>+44</td></tr></table>
======================================
<table><thead><th>STATUS</th><th>DESCRIPTION</th></thead><tr><td>I</td><td>A healthy patient without systemic disease</td></tr><tr><td>IL</td><td>A patient with mild systemic disease</td></tr><tr><td>Il</td><td>A patient with severe systemic disease</td></tr><tr><td>IV</td><td>A patient with severe systemic disease that is a constant threat to life</td></tr><tr><td>Vv</td><td>A moribund patient not expected to survive without the operation</td></tr><tr><td>VI</td><td>A declared brain-dead patient whose organs are being removed for donation</td></tr></table>
======================================
<table><thead><th>TIME BEFORE SURGERY</th><th>FOOD OR FLUID INTAKE</th></thead><tr><td>Up to 8 hours</td><td>Food and fluids as desired</td></tr><tr><td>Up to 6 hours*</td><td>Light meal, infant formula</td></tr><tr><td>Up to 4 hours</td><td>Breast milk</td></tr><tr><td>Up to 2 hours</td><td>Clear liquids only</td></tr></table>
======================================
<table><tr><td>Men</td><td>Cutoff for time to walk 15 feet criterion for frailty</td></tr><tr><td>Height &lt;173 cm</td><td>27 seconds</td></tr><tr><td>Height &gt;173 cm</td><td>26 seconds</td></tr><tr><td colspan="2">Women</td></tr><tr><td>Height &lt;159 cm</td><td>27 seconds</td></tr><tr><td>Height &gt;159 cm</td><td>26 seconds</td></tr></table>
======================================
<table><thead><th>fWEETE</th></thead><thead><th>BMI &lt;24</th></thead><tr><td>BMI 24.1-26</td></tr><tr><td>BMI 26.1-28</td></tr><tr><td>BMI &gt;28</td></tr><tr><td>Women</td></tr><tr><td>BMI &lt;23</td></tr><tr><td>BMI 23.1-26</td></tr><tr><td>BMI 26.1-29</td></tr><tr><td>BMI &gt;29</td></tr></table>
======================================
<table><tr><td>Nu-DESC Screen: Score</td><td></td></tr><tr><td colspan="2">Each item scored 0-2 Ye</td></tr><tr><td>* Disorientation</td><td>Dif</td></tr><tr><td colspan="2">¢ Inappropriate behavior |/—</td></tr><tr><td colspan="2">¢ Inappropriate communication</td></tr><tr><td colspan="2">¢ Illusions/hallucinations</td></tr><tr><td>¢ Psychomotor retardation</td><td></td></tr></table>
======================================
<table><tr><td>Risk Factors</td><td></td></tr><tr><td>- Age &gt;65 - Cognitive - Comorbidity - Poor functional - Hearing/vision</td><td>impairment burden status impairment</td></tr><tr><td>- Depression</td><td>Precipitating Factors, ina addition to SURGERY</td></tr><tr><td></td><td>- Physical restraints</td></tr></table>
======================================
<table><thead><th colspan="2">Core Competencies in surgical palliative care</th></thead><thead><th>DOMAIN</th><th>COMPETENCY</th></thead><tr><td>Patient Care</td><td>Possess the capacity to guide the transition from curative and palliative goals of treatment to palliative goals alone based on patient information and preferences, scientific and outcomes evidence, and sound clinical judgment Perform an assessment and gather essential clinical information about symptoms, pain, and suffering Perform palliative procedures competently and with sound judgment to meet patient goals of care at the end of life Provide management of pain and other symptoms to alleviate suffering Communicate effectively and compassionately bad news and poor prognoses Conduct a patient and family meeting regarding advance directives and end-of-life decisions Exercise sound clinical judgment and skill in the withdrawal and withholding of life support</td></tr><tr><td>Medical knowledge</td><td>Acute and chronic pain management Non-pain symptom management Ethical and legal basis for advance directives, informed consent, withdrawal and withholding of life support, and futility Grief and bereavement in surgical illness Quality of life outcomes and prognostication Role of spirituality at the end of life</td></tr><tr><td>Interpersonal and communication skills</td><td>Surgeons must be competent and compassionate communicators with patients, families, and other health care providers. They should be effective in communicating bad news and prognosis and in redefining hope in the context of cultural diversity. The interdisciplinary nature of palliative care requires that the surgeon is skilled as both a leader and a member of an interdisciplinary team and maintains collegial relationships with other health care providers.</td></tr><tr><td>Professionalism</td><td>Surgeons must maintain professional commitment to ethical and empathic care, which is patient focused, with equal attention to relief of suffering along with curative therapy. Respect and compassion for cultural diversity, gender, and disability is particularly important around rituals and bereavement at the end of life. Maintenance of ethical standards in the withholding and withdrawal of life support is essential.</td></tr><tr><td>Systems-based practice</td><td>Surgeons must be aware and informed of the multiple components of the health care system that provide palliative and end-of-life care. Surgeons should be knowledgeable and willing to refer patients to hospice, palliative care consultation, pain management, pastoral care, social services, etc., and to understand resource utilization and reimbursement issues involved.</td></tr></table>
======================================
<table><thead><th>FUNCTIONAL LEVEL</th><th>PERFORMANCE STATUS (ECOG)</th><th>| PROGNOSIS</th></thead><tr><td>Able to perform all basic ADLs independently and some IADLs</td><td>| 2</td><td>Months</td></tr><tr><td>Resting/sleeping up to 50% or more of waking hours and requiring some assistance with basic ADLs</td><td>3</td><td>Weeks to a few months</td></tr><tr><td>Dependent for basic ADLs and bed-to-chair existence</td><td>4</td><td>Days to a few weeks at most</td></tr></table>
======================================
<table><thead><th>DRUG</th><th>INITIAL DOSING (ADULT, &gt;60 kg)</th><th>COMMENTS</th></thead><tr><td>Mild persistent pain, visual analogue scale (VAS) 1-3 Acetaminophen (Tylenol)</td><td>325-650 mg PO four times a day Maximum = 3200 mg/24 h</td><td>Use &lt;2400 mg if other potentially hepatotoxic drugs taken. Acetaminophen contained in concurrent nonprescription medications can easily exceed maximum daily allowable dose.</td></tr><tr><td>Aspirin</td><td>600-1500 mg PO four times a day</td><td>Gastric bleeding, platelet dysfunction</td></tr><tr><td>Choline magnesium trisalicylate (Trilisate)</td><td>750-1500 mg PO twice a day</td><td>Useful for avoiding platelet dysfunction</td></tr><tr><td>Ibuprofen (Advil, Motrin)</td><td>200-400 mg PO four times a day Maximum = 3200 mg/24 h</td><td>Gastropathy, nephropathy, decreased platelet aggregation</td></tr><tr><td>Naproxen (Naprosyn)</td><td>250 mg PO twice a day Maximum = 1300 mg/24 h</td><td>Available as a transcutaneous gel</td></tr><tr><td>Moderate persistent pain, VAS 4-6 Hydrocodone (Vicodin, Lortab)</td><td>5-7.5 mg PO every 4 hours</td><td>Most prescribed drug in the United States Acetaminophen in compounded drug limits use to moderate pain</td></tr><tr><td>Oxycodone</td><td>5 mg PO every 4 hours</td><td>Sold as single agent or compounded with aspirin or acetaminophen Slow release form available (Oxycontin)</td></tr><tr><td>Severe persistent pain, VAS 7-10 Morphine</td><td>10 mg PO every 2-4 hours 24 mg IV, SC every 1-2 hours</td><td>Standard drug for comparison to alternative opioids. Avoid or caution when giving to older adults, patients with diminished glomerular filtration rate, or liver disease. Slow release PO form available (MS Contin).</td></tr><tr><td>Hydromorphone</td><td>1-3 mg PO, PR every 4 hours 1 mg IV, SC every 1-2 hours</td><td>Suppository form available Oral dose forms limited to 4 mg maximum</td></tr><tr><td>Fentanyl, transdermal</td><td>12 ug/h patch every 72 hours</td><td>Not for acute pain management. Do not use on opioid-naive patients. Absorption unpredictable in cachectic patients.</td></tr><tr><td>Methadone</td><td>Consultation with pain management, clinical pharmacists, or palliative care/hospice services skilled in methadone use is recommended for those inexperienced in prescribing methadone.</td><td>Not a first-line agent, although very effective, especially for pain with a neuropathic component Very inexpensive Can be given PO, IV, SC, PR, sublingually, and vaginally Its long half-life makes dosing more difficult than alternative opioids and close monitoring is required when initiating. Numerous medications, alcohol, and cigarette smoking can alter its serum levels. Physicians who write methadone prescriptions for pain should specify this indication. Methadone use for drug withdrawal treatment requires special licensure.</td></tr></table>
======================================
<table><thead><th>DRUG CLASS</th><th>INITIAL DOSING (ADULT, &gt;60 kg)</th><th>COMMENTS</th></thead><tr><td>Tricyclic antidepressants Best for continuous burning or tingling and</td><td>Amitriptyline 10-25 mg PO before bed</td><td>Sedating properties may be useful for relief of other concurrent symptoms. Side effects benefit.</td></tr><tr><td>pain allodynia Efficacy for pain not due to</td><td>Nortriptyline 10-25 mg PO one per day</td><td>may precede Avoid in older adult patients due to</td></tr><tr><td>antidepressant effect Dose generally less than that required</td><td>Doxepin 10-25 mg PO before bed</td><td>anticholinergic side effects. Less anticholinergic effect</td></tr><tr><td>for antidepressant effect Dose titrated up every few days until effect. Pain may respond to alternative antidepressants if no</td><td>Imipramine 10-25 mg PO one per day</td><td></td></tr><tr><td>response to initial agent. Anticonvulsants For shooting, stabbing pain</td><td>Gabapentin 100-1200 mg PO three times a day. Titrate up rapidly as needed. Max: 3600 mg daily in divided doses</td><td>Commonly used first-line agent. Generally well tolerated. Does not require blood level monitoring.</td></tr><tr><td>Local anesthetics Systemic use requires monitoring. Nebulized local anesthetics (lidocaine, bupivacaine) can be used for severe, refractory cough.</td><td>Lidocaine transdermal patch 5%. Apply to painful areas. Max: 3 simultaneous patches over 12 hours (each patch contains 700 mg lidocaine). Lidocaine/prilocaine topical. Apply to painful areas.</td><td>Systemic toxicity can result from applying more than recommended number per unit time and in patients with liver failure. Effective for postherpetic neuralgia.</td></tr><tr><td rowspan="4">Miscellaneous</td><td></td><td>Bisphosphonates (pamidronate, zoledronic acid)</td><td>For bone pain and reduced incidence of skeletal complications secondary to malignancy—best results in myeloma and breast cancer. Contraindicated in renal failure.</td></tr><tr><td>Calcitonin nasal spray</td><td>Refractory bone pain</td></tr><tr><td></td><td>Dexamethasone</td><td>For bone pain, acute nerve compression, visceral pain secondary to tumor infiltration or luminal obstruction by reducing inflammatory component of tumor</td></tr><tr><td></td><td>Radionuclides (Sr-89)</td><td>For malignant bone pain secondary to</td></tr></table>
======================================
<table><thead><th>DCP3</th><th>LCGS</th></thead><tr><td>Provision of essential surgery in LMICs would prevent 1.5 million deaths, or 6.7% of all avertable deaths</td><td>5 billion people lack access to safe, affordable surgical and anesthesia care when needed</td></tr><tr><td>Essential surgical procedures rank among the most cost-effective of all health interventions</td><td>143 million more operations are needed in LMICs, where only 6% of all worldwide procedures are now done</td></tr><tr><td>Effective and affordable measures (such as task- sharing) increase access to surgical care</td><td>33 million face catastrophic health expenditure from surgery and anesthesia care each year</td></tr><tr><td>Investments must be made to expand capacity building</td><td>Without urgent investment, LMICs will lose US $12.3 trillion in economic productivity between 2015 and 2030</td></tr><tr><td>Substantial disparities exist between countries in safety of surgical and anesthetic care. Feasible and affordable measures (e.g., surgical safety checklist)</td><td>Surgery is an indivisible, indispensable part of health care. Surgical care should be part of the National Health Care System, and should be “available, accessible, safe,</td></tr><tr><td>improve safety and quality Universal coverage of essential surgery should</td><td>timely, and affordable.”</td></tr></table>
======================================
<table><thead><th>1</th><th>No poverty</th></thead><tr><td>2</td><td>Zero hunger</td></tr><tr><td>3</td><td>Good health and well-being</td></tr><tr><td>4</td><td>Quality education</td></tr><tr><td>5</td><td>Gender equality</td></tr><tr><td>6</td><td>Clean water and sanitation</td></tr><tr><td>7</td><td>Affordable and clean energy</td></tr><tr><td>8</td><td>Decent work and economic growth</td></tr><tr><td>9</td><td>Industry, innovation, and infrastructure</td></tr><tr><td>10</td><td>Reduced inequalities</td></tr><tr><td>11</td><td>Sustainable cities and communities</td></tr><tr><td>12</td><td>Responsible consumption and production</td></tr><tr><td>13</td><td>Climate action</td></tr><tr><td>14</td><td>Life below water</td></tr><tr><td>15</td><td>Life on land</td></tr><tr><td>16</td><td>Peace, justice, and strong institutions</td></tr><tr><td>17</td><td>Partnerships for the goals</td></tr></table>
======================================
<table><thead><th>Wound debridement</th></thead><tr><td>Wound suturing, dressing, suture removal</td></tr><tr><td>Incision and drainage of abscesses</td></tr><tr><td>Resuscitation</td></tr><tr><td>Fracture management</td></tr><tr><td>Penetrating injuries</td></tr><tr><td>Blunt injuries</td></tr><tr><td>Amputation</td></tr><tr><td>Burns management</td></tr><tr><td>Skin grafting</td></tr><tr><td>Contracture release</td></tr><tr><td>Chest tube insertion</td></tr><tr><td>Cricothyroidotomy/Tracheostomy</td></tr><tr><td>Removal of foreign body</td></tr><tr><td>Venous peripheral cutdown</td></tr><tr><td>Uterine rupture/ectopic pregnancy</td></tr><tr><td>Suprapubic puncture/cystostomy</td></tr><tr><td>Local anaesthestic infiltration</td></tr></table>
======================================
<table><thead><th>Before induction of anaesthesia —-——————</th><th>Before skin incision —-----_&gt;_</th><th>Before patient leaves operating room</th></thead><tr><td>(with at least nurse and anaesthetist)</td><td>(with nurse, anaesthetist and surgeon)</td><td>(with nurse, anaesthetist and surgeon)</td></tr><tr><td>Has the patient confirmed his/her identity, site, procedure, and consent? Yes</td><td>members have by name and role. it’s name, procedure,</td><td>Nurse verbally confirms: The name of the procedure Completion of instrument, sponge and</td></tr><tr><td>Is the site marked? Yes Not applicable Is the anaesthesia machine and medication</td><td>incision will be made.</td><td>needle counts Specimen labeling (read specimen labels aloud, including patient name) Whether there are</td></tr><tr><td>check complete? Yes</td><td>I events</td><td>any equipment problems to be addressed To surgeon, anaesthetist and nurse:</td></tr><tr><td>Is the pulse oximeter on the patient and functioning? Yes</td><td>itical or non-routine steps? le case take?</td><td>What are the key concerns for recovery and management of this patient?</td></tr><tr><td>Does the patient have a: Known allergy? No Yes Difficult airway or aspiration risk? No Yes, and equipment/assistance available Risk of &gt;500 ml blood loss (7 ml/kg in children)? No Yes, and two IVs/central access and fluids planned</td><td>icipated blood loss? tient-specific concerns? uding indicator results) 2 jent issues or any concerns?</td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan="3">This checklist is not intended to be comprehensive. Additions and modifications to fit local practice are encouraged.</td></tr><tr><td></td><td>Based on the WHO Surgical Safety Checklist http://whqlibdoc.who.int/publications/2009/9789241598590_eng_Checklist.pdf © World Health Organization 2009 All rights reserved</td><td></td></tr></table>
======================================
<table><tr><td colspan="3">Prevention strategies</td></tr><tr><td>PREVENTION STRATEGY</td><td>TARGET</td><td>GOAL</td></tr><tr><td>1. Primary</td><td>Root causes of disease</td><td>Eliminate or reduce risk of developing illness</td></tr><tr><td>2. Secondary |</td><td>Illness or disease at earliest stages</td><td>| Limit progression of disease</td></tr><tr><td>3. Tertiary</td><td>Disease at later stages</td><td>Cure or limit the effect of existing disease</td></tr></table>
======================================
<table><thead><th>The role of surgery for primary</th><th>prevention of cancer</th></thead><tr><td>TERTIARY SURGICAL PROCEDURE</td><td>PRIMARY CANCER PREVENTED</td></tr><tr><td>Breast lumpectomy for ductal carcinoma in situ</td><td>Breast</td></tr><tr><td>Colonoscopic polypectomy</td><td>Colon</td></tr><tr><td>Colposcopy and excision</td><td>Cervical</td></tr><tr><td>Resection of actinic keratosis</td><td>Skin</td></tr><tr><td>Resection of leukoplakia and erythroplakia</td><td>Oral</td></tr></table>
======================================
<table><thead><th>Prioritization</th><th>of surgical</th><th>conditions</th><th></th></thead><thead><th></th><th>PUBLIC HEALTH</th><th>SURGICAL PROCEDURE</th><th>COST-EFFECTIVE AND FEASIBLE TO PROMOTE</th></thead><thead><th>PRIORITY”</th><th>| BURDEN</th><th>SUCCESSFUL</th><th>GLOBALLY</th></thead><tr><td>1</td><td>High</td><td>Highly</td><td>Highly</td></tr><tr><td>2</td><td>Moderate</td><td>| Moderately</td><td>Moderately</td></tr><tr><td>3</td><td>Low</td><td>Neither highly or moderately</td><td>| Low</td></tr></table>
======================================
<table><thead><th>Trauma care</th><th>Prevention of death and chronic disability by the provision of timely. expert, and complete surgical care</th></thead><tr><td>Obstetrical emergencies</td><td>Timely surgical intervention in obstructed labor, in pre- and post- partum hemorrhage, and other obstetrical complications</td></tr><tr><td>Acute surgical emergencies</td><td>Provision of competent surgery to treat a wide range of emergency abdominal and nonabdominal conditions</td></tr><tr><td>Nonacute surgical conditions</td><td>Surgical care for several elective conditions that have a significant effect on the quality of life such as cataract, otitis media, clubfoot, and hernias</td></tr></table>
======================================
<table><thead><th rowspan="2">KNOWLEDGE AND SKILLS</th><th colspan="4">FACILITY LEVEL</th></thead><thead><th></th><th>BASIC</th><th>GENERAL PRACTITIONER</th><th>SPECIALIST</th><th>TERTIARY</th></thead><tr><td>Assessment of airway compromise</td><td>E</td><td>1B</td><td>1B</td><td>1B</td></tr><tr><td>Manual maneuvers (chin lift, jaw thrust)</td><td>E</td><td>E</td><td>E</td><td>E</td></tr><tr><td>Insertion of oral or nasal airway</td><td>D</td><td>1B</td><td>1B</td><td>1B</td></tr><tr><td>Endotracheal Intubation</td><td>D</td><td>D</td><td>1B</td><td>1B</td></tr><tr><td colspan="5">Equipment and supplies</td></tr><tr><td>Oral or nasal airway</td><td>D</td><td>E</td><td>1B</td><td>1B</td></tr><tr><td>Laryngoscope</td><td>D</td><td>D</td><td>1B</td><td>1B</td></tr><tr><td>Endotracheal tube</td><td>D</td><td>D</td><td>1B</td><td>1B</td></tr><tr><td>Capnography</td><td>I</td><td>D</td><td>D</td><td>D</td></tr></table>
======================================
<table><tr><td>Accessible</td><td>Entire population Care at local level</td></tr><tr><td>Appropriate</td><td>Care comparable to western standards Disease with high incidence/prevalence</td></tr><tr><td>Disruptive technology</td><td>Designed $4 lens Local business</td></tr><tr><td>Sustainable growth</td><td>Skills transfer Building infrastructure</td></tr><tr><td>Affordable</td><td>Delivery model $20 cost/cataract</td></tr><tr><td>Sustainability</td><td>Meet needs of current population Culturally and economically acceptable</td></tr></table>
======================================
<table><thead><th>INSTITUTION</th><th>NAME OF GLOBAL SURGERY CENTER</th></thead><tr><td>Brigham and Women’s Hospital</td><td>Center for Surgery and Public Health</td></tr><tr><td>Emory University School of Medicine</td><td>Global Surgery Program</td></tr><tr><td>Harvard Medical School</td><td>Program in Global Surgery and Social Change</td></tr><tr><td>King’s College London</td><td>King’s Center for Global Health and Health Partnerships</td></tr><tr><td>McGill University</td><td>Centre of Global Surgery</td></tr><tr><td>Oregon Health and Sciences University</td><td>Global Health Advocacy Program in Surgery</td></tr><tr><td>University of British Columbia</td><td>Branch for International Surgical Care</td></tr><tr><td>University of California San Francisco</td><td>Center for Global Surgical Studies</td></tr><tr><td>University of Chicago</td><td>Global Surgery Program</td></tr><tr><td>University of Utah</td><td>Center for Global Surgery</td></tr></table>
======================================
<table><thead><th>Preoperative phase</th><th>Intraoperative phase</th><th>Postoperative phase</th></thead><tr><td>Patient education &amp; set expectations</td><td></td><td>Goal-directed fluid therapy</td></tr><tr><td>Smoking &amp; alcohol cessation</td><td></td><td>Prevention of PONV</td></tr><tr><td>Prehabilitation with diet &amp; exercise</td><td></td><td>Early ambulation</td></tr><tr><td>fo) a o 5) 2 Q s Bh 5 ea</td><td></td><td>Early feeding</td></tr><tr><td>Antimicrobial prophylaxis</td><td></td><td>Multimodal pain relief</td></tr><tr><td>VTE prophylaxis</td><td></td><td>Early urinary catheter removal</td></tr><tr><td>Minimize bowel preparation</td><td></td><td>Defined discharge criteria</td></tr></table>
======================================
<table><thead><th></th><th>RELATIVE</th><th>RISK</th><th>95% CONFIDENCE INTERVALS</th></thead><tr><td>Impaired wound healing</td><td>3.25</td><td></td><td>1.35-7.84</td></tr><tr><td>Cardiac disorders</td><td>4.49</td><td></td><td>1-20.16</td></tr><tr><td>Blood transfusion</td><td>1.33</td><td></td><td>1.06-1.66</td></tr></table>
======================================
<table><thead><th></th><th>ADVANTAGES</th><th>DISADVANTAGES</th></thead><tr><td>141 Opioids</td><td>Relieve pain immediately after administration</td><td>Worsen pain scores after opioids wear off Increase postoperative opioid requirements Central Nervous System: Euphoria/dysphoria Sedation Respiratory depression Nausea/vomiting Cough suppression Cardiovascular: Bradycardia/tachycardia Arterial/venous dilation Renal: Antidiuretic Increased sodium resorption Urinary retention Gastrointestinal: Decreased motility Constipation Biliary colic Endocrine: Stimulates release of antidiuretic hormone Stimulates release of prolactin Stimulates release of somatotropin Decreases luteinizing hormone Immunologic: Decreased immune system function Cancer growth</td></tr><tr><td>NSAIDs"?</td><td>Reduce inflammation Synergistic effect with opioids</td><td>Renal insufficiency Increased bleeding Delay healing Adverse cardiovascular risk</td></tr><tr><td>Local anesthetics 140</td><td>Opioid-sparing effect Decrease PONV Reduce ileus Possible anticancer effect</td><td>Cardiac toxicity Central nervous system toxicity</td></tr><tr><td>Ketamine!3137.143</td><td>Opioid-sparing effect May prevent opioid-induced hyperalgesia and chronic pain syndromes</td><td>Dysphoria Hallucinations</td></tr><tr><td>Gabapentinoids 130-135</td><td>Opioid-sparing effect</td><td>Visual disturbances</td></tr></table>
======================================
<table><thead><th>QUESTION</th><th>STEP 1 (LEVEL 1")</th><th>STEP 2 (LEVEL 2")</th><th>STEP 3 (LEVEL 3°)</th><th>STEP 4 (LEVEL 4°)</th><th>STEP 5 (LEVEL 5)</th></thead><tr><td>How common is the problem?</td><td>Local and current random sample surveys (or censuses)</td><td>Systematic review of surveys that allow matching to local circumstances**</td><td>| Local non-random _| sample**</td><td>Case-series**</td><td></td></tr><tr><td>Is this diagnostic or monitoring test accurate? (Diagnosis)</td><td>Systematic review of cross-sectional studies with consistently applied reference standard and blinding</td><td>Individual cross- sectional studies with consistently applied reference standard and blinding</td><td>Non-consecutive studies, or studies without consistently applied reference standards**</td><td>Case-control studies, or “poor or non- independent reference standard**</td><td>Mechanism-based reasoning</td></tr><tr><td>What will happen if we do not add a therapy? (Prognosis)</td><td>| Systematic review of inception cohort studies</td><td>| Inception cohort studies</td><td>Cohort study or control arm of randomized trial*</td><td>Case-series or case- | control studies, or poor quality prognostic cohort study**</td><td></td></tr><tr><td>Does this intervention help? (Treatment Benefits)</td><td>Systematic review of randomized trials or n-of-1 trials</td><td>| Randomized trial or observational study with dramatic effect</td><td>Non-randomized controlled cohort/ follow-up study**</td><td>Case-series, case- control studies, | _ or historically controlled studies**</td><td>Mechanism-based reasoning</td></tr><tr><td>What are the COMMON harms? (Treatment Harms)</td><td>Systematic review of randomized trials, systematic review of nested case-control studies n-of-1 trial} with the patient you are raising the question about, or observational study with dramatic effect</td><td>Individual randomized trial or (exceptionally) observational study with dramatic effect</td><td>Non-randomized controlled cohort/ follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long- term harms the duration of follow-up must be sufficient.)**</td><td>Case-series, case-control, or historically controlled studies**</td><td>Mechanism-based reasoning</td></tr><tr><td>What are the RARE harms? (Treatment Harms)</td><td>Systematic review of randomized trials or n-of-1 trial</td><td>| Randomized trial or (exceptionally) observational study with dramatic effect</td><td></td><td></td><td></td></tr><tr><td>Is this (early detection) test worthwhile? (Screening)</td><td>Systematic review of randomized trials</td><td>Randomized trial</td><td>Non-randomized controlled cohort/ follow-up study**</td><td>Case-series, case-control, | — or historically controlled</td><td>Mechanism-based reasoning</td></tr></table>
======================================
<table><thead><th rowspan="3">Outcomes</th><th colspan="2">Illustrative comparative risks* (95% Cl)</th><th rowspan="3">Relative effect | (95% Cl)</th><th rowspan="3">Number of participants (studies)</th><th rowspan="3">Quality | of the evidence (GRADE)</th><th rowspan="3">Comments</th></thead><thead><th></th><th rowspan="2">Assumed risk Without stockings</th><th rowspan="2">Corresponding risk With stockings</th><th></th><th></th><th></th><th></th></thead><thead><th></th><th></th><th></th><th></th><th></th><th></th><th></th></thead><tr><td>Symptomatic deep vein thrombosis (DVT)</td><td>See comment</td><td>See comment</td><td>Not estimable</td><td>2821 (9 studies)</td><td>See comment</td><td>0 participants developed symptomatic DVT in these studies.</td></tr><tr><td rowspan="4">Symptom-less deep vein thrombosis</td><td colspan="2">Low risk population?</td><td rowspan="4">RR 0.10 (0.04 to 0.26) |</td><td rowspan="4">2637 (9 studies)</td><td rowspan="4">+4+++ High</td><td rowspan="4"></td></tr><tr><td></td><td>10 per 1000</td><td>1 per 1000 (0 to 3)</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td colspan="2">High risk population?</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>30 per 1000</td><td>3 per 1000 (1 to 8)</td><td></td><td></td><td></td><td></td></tr><tr><td>Superficial vein thrombosis</td><td>13 per 1000</td><td>6 per 1000 (2 to 15)</td><td>RR 0.45 (0.18 to 1.13) |</td><td>1804 (8 studies)</td><td>+++0 Moderate’</td><td></td></tr><tr><td>Oedema Post-flight values measured on a scale | from 0, no oedema, to 10, maximum oedema.</td><td>The mean oedema score ranged across | control groups from | 6to9.</td><td>The mean oedema score in the intervention groups was on average 4.7 lower (95% Cl -4.9 to -4.5).</td><td></td><td>1246 (6 studies)</td><td>++00 Low*</td><td></td></tr><tr><td>Pulmonary embolus</td><td>| See comment</td><td>See comment</td><td>Not estimable |</td><td>2821 (9 studies)</td><td>See comment |</td><td>0 participants developed pulmonary embolus in these studies.°</td></tr><tr><td>Death</td><td>See comment</td><td>See comment</td><td>Not estimable |</td><td>2821 (9 studies)</td><td>See comment |</td><td>0 participants died in these studies.</td></tr><tr><td>Adverse effects</td><td>See comment</td><td>See comment</td><td>Not estimable |</td><td>1182 (4 studies)</td><td>See comment |</td><td>The tolerability of the stockings was described as very good with no complaints of side effects in 4 studies.®</td></tr></table>
======================================
<table><tr><td>FACTOR</td><td>EXAMPLES OF STRONG RECOMMENDATIONS</td><td>EXAMPLES OF WEAK RECOMMENDATIONS</td></tr><tr><td>Quality of evidence</td><td>Many high quality randomized trials have shown the benefit of inhaled steroids in asthma</td><td>Only case series have examined the utility of pleurodesis in pneumothorax</td></tr><tr><td>Uncertainty about the balance between desirable and undesirable effects</td><td>Aspirin in myocardial infarction reduces mortality with minimal toxicity, inconvenience, and cost</td><td>Warfarin in low risk patients with atrial fibrillation results in small stroke reduction but increased bleeding risk and substantial inconvenience</td></tr><tr><td>Uncertainty or variability in values and preferences</td><td>Young patients with lymphoma will invariably place a highervalue on the life prolonging effects of chemotherapy than on treatment toxicity</td><td>Older patients with lymphoma may not place a higher value on the life prolonging effects of chemotherapy than on treatment toxicity</td></tr><tr><td>Uncertainty about whether the intervention represents a wise use of resources</td><td>The low cost of aspirin as prophylaxis against stroke in patients with transient ischemic attacks</td><td>The high cost of clopidogrel and of combination dipyridamole and aspirin as prophylaxis against stroke in patients with transient ischaemic attacks</td></tr></table>
======================================
<table><thead><th>Section</th><th>Item No</th><th>| Checklist item</th></thead><tr><td>Title and Abstract</td><td>ta 1b</td><td>Identification as a randomized trial in the title Structured summary of trial design, methods, results, and conclusions</td></tr><tr><td>Background and Objectives |</td><td>2a 2b</td><td>Scientific background and explanation of rationale Specific objectives or hypotheses</td></tr><tr><td>Trial Design</td><td>3a 3b</td><td>Description of trial design (such as parallel, factorial) including allocation ratio Important changes to methods after trial commencement with reasons</td></tr><tr><td>Participants</td><td>4a Ab</td><td>Eligibility criteria for participants Settings and locations where the data were collected</td></tr><tr><td>Interventions</td><td>5</td><td>The interventions for each group with sufficient details to allow replication, including how and when they were administered</td></tr><tr><td>Outcomes</td><td>6a 6b</td><td>Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed Any changes to trial outcomes after the trial commenced, with reasons</td></tr><tr><td>Sample size</td><td>7a 7b</td><td>How sample size was determined When applicable, explanation of any interim analyses and stopping guidelines</td></tr><tr><td colspan="3">Randomization:</td></tr><tr><td>Sequence Generation</td><td>8a 8b</td><td>Method used to generate the random allocation sequence Type of randomization; details of any restriction (such as blocking and block size)</td></tr><tr><td>Allocation concealment</td><td>9</td><td>Mechanism used to implement the random allocation sequence</td></tr><tr><td>mechanism</td><td></td><td></td></tr><tr><td>Implementation</td><td>10</td><td>Who generated the random allocation sequence, who enrolled participants, and who assigned interventions</td></tr><tr><td>Blinding</td><td>tla 11b</td><td>If done, who was blinded after assignment to interventions and how If relevant, description of the similarity of interventions</td></tr><tr><td colspan="3">Results</td></tr><tr><td>Participant flow</td><td>13a 13b</td><td>For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome For each group, losses and exclusions after randomization, together with reasons</td></tr><tr><td>Recruitment</td><td>14a 14b</td><td>Dates defining the periods of recruitment and follow-up Why the trial ended or was stopped</td></tr><tr><td>Baseline data</td><td>15</td><td>A table showing baseline demographic and clinical characteristics for each group</td></tr><tr><td>Numbers analyzed</td><td>16</td><td>For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups</td></tr><tr><td>Outcomes and estimation</td><td>17a 17b</td><td>For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) For binary outcomes, presentation of both absolute and relative effect sizes is recommended</td></tr><tr><td>Ancillary analyses</td><td>18</td><td>Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory</td></tr><tr><td>Harms</td><td>19</td><td>All important harms or unintended effects in each group</td></tr><tr><td colspan="3">Discussion</td></tr><tr><td>Limitations</td><td>20</td><td>Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses</td></tr></table>
======================================
<table><tr><td colspan="4">Decisions regarding the hypothesis</td></tr><tr><td></td><td></td><td>HYPOTHESIS</td><td>(H,) IS</td></tr><tr><td>TABLE OF ERROR</td><td>TYPES |</td><td>TRUE</td><td>FALSE</td></tr><tr><td>Decision about</td><td>Reject |</td><td>Type | error (false positive)</td><td>Correct inference (true positive)</td></tr><tr><td>hypothesis (H,)</td><td>| Fail to | reject</td><td>Correct inference (true negative)</td><td>| Type II error (false negative)</td></tr></table>
======================================
<table><tr><td>OP AT</td><td>10 PROCEDURES PERFORMED AMBULATORY SURGICAL CENTERS BY VOLUME AND CPT [ODE</td><td>NUMBER PERFORMED |</td><td>AVG PAY | PER CLAIM</td><td>SAVINGS | AT ASC |</td><td>TOP 10 PROCEDURES PERFORMED AT HOSPITAL OUTPATIENT | DEPARTMENTS (HOPD) BY VOLUME AND CPT CODE</td><td>NUMBER PERFORMED |</td><td>AVG PAY PER CLAIM</td></tr><tr><td>1.</td><td>Cataract surgery with intraoccular lens(66984)</td><td>1155, 283</td><td>| $959</td><td>$219</td><td>1. Subcutaneous tissue debridement (11042)</td><td>841,517</td><td>$213</td></tr><tr><td>2.</td><td>Esophagogastro- duodenoscopy with biopsy (43239)</td><td>524,082</td><td>$301</td><td>$110</td><td>2. Esophagogastro- duodenoscopy with biopsy (43239)</td><td>628,900</td><td>$411</td></tr><tr><td>3.</td><td>Colonoscopy and biopsy (45380)</td><td>416,218</td><td>$352</td><td>$172</td><td>3. Aspiration/injection of joint (20610)</td><td>578,407</td><td>$141</td></tr><tr><td>4.</td><td>Colonoscopy with lesion removal (45385)</td><td>331,565</td><td>$401</td><td>$20</td><td>4. Cataract surgery with IOL implant (66984)</td><td>| 512,191</td><td>$1,178</td></tr><tr><td>5.</td><td>Spine epidural injection foraminal (64483)</td><td>282,962</td><td>$335</td><td></td><td>5. Colonoscopy and biopsy (45380)</td><td>472,886</td><td>$524</td></tr><tr><td>6.</td><td>Postlaser cataract surgery capsulotomy (66821)</td><td>275,760</td><td>$227</td><td></td><td>6. Colonoscopy with lesion removal (45385)</td><td>350,001</td><td>$421</td></tr><tr><td>7.</td><td>Spine epidural injection lumbar, sacral (62311)</td><td>210,159</td><td>$358</td><td>$120</td><td>7. Spine epidural injection lumbar, sacral (62311)</td><td>326,956</td><td>$478</td></tr><tr><td>8.</td><td>Injection, paravertebral facet joint (64493)</td><td>174,450</td><td>$306</td><td></td><td>8. Insertion of temporary bladder catheter (51702)</td><td>308,614</td><td>$69</td></tr><tr><td>9.</td><td>Diagnostic colonoscopy (45378)</td><td>157,951</td><td>$401</td><td>$100</td><td>9. Appl. of multilayer compression system (29581)</td><td>303,026</td><td>$97</td></tr><tr><td>10.</td><td>Colorectal screening, high- risk individual (G0105)</td><td>128,181</td><td>$333</td><td></td><td>10. Diagnostic colonoscopy (45378)</td><td>253,350</td><td>$501</td></tr></table>
======================================
<table><thead><th>AUTHOR (YEAR)</th><th>PARTICIPANTS (N) AND SIMULATOR</th><th>PROCEDURE ASSESSED |</th><th>CONCLUSION</th></thead><tr><td>Ahlberg et al®* (2007)</td><td>|PGY 1-2 surgery residents IG (7); Lap Sim VR simulator CG (6) no simulation</td><td>Laparoscopic cholecystectomy</td><td>IG made fewer errors (P = 0.004), exposure (P = 0.040), clipping and tissue division (P &lt;0.008), and dissection (P &lt;0.031) compared with CG</td></tr><tr><td>Banks et al® (2007)</td><td>PGY | GYN residents IG (10); Limbs &amp; Things box trainer CG (10) no simulation</td><td>Bilateral tubal ligation</td><td>IG scored higher than CG with all three evaluation tools: task-specific checklist (P = 0.002), OSATS (P = 0.003), pass-fail grade (P = 0.003)</td></tr><tr><td>Cosman et al’ (2007)</td><td>| Junior surgical trainees IG (5); Lap Sim VR simulator CG (5) no simulation</td><td>Laparoscopic cholecystectomy (clip application and cystic artery division)</td><td>IG had fewer errors (P = 0.05), better bimanual coordination (P = 0.05), higher global score (P = 0.04) than CG</td></tr><tr><td>Gala et al’! (2013)</td><td>GYN residents IG (48); FLS box trainer CG (54) no simulation</td><td>Pomeroy bilateral tubal | ligation</td><td>IG had higher OSATS progression score than CG (P = 0.03)</td></tr><tr><td>Hogle et al” (2009)</td><td>PGY | surgery residents IG (6); Lap Sim VR simulator CG (6) no simulation</td><td>Laparoscopic cholecystectomy</td><td>No significant difference between IG and CG in GOALS Domain areas of depth perception, bimanual dexterity, efficiency, tissue handling, autonomy</td></tr><tr><td>Larsen et al’ _ (2009)</td><td>First- and second-year OB-GYN registrars IG (13); Lap Sim VR simulator CG simulation</td><td>Salpingectomy</td><td>IG had higher score than CG in OSA-LS scale (P &lt;0.001). IG completed procedure faster than CG (P &lt;0.001)</td></tr><tr><td>Sroka et al*® (2010)</td><td>(11) no PGY 1-3 surgery residents IG (8); FLS box trainer CG (8) no simulation</td><td>Laparoscopic cholecystectomy (excision from liver bed)</td><td>IG had higher total GOALS score than CG (P &lt;0.001) and better GOALS domain scores for bimanual dexterity (P = 0.04), tissue handling (P = 0.04)</td></tr><tr><td>Van Sickle et al” (2008)</td><td>PGY 3, 5-6 surgery residents IG (11); MIST-VR simulator CG no simulation</td><td>| Nissen fundoplication | (placement of intracorporeal sutures)</td><td>IG completed task in less time (P &lt;0.003), committed fewer errors (P &lt;0.01), and had fewer needle manipulations (P &lt;0.05) than CG</td></tr><tr><td>Zendejas et al’&gt; (2011)</td><td>Surgery residents IG (26); Guildford MATTU TEP hernia task trainer CG (24) no simulation</td><td>TEP inguinal hernia repair</td><td>IG faster on first procedure (P &lt;0.001) and had higher participation rates (P &lt;0.001). For subsequent repairs IG remained faster than CG. GOALS score higher for IG (P = 0.001). Complications and overnight stay less likely for first TEP procedure in IG (P &lt;0.05).</td></tr><tr><td>Palter et al’ (2012)</td><td>PGY 2-4 surgery residents IG (9); curriculum including simulation training on LapSim VR simulator CG (9) no simulation</td><td>Right hemicolectomy</td><td>IG had higher OSATS score (P = 0.030) than CG. IG able to perform more operative steps than CG (P =0.021)</td></tr><tr><td>Palter et al” (2013)</td><td>PGY 1-2 surgery residents IG (9); curriculum including simulation training on</td><td>Cholecystectomy</td><td>IG had higher OSATS scores for first four procedures (P = 0.004, P = 0.036, P = 0.021, P = 0.023)</td></tr></table>
======================================
<table><thead><th>AUTHOR (YEAR)</th><th>STUDY ARMS (N)</th><th>| SUBJECTS</th><th>PROFICIENCY- BASED TRAINING?</th><th>CONCLUSIONS</th></thead><tr><td>Hamilton et al” (2002)</td><td>VR (24) Box trainer (25)</td><td>First- and second-year surgical residents</td><td>| No</td><td>Improved rater-blinded global assessments of laparoscopic cholecystectomy for VR but not box-trainer trained subjects</td></tr><tr><td>Youngblood et al? (2005)</td><td>VR (16) Box trainer (17) No training (13)</td><td>Medical students</td><td>No</td><td>VR-trained students performed better than box trainer-trained on selected tasks in live porcine model. Both trained groups outperformed nontrained.</td></tr><tr><td>Diesen et al* (2011)</td><td>VR (10) Box trainer (8)</td><td>Interns Medical students</td><td>No</td><td>No difference in interval blinded video assessments of animal OR task performance</td></tr></table>
======================================
<table><thead><th colspan="2">psychomotor of robotic surgery curriculum</th></thead><thead><th>Task 1: Docking/ Instrument Insertion</th><th>The first psychomotor exercise provides training and assessment of proper docking and instrument insertion using the simulated abdomen.</th></thead><tr><td>Task 2: Ring Tower Transfer</td><td>The trainee removes a ring from the right middle tower and places it on the lower left tower. Primary skills assessed include hand, eye, and instrument coordination, camera navigation, and use of the camera pedal.</td></tr><tr><td>Task 3: Knot Tying</td><td>The trainee ties a surgeon’s knot to approximate two eyelets such that they touch each other. Primary skills assessed include appropriate handling of suture material and tying secure knots.</td></tr><tr><td>Task 4: Railroad Track</td><td>The trainee must perform horizontal mattress suturing through a series of target points to approximate the tissue. Primary skills assessed include holding and manipulation of the needle, following the curve of the needle, utilizing the full range of motion of the</td></tr><tr><td>Task 5: 3rd Arm Cutting</td><td>The trainee must switch control between different instruments to use the monopolar scissors to cut a simulated vein. Primary skills assessed include switching between and controlling multiple robot arms and cutting.</td></tr><tr><td>Task 6: Puzzle Piece Dissection Task 7: Vessel</td><td>In this task, the trainee must cut and remove a puzzle shape without incising the underlying tissue or cutting outside of the lines. Primary skills assessed include dissection, cutting, atraumatic tissue handling, sharp dissection, and blunt dissection. The trainee must dissect fat</td></tr><tr><td>Energy Dissection</td><td>through a layer to expose a vessel then coagulate the vessel at two points and finally cut the vessel between the two coagulated points. Primary skills assessed include accurate activation and use of energy sources, dissection of vessels and tissues, cutting and coagulation of vessels, and multiple arm control.</td></tr></table>
======================================
<table><thead><th>Error prevention</th><th>Error recognition</th><th>Error rescue</th><th>Error prevention</th><th>Error recognition</th><th>Error rescue</th></thead><tr><td>What should you be concerned about?</td><td>Which of these may result in an error?</td><td>Describe what you would do if</td><td>Pre-error- makes adjustments to technical approach based on error prevention</td><td>Near miss - recognition followed by corrective action</td><td>_ Post-error - knows and executes options for error correction</td></tr><tr><td>What will prevent an error?</td><td>Estimate error risk for: technical approach and patient selection</td><td>What are your options for error rescue?</td><td></td><td></td><td></td></tr><tr><td>technique; natural hx of disease; how to avoid an error</td><td>technique; potential error: error risk</td><td>surgical options</td><td>ahead of time adjust tension to during knot tying based on tissue type</td><td>that the first knot was alittle tight then makes an adjustment to get the second knot just right</td><td>pulled through _ Rescue: Freshens tissue edge, places a new stitch</td></tr><tr><td>Select - the right operation; the right stitch; the right instrument</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>Error</td><td>loop</td><td></td></tr></table>
======================================
<table><tr><td>KIRKPATRICK |</td><td>LEVEL</td><td></td></tr><tr><td>LEVEL</td><td>DESCRIPTION</td><td>| DESCRIPTION FOR SIMULATION</td></tr><tr><td>Level |</td><td>Reaction</td><td>Did the learner perceive value in using a simulator or participating in simulation training?</td></tr><tr><td>Level 2</td><td>Learning</td><td>Did the learner’s knowledge, skill, or attitude improve as a result of the simulation training?</td></tr><tr><td>Level 3</td><td>Behavioral | change</td><td>Did the knowledge, skills, and attitudes acquired during simulation transfer to the clinical environment?</td></tr><tr><td>Level 4</td><td>Institutional impact</td><td>| Did the simulation training program lead to improved patient outcomes?</td></tr></table>
======================================
<table><thead><th>Ten</th><th>tips for setting up an online journal club</th></thead><tr><td></td><td>TIP Create an online home page that serves as a launching pad for your journal club discussions</td></tr><tr><td></td><td>Develop and register a hashtag on Twitter</td></tr><tr><td></td><td>Incorporate not only Twitter but other collaborative platforms as part of your online journal club</td></tr><tr><td></td><td>Ensure that the time of the journal club is convenient for your target audience</td></tr><tr><td></td><td>Help prepare participants by aggregating other online resources relevant to the article</td></tr><tr><td></td><td>Consider inviting the authors of the featured article or other experts in the field</td></tr><tr><td></td><td>Suggest journal club participants consider using specific Twitter management applications during the Tweet chat</td></tr><tr><td></td><td>Engage the participants to cultivate and incentivize more discussion</td></tr><tr><td></td><td>Connect to the online community by following and engaging with other relevant social media accounts</td></tr><tr><td>10</td><td>Link back to the original paper by inserting a comment on PubMed Commons</td></tr></table>
======================================
<table><tr><td>@Userl 123</td><td>@User3 27</td></tr><tr><td>@User2 65</td><td>@User11 25</td></tr><tr><td>@User3 62</td><td>@User7 23</td></tr><tr><td>@User4 46</td><td>@User4 23</td></tr><tr><td>@User5 42</td><td>@User12 19</td></tr><tr><td>@User6 32</td><td>@User13 13</td></tr><tr><td>@User7 21</td><td>@User14 12</td></tr><tr><td>@User8 19</td><td>@User15 11</td></tr><tr><td>@User9 17</td><td>@User2 10</td></tr><tr><td>@User10 16</td><td>@User1 9</td></tr></table>
======================================
<table><tr><td>Professionalism medical Position 1</td><td>published a position paper on online professionalism Use of online media can bring significant</td></tr><tr><td></td><td>educational benefits to patients and physicians, but it may also pose ethical challenges. Maintaining trust in the profession and in patient—physician relationships requires that physicians consistently apply ethical principles for preserving the relationship, confidentiality, privacy, and respect for persons to online settings and communications.</td></tr><tr><td>Position 2</td><td>The boundaries between professional and social spheres can blur online. Physicians should eep the two spheres separate and comport themselves professionally in both.</td></tr><tr><td>Position 3</td><td>Email or other electronic communications should only be used by physicians in an established patient—physician relationship and with patient consent. Documentation about patient care communications should be included in the patient’s medical record.</td></tr><tr><td>Position 4 Position 5</td><td>Physicians should consider periodically “self- auditing” to assess the accuracy of information available about them on physician-ranking websites and other sources online. The reach of the internet and online communications is far and often permanent.</td></tr><tr><td>Data from</td><td>Physicians, trainees, and medical students should be aware that online postings may have future implications for their professional lives. Farnan JM1, Snyder Sulmasy L, Worster BK, et al: Online</td></tr></table>